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Human height varies greatly between and within populations, and some individuals 
fall at the extreme ends of this wide spectrum. At the lower end of this distribution, 
individuals demonstrating extreme prenatal-onset reduction in body size and brain growth 
are classified as having microcephalic primordial dwarfism (MPD), which encompasses a 
group of rare single-gene disorders, usually inherited in an autosomal recessive manner. The 
human brain is particularly susceptible to perturbation during embryonic development, and 
the inability of neural progenitor cells to complete timely proliferation is thought to be an 
important contributor to the observed reduction in cerebral cortical size.  
Studying genes whose disruption leads to severe reduction in human growth can 
facilitate our understanding of the molecular pathways underlying cell proliferation and 
organism development. Mutations in many identified MPD genes result in the extended 
length of the cell cycle and impaired cell division by affecting essential cellular processes, 
such as DNA replication, DNA damage response (DDR) signalling, centriole biogenesis and 
mRNA splicing. The ability of cells to efficiently copy DNA and maintain the stability of their 
genome by promoting error-free repair of various types of DNA damage caused by 
endogenous and exogenous sources is particularly important for the timely cell cycle 
completion and cell survival. Therefore, it is not surprising that many MPD genes play a role 
in DNA replication, DDR and DNA repair. 
In this thesis, three DNA replication and DDR genes, mutated in MPD, are 
investigated. DNA2, encoding an ATP-dependent helicase/nuclease, was found to be 
mutated in four MPD patients. Experiments to confirm pathogenicity of the identified 
mutations indicated that they are likely to cause disease by affecting DNA2 transcript splicing 
and its enzymatic activities. My work described here also analyses the cellular role of TRAIP, 
an E3 ubiquitin ligase, which was linked to MPD by our laboratory (Harley et al., 2016). Cell 
experiments using TRAIP knockout cell lines, generated with CRISPR/Cas9 genome editing 
technology, demonstrated the requirement for TRAIP and its E3 ligase activity in DDR and 
repair of camptothecin (CPT)-induced DNA damage. Additionally, TRAIP was important for 
cell survival after mitomycin C (MMC)-induced DNA damage, but no epistasis with the 
Fanconi Anaemia (FA) interstrand crosslink (ICL) repair pathway was demonstrated, 
indicating an additive effect of TRAIP and FA-ICL pathways to repair these DNA lesions. 
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Finally, generation of a mouse model of MPD caused by mutations in DONSON, a 
novel replication fork protection factor (Reynolds et al., 2017), is described in this thesis. 
DONSON MPD mice, harbouring the mouse equivalent of one of the human MPD missense 
mutations, showed embryonic lethality, with homozygous mutant embryos significantly 
smaller than their littermates and exhibiting limb abnormalities. Increased levels of 
spontaneous DNA damage were observed in mouse embryonic fibroblasts established from 
these embryos, mimicking the cellular phenotype of human DONSON deficiency. 
In summary, this thesis advances our knowledge of the cellular and developmental 





















Variation in size is one of the most striking features in mammals, ranging from a tiny 
bumblebee bat to a large blue whale, with a 75 million-fold weight difference. Human 
population also exhibits noticeable differences in size and height, influenced both by 
environment and genetics. However, in rare cases, some individuals can be extremely small 
for their age, showing proportional reduction in both body growth and brain size, which starts 
before birth and continues into adulthood. These conditions are classified as microcephalic 
primordial dwarfism (MPD), which encompasses a number of disorders caused by 
inactivation of a single gene. Studying these syndromes and their genetic causes can give us 
insight into what underlies human growth at the level of an individual cell. 
One of the most important biological processes taking place in cells is DNA 
replication, which is the copying of all the genetic information and has to be completed 
without any errors. This allows cells to divide creating two new copies of a cell and is crucial 
for an organism to grow. Various alterations to DNA structure, collectively called DNA 
damage, can prevent the timely DNA replication and cell division. Perhaps not surprisingly, 
previous research by our and other laboratories demonstrated that mutations in multiple 
proteins that participate in DNA replication and repair of the DNA damage can cause MPD. 
 The work described in this thesis aims to investigate the cellular roles of three distinct 
DNA replication and repair genes, mutated in MPD. In our laboratory, several MPD patients 
were found to have mutations in the DNA replication and repair gene DNA2. The approaches 
taken to demonstrate the harmful effect of these mutations indicated that disruption of the 
DNA2 enzymatic activities may underlie the human disease. Another MPD gene, TRAIP, which 
encodes a protein needed to signal DNA damage in cells, is shown to be required for efficient 
cell response to various types of DNA damage. A third gene, DONSON, encodes a recently 
established DNA replication factor. A mouse model of MPD was made with mutations in this 
gene to understand its role during embryonic development. 
 Taken together, the work presented in this thesis provides new insights into the roles 
of three MPD genes, involved in DNA replication, DNA damage signalling and repair, at the 
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1.1. Disorders of brain size and body growth 
 
1.1.1. Microcephaly and primordial dwarfism 
 
Human height is a classical quantitative trait with a polygenic additive mode of 
inheritance (Visscher, 2008). However, mutations in certain genes can cause extreme 
alterations in stature and brain size, ranging from primary microcephaly to microcephalic 
primordial dwarfism. Primary autosomal recessive microcephaly is a congenital condition, 
defined by the reduction of the occipito-frontal circumference (OFC) of the head by at least 4 
standard deviations (SD) below the age- and sex-matched average, with overall height 
normally unaffected (Faheem et al., 2015; Jackson et al., 2002; Roberts et al., 2002). It is 
associated with impaired fetal brain growth, mild or moderate cognitive impairment, 
simplification of the cerebral cortical gyral pattern, and the absence of additional neurological 
deficits (Ross and Frias, 1977; Woods et al., 2005). Primary microcephaly occasionally occurs 
alongside primordial dwarfism or other congenital abnormalities (Woods and Parker, 2013). 
Microcephalic primordial dwarfism (MPD) is defined as a group of single-gene disorders, where 
both brain and body size get severely affected very early during fetal development and 
continue to be impaired after birth (Klingseisen and Jackson, 2011). Adult height of individuals 
affected by such an extreme global growth failure may be as little as 1 metre, and growth 
hormone supplementation does not increase the height of these patients (Hall et al., 2004). 
MPD is an umbrella term for several distinct, usually autosomal recessive, growth 
failure syndromes, characterised by marked growth retardation throughout the body, with the 
head size as affected or more affected than the overall body growth (Woods and Parker, 2013). 
In microcephalic osteodysplastic primordial dwarfism type 2 (MOPD II), the affected individuals 
are proportionally small, with severe prenatal and postnatal retardation in height, weight and 
OFC, with OFC ranging from −5 SD to −15 SD (Rauch, 2011; Woods and Parker, 2013). Although 
their intellectual abilities are largely unaffected, individuals with MOPD II tend to have mild 
skeletal and facial abnormalities and suffer from juvenile mortality due to neurovascular and 
cardiac problems, as well as insulin resistance (Bober et al., 2010; Rauch, 2011; Woods and 
Parker, 2013). In contrast, microcephalic osteodysplastic primordial dwarfism type 1 (MOPD I) 
patients frequently have cortical malformations, incompletely developed corpus callosum, 
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seizures, skin and hair problems, and skeletal abnormalities (Khetarpal et al., 2016). 
Disproportionate growth retardation, which affects head circumference to a larger extent than 
the body size, represents another type of MPD, known as Seckel syndrome. Individuals with 
Seckel syndrome are very small at birth and usually show severe reduction in head size, 
prominent bird-like facial features and mental retardation (Majewski et al., 1982). Lastly, 
Meier-Gorlin syndrome (MGS), also called ear-patella-short stature syndrome (EPS), is 
characterised not only by the impairment of intrauterine and postnatal growth and 
microcephaly, but also by absent or underdeveloped patellae and small ears, and despite the 
presence of microcephaly, intellectual abilities of patients are largely unaffected (Bongers et 
al., 2001; Bicknell, Walker, et al., 2011).  
During the recent Zika virus outbreak in Brazil in 2015, Zika virus infection during 
pregnancy was strongly associated with congenital brain abnormalities and microcephaly (de 
Araújo et al., 2017). Although it remains difficult to estimate the number of affected newborn 
children, Brazilian Ministry of Health reported an apparent 20-fold increase in microcephaly 
incidence, compared to historical statistics (Koppolu and Raju, 2018). Although causes and 
phenotypic characteristics of Zika virus-associated microcephaly and primary autosomal 
recessive microcephaly are distinct (Aragao et al., 2016; Merfeld et al., 2017), this epidemic 
has brought microcephaly to people’s attention worldwide.  
 
 
1.1.2. The genetics of microcephalic primordial dwarfism 
 
To date, mutations in at least 40 genes have been associated with microcephaly and 
MPD (Table 1.1), and many of them are thought to cause disease by prolonging the cell cycle 
and affecting cell proliferation, particularly of neural progenitor cells, subsequently resulting 
in the reduction of total cell numbers throughout the body and brain (Klingseisen and Jackson, 
2011). The proteins encoded by these genes are frequently found to participate in several 
essential cellular processes, including DNA damage response (DDR) signalling, DNA replication, 
cell division and mRNA splicing (Table 1.1). The first gene identified to cause Seckel syndrome 
was ATR, encoding the Phosphotidyl-Inosine-3 Kinase (PI3K)-like Ataxia-Telangiectasia and 
Rad3-related kinase (O’Driscoll et al., 2003). ATR is a key DDR kinase that is activated in 
response to replication fork stalling by sensing single-stranded DNA (ssDNA) coated with 
Replication Protein A complex (RPA) (Cimprich and Cortez, 2008). A synonymous homozygous 
mutation in ATR that affected its splicing was identified as a disease-causing variant, resulting 
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in highly reduced levels of functional ATR protein and consequent defective H2AX 
phosphorylation following UV irradiation, which marks ATR-dependent DDR activation 
(O’Driscoll et al., 2003). Compound heterozygous mutations in ATRIP, encoding ATR-
Interacting Protein required for ATR stability and recruitment to DNA damage sites (Cortez et 
al., 2001), were also demonstrated as a cause of MPD via reduced ATRIP and ATR protein levels 
(Ogi et al., 2012). Furthermore, the first gene identified to cause primary microcephaly, 
microcephalin (MCPH1), was also shown to function in the ATR signalling pathway (Alderton 
et al., 2006). In recent years, several other DDR and DNA repair factors were also associated 
with MPD. Biallelic mutations in RBBP8, encoding CtBP-Interacting Protein (CtIP), were found 
to cause Seckel syndrome through impaired DNA end resection and ATR activation in response 
to DNA damage (Qvist et al., 2011). Additionally, mutations affecting XRCC4 and LIG4, 
components of the Non-Homologous End Joining (NHEJ) DNA double-strand break (DSB) repair 
pathway, were also demonstrated to cause MPD (Murray et al., 2015, 2014). More recently, 
homozygous missense and nonsense mutations in TRAIP, encoding an E3 ubiquitin ligase, were 
found to cause Seckel-like syndrome (Harley et al., 2016). Moreover, a large cohort of MPD 
patients with homozygous splicing or missense mutations in DONSON, which encodes a 
replication fork protection factor, were identified (Reynolds et al., 2017). These studies provide 
a strong link between defective DNA repair and severe reduction in human growth, and it is 
likely that other MPD-causing variants in DDR signalling factors will be identified in the future. 
 
Table 1.1. Primary microcephaly and microcephalic primordial dwarfism genes. 
Summary of primary microcephaly and microcephalic primordial dwarfism (MPD) genes, 
identified so far and given Mendelian Inheritance in Man (MIM) disorder code in Online 
































616171 PLK4 Centriole biogenesis Truncating Martin et al.  (2014) 
251270 TUBGCP6 Centriole biogenesis Truncating/ missense 
Puffenberger 
et al. (2012); 
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615414 PHC1 Cell cycle regulation, chromatin remodelling Missense 











































(CENPJ) Centriole biogenesis Splicing 
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Truncating Sir et al. (2011) 
614851 NIN 
Asymmetric cell division, 
component of 
centrosome 
Missense Dauber et al. (2012) 
210600 ATR DNA damage response signalling Splicing 
O’Driscoll et 
al. (2003) 
210600 ATRIP DNA damage response signalling Truncating 
Ogi et al. 
(2012) 
606744 RBBP8 DNA repair Splicing/ missense 
Qvist et al.  
(2011) 
615807 DNA2 DNA replication and repair Splicing 
Shaheen et 
al.  (2014) 
616777 TRAIP DNA damage response signalling 
Truncating/ 
missense 
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Kia et al. 
(2012) 
615789 CRIPT Cytoskeletal-membrane interactions Truncating 
Shaheen et 
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210710 RNU4ATAC mRNA splicing Missense 
Edery et al., 




Genes encoding subunits of the pre-Replication Complex (pre-RC), ORC1/4/6, CDC6, 
and CDT1, were identified as another functionally distinct group of MPD genes, causing Meier-
Gorlin syndrome (MGS) (Bicknell et al., 2011a, 2011b; Guernsey et al., 2011). This protein 
complex licenses DNA replication as it assembles on genomic DNA at origins of replication 
during late M and early G1 phase of the cell cycle, subsequently facilitating recruitment of the 
Mini-Chromosome Maintenance (MCM2-7) complex, which is a part of the replicative CMG 
(CDC45-MCM-GINS) helicase (Bochman and Schwacha, 2009). The MPD-associated partial loss-
of-function mutations in the ORC complex subunits are likely to lead to inefficient MCM 
loading, which then results in fewer replication origins being licensed. Indeed, patient-derived 
ORC1-deficient cells showed a subtle delay in G1/S transition and S phase progression, most 
likely because a certain number of fully licensed origins must be reached before a cell can enter 
S phase (Bicknell et al., 2011b). Efficient licensing of replication origins might become crucial 
during very rapid cell proliferation with shortened G1 phase, which occurs during mammalian 
development (Takahashi et al., 1995). Defective function of the replication licensing complex 
may then become a limiting factor, slowing cellular proliferation and consequently resulting in 
reduced cell number and a smaller individual. Further strengthening the link between 
defective DNA replication initiation and MGS, mutations in MCM5 (Vetro et al., 2017) and 
CDC45 (Fenwick et al., 2016), which encode subunits of the replicative CMG helicase, were also 
recently associated with this syndrome. Furthermore, MGS was also shown to be caused by 
dominant gain-of-function mutations in GMNN (Burrage et al., 2015), encoding CDT1 inhibitor 
geminin, which prevents the incorporation of the MCM complex into the pre-RC (McGarry and 
Kirschner, 1998; Wohlschlegel et al., 2000). The de novo GMNN mutations were shown to 
result in proteins lacking the destruction box, consequently leading to increased protein 
stability and impaired replication licensing (Burrage et al., 2015). Thus, DNA replication 
initiation is one of the cellular processes impaired in MPD, and other associated genes are likely 
to be identified as causative in the future.  
Dysfunctional centriole function and mitotic spindle defects represent another 
pathway leading to pathogenesis observed in microcephaly and MPD syndromes. Biallelic 
mutations associated with impaired cell division are more likely to disproportionately affect 
the brain size, resulting in prominent primary microcephaly (Table 1.1). In contrast, biallelic 
truncating mutations in PCNT cause equal reduction of both body and head size (Griffith et al., 
2008; Rauch et al., 2008). Mutations in this gene, which encodes the centrosomal protein 
pericentrin that facilitates formation of the mitotic spindle, resulted in failure to produce 
functional PCNT protein, thus impairing mitosis (Griffith et al., 2008; Rauch et al., 2008). 
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Additionally, MPD patients with mutations in PCNT had defects in ATR-dependent checkpoint 
signalling, linking this centrosomal protein to DDR (Griffith et al., 2008). Several genes playing 
key roles in centriole biogenesis were also associated with primary microcephaly and MPD, 
notably PLK4 (Martin et al., 2014), CENPJ (Bond et al., 2005; Leal et al., 2003) and CEP152 
(Guernsey et al., 2011; Kalay et al., 2011), strengthening the idea that slower cell cycle 
progression and inefficient mitosis could explain the reduced cell number and thus overall 
growth failure in MPD patients. 
Finally, another type of MPD, MOPD I, a condition with severe growth retardation and 
body malformations, was shown to be caused by loss-of-function mutations in RNU4ATAC, 
encoding a minor spliceosome component, the U4atac small nuclear RNA (snRNA) (Edery et 
al., 2011; He et al., 2011). U4atac is essential for splicing of atypical U12-type introns, which 
can be found in about 700 human genes that are involved in DNA replication and repair, 
transcription, mRNA processing, and translation (Sheth et al., 2006; Will and Lührmann, 2005). 
It is possible that defective splicing of certain U12 intron-containing transcripts could explain 
the phenotype of MOPD I patients. More recently, mutations in RNU4ATAC were also 
demonstrated to cause Roifman Syndrome through a characteristic compound heterozygosity 
pattern, with one variant always affecting U4atac elements already implicated in MOPD I 
(Merico et al., 2015). Although Roifman Syndrome is also characterised by poor pre- and 
postnatal growth, it is phenotypically distinct from MOPD I and is additionally associated with 
antibody deficiency, bone dysplasia and retinal dystrophy (Roifman, 1999). 
Recent improvements in next-generation sequencing technology greatly facilitated 
the discovery of new disease-associated genes, and it is likely that many novel primary 
microcephaly and MPD genes will be identified in the near future. Moreover, novel cellular 
processes may be implicated in MPD pathogenesis, and their identification will provide a more 








1.2. DNA replication 
 
1.2.1. Replication initiation, replisome assembly and replication elongation 
 
 As one of the fundamental processes of life, DNA replication has been a major focus 
of molecular biology studies from the very beginning of its discovery, although many aspects 
of it still remain to be defined. During each cell cycle, all genetic material of a cell has to be 
accurately copied once, and only once, for cell division to take place. DNA replication is a highly 
regulated and coordinated process that the cell has to perform flawlessly to ensure the survival 
of its genetic content. To accomplish the error-free copying of billions of base pairs, multiple 
specialised proteins are needed, some of which will be discussed in this section.  
 DNA replication is initiated in a multi-step process at replication origins, which provide 
a platform for assembly of a large group of proteins known as the pre-Replication Complex 
(pre-RC) (Parker et al., 2017) (Figure 1.1). During final stages of mitosis or G1 phase, the 
heterohexameric Origin Recognition Complex (ORC) binds the origin DNA in eukaryotic cells 
and, once joined by the helicase loader CDC6 and the chaperone CDT1, aids the head-to-head 
loading of inactive double heterohexamers of the Mini-Chromosome Maintenance 2-7 
(MCM2-7) replicative helicase complex (Riera et al., 2014). The presence of the core MCM 
complex renders chromatin ‘licensed’ for replication and the origin ready to be activated. As 
the binding of the human ORC complex is not restricted to specific DNA sequences, epigenetic 
mechanisms, such as nucleosome positioning and chromatin structure, have been suggested 
to play an important role in regulating replication initiation (Schaarschmidt et al., 2004; Vashee 
et al., 2003). More recently, ORC was indeed demonstrated to bind open chromatin regions 
with active chromatin marks, such as acetylated histone H3 and methylated H3 lysine 4 (Dellino 
et al., 2013; Miotto et al., 2016). Additionally, histone acetylase HBO1 (Feng et al., 2015; 
Miotto and Struhl, 2010), ATP-dependent chromatin remodeler SNF2H (Sugimoto et al., 2011; 
Zhou et al., 2005) and histone chaperone GRWD1 (Sugimoto et al., 2015) were also implicated 
in rearranging chromatin at replication origins and thus promoting MCM2-7 loading, 
replication licensing and initiation. Furthermore, RAP1-Interacting Factor 1 (RIF1)-directed 
protein phosphatase 1 (PP1) was shown to promote origin licencing by inhibiting premature 
phosphorylation and degradation of ORC1, as well as limit DNA replication by 
dephosphorylating the MCM complex subunits (Hiraga et al., 2017, 2014). However, it remains 
unclear how the loaded MCM complexes are selected for activation, as many of them are 
rendered functionally inactive in each cell cycle once they are passed by a replisome originated 
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at another locus (Santocanale et al., 1999). In each cell cycle, the selection of active MCM 
complexes is likely to be governed by a rather stochastic mechanism, where the MCM 
activation at some replication origins simply takes place earlier than at the others (Kelly, 2017). 
Once cells enter S phase, the downregulation, suppression or relocalisation of the pre-
RC complex components prevents DNA re-replication (Calzada et al., 2000; Labib et al., 1999; 
Nguyen et al., 2001, 2000). To initiate DNA replication, many replication fork proteins assemble 
on the pre-RC-bound replication origins to form the pre-initiation complex (pre-IC) (Figure 1.1). 
Two kinases, DDK (Dbf4-Dependent CDC7 Kinase) and S-CDK (S phase Cyclin-Dependent 
Kinase), phosphorylate MCMs and other replication fork proteins and promote recruitment of 
CDC45 (Cell Division Cycle 45) and the four-subunit complex GINS (Go-Ichi-Ni-San), which are 
essential for the conversion of the MCM2-7 complex into the fully active CMG (CDC45-MCM-
GINS) helicase capable of translocating on ssDNA (Heller et al., 2011; Yeeles et al., 2015). In 
addition to the protein kinases, the correct assembly and activity of the CMG helicase relies 
upon several other proteins, including RECQL4, Treslin and TOPBP1, which were shown to 
interact with DNA Polymerase epsilon (Pol ε) once it associates with the helicase (Araki et al., 
1995; Kamimura et al., 2001, 1998; Tanaka and Araki, 2013). The initial DNA unwinding and 
initiation of the replication bubble at an origin is driven by one additional protein, MCM10, 
which was demonstrated to bind MCM2, alter structural conformation of CMG and 
subsequently stabilise CDC45 and GINS association with the MCM complex, as well as facilitate 
replication elongation later on (Kanke et al., 2012; Lõoke et al., 2017; van Deursen et al., 2012; 
Watase et al., 2012). Once DNA is unzipped, ssDNA-binding Replication Protein A (RPA) is 
needed to protect the exposed ssDNA regions from winding back on itself and restrict 
formation of aberrant secondary structures (Chen et al., 2013). As the CMG helicase unzips the 
double helix, topological alterations due to the rotational motion of the enzyme generate 
supercoiled DNA ahead of the helicase, and specialised enzymes, called topoisomerases, are 





Figure 1.1. A model for the key events preceding eukaryotic replication initiation. 
During late mitosis and G1 phase of cell cycle, the inactive MCM2-7 helicase complex is 
recruited to origin DNA by the ORC proteins, CDC6 and CDT1 to form the pre-Replication 
Complex (pre-RC) (a). Origin activation in late G1/S phase involves the formation of pre-
Initiation Complex (pre-IC) and conversion of the MCM2-7 complex into the fully active CMG 
(CDC45-MCM-GINS) helicase (b, c). Assembly of pre-IC is facilitated by DDK- and S-CDK-
dependent phosphorylation of several replication factors, promoting their loading on 
replication origins. Activation of replicative helicase promotes recruitment of RFC, PCNA and 
RPA, which convert the pre-IC into two functional replisome-containing replication forks. Some 
licenced origins remain inactive, with their inhibition controlled by the DDR kinases ATR and 
ATM, as well as their substrates CHK1 and CHK2. Figure reproduced from Fragkos et al. (2015). 
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The activated ring-shaped CMG helicase is capable of acting as a motor for DNA 
synthesis by processively unwinding and separating strands of the parental DNA double helix 
to form a replication bubble. However, its activation is not enough, and multiple other proteins 
are recruited to generate a complete replisome at a replication fork, necessary for replication 
elongation. The recent pioneering work to reconstitute replication of naked DNA and 
chromatin in vitro facilitated identification of the factors that are strictly required for 
eukaryotic DNA replication to take place (Devbhandari et al., 2017; Kurat et al., 2017; Yeeles 
et al., 2017). Three DNA polymerases, Pol α, δ and Ɛ, play distinct essential roles during 
initiation and efficient continuation of DNA replication (Garg and Burgers, 2005; Johnson and 
O’Donnell, 2005). Due to the antiparallel nature of the DNA duplex strands, one of the strands, 
called the lagging strand, has to be synthesised discontinuously and multiple short Okazaki 
fragments ligated to produce a continuous strand. DNA Pol α-primase primes DNA synthesis 
de novo by generating a short tract of RNA complement to the template strand, which can 
subsequently be extended by the other two DNA polymerases (Arezi and Kuchta, 2000; Kunkel 
and Burgers, 2008). Before DNA ligase I can stitch the Okazaki fragments together to complete 
lagging strand synthesis, RNA primers need to be removed, which is thought to occur via strand 
displacement by the lagging-strand DNA Pol δ and subsequent nucleolytic cleavage of the 5’ 
flaps by nucleases FEN1 (for short flap processing) and DNA2 (for long flap processing) 
(Balakrishnan and Bambara, 2013). 
The other strand of the original DNA, called the leading strand, can be replicated 
continuously. It was shown in in vitro reconstitution experiments that fast replication of the 
leading strand at a rate comparable to the one required in vivo can only be achieved by DNA 
polymerase epsilon (Pol ε) and the processivity factor Proliferating Cell Nuclear Antigen (PCNA) 
(Devbhandari et al., 2017; Yeeles et al., 2017). While the CMG-associated Pol ε is responsible 
for the speedy replication of the leading strand, the sliding DNA clamp PCNA, which is 
deposited onto DNA by the five-subunit ATPase Replication Factor C (RFC), is needed to 
enhance processivity of the lagging-strand DNA Pol δ (Langston and O’Donnell, 2008). 
Moreover, PCNA provides a platform for recruitment of various replisome-associated proteins 
(Moldovan et al., 2007) and allows the switch between the Pol α-primase to a replicative 
polymerase during replication initiation (Garg and Burgers, 2005). After Okazaki fragment 
ligation is completed, PCNA is unloaded from chromatin by the ATPase ATAD5 and recycled 
(Kubota et al., 2015, 2013; Lee et al., 2013; Shiomi and Nishitani, 2013). 
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Pol δ was shown to be significantly slower in the reconstitution studies than Pol ε, 
although able to replace defective DNA Pol ε for the leading strand synthesis if required (Yeeles 
et al., 2017). Nevertheless, the speed of DNA Pol δ is sufficient for the completion of the lagging 
strand synthesis, and its strand displacement synthesis role is essential to successfully join 
nascent Okazaki fragments (Devbhandari et al., 2017). Reconstitution studies also suggested 
that replisome-associated factors Claspin and Timeless/Tipin contribute to the processivity and 
translocation rate of the CMG helicase, thus enhancing the speed of DNA replication (Yeeles 
et al., 2017). It was also demonstrated that the dimeric histone chaperone FACT is necessary 
for replication to take place, potentially due to its role in removing nucleosomes ahead of the 
replication fork (Kurat et al., 2017). Other chromatin factors, such as chaperone NHP6, 
chromatin remodelers INO80 and ISW1A, and histone acetyltransferases pNUA4 and pSAGA, 
also emerged as important players in proper and speedy replication fork movement (Kurat et 
al., 2017). Overall, the recent in vitro replication reconstitution studies (Devbhandari et al., 
2017; Kurat et al., 2017; Yeeles et al., 2017) shed light on the essential factors of the replication 
machinery, and provided a good starting point for future investigations into how the interplay 
and coordination between the multitude of proteins at the replisome is achieved. 
 
 
1.2.2. Replication termination and replisome disassembly 
 
When two convergent replication forks meet, DNA synthesis has to be completed, the 
replisome dismantled and the two DNA molecules separated. Eukaryotic replication 
termination is thought to happen in a few distinct steps (Dewar and Walter, 2017) (Figure 1.2). 
At first, the two replication forks moving towards each other converge, and DNA synthesis is 
then completed locally through gap filling and maturation of the last remaining Okazaki 
fragment. The replisomes are dismantled and the CMG helicase is extracted from chromatin 
by specialised proteins in a timely manner. Once the replicative helicase is disassembled, gaps 
in nascent DNA strands are promptly filled in by enzymes that carry out Okazaki fragment 
maturation, such as Pol δ, FEN1 and DNA2. Lastly, the introduced topological stress is resolved 




Figure 1.2. A model for the key events of eukaryotic replication termination. 
The model shown is based on experiments using X. laevis egg extracts. The convergence of two 
replisomes, where each CMG complex encircles ssDNA, introduces topological stress, which is 
relieved by the formation of pre-catenanes (a). Without detectable fork stalling, the 
converging CMG complexes bypass each other (b) and translocate onto dsDNA, allowing 
leading strands to be joined to the downstream Okazaki fragments (c). The processing of the 
final Okazaki fragment likely requires DNA Pol δ and flap endonuclease 1 (FEN1) (d). The 
dsDNA-encircling CMG is poly-ubiquitinated on its MCM7 subunit by specialised E3 ubiquitin 
ligases, SCFDIA2 (Skp, Cullin, F-box-containing complex associated with DIA2) in S. cerevisiae or 
CRL2LRR1 (Cullin RING ligase 2 associated with LRR1) in C. elegans and X. laevis, followed by 
p97/CDC48-mediated CMG extraction from chromatin (e). Finally, catenanes are removed and 





In Saccharomyces cerevisiae, the termination sites were shown to be largely 
influenced by replication initiation patterns, rather than specific genomic sequences 
(McGuffee et al., 2013). During artificially synchronised locus-specific termination events in 
clawed frog (Xenopus laevis) egg extracts, replication fork convergence takes place without a 
noticeable change in replication fork speed (Dewar et al., 2015), suggesting that topological 
stress gets resolved very efficiently during this termination step. When the two replisomes 
encounter each other in X. laevis egg extracts, the converging CMG helicases bypass each other 
without any hindrance and pass onto double-stranded DNA (dsDNA), followed by the ligation 
of leading strands to downstream lagging strands (Dewar et al., 2015). The removal of the CMG 
helicase from chromatin is considered to be one of the key events in eukaryotic replication 
termination, and one of the requirements for it to take place appears to be poly-ubiquitination 
of the CMG helicase component MCM7 (Fullbright et al., 2016; Long et al., 2014; Semlow et 
al., 2016). Several E3 ubiquitin ligases were recently demonstrated to play an important role 
in the CMG unloading during replication termination. The E3 ubiquitin ligase SCFDIA2 (Skp, 
Cullin, F-box-containing complex associated with DIA2) was shown to promote both MCM7 
poly-ubiquitination and CMG extraction from chromatin in S. cerevisiae (Maric et al., 2014), 
whereas CRL2LRR1 (Cullin RING ligase 2 associated with LRR1) was implicated in the same 
process in Caenorhabditis elegans and X. laevis (Dewar et al., 2017; Sonneville et al., 2017). 
Ubiquitinated CMG acts as a substrate for the ATPase and protein remodeler p97/CDC48, 
which extracts the CMG helicase from DNA (Maric et al., 2014; Moreno et al., 2014). In X. laevis 
egg extracts, the proteasome does not play any significant role in the turnover of ubiquitinated 
MCM7, suggesting degradation-independent MCM7 deubiquitination and recycling (Fullbright 
et al., 2016). The lack of CRL2LRR1 in C. elegans causes CMG to remain on chromatin until 
prophase, when it gets removed by an alternative pathway orchestrated by p97 and UBXN3 
(UBX domain-containing 3), the C. elegans orthologue of human FAF1 (FAS-Associated Factor 
1) (Sonneville et al., 2017). Combined absence of LRR1 and UBXN3 obliterates both replisome 
unloading pathways, leaves CMG bound to chromatin until metaphase and is synthetic lethal, 
showing that replisome disassembly and removal from chromatin is essential for cell viability 
(Sonneville et al., 2017). It is yet to be determined whether a mitotic CMG unloading pathway 
is present in vertebrates, which E3 ubiquitin ligase is responsible for CMG unloading in 




The importance of the timely replisome disassembly is exemplified by the synthetic 
lethality due to inhibition of both replisome unloading pathways (Sonneville et al., 2017). 
Additionally, premature helicase removal, which could lead to replication fork stalling and 
collapse, should also be avoided. The main physical trigger for the CMG unloading has not been 
firmly established yet. One of the proposed hypotheses suggests that the terminating CMG 
helicase senses dsDNA within its central channel when encountering a downstream Okazaki 
fragment, which induces structural changes in the CMG complex and facilitates the 
recruitment or activation of the E3 ubiquitin ligase that ubiquitinates MCM7 (Dewar and 
Walter, 2017). This model would provide an explanation for the cell adaptation to allow CMG 
unloading only once dsDNA is encircled, thus preventing the early removal of CMG from active 
replication forks, where the helicase translocates on ssDNA (Fu et al., 2011). If this hypothesis 
is confirmed, cells should additionally be able to distinguish between the terminating CMG 
complexes and newly licensed MCM2-7 helicases in the G1 phase, which also encircle dsDNA. 
This could be achieved by preventing the CMG unloading when CDC45 and/or GINS bound to 
MCM2-7 are detected, or when MCM2-7 complexes are dimerised, as during replication 
licencing (Dewar and Walter, 2017). Moreover, the CMG complex should be prevented from 
translocating along dsDNA for extended distances before gap filling takes place, as 
encountering a downstream Okazaki fragment with a 5’ flap may initiate genome re-replication 
(Dewar and Walter, 2017). Indeed, the C. elegans E3 ubiquitin ligase CRL2LRR1 was shown to be 
necessary to supress re-replication (Merlet et al., 2010), reiterating the importance of the E3 
ubiquitin ligases in eukaryotic replication termination and maintenance of genome stability. In 
the future, it will be important to determine whether re-replication of parts of the genome in 




1.2.2.1. Replisome disassembly during interstrand crosslink repair 
 
Active disassembly of replisome also takes place when replication forks stall at DNA 
roadblocks, such as DNA Interstrand Crosslinks (ICLs) (Fu et al., 2011; Long et al., 2014). ICLs 
are defined as covalent links between the two strands of the double helix, creating a physical 
obstacle for cellular processes that require DNA strand separation, notably DNA replication 
and transcription (see Section 1.3.5). To repair the highly toxic ICLs, CMG needs to be unloaded 
from chromatin, and its unloading mechanism at ICLs differs from the conventional CMG 
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unloading during replication termination (Dewar and Walter, 2017). Although the requirement 
for MCM7 poly-ubiquitination and p97-mediated CMG extraction is conserved, the replisome 
disassembly mechanism at ICLs acts on CMG complexes that encircle ssDNA on both sides of a 
lesion (Fullbright et al., 2016). Moreover, in contrast to termination-promoting CMG 
unloading, the heterodimeric complex comprising BRCA1, the tumour suppressor protein and 
homologous recombination (HR) factor, and BARD1 (BRCA1-Associated RING Domain protein 
1) is also necessary for stalled CMG unloading to initiate cisplatin-induced ICL repair in X. laevis 
egg extracts (Fullbright et al., 2016; Long et al., 2014). Ubiquitin signalling is required to recruit 
BRCA1 to the cisplatin-ICL sites and promote removal of the replicative helicase, allowing the 
extension of leading strands towards the DNA damage site, as well as subsequent FANCI- and 
FANCD2-dependent endonucleolytic cleavage at the crosslink, lesion bypass, and DSB repair 
(Long et al., 2014). Although no direct proof for BRCA1-BARD1-dependent CMG ubiquitination 
was provided by Long et al. (2014), their observation supports the previously proposed early 
HR-independent role of BRCA1 at ICLs before DSB formation (Bunting et al., 2012). Although 
CRL2LRR1 was identified as the E3 ligase that promotes replication termination in vertebrates 
(Dewar et al., 2017), the E3 ligase that initiates CMG removal from chromatin in response to 















1.3. Replication stress, DNA damage response and DNA repair 
 
1.3.1. Replication stress and the ATR-CHK1 signalling cascade 
 
To combat threats posed by DNA damage, cells have evolved mechanisms – 
collectively termed the DNA damage response (DDR) – to detect DNA lesions, signal their 
presence and promote their repair, thus ensuring genomic stability. Replication stress 
describes the events that take place in cells exposed to a wide variety of endogenous and 
exogenous stresses, resulting in the slowing or stalling of replication fork progression and DNA 
synthesis (Branzei and Foiani, 2010; Osborn et al., 2002). Sources of replication stress include 
but are not limited to unrepaired DNA lesions, nicks and gaps, repetitive sequences, 
misincorporated ribonucleotides, secondary DNA structures, DNA–RNA hybrids, dormant 
replication origins, collisions between replication and transcription complexes, chromatin 
inaccessibility, fragile sites, and overexpression or constitutive activation of oncogenes 
(Mazouzi et al., 2014; Zeman and Cimprich, 2014). The replisome is not only extremely efficient 
at carrying out fast and accurate genome replication, but is also well adapted to overcome 
various replication barriers along the way, which can result in replication stress (Leman and 
Noguchi, 2013). Nevertheless, chronic stress or disruption of the major cell signalling pathways 
that respond to replication stress can lead to the emergence of genomic instability, one of the 
main hallmarks of cancer (Gaillard et al., 2015). To resolve problematic DNA structures or 
lesions obstructing the replication machinery, a complex network of signalling pathways is 
required, leading either to the repair of the lesion, followed by normal cell cycle progression, 
or to programmed cell death (apoptosis) (Mazouzi et al., 2014).  
One of the key proteins that mediate the cellular response to replication stress is PI3K-
related serine-threonine protein Kinase (PIKK) Ataxia Telangiectasia and Rad3-related (ATR). 
Replication stress can result in replication fork stalling, which involves pausing of an ongoing 
replication fork due to inhibition of either the replicative helicase or polymerase (Labib and 
Hodgson, 2007). Replication stress-induced fork stalling often leads to the generation of 
extensive regions of ssDNA, as the replicative helicase continues to unwind the parental DNA 
after the polymerase has stalled (Pacek and Walter, 2004). ATR is the major kinase that initiates 
a phosphorylation-based signalling cascade to mediate the cellular response to such ssDNA 
stretches (López-Contreras and Fernandez-Capetillo, 2010). The ATR signalling pathway is 
initiated when ATR is activated at sites of RPA-coated ssDNA in a multi-step process (Saldivar 
et al., 2017) (Figure 1.3). Firstly, RPA recruits ATR binding partner and substrate ATR-
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Interacting Protein (ATRIP) (Cortez et al., 2001); secondly, RPA promotes accumulation of the 
ATR–ATRIP complex at sites of DNA damage and stalled replication forks (Ball et al., 2005). 
Thirdly, RPA recruits RAD17–RFC2–5 (replication factor C subunits 2–5) clamp loader, which is 
necessary to position the heterotrimeric RAD9–RAD1–HUS1 (9-1-1) complex on chromatin in 
response to genotoxic damage (Parrilla-Castellar et al., 2004; Zou et al., 2003). The 9-1-1 
complex is essential for recruitment and positioning of TOPBP1 (DNA Topoisomerase II Binding 
Protein) (Bermudez et al., 2003), which activates the ATR–ATRIP complex (Kumagai et al., 
2006). Additionally, TOPBP1 recruitment to chromatin is influenced by RHINO (RAD9–RAD1–
HUS1-Interacting Nuclear Orphan) (Cotta-Ramusino et al., 2011; Lindsey-Boltz et al., 2015) and 
the MRE11–RAD50–NBS1 (MRN) complex (Duursma et al., 2013; Lee and Dunphy, 2013). More 
recently, Ewing Tumor-Associated Antigen 1 (ETAA1) was established as a novel ATR activator, 
in addition to and independent of TOPBP1 (Bass et al., 2016; Haahr et al., 2016; Lee et al., 
2016; Feng et al., 2016). The subsequent ATR activation was shown to be dependent on a single 
auto-phosphorylation event at threonine 1989 (T1989) (Liu et al., 2011). 
 
 
Figure 1.3. Main components of the ATR activation pathway. 
Replication fork stalling on the lagging strand results in a stretch of RPA-bound ssDNA, 
generating a platform for ATR activation. The RAD9–RAD1–HUS1 (9-1-1) clamp complex is 
loaded at the 5’-ended ssDNA–dsDNA junctions by the RAD17–RFC2–5 clamp loader. The 9-1-
1 complex, acting together with RHINO and the MRE11–RAD50–NBS1 (MRN) complex, recruits 
the ATR activator TOPBP1, allowing activation of ATR and phosphorylation of its downstream 
effectors, including CHK1 kinase. ETAA1 bound to RPA activates ATR in a parallel TOPBP1-
independent pathway. Figure reproduced from Saldivar, Cortez and Cimprich (2017). 
 
Globally, ATR signalling provides cells experiencing replication stress with additional 
time for DNA repair and ensures the continuation of DNA synthesis in the presence of stalled 
replication forks; locally, it stabilises and promotes restart of stalled forks and supresses 
recombination (Cimprich and Cortez, 2008; Zeman and Cimprich, 2014) (Figure 1.4a). The key 
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event in the ATR signalling cascade is ATR-dependent phosphorylation of CHeckpoint Kinase 1 
(CHK1) at serine 345 (S345) and its consequent activation (Q. Liu et al., 2000; Patil, Pabla and 
Dong, 2013). Thus, elevated levels of ATR-dependent pCHK1-S345 signal, as well as direct 
detection of ssDNA through native BrdU immunofluorescence, are considered to be good 
readouts of replication stress (Maréchal and Zou, 2013; Nam and Cortez, 2013). Although 
phosphorylation of the histone variant H2AX at serine 139 (γH2AX) can also be used as a 
replication stress marker (Ward et al., 2004; Ward and Chen, 2001), H2AX is also 
phosphorylated by several other kinases in response to DSBs (Wang et al., 2005), making it a 
less specific readout of replication stress.  
One of the main consequences of CHK1 activation is the inhibition of cell cycle 
progression, allowing sufficient time for DNA repair before replication or mitosis resumes. It is 
achieved through CHK1-regulated inhibitory phosphorylation of Cyclin-Dependent Kinases 
(CDKs) (López-Contreras and Fernandez-Capetillo, 2010), which play a major role in cell cycle 
control. Moreover, CHK1-mediated phosphorylation of the CDC25 phosphatases, CDC25A, 
CDC25B and CDC25C, which control the G1/S and G2/M transitions through dephosphorylation 
and activation of CDKs (Blomberg and Hoffmann, 1999; Hoffmann et al., 1994; Mailand et al., 
2002), leads to their proteasome-mediated degradation and cell cycle arrest (Jin et al., 2003; 
Xiao et al., 2003). 
ATR-CHK1 signalling also suppresses late origin firing to limit the total number of active 
replication forks and ensure sufficient supply of DNA precursors and replication factors, 
necessary for fork progression (Katsuno et al., 2009). Replication initiation in response to 
replication stress can be inhibited by preventing CDC45 recruitment to the MCM complex via 
CHK1-mediated phosphorylation of Treslin (Guo et al., 2015). Moreover, ATR-CHK1 pathway 
activation prevents CDC45 loading and replicative helicase activation by downregulating the 
kinase activities of S-CDK and DDK via CHK1-dependent phosphorylation of CDC25A, triggering 
its rapid degradation and CDK inhibition (Mailand et al., 2000; Zhao et al., 2002). Additionally, 
ATR-mediated activation of CHK1 allows it to inhibit new origin firing (Toledo et al., 2013). This 
suppression of new origins in the presence of replication stress prevents exhaustion of nuclear 
RPA by limiting the number of stalled forks that need to be coated by RPA (Toledo et al., 2013). 
When ATR signalling is disrupted, dormant origins fire, the arising ssDNA rapidly depletes 
nuclear RPA and results in stretches of unprotected ssDNA, which subsequently cause DSB 





Figure 1.4. The ATR-mediated replication stress response, fork rescue, and fork collapse. 
a) ATR and its binding partner ATRIP are activated at the stalled replication fork, where ATR 
promotes a signalling cascade via phosphorylation and activation of its effector kinase CHK1. 
The ATR-CHK1 signalling axis facilitates stabilisation and restart of stalled forks, inhibits cell 
cycle progression and supresses late origin firing and recombination until replication stress is 
resolved.  
b) ATR-dependent stabilisation of stalled replication forks can promote their restart via several 
mechanisms, including dormant origin firing, replication re-priming, fork reversal, or activation 
of the DNA damage tolerance (DDT) pathways. Red star indicates a DNA lesion. 
c) The lack of stabilisation of stalled replication forks will result in their collapse, preventing 
replication restart. The possible mechanisms of replication fork collapse include dissociation 
of replisome components, aberrant nuclease digestion of a reversed or stalled fork or 
replication run-off. 
Figure reproduced from Zeman and Cimprich (2014). 
 
Replication fork reversal occurs when a typical three-arm replication fork is converted 
into a four-way junction (‘chicken-foot’ structure) by the annealing of the two newly 
synthesized strands to form a ‘regressed’ arm (Neelsen and Lopes, 2015). One of the ATR 
functions is to prevent nuclease-mediated cleavage of stalled replication forks by regulating 
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fork reversal. For example, ATR-dependent phosphorylation of the DNA translocase 
SMARCAL1 was shown to inhibit its ability to reverse forks in vitro, thus preventing excessive 
fork remodelling and suppressing fork collapse in cells (Couch et al., 2013). In ATR-deficient 
cells, structure-specific SLX4-dependent endonucleases SLX1, XPF, MUS81-EME1 and GEN1 
were proposed to process the reversed replication forks, leading to the formation of DSBs 
(Couch et al., 2013; Ragland et al., 2013). This may occur due to premature CDK-dependent 
upregulation of these endonuclease complexes, which normally act in the G2/M phase to 
resolve under-replicated loci and Holliday junctions, the four-way DNA intermediates formed 
during HR (Wyatt et al., 2013). CHK1 itself is also involved in stabilising stalled replication forks, 
as its inhibition results in fork collapse dependent on the endonuclease MUS81 (Forment et 
al., 2011; Murfuni et al., 2013; Técher et al., 2016). Finally, upon replication fork stalling, the 
ATR-CHK1 pathway was shown to activate the CDC7–ASK kinase complex, promoting efficient 
lesion bypass repair and preventing fork collapse (Yamada et al., 2013). Overall, the ATR-CHK1 
signalling axis stabilises stalled replication forks, prevents their collapse and facilitates their 
restart, ensuring genome stability. 
 
 
1.3.2. Collapsed replication forks and the ATM-CHK2 signalling cascade 
 
Once replication stress is resolved, replication forks stabilised by the ATR-CHK1 
pathway can be restarted (Petermann and Helleday, 2010) (Figure 1.4b). Additional time for 
the removal of DNA lesions can be gained by the reversal of stalled replication forks, generating 
a ‘chicken foot’ structure (Ray Chaudhuri et al., 2012) (Figure 1.4b). However, some restart 
mechanisms are active even when the stress cannot be resolved to prevent prolonged 
replication fork stalling and collapse. Collectively known as DNA damage tolerance (DDT), 
these processes result in the bypass of the unrepaired DNA lesion using either specialised 
TransLesion Synthesis (TLS) DNA polymerases or the sister chromatid as a template (template 
switching) (Gao et al., 2017) (Figure 1.4b). However, collapse of some stalled forks may occur 
in the presence of ongoing replication stress (Petermann et al., 2010), when they can no longer 
be efficiently stabilised by the ATR-CHK1 pathway components (Carr et al., 2011; Segurado and 
Diffley, 2008).  
Fork collapse is defined as a lost capacity of a replication fork to perform DNA 
synthesis, often resulting from the failure to stabilise stalled replication forks, leading to 
replisome dissociation and formation of DSBs (Cortez, 2015; Zeman and Cimprich, 2014) 
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(Figure 1.4c). Fork collapse poses a danger to cell viability, as a DSB at the replication fork can 
be formed either via aberrant structure-specific nuclease-mediated cleavage of reversed forks 
or failed HR-mediated replication restart (Hanada et al., 2007; Petermann et al., 2010; 
Segurado and Diffley, 2008) (Figure 1.4c). Moreover, persisting stretches of unprotected 
ssDNA, resulting from prolonged replication fork stalling, may also be cleaved by 
endonucleases or undergo spontaneous breakage, leading to the generation of a DSB (Lopes 
et al., 2006, 2001; Sogo et al., 2002) (Figure 1.4c). The presence of DSBs, which can also be 
induced by exogenous DNA damaging agents, such as ionising radiation (IR), leads to the 
activation of two other DDR kinases of the PIKK family: Ataxia Telangiectasia Mutated (ATM) 
and DNA-dependent Protein Kinase (DNA-PK) (Ciccia and Elledge, 2010). 
ATM is the main signal transducer at DSBs, and ATM-mediated phosphorylation of its 
substrates promotes DNA repair, cell cycle arrest or apoptosis (Lavin, 2008; Shiloh, 2003) 
(Figure 1.5). Like ATR, ATM activation is a multi-step process. The heterotrimeric MRN complex 
and the MDC1 (Mediator of DNA Damage Checkpoint 1) adaptor protein are initial sensors of 
DSBs (Coster and Goldberg, 2010; van den Bosch et al., 2003), and their accumulation 
facilitates recruitment of ATM, which binds MDC1 (Lou et al., 2006) and NBS1 (Cerosaletti et 
al., 2006; You et al., 2005). ATM is activated by dissociation of the inactive ATM homodimer 
and trans-autophosphorylation at five residues (S367, T1885, S1893, S1981, and S2996) 
(Bakkenist and Kastan, 2003; Kozlov et al., 2011), as well as acetylation of lysine 3016 (K3016) 
by the histone acetyltransferase TIP60 (Sun et al., 2007). Histone variant H2AX (Burma et al., 
2001) and MDC1 (Luo et al., 2011; Matsuoka et al., 2007) are phosphorylated in an ATM-
dependent manner, and form a scaffold to ensure the retention of DNA damage repair proteins 
on chromatin. MDC1 also recruits the ubiquitin ligase RNF8 (RING-finger protein 8), which 
ubiquitinates H2AX to promote recruitment of BRCA1 (breast cancer susceptibility protein 1) 
and 53BP1 (p53 Binding Protein 1) at the DSB (Huen et al., 2007; Kolas et al., 2007; Mailand et 
al., 2007), both of which are also phosphorylated by ATM (Gatei et al., 2000; Rappold et al., 
2001). One of the key substrates of the ATM kinase activity is CHeckpoint Kinase 2 (CHK2) 
(Bartek et al., 2001; McGowan, 2002). Both ATM and CHK2 phosphorylate tumour suppressor 
p53, disrupting its interaction with the ubiquitin ligase MDM2 (Mouse Double Minute 2), the 
inhibitor of p53 (Chen et al., 2005). Thus, the ATM-CHK2 signalling axis facilitates activation 
and stabilisation of p53, promoting G1/S checkpoint activation (Senturk and Manfredi, 2013). 
Additionally, ATM- and CHK2-dependent phosphorylation of the CDC25A phosphatase inhibits 
its activity, preventing the dephosphorylation of CDK2 and leading to a transient arrest of DNA 
replication (Falck et al., 2001). Finally, ATM signalling also directly influences DSB repair 
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pathway choice via phosphorylation of two breast cancer susceptibility proteins, BRCA1 (Lee 
et al., 2000) and BRCA2 (Bahassi et al., 2008), promoting homologous recombination (HR) over 
Non-Homologous End Joining (NHEJ) (see Section 1.3.3). 
 
 
Figure 1.5. ATM signalling in response to DNA double-strand breaks. 
DNA DSBs are sensed by the MRN complex, followed by recruitment and activation of ATM. 
ATM also interacts with and phosphorylates other sensor proteins, MDC1 and histone variant 
H2AX, which create a platform for rapid accumulation of other DNA repair factors at the DSB 
sites. One of the main effectors of ATM is the kinase CHK2, phosphorylated in an ATM-
dependent manner at threonine 68 (T68), which in turn phosphorylates its own substrates, 
resulting in cell cycle arrest. ATM and CHK2 also activate and stabilise tumour suppressor p53 
via negative regulation of its inhibitor MDM2. Other effectors of ATM include KRAB-associated 
protein 1 (KAP1), which promotes chromatin relaxation to facilitate recruitment of DNA repair 
factors, and AKT kinase, which promotes cell survival. ATM pathway also facilitates BRCA1-




1.3.3. DNA double-strand break repair and pathway choice 
 
Accurate repair of DSBs is essential for the maintenance of genomic integrity, as the 
aberrant joining of DNA ends can lead to gross chromosomal rearrangements and genomic 
instability (Brandsma and Gent, 2012). The two major pathways eliminating these DNA lesions 
are NHEJ and HR (Figure 1.6). The intrinsically mutagenic NHEJ pathway, which is active 
throughout the cell cycle and predominantly used in the G1 phase, relies on co-joining and 
ligating the broken DNA ends (Chiruvella et al., 2013). In contrast, the error-free HR pathway 
50 
 
is restricted to S and G2 phase, where the sister chromatid is available to act as a template 
(Thompson and Schild, 2001). The molecular mechanism of DSB repair pathway choice has 
been extensively studied, and it has become clear that DNA end resection at a break is a major 
factor favouring HR repair (Chapman et al., 2012; Symington and Gautier, 2011). Several 
distinct nucleases were demonstrated to process DNA ends at DSBs: the DSB repair protein 
MRE11, a component of the MRN complex, initiates short-range resection together with CtIP, 
whereas the 5’-3’ exonuclease EXO1 and the ATP-dependent helicase/nuclease DNA2, acting 
together with BLM helicase, perform long-range resection (Daley and Sung, 2014; Mimitou and 
Symington, 2011; Niu et al., 2009). The exposed 3’ DNA overhangs are immediately coated by 
RPA to inhibit formation of DNA hairpins (Chen et al., 2013) (Figure 1.6). The major facilitator 
of HR is the RAD51 recombinase, which displaces ssDNA-bound RPA to form RAD51-ssDNA 
nucleoprotein filaments (Figure 1.6). The main function of the RAD51 nucleofilament is to 
search for and pair with a homologous sequence elsewhere in the genome to form a 
heteroduplex displacement DNA (D-loop), where DNA synthesis takes place to repair a DSB 
(Brandsma and Gent, 2012; Krejci et al., 2012; Sung and Robberson, 1995). Accommodation of 
both the invading and donor ssDNA strands within the filament leads to the formation of 
RAD51-dsDNA filament, and once RAD51 is released from dsDNA, it exposes the 3’-hydroxyl as 
a primer for DNA synthesis (Krejci et al., 2012). The D-loop is finally resolved either via the 
synthesis-dependent strand annealing (SDSA) pathway or via migrating double Holliday 
junction intermediates, which are either dissolved by the BLM–RMI–TOP3α complex or 
processed by resolvases (Panier and Boulton, 2014). 
Meanwhile, classical NHEJ is initiated by the rapid binding of the Ku70/80 heterodimer 
to the non-resected DNA ends (Fell and Schild-Poulter, 2015) and the recruitment of DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) (Davis et al., 2014), which belongs to 
the PIKK family (Figure 1.6). DNA-PKcs maintains the broken DNA ends in close proximity and 
recruits end-processing factors, such as Artemis, PolyNucleotide Kinase/Phosphatase (PNKP), 
AP Endonuclease 1 (APE1) and Tyrosyl–DNA Phosphodiesterase 1 (TDP1), necessary to 
generate DNA ends that can be ligated by the protein complex containing XRCC4 (X-ray Repair 
Cross-Complementing protein 4), XLF (XRCC4-Like Factor), and LIG4 (DNA Ligase 4) (Davis et 






Figure 1.6. Non-homologous end joining and homologous recombination in DNA double-
strand break repair. 
Repair of DSBs is primarily co-ordinated by 53BP1, which promotes Non-Homologous End 
Joining (NHEJ), and BRCA1, CtIP and MRN, which facilitate homologous recombination (HR). 
NHEJ starts with recognition of the DNA ends by the Ku70/80 heterodimer, which recruits DNA-
PKcs kinase. Once the DNA ends are processed by nucleases, such as Artemis, the XRCC4–XLF–
LIG4 ligation complex can seal the break. In HR, primarily co-ordinated by BRCA1, MRN and 
CtIP initiate DNA end resection at DSBs to generate ssDNA overhangs and inhibit the NHEJ 
repair pathway. The ssDNA stretches are first coated by RPA, followed by its subsequent 
BRCA2-mediated replacement by RAD51 nucleoprotein filaments, which mediate strand 
invasion on the homologous template. Extension of the heteroduplex DNA (D-loop) and 




Several proteins were shown to strongly influence the balance between the NHEJ and 
HR repair pathways. The onset of DNA end resection was proposed to be primarily controlled 
by two factors that functionally antagonise each other: the ATM kinase substrate 53BP1 and 
the tumour suppressor BRCA1, implicated in homology-directed repair (Daley and Sung, 2014) 
(Figure 1.7). 53BP1 is known to suppress the nucleolytic processing of DNA termini, thus 
preventing HR (Hustedt and Durocher, 2017; Panier and Boulton, 2014). The accumulation of 
53BP1 at DNA damage foci is dependent on PIKK-induced H2AX phosphorylation (Fernandez-
Capetillo et al., 2002; Ward et al., 2003), which in turn stimulates recruitment of the E3 
52 
 
ubiquitin ligases RNF8 and RNF168 (Doil et al., 2009; Huen et al., 2007; Kolas et al., 2007; 
Mailand et al., 2007; Stewart et al., 2009) to initiate histone ubiquitination at DSBs. The 
retention of 53BP1 at damaged chromatin is thought to occur via its interaction with 
constitutive chromatin marks that get exposed upon histone ubiquitination, such as histone 
H4 di-methylated on lysine 20 (H4K20me2) (Botuyan et al., 2006) (Figure 1.7). RIF1 was 
identified by multiple studies as an effector of 53BP1, shown to be required for NHEJ and 
removed from DSBs in the S/G2 phase in a BRCA1- and CtIP-dependent manner (Chapman et 
al., 2013; Di Virgilio et al., 2013; Escribano-Díaz et al., 2013; Zimmermann et al., 2013). 53BP1 
also recruits REV7/MAD2L2 to the break sites (Boersma et al., 2015; G. Xu et al., 2015) and 
interacts with PTIP (Munoz et al., 2007), which recruits nuclease Artemis to prevent DNA end 
resection and promote NHEJ (Wang et al., 2014) (Figure 1.7). More recently, a novel 53BP1 
effector complex, shieldin, constituting of SHLD1, SHLD2, SHLD3 and REV7, was reported by 
multiple laboratories to localise to DSBs in a 53BP1- and RIF1-dependent manner and protect 
DNA ends from hyper-resection (Dev et al., 2018; Ghezraoui et al., 2018; Gupta et al., 2018; 
Mirman et al., 2018; Noordermeer et al., 2018).  
In S phase, BRCA1 is thought to promote dissociation of NHEJ proteins, such as 53BP1, 
from DSBs to facilitate DNA end resection and HR (Bunting et al., 2010) (Figure 1.7). In cells 
without BRCA1, DNA end resection in S phase is dysfunctional and aberrant NHEJ takes place 
at replication-associated DSBs instead, contributing to genomic instability (Bouwman et al., 
2010; Bunting et al., 2010; Daley & Sung, 2014). More recently, BRCA1 was also demonstrated 
to promote 53BP1 dephosphorylation, which subsequently leads to RIF1 release and promotes 
DNA end resection (Isono et al., 2017). The DNA endonuclease CtIP was shown to be the major 
mediator of the switch between accumulation of 53BP1 in G1 and BRCA1 in the S/G2 phases 
of the cell cycle. CtIP physically and functionally interacts with the MRN complex to promote 
DNA end resection at DSBs, as well as RPA and ATR recruitment to these lesions through 
stimulation of MRE11 endonuclease activity (Sartori et al., 2007; Shibata et al., 2014). CDK-
mediated phosphorylation of CtIP at threonine 847 was demonstrated to be required for the 
initiation of DNA end resection (Huertas and Jackson, 2009). Histone ubiquitination at DSBs 
was also implicated in the recruitment of BRCA1 and BARD1. For example, the RNF20-RNF40 
heterodimer of RING finger E3 ubiquitin ligases, which mono-ubiquitinate histone H2B (Moyal 
et al., 2011), promote BRCA1 recruitment by facilitating histone eviction and nuclease-
mediated processing of DNA termini (Daley and Sung, 2014). RAP80 (Receptor-Associated 
Protein 80) and its associated proteins were implicated in targeting the BRCA1-BARD1 complex 
to ubiquitin marks on chromatin (Sobhian et al., 2007; Wang et al., 2007). Although RNAi-
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mediated depletion of RAP80 led to the reduction in BRCA1 foci, it was also found to increase 
the frequency of HR (Hu et al., 2011), suggesting that RAP80 may be important to inhibit 




Figure 1.7. The 53BP1–BRCA1 network regulates repair pathway choice at DNA double-
strand breaks. 
53BP1 acts as the main suppressor of the HR pathway for DSB repair, which is achieved by its 
recruitment of the downstream regulators RIF1, REV7 and PTIP. These factors inhibit DNA end 
resection via their recruitment of nuclease Artemis, which processes potentially 
recombinogenic ssDNA tracts at the lesion site. 53BP1 is antagonised by multiple factors in 
several different ways: competition for chromatin binding sites (JMJD2A, L3MBTL, RNF169), 
inhibition of 53BP1 recruitment (TIP60, TIRR), inhibited recruitment of downstream 
modulators of 53BP1 (SCAI), or degradation of 53BP1 (Ubch7). BRCA1 is recruited to DSBs via 
RAP80 and activated to promote HR via its interaction with ZMYM3. Additionally, BRCA1 
antagonises 53BP1 through recruitment of UHRF, which ubiquitinates RIF1, thus preventing it 
from being stably retained at the break site. Figure reproduced from Her and Bunting (2018). 
 
 
1.3.4. TOP1 inhibition and repair of TOP1-mediated DNA damage 
 
Covalent DNA–protein crosslinks (DPCs), also referred to as protein adducts, create 
bulky obstructions to DNA replication and transcription and are highly toxic to cells, requiring 
specialised removal pathways (Stingele et al., 2017). Platinum derivatives that are widely used 
in cancer therapy, such as cisplatin, cause non-enzymatic DPCs by non-specific crosslinking of 
chromatin-interacting proteins to DNA (Chválová et al., 2007). Meanwhile, certain 
chemotherapeutic agents, such as camptothecin, etoposide and olaparib, selectively trap 
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specific enzymes on DNA: DNA topoisomerases I and II and poly(ADP-ribose) polymerase 1 
(PARP1), respectively (Murai et al., 2012; Pommier and Marchand, 2012). 
Mammalian type IB DNA topoisomerase I (TOP1) is an enzyme that relaxes supercoiled 
DNA via transient cleaving and re-joining of one strand of the DNA duplex (Wigley, 1995), thus 
supporting replication fork movement during DNA replication. TOP1 introduces a single-strand 
break (SSB) via transesterification at a target DNA site, and the resulting phosphodiester and 
the catalytic tyrosine of TOP1 form a DNA-(3'-phosphotyrosyl)-enzyme intermediate (TOP1 
cleavage/covalent complex, or Top1cc) (Pommier, 2013) (Figure 1.8). The released DNA strand 
can freely rotate around the intact strand, thus removing torsional tension generated during 
DNA replication or transcription. Lastly, re-ligation takes place, where the 5'-hydroxyl of the 
terminal deoxyribonucleotide attacks the ternary intermediate to expel the catalytic tyrosine, 
restoring the DNA phosphodiester backbone (Pommier, 2013).  
Camptothecin (CPT) is an anti-tumour agent, which was discovered in 1966 in a 
screening of natural products for anti-cancer drugs and isolated from Camptotheca acuminata, 
a tree growing in China that was well-known for its anti-cancer properties in Traditional 
Chinese Medicine (Wall et al., 1966). This small-molecule inhibitor and its derivatives 
topotecan and irinotecan act by stabilising a short-lived covalent DNA-protein reaction 
intermediate generated between DNA and TOP1 at SSBs and thus interfering with DNA 
replication and transcription (Hsiang et al., 1985; Pommier et al., 1998; L. F. Liu et al., 2000). 
This stabilisation prevents re-ligation of two DNA ends, inhibits resolution of the SSB and can 
lead to the emergence of a replication-associated one-ended DSB once the replication fork 
collides with the ternary CPT-TOP1-DNA complex. Thus, the dissolution of the stabilised 





Figure 1.8. Repair of replication-associated TOP1-mediated DNA damage. 
Camptothecin (CPT) stabilises TOP1 cleavage complexes, and once the replication fork catches 
up with the ternary CPT-TOP1-DNA complex, a replication-associated one-ended DSB is 
generated on the leading strand (1). Replication fork reversal by formation of a ‘chicken foot’-
like DNA structure can facilitate the dissociation of the newly replicated DNA strand from its 
template and the consequent spontaneous re-ligation of the broken template (2). In most 
cases, repair of the replication-associated one-ended DSB will involve either HR or NHEJ (3). 
Moreover, trapped TOP1 can be eliminated via various TOP1 excision pathways. For example, 
5’-hydroxyl-containing DNA strand invasion can release TOP1, resulting in non-homologous 
recombination (4). One of the main pathways for TOP1 excision involves tyrosyl-DNA 
phosphodiesterase (TDP1), which hydrolyses the tyrosyl-DNA covalent bond (5). TDP1-
mediated repair is greatly facilitated by TOP1 proteolysis (6). Lastly, endonucleases can also 




Generally, cells use two distinct pathways to deal with Top1cc. The tyrosyl-DNA 
phosphodiesterase (TDP1) pathway involves ubiquitination and proteasome-mediated 
degradation of TOP1 to generate the 3’-phosphate end, which can subsequently be processed 
by PolyNucleotide Kinase 3ʹ-Phosphatase (PNKP) and turned into a 3’-hydroxyl (El-Khamisy and 
Caldecott, 2006). Finally, the nick is repaired by canonical SSB repair proteins, such as PARP1, 
XRCC1 (X-ray Repair Cross-Complementing protein 1) and LIG3 (DNA Ligase 3) (El-Khamisy et 
al., 2005; Plo et al., 2003) (Figure 1.9). The alternative endonuclease pathway for Top1cc repair 
requires contribution of structure-specific 3’-flap endonucleases, such as ERCC1-XPF 
(Rad1/Rad10 in budding yeast), MUS81-EME1, and MRE11-RAD50 (Regairaz et al., 2011; Sacho 
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and Maizels, 2011; Takahata et al., 2015), to cut near the DNA lesion allowing release of the 
DNA-TOP1 complex (Figure 1.8). 
 
 
Figure 1.9. Mechanism of TOP1 covalent complex repair by tyrosyl-DNA phosphodiesterase 
1. 
Repair of covalently-trapped DNA topoisomerase I (TOP1) is initiated by proteasomal 
degradation of the trapped enzyme, allowing TDP1 to hydrolyse the phosphotyrosyl bond 
between the protein and the DNA. TDP1-mediated hydrolysis generates a SSB with a 3′-
phosphate and 5′-hydroxyl end, which cannot be re-ligated by the SSB repair factors. 
Subsequent processing of the SSB by PNKP results in dephosphorylation of the 3′ end and 
phosphorylation of the 5′ DNA end, allowing canonical SSB repair machinery (PARP1, XRCC1 
and LIG3) to re-ligate the DNA. Figure reproduced from Stingele, Bellelli and Boulton (2017). 
 
 
Replication fork collision is the main mechanism of toxicity of TOP1 poisons in dividing 
cells. If the SSB is not repaired before the start of S phase, it can give rise to a one-ended DSB 
upon collision with an ongoing replication fork via ‘replication run-off’ (Pommier, 2006) (Figure 
1.8). If unrepaired, a single DSB can be lethal to a cell (Pitcher et al., 2005), as it can cause 
major chromosomal rearrangements and genomic instability. Replication-associated DSBs lead 
to several molecular responses, such as rapid phosphorylation of the histone variant H2AX 
(Furuta et al., 2003), as well as subsequent phosphorylation of RPA, ATM, checkpoint kinases 
CHK1 and CHK2, the Bloom syndrome helicase (BLM) and p53 (Pommier, 2006). The RPA2 
subunit of the RPA heterotrimer gets phosphorylated within an hour of CPT treatment and 
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remains modified on serine 33 (S33) and serine 4 and 8 (S4/S8) while DNA synthesis is inhibited 
(Shao et al., 1999; Vassin et al., 2009). The kinases thought to be primarily involved in RPA2 
and H2AX phosphorylation after CPT treatment are DNA-PK and ATR (Furuta et al., 2003; Shao 
et al., 1999). CPT-induced replication-associated DSBs were also shown to activate ATM–CHK2 
signalling, with its activation defect leading to CPT hypersensitivity (Takemura et al., 2006). 
Overall, the efficient repair of CPT-TOP1-DNA complexes requires an extensive cellular 
response with multiple sensors and effectors of the DNA repair network acting together.  
In proliferating cells, the repair of replication-associated DSBs is largely dependent on 
HR (Brandsma and Gent, 2012; Pommier, 2006), which subsequently facilitates the restoration 
of replication forks to restart DNA replication (Figure 1.8). Additionally, it was shown that low 
doses of TOP1 inhibitor can induce PARP1- and RAD51-mediated replication fork regression 
(Ray Chaudhuri et al., 2012; Zellweger et al., 2015), resulting in a ‘chicken foot’ DNA structure 
(Figure 1.8). This repair intermediate is not likely to generate any DSBs, thus avoiding the 
formation of highly deleterious lesions and potential activation of error-prone NHEJ. The 
resulting replication fork slowing prevents excessive accumulation of ssDNA and allows time 
for repair machinery to remove trapped TOP1 (Neelsen and Lopes, 2015; Ray Chaudhuri et al., 
2012; Zellweger et al., 2015).  
 More water-soluble CPT derivatives, such as topotecan and irinotecan, are approved 
by the Food and Drug Administration (FDA) in the United States of America and widely used in 
cancer therapy today, as they preferentially affect fast-dividing cancer cells that are highly 
dependent on efficient DNA replication. CPT itself continues to be used in DNA repair research 
as an initiator of replication-associated DDR, allowing the identification of novel factors 
needed for efficient resolution of replication-associated one-ended DSBs. 
 
 
1.3.5. DNA interstrand crosslink repair and Fanconi Anaemia pathway 
 
 DNA interstrand crosslinks (ICLs) are considered to be amongst the most deleterious 
DNA lesions, obstructing both DNA replication and transcription (Kee and D’Andrea, 2010). A 
single unrepaired ICL was shown to be sufficient to kill a bacterial or yeast cell (Magana-
Schwencke et al., 1982), and approximately 40 unrepaired ICLs can kill a mammalian cell 
(Lawley and Phillips, 1996). ICLs can be induced by a variety of DNA crosslinking agents, used 
in cancer therapy, including psoralens, platinum compounds and mitomycins (Deans and West, 
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2011). Deleterious ICLs can also be generated by endogenous by-products of cellular 
metabolism, such as acetaldehyde and formaldehyde (Langevin et al., 2011; Pontel et al., 
2015). One of the mitomycins commonly used clinically, mitomycin C (MMC), was discovered 
in 1950s as a fermentation product of the microorganism Streptomyces caespitosus (Hata et 
al., 1956) and was shown to have multiple specific biological effects in mammalian cells, such 
as suppression of DNA synthesis, mutagenesis, enhanced recombination and genomic 
instability (Tomasz, 1995). Reductive activation of MMC leads to the formation of mitosene, 
which alkylates two guanine nucleosides in the sequence 5’-CpG-3’ (Tomasz, 1995), thus 
crosslinking opposite DNA strands. If unrepaired, such a crosslink will block DNA replication 
and transcription, subsequently inducing genomic instability. 
ICL repair through the Fanconi Anaemia (FA) pathway is extensively studied and 
involves a group of FA proteins whose collective function is to recognise a DNA crosslink and 
initiate nucleolytic processing of the damaged DNA, followed by lesion bypass, mediated by 
the TLS pathway, and the repair of the generated DSB by HR (reviewed by Deans and West, 
2011) (Figure 1.10). The FA protein family includes 19 distinct proteins, and nine of these 
comprise the FA core complex that activates the FANCI-FANCD2 heterodimer through mono-
ubiquitination (Alpi et al., 2008; Garcia-Higuera et al., 2001; Smogorzewska et al., 2007; Wang, 
2007). The remaining eight FA factors are required for recombinational and nucleolytic 
processes to complete ICL repair (Zhang and Walter, 2014). Mutations in most FA genes result 
in a rare predominantly autosomal recessive chromosomal instability disorder, characterised 
by various developmental abnormalities affecting the skeleton, kidneys and heart, pre- and 
postnatal growth retardation, progressive bone marrow failure and cancer predisposition 
(Joenje and Patel, 2001; Kim and D’Andrea, 2012). FA patient-derived cells exhibit ICL 
hypersensitivity and accumulation of ICL-induced replication-associated DNA damage, with 
aberrant repair of ICLs leading to the appearance of highly toxic DNA structures called radial 
chromosomes, which are considered to be the cellular signature of Fanconi Anaemia (Michl et 




Figure 1.10. The Fanconi Anaemia (FA) pathway of interstrand crosslink (ICL) repair. 
Upon replication fork stalling at ICLs, BRCA1-mediated signalling facilitates replisome 
disassembly, and RAD51 binds ssDNA to protect the fork. The FANCM–FAAP24–MHF1/2 
complex is involved in the initial ICL recognition, activation of the ATR signalling cascade and 
recruitment of the FA core complex. The core complex ubiquitinates the FANCI-FANCD2 
heterodimer, which acts as a platform to recruit multiple SLX4-dependent endonucleases 
involved in ICL processing (ERCC1-XPF, SLX1 and MUS81-EME1). Nucleolytic incisions unhook 
the ICL and promote lesion bypass via TLS, mediated by REV1 and DNA polymerase zeta (Pol 
ζ). Finally, the introduced DSB is repaired by HR, mediated by RAD51/FANCR, BRCA1/FANCS, 
BRCA2/FANCD1, PALB2/FANCN, BRIP1/FANCJ and other HR factors. Figure reproduced from 
Michl, Zimmer and Tarsounas (2016). 
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 The current model for ICL repair suggests that when two convergent replication forks 
undergo stalling at an ICL site, the replisome has to be dismantled via extraction of the 
replicative CMG helicase from chromatin (Amunugama et al., 2018; Fu et al., 2011; Fullbright 
et al., 2016; Semlow et al., 2016). The unprotected ssDNA is promptly bound by RPA and 
RAD51 to prevent fork breakage or aberrant nucleolytic degradation, as well as to ensure 
regulated incisions (Long et al., 2011; Wang et al., 2015). Replisome disassembly allows ICL 
recognition by FANCM and its binding partners FAAP24 and MHF1/2 (Ciccia et al., 2007; Collis 
et al., 2008) (Figure 1.10). The presence of FANCM at ICLs facilitates recruitment of the core 
FA complex (de Winter and Joenje, 2009; Kim et al., 2008), as well as ATR-dependent 
checkpoint activation through chromatin retention of TOPBP1 (Schwab et al., 2010). The 
central event in the FA-mediated ICL repair is mono-ubiquitination of the FANCI–FANCD2 
complex on lysines 523 and 561, respectively, triggered by the FA core complex and performed 
by the E3 ubiquitin ligase FANCL (Longerich et al., 2014) (Figure 1.10). Mono-ubiquitinated 
FANCI–FANCD2 heterodimer initiates downstream ICL repair processes, including 
endonucleolytic incision of the DNA lesion, TLS and HR-mediated DSB repair (Garcia-Higuera 
et al., 2001; Knipscheer et al., 2009) (Figure 1.10). Meanwhile, SUMOylation of FANCI–FANCD2 
was shown to be required for its removal from sites of DNA damage, suggesting that ubiquitin-
SUMO interplay regulates the presence of the FANCI–FANCD2 complex at DNA lesions (Gibbs-
Seymour et al., 2015). Several SLX4-dependent endonucleases were implicated in the incision 
of parental DNA on either side of the ICL (‘unhooking’), including MUS81-EME1, SLX1-SLX4, 
Fanconi-associated nuclease 1 (FAN1), SNM1A and SNM1B (Michl et al., 2016; Zhang and 
Walter, 2014); however, the key nuclease mediating direct incision that unhooks the crosslink 
is thought to be XPF-ERCC1 (FANCQ) (Douwel et al., 2014). The ICL excision results in a DNA 
lesion on one sister chromatid, which is bypassed by REV1- and DNA polymerase zeta (Pol ζ)-
mediated TLS (Budzowska et al., 2015), followed by the adduct removal via nucleotide excision 
repair (NER). Finally, the DSB generated on the second sister chromatid is repaired via HR, 






1.4. ATP-dependent DNA helicase/nuclease DNA2 
 
1.4.1. Cellular roles of DNA2 
 
The ATP-dependent DNA helicase/nuclease DNA2 is a multi-functional enzyme, which 
has been extensively studied in the past years and established to have important roles during 
DNA replication and repair (Figure 1.11).  
During DNA replication, the lagging strand is copied discontinuously in Okazaki 
fragments, initiated by an RNA primer (8-10 nt) and extended by 150-200 nt of DNA (Arezi and 
Kuchta, 2000). The joining of Okazaki fragments requires strand displacement synthesis from 
one fragment to displace the RNA primer region of the adjacent fragment, generating a flap. 
The current model is that the majority of flaps are short and primarily removed by FEN1 (Flap 
Endonuclease 1), whereas the flaps that escape FEN1 activity and are long enough to be coated 
by RPA (more than 30 nt-long) are processed by DNA2, which displaces RPA and cleaves the 
flap until it becomes a suitable substrate for FEN1 (Ayyagari et al., 2003; Rossi et al., 2006) 
(Figure 1.12). Indeed, DNA2 was first characterised in yeast as an essential gene encoding a 
protein with helicase and endonuclease activities that was involved in long flap Okazaki 
fragment maturation during DNA lagging strand synthesis (Budd and Campbell, 1997; Kang et 
al., 2000; Parenteau and Wellinger, 1999). In vitro analyses showed that human DNA2 (hDNA2) 
can also perform this process (Gloor et al., 2012). However, evidence supporting this role for 
DNA2 in mammalian cells is lacking, as BrdU-alkaline comet assays in U2OS cells failed to detect 
any significant contribution of DNA2 to Okazaki fragment maturation (Duxin et al., 2012). 
 
 
Figure 1.11. DNA2 is a multi-functional enzyme, involved in DNA replication and repair. 
The outline of the main cellular functions of DNA2 in maintaining genome stability. Figure 




Figure 1.12. The role of DNA2 in Okazaki fragment processing. 
DNA2 cooperates with FEN1 in Okazaki fragment maturation during lagging strand synthesis. 
When DNA Pol δ displaces the preceding Okazaki fragment, a flap structure is formed, which 
acts as a substrate for FEN1 cleavage. However, long flaps are partly covered by RPA proteins, 
blocking FEN1 activity. DNA2 trims these long flap structures, thus enabling FEN1 to complete 
flap processing. Figure reproduced from Pawłowska, Szczepanska and Blasiak (2017). 
 
 
DNA2 also plays a role in initiating HR-mediated DSB repair through 5’-end DNA 
resection at DSBs (Cejka et al., 2010; Karanja et al., 2012; Nimonkar et al., 2011; Niu et al., 
2010; Sturzenegger et al., 2014). In vitro reconstitution of DNA end resection using purified 
human proteins suggested that RPA- and MRN-dependent cooperation between the nuclease 
activity of DNA2 and the helicase activity of BLM (Bloom syndrome protein) results in the 
degradation of 5'-ssDNA, whereas RPA-coated 3'-ssDNA remains intact (Nimonkar et al., 2011). 
This finding was supported by Sturzenegger et al. (2014), demonstrating that BLM and WRN 
(Werner syndrome ATP-dependent helicase) act epistatically with DNA2 to promote long-
range resection of DSB ends in human cells. Additionally, DNA2 was demonstrated to 
participate in DNA end resection during replication-coupled repair of ICLs, with its depletion 
leading to defective HR, S phase checkpoint activation, genome instability and sensitivity to 
replication stress-inducing agents (Karanja et al., 2012). DNA2 was also shown to interact with 
FANCD2 (Karanja et al., 2012), suggesting that DNA2 may be involved in mediating the 
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interplay between HR and the FA pathways during ICL repair. However, exonuclease 1 (EXO1) 
was shown to fully compensate for the absence of DNA2 in DNA end resection, demonstrating 
functional redundancy between these two nucleases (Karanja et al., 2012; Nimonkar et al., 
2011; Zhu et al., 2008). Additionally, DNA2 was suggested to degrade reversed replication forks 
and promote replication restart after genotoxic stress in human cells, and this depended on 
the interaction between DNA2 and WRN (Thangavel et al., 2015) (Figure 1.13). Unexpectedly, 
EXO1, MRN and CtIP were shown not to be required for this reversed fork processing pathway, 
whereas RECQ1 restricted DNA2-WRN activity by preventing extensive nascent strand 
degradation (Thangavel et al., 2015). Finally, DNA2-depleted U2OS cells showed elevated 
levels of aneuploidy and internuclear chromatin bridges, indicating that hDNA2 plays an 
important role in ensuring genome stability in unperturbed cells as well (Duxin et al., 2009). 
Overall, these studies define the roles of DNA2 in maintaining genome integrity via its 
nucleolytic activities at DSBs and damaged replication forks. 
DNA2 was also implicated as a regulator of replication checkpoint activation (Duxin et 
al., 2012). Duxin et al. (2012) reported cell-cycle dependent association between DNA2 and 
AND-1 (Acidic Nucleoplasmic DNA-binding protein 1), a replisome protein that anchors the 
lagging strand DNA Pol α to the CMG replicative helicase complex (Guan et al., 2017). DNA2 
depletion in U2OS cells led to S/G2 phase-specific DNA damage, such as increased γH2AX 
levels, RPA foci and CHK1 activation, suggesting activation of the ATR-mediated S phase 
checkpoint in unperturbed DNA2-deficient cells (Duxin et al., 2012).  
As it was reported to localise to telomeres in G1 and late S/G2 phases, DNA2 is also 
thought to be involved in telomere maintenance (telomere capping and telomere replication) 
(Choe et al., 2002). In in vitro experiments, both yeast and hDNA2 enzymes were shown to 
recognise, unwind and cleave the 5’ end of G quadruplexes (G4) in the presence of RPA 
(Masuda-Sasa et al., 2008). G4 DNA structures are stable guanine-rich DNA sequences that 
occur at telomeres, and that can cause replication fork stalling, impairing efficient telomere 
replication and leading to telomere instability (Bochman et al., 2012). As G4 DNA is resistant 
to most helicases and nucleases that act during DNA replication and repair, DNA2 was 
suggested to have a crucial role in maintaining telomeres by acting on these structures 
(Masuda-Sasa et al., 2008). In support of this, a recent study reported that S. cerevisiae DNA2 





Figure 1.13. The role of DNA2 in restarting reversed replication forks. 
Excessive unwinding of the template in DNA replication leads to replication fork regression by 
pairing of the newly synthesised strands. Resulting ‘chicken foot’-like structures are primarily 
resolved by RECQ1 helicase, but in its absence, DNA2, acting together with WRN, can cleave 
the 5′ DNA end of the regressed fork. Subsequent replication restart is preceded by the action 
of branch migration factors or homologous recombination repair (HRR) factors. Figure 
reproduced from Pawłowska, Szczepanska and Blasiak (2017). 
 
 
Finally, hDNA2 also localises to mitochondria and has been proposed to play a role in 
mitochondrial DNA (mtDNA) maintenance, as its depletion decreased mtDNA replication 
intermediates and caused inefficient repair of damaged mtDNA (Duxin et al., 2009). 
Additionally, Zheng et al. (2008) found that mtDNA polymerase gamma (Pol γ) 
immunoprecipitated with DNA2, and that this interaction enhanced Pol γ activity. The study 
also showed that DNA2 functions as the flap endonuclease in the mitochondrial long-patch 
base excision repair (LP-BER) pathway, suggesting the role for hDNA2 in the mitochondrial DNA 
replication and repair. Supporting the importance of this cellular role, monoallelic mutations 
in DNA2 were shown to cause myopathy and mitochondrial disease (Chae et al., 2015; 
Phowthongkum and Sun, 2017; Ronchi et al., 2013). Taken together, the studies on DNA2 
suggest that it is a multifaceted enzyme, whose activity plays important roles in several aspects 
of DNA replication and repair, contributing to genome stability. 
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1.4.2. The cryptic helicase activity of DNA2  
 
The DNA2 nuclease activity is essential for its various roles in DNA replication and 
repair. Although DNA2 also has ATP-dependent helicase activity, in many DNA2-dependent 
processes this activity is provided by other helicases, such as BLM or WRN during DNA end 
resection (Nimonkar et al., 2011; Sturzenegger et al., 2014) and WRN during degradation of 
reversed replication forks (Thangavel et al., 2015). Thus, although the biological importance of 
DNA2 nuclease activity has been well-established, the functional role of its ATP-dependent 
helicase activity both in yeast and humans was long poorly understood. In an initial 
biochemical analysis of DNA2 enzymatic activities, Budd and Campbell (1995) showed the ATP-
dependent ability of affinity-purified S. cerevisiae DNA2 (scDNA2) to unwind DNA duplex in a 
3’-5’ direction. Moreover, a mutation in the ATP-binding motif of scDNA2 led to inactivation of 
both ATPase and helicase activities and caused lethality (Budd et al., 1995), suggesting that 
yeast DNA2 ATP-dependent helicase activity has an important function in vivo. However, initial 
biochemical analyses of hDNA2 found no evidence for its helicase activity. Human DNA2 was 
detected to have strong ssDNA-specific endonuclease and ATPase activities in vitro, but no 
helicase activity (Kim et al., 2006). In contrast, another study showed that recombinant hDNA2 
was able to perform ATP-dependent unwinding of a forked structure with a non-
complementary 18 nt-long 5' tail, even though this activity was weaker than for other 
helicases, including scDNA2 (Masuda-Sasa et al., 2006). More recent studies showed that both 
scDNA2 and hDNA2 have processive helicase activity; however, it is inhibited by the nuclease 
activity cleaving the ssDNA overhangs required for helicase loading (Levikova et al., 2013; Pinto 
et al., 2016), explaining why the helicase activity appears to be cryptic and hard to detect. 
At this stage, the cellular function of this DNA2 motor activity still remained unclear. 
Mutations in the ATPase motif of the scDNA2 helicase domain had almost no effect on 5’ flap 
processing and DSB resection in vitro (Cejka et al., 2010; Niu et al., 2010; Zhu et al., 2008), 
implying that the helicase activity is not important for the most studied cellular roles of DNA2. 
However, cell cycle defects observed in DNA2-depleted U2OS cells were rescued upon 
expression of the wild-type allele, but, like the nuclease-deficient allele, the helicase-deficient 
allele failed to do so (Duxin et al., 2012). This indicates that both nuclease and helicase 
activities of DNA2 are essential for maintaining genomic stability in human cells. Unexpectedly, 
U2OS cells expressing nuclease-deficient DNA2 exhibited cell cycle defects that were more 
severe than those in DNA2-depleted cells (Duxin et al., 2012). This suggests not only that the 
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nuclease and helicase activities of hDNA2 are coupled, but also that the helicase activity of 
hDNA2 can become toxic when nuclease activity is abolished.  
Recent biochemical studies offered another explanation for the importance of the 
ATPase/helicase domain of both yeast and human DNA2, demonstrating that it functions 
primarily as a translocase along ssDNA, to promote efficient DNA end resection, while the lead 
helicase function is performed by a cognate RecQ helicase, either BLM or WRN (Levikova et al., 
2017; Miller et al., 2017) (Figure 1.14). The translocase function of DNA2 is potentiated by its 
interaction with RPA and contributes to rapid DNA degradation, resulting in longer DNA 
cleavage products (Levikova et al., 2017). While DNA2 helicase function was masked by its 
nuclease activity (Levikova et al., 2013; Pinto et al., 2016), the nuclease activity did not prevent 
translocation on ssDNA (Levikova et al., 2017; Miller et al., 2017). This suggests that ssDNA 




Figure 1.14. Model for the involvement of DNA2 helicase in DNA end resection. 
As WRN/BLM helicase functions as the lead helicase translocating in the 3’-5’ direction, the 
motor activity of DNA2 allows translocation on the unwound 5′-terminated DNA strand, which 
is degraded by its nuclease activity (a). The RPA- and ATP hydrolysis-dependent translocase 
activity of DNA2 accelerates ssDNA processing, resulting in long DNA degradation fragments 
(b, top panel). In contrast, for helicase-dead DNA2 without active translocation, DNA2-
dependent ssDNA degradation is slow, resulting in short DNA degradation fragments (b, 
bottom panel). Figure adapted from Levikova, Pinto and Cejka (2017). 
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1.5. E3 ubiquitin ligase TRAIP 
 
1.5.1. Mutations in TRAIP cause microcephalic primordial dwarfism 
 
In the Andrew Jackson laboratory, TRAIP, which encodes an E3 ubiquitin ligase, was 
recently identified as a causative gene of Seckel syndrome, a form of MPD (Harley et al., 2016) 
(see Section 1.1, Table 1.1) (Figure 1.15a-c). During whole exome sequencing (WES) of MPD 
patients, a homozygous nonsense mutation in TRAIP (c.553C>T) was identified in one affected 
individual (P1). This mutation results in a premature stop codon (p.R185*). Sanger sequencing 
of the TRAIP coding exons in a cohort of 262 primary microcephaly and MPD patients identified 
a second individual (P2) homozygous for the same variant. Finally, WES performed by the 
Berndt Wollnik laboratory on 28 patients with Seckel syndrome-like characteristics identified 
a third individual (P3) with a different homozygous variant in TRAIP: a missense mutation 
c.52C>T, resulting in p.R18C substitution. The affected arginine is an evolutionary highly 
conserved residue within the N-terminal RING finger domain of TRAIP, which was previously 
demonstrated to exhibit enzymatic E3 ubiquitin ligase activity in vitro (Besse et al., 2007) 
(Figure 1.15a). All three patients with mutations in TRAIP were phenotypically similar: they 
exhibited microcephaly and global growth failure of prenatal onset (Figure 1.15b), as well as a 
reduction in cerebral cortex size, simplified folding of gyri, a narrow elongated face and a small 
jaw (Figure 1.15c). Moreover, there was evidence for an increased susceptibility to infections 
in these patients. As no link between TRAIP and the MPD phenotype had previously been 
reported at the time, our laboratory carried out experiments to investigate the underlying 
mechanism of how mutations in TRAIP result in reduced growth in MPD patients (Harley et al., 
2016). 
Firstly, using cell lines derived from all three patients, the deleterious effects of TRAIP 
mutations on transcript and protein levels were established (Harley et al., 2016). The p.R185* 
mutation was shown to result in nonsense-mediated decay (NMD) of the transcript, leading to 
a marked reduction in the full-length TRAIP transcript, as well as greatly reduced protein levels. 
However, consistent with the finding that TRAIP is an essential gene for early embryonic 
development in mice (Park et al., 2007), residual TRAIP protein was present in p.R185* patient-
derived cell lines. Additionally, RT-PCR analysis demonstrated the presence of alternatively 
spliced transcripts allowing production of TRAIP protein products with small internal deletions 
(Harley et al., 2016). The p.R18C mutation did not affect transcript levels but resulted in 
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markedly reduced TRAIP protein levels in the patient-derived cell line, likely caused by reduced 





Figure 1.15. TRAIP is mutated in microcephalic primordial dwarfism. 
a) A schematic structure of the TRAIP gene and TRAIP protein, with locations of MPD patient 
mutations c.52C>T (p.R18C; P3) and c.553C>T (p.R185*; P1 and P2) indicated in red (Harley et 
al., 2016). The four distinct domains of TRAIP are indicated as well (PIP = PCNA-interacting 
protein box motif) (Harley et al., 2016; Hoffmann et al., 2016; W. Feng et al., 2016).  
b) Patients with TRAIP mutations have prenatal onset severe growth failure with 
disproportionate microcephaly. Birth weight (Bwgt), current height (Hgt) and current head 
circumference (OFC) are plotted; black bars indicate mean values. 97.5% of the general 
population will lie above the dashed line at −2 SD. Adapted from Harley et al. (2016).  
c) Photographs of TRAIP patients demonstrating their facial similarities (adapted from Harley 
et al., 2016). 
 
 
The protein encoded by TRAIP (Tumour Necrosis Factor (TNF) Receptor-Associated 
Factor (TRAF)-Interacting Partner; TRIP; RNF206) contains an N-terminal RING finger motif, a 
long coiled-coil domain, a leucine zipper domain, and a PCNA-Interacting Protein (PIP)-box 
domain (Lee, Lee and Choi, 1997; Hoffmann et al., 2016; W. Feng et al., 2016) (Figure 1.15a). 
TRAIP was first described as a component of TNFR2 (TNF Receptor 2)- or CD30-containing 
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signalling complexes, and shown to act as an inhibitor of TRAF2-mediated NF-κB activation, 
thus preventing TRAF-mediated cell activation and promoting cell death signalling (Lee et al., 
1997). TRAIP-mediated inhibition of NF-κB activation was also shown to downregulate 
production of pro-inflammatory cytokines (E. S. Park et al., 2015), suggesting that TRAIP may 
have an anti-inflammatory effect. TRAIP was further implicated in downregulation of 
interferon beta (IFN-β) production and antiviral response through poly-ubiquitination of TBK1 
(TANK-Binding Kinase 1), leading to its proteasomal degradation (Zhang et al., 2012). The 
potential role of TRAIP as an anti-inflammatory factor may explain the increased severity of 
infections in MPD patients with TRAIP mutations. 
 TRAIP has also been implicated in mitosis, as it was shown to localise to mitotic 
chromosomes, ensure correct chromosome alignment, and regulate the spindle assembly 
checkpoint (Chapard et al., 2014). Moreover, TRAIP protein levels were reported to peak in the 
G2/M phase of the cell cycle (Chapard et al., 2015), and its regulation of mitotic progression 
required its homodimerisation via the coiled-coil domain (I. S. Park et al., 2015). Finally, TRAIP 
was also shown to facilitate stable kinetochore-microtubule attachment during meiosis in 
mouse oocytes, with its knockdown leading to misaligned chromosomes and aneuploidy (Yuan 
et al., 2016). A role for TRAIP in the spindle assembly checkpoint could also underlie the growth 
phenotype in TRAIP MPD patients, with increased aneuploidy causing increased cell death. 




1.5.2. TRAIP in UV-induced DNA damage response signalling 
 
The phenotype of the three MPD patients with TRAIP mutations resembled that of 
Seckel syndrome patients with defective ATR pathway signalling (O’Driscoll et al., 2003). The 
PI3K-like kinase ATR is one of the key players in sensing DNA damage and signalling it to 
downstream DDR factors, and is thought to primarily respond to stretches of ssDNA resulting 
from stalled replication forks (see Section 1.3.1). Additionally, ATR signalling is known to be 
involved in facilitating the repair of DNA damage induced by ultraviolet (UV) radiation (Zou et 
al., 2003; Zou and Elledge, 2003). UV radiation induces a variety of mutagenic and cytotoxic 
DNA lesions, with three major classes representing cyclobutane pyrimidine dimers (CPDs), 6-4 
photoproducts (6-4PPs), and 6-4 Dewar dimers (Rastogi et al., 2010). UV-induced DNA lesions 
are commonly repaired via nucleotide excision repair (NER), base excision repair (BER), and 
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mismatch repair (MMR) pathways (Rastogi et al., 2010). Additionally, they can undergo post-
replication repair, which utilises TransLesion Synthesis (TLS) or template switching (TS) to 
bypass or avoid DNA lesions and prevent accumulation of ssDNA gaps (Gao et al., 2017). If 
unrepaired, these bulky DNA lesions obstruct essential processes, such as DNA replication and 
transcription, and can lead to production of highly deleterious DSBs resulting from collapsed 
replication forks (Batista et al., 2009; Limoli et al., 2002). 
Harley et al. (2016) analysed the possible involvement of TRAIP in DDR signalling after 
UV irradiation and demonstrated that TRAIP promptly relocalises to DNA damage sites after 
exposure to UV-C (<280 nm). Moreover, patient-derived cells, as well as TRAIP-depleted HeLa 
cells, showed a significant reduction in UV-C-induced RPA2 phosphorylation on serine residues 
4 and 8 (pRPA2-S4/S8) and H2AX phosphorylation on serine 139 (γH2AX). Both were rescued 
by retroviral complementation of TRAIP-deficient cells with wild-type TRAIP. TRAIP deficiency 
specifically compromised pRPA2-S4/S8 and γH2AX levels in EdU-positive cells after UV-C-
induced DNA damage, suggesting that TRAIP acts during S phase to ensure optimal 
phosphorylation of these proteins after UV irradiation. TRAIP-deficient cells also had slower 
doubling times, which were rescued by re-introduction of wild-type TRAIP. Moreover, these 
cells showed slower progression through S phase compared to control cells, pointing towards 
a replication-related cell cycle delay. DNA fibre analyses also revealed significantly increased 
levels of replication fork stalling after UV-C treatment in patient-derived cells, as well as 
marked fork asymmetry indicative of replication problems caused by bulky UV-associated DNA 
lesions. Taken together, Harley et al. (2016) demonstrated that TRAIP has an S phase-specific 
role in ensuring replication fork progression past bulky polymerase-stalling UV adducts.  
Although a clear reduction in pRPA2-S4/S8 signal was observed in TRAIP-deficient cells, 
DDR-associated phosphorylation of other key substrates of the PI3K kinases ATR, ATM and 
DNA-PK was not substantially altered (Harley et al., 2016). Moreover, the G2/M checkpoint 
was not affected in response to UV-C irradiation in TRAIP-depleted cells (Harley et al., 2016). 
These results suggested that TRAIP deficiency did not result in global ATR signalling defects but 
rather specifically compromised phosphorylation of DNA damage markers H2AX and RPA2 
after induction of UV damage. Serine 139 (S139) phosphorylation of H2AX, a marker of DSBs, 
can be mediated by other members of PI3K kinase family, with ATM proposed to be its main 
modifier (Burma et al., 2001). Additionally, previous cell-free and cell-based studies indicated 
that RPA2 phosphorylation at S4 and S8 is primarily mediated by DNA-PK in response to DSBs 
(Anantha et al., 2007; Zernik-Kobak et al., 1997). These studies, combined with results 
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obtained by Harley et al. (2016), suggest that a fraction of ongoing replication forks undergo 
collapse after UV-C irradiation, generating DSBs and inducing DNA-PK-mediated RPA2 and 
ATM-mediated γH2AX hyperphosphorylation.  
A previous developmental study proposed that overexpression of the Drosophila 
melanogaster orthologue of TRAIP, Nopo, promotes TLS by increased ubiquitination of DNA 
polymerase eta (Pol ŋ) (Wallace et al., 2014). As TLS is a DNA damage tolerance mechanism 
that facilitates DNA replication past bulky DNA lesions (Section 1.3.2), it involves temporarily 
switching replicative DNA polymerases for highly specialised Y family translesion polymerases 
with larger active sites (Waters et al., 2009). Although the lack of a 3’-to-5’ proofreading 
activity in most translesion polymerases contributes to their low fidelity, Pol ŋ is specifically 
adapted to mediate error-free bypass of lesions induced by UV treatment, namely CPDs 
(Waters et al., 2009). However, it is not clear whether the link between TRAIP overexpression 
and Pol ŋ ubiquitination, observed by Wallace et al. (2014), is relevant to the role of TRAIP in 
responding to UV-induced DNA lesions, reported by Harley et al. (2016). Wallace et al. (2014) 
proposed TRAIP-mediated ubiquitination of Pol η based on the data obtained from examining 
TRAIP overexpression in the absence of exogenous DNA damage. Partial loss-of-function 
mutations in the Pol η-encoding POLH gene cause an autosomal recessive disorder Xeroderma 
Pigmentosum Variant (XP-V) (Johnson et al., 1999; Masutani et al., 1999), characterised by 
sunlight sensitivity, photophobia, freckle-like pigmentation and an increased risk of developing 
skin cancer (Lehmann et al., 2011). However, none of the XP-V clinical features were observed 
in MPD patients with mutations in TRAIP. The substantially different clinical phenotypes due 
to POLH and TRAIP mutations therefore suggest different molecular mechanisms. One of the 
possible roles for TRAIP in UV-induced DDR could be its involvement in template switching (TS), 
a parallel Pol ŋ-independent HR-mediated pathway to bypass UV-induced replication blocking 
DNA lesions (X. Xu et al., 2015). RPA2 phosphorylation is known to facilitate RAD51 recruitment 
and initiate HR at sites of replication fork arrest (Shi et al., 2010). Decreased RPA2 
phosphorylation in TRAIP-deficient cells may therefore compromise the TS pathway that 









1.5.3. TRAIP in DNA damage response signalling after other types of DNA damage 
 
TRAIP was implicated not only in UV-induced DDR signalling during genome replication 
(Harley et al., 2016); several studies also linked TRAIP to the cellular response to other types 
of DNA damage, including hydroxyurea (HU)-induced replication stress, camptothecin (CPT)-
induced DNA-TOP1 crosslinks, mitomycin C (MMC)-induced interstrand crosslinks (ICLs), and 
ionising radiation (IR)-induced DSBs (Hoffmann et al., 2016; Soo Lee et al., 2016; W. Feng et 
al., 2016) (Table 1.2). As some observations in these recent studies seem contradictory, the 
precise DDR-associated roles of TRAIP remain unclear. For example, Harley et al. (2016) 
observed increased replication fork stalling in TRAIP-deficient cells only following UV-C 
exposure, but not HU, MMC or aphidicolin treatment, suggesting a specific role for TRAIP in 
promoting efficient bypass of UV-induced DNA lesions (Figure 1.16a). In contrast, W. Feng et 
al. (2016) reported compromised replication fork stability, progression and restart in HU-
treated TRAIP-depleted cells (Figure 1.16c). Moreover, Harley et al. (2016) reported reduced 
pRPA2-S4/S8 and γH2AX levels in S phase only after UV-C treatment, whereas Hoffmann et al. 
(2016) observed the same outcome after HU, CPT and MMC treatment as well (Figure 1.16b). 
Finally, IR-induced cell survival defect in TRAIP-depleted cells was observed by Soo Lee et al. 
(2016) (Figure 1.16d), but not by Hoffmann et al. (2016). 
 
 
Table 1.2. Summary of recent studies about the role of TRAIP in DDR. 
The cell lines used in each report are indicated, as well as methods of TRAIP depletion, types 
of DNA damage analysed and outcomes of TRAIP deficiency observed (in unperturbed cells and 
after DNA damage). 




Type of DNA 
damage Outcomes of TRAIP deficiency 
Harley  











• Impaired cell proliferation;  
• Increase in late S phase and/or G2 cells;  
• No alteration in replication fork velocity, 
inter-origin distance and fork stalling 
UV-C 
• Reduced pRPA2-S4/S8 and γH2AX levels in 
S phase;  
• Increased frequency of replication fork 
stalling and fork asymmetry; 
• Reduced levels of ongoing replicating forks 
Aphidicolin • No effect on replication fork asymmetry  
MMC • No effect on replication fork asymmetry 
and stalling 
HU • No impairment of replication restart 
HeLa RNAi — • Increase in late S phase and/or G2 cells 
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Type of DNA 
damage Outcomes of TRAIP deficiency 
UV-C • Reduced pRPA2-S4/S8 and γH2AX levels in 
S phase 
Hoffmann  






• Accumulation of G2-phase cells; 
• Mildly reduced replication fork rates; 
• Increase in cells with γH2AX–positive 
micronuclei; 
• Increase in chromosome alignment and 
segregation defects in mitosis  
CPT 
• Reduced intensity of RPA foci; 
• Reduced RPA, CHK1 and H2AX 
phosphorylation in S phase; 
• Reduced ssDNA generation 
MMC 
• Reduced RPA, CHK1 and H2AX 
phosphorylation in S phase; 
• Elevated rate of chromosomal aberrations; 
• Reduced cell survival 
HU 
• Reduced RPA, CHK1 and H2AX 
phosphorylation in S phase; 
• Reduced replication fork rates 
IR • No effect on cell survival 
W. Feng  






— • Increase in mitotic aberrations; 
• No effect on duration of mitosis  
HU 
• Increase in mitotic aberrations; 
• No effect on duration of and cell 
percentage in mitosis 
U2OS RNAi 
— • Increase in late S phase and/or G2 cells 
HU 
• Increase in the formation of micronuclei, 
gross chromosomal aberrations and 
γH2AX–positive cells; 
• Reduced cell survival; 
• Compromised fork stability, progression 
and restart; 
• Persistence of PCNA and RPA1 
accumulation on chromatin 
UV • Increased chromatin-bound RPA1 levels 
Aphidicolin • Increased chromatin-bound RPA1 levels 
Soo Lee  





— • Reduced efficiency of HR repair 
Microirradiation • Impaired accumulation of RAP80 at laser 
stripes 
IR • Reduced chromatin localisation of RAP80 
HeLa RNAi IR 
• Increased numbers of γH2AX foci; 
• Impaired G2/M checkpoint;  
• Reduced cell survival 






Figure 1.16. Models for the proposed roles of TRAIP in DNA damage response signalling.  
a) Harley et al. (2016) showed that TRAIP promotes S phase-specific RPA2 and H2AX 
phosphorylation after DNA damage induction and suggested the role for TRAIP in ensuring 
replication fork progression past bulky polymerase-stalling DNA lesions induced by UV.  
b) Hoffmann et al. (2016) showed that TRAIP interacts with PCNA and promotes ssDNA 
formation at stalled replication forks, as well as phosphorylation of RPA, H2AX and CHK1 and 
in response to CPT-, MMC- and HU-induced replication stress. The authors suggested that 
TRAIP may be involved in uncoupling replicative helicase and polymerase after replication 
stress. 
c) W. Feng et al. (2016) suggested that TRAIP participates in regulating PCNA unloading from 
stressed replication forks. According to the authors, TRAIP senses nucleotide shortage after 
HU treatment and localises to stalled replication forks, where it promotes PCNA unloading via 
a yet unknown mechanism. TRAIP depletion was suggested to compromise PCNA turnover 
from chromatin and DNA synthesis. Figure adapted from a working model described by W. 
Feng et al. (2016). 
d) Soo Lee et al. (2016) proposed that TRAIP is required for recruitment of RAP80 and its 
functional downstream partners, including BRCA1, to sites of DNA damage. TRAIP itself is 
suggested to localise to chromatin via direct interaction with RNF20–RNF40 complex, which 
mono-ubiquitinates histones and facilitates their eviction. Histone chaperone FACT promotes 
displacement of H2A/H2B at transcription-blocked sites. Figure based on a working model 
described by Soo Lee et al. (2016). 
 
 
As each of these studies used slightly different approaches (e.g. different cell lines) to 
arrive at their conclusions, some of the differences in observations may be explained by this. 
Hoffmann et al. (2016) used CHROMASS (chromatin mass spectroscopy) (Räschle et al., 2015) 
to show that TRAIP localised to psoralen-induced ICL-containing chromatin in X. laevis egg 
extracts, and suggested that TRAIP enrichment at those sites was triggered specifically by the 
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replication fork encountering such DNA roadblocks. TRAIP was further suggested by this study 
to play a role in responding to several types of DNA damage-inducing agents: MMC, CPT and 
HU. Replication fork stalling following cell treatment with MMC led to prominent relocalisation 
of TRAIP from the nucleolus, where it resides in unperturbed cells, to the nucleoplasm 
(Hoffmann et al., 2016). After MMC treatment, TRAIP-depleted cells exhibited reduced levels 
of chromatin-bound pRPA and γH2AX, as well as elevated rates of chromosomal aberrations 
and reduced cell survival (Hoffmann et al., 2016). In TRAIP-depleted cells treated with CPT, the 
same reduction in chromatin-bound pRPA and γH2AX was observed, as well as reduced RPA 
loading in S phase (Hoffmann et al., 2016). Treatment with HU also resulted in pRPA and γH2AX 
signalling defects in TRAIP-depleted cells, as well as reduced replication fork rates (Hoffmann 
et al., 2016). However, IR treatment had no effect on cell survival in TRAIP-depleted cells. As 
similar cellular outcomes were observed after distinct replication stress-inducing agents in 
TRAIP-depleted cells, but not after IR, Hoffmann et al. (2016) proposed a role for TRAIP in 
reconfiguring stalled replication forks, rather than promoting DNA resection of DSBs (Figure 
1.16b). 
The importance of TRAIP for replication fork recovery and progression was also noted 
by W. Feng et al. (2016) (Figure 1.16c). This study demonstrated that TRAIP depletion, 
combined with HU treatment, which slows down DNA synthesis by causing rapid depletion of 
dNTP pools, leads to reduced cell survival, as well as an increase in micronuclei formation, 
chromosomal aberrations and γH2AX foci. Consistent with Harley et al. (2016) and Hoffmann 
et al. (2016), W. Feng et al. (2016) observed the interaction of TRAIP with PCNA, the DNA-
encircling processivity factor of DNA polymerases with multiple roles in DNA replication and 
repair (Moldovan et al., 2007). In agreement with Hoffmann et al. (2016), W. Feng et al. (2016) 
also found that TRAIP was recruited to damaged chromatin in response to various sources of 
replication stress-inducing agents, such as aphidicolin, MMC, UV radiation and cisplatin, but 
not IR, once again suggesting that TRAIP may have an important role in restructuring and 
restart of stalled replication forks but may not be required for DSB repair. Moreover, DNA 
combing analysis of fork progression demonstrated that TRAIP-depleted cells have shorter 
CldU tracks upon release from HU treatment, strengthening the hypothesis that TRAIP has a 
role in maintaining fork stability and ensuring restart after replication stress (W. Feng et al., 
2016). As TRAIP Q460A/L463A mutant, impaired in PCNA binding, displayed defects in fork 
progression during cell recovery from HU treatment, W. Feng et al. (2016) proposed that the 
TRAIP-PCNA interaction is important for repair and recovery of HU-stalled forks. Meanwhile, 
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TRAIP PIP domain deletion (Δ460–469 aa) mutant, used by Hoffmann et al. (2016), resulted in 
impaired HU- and CPT-induced RPA phosphorylation, but did not negatively affect long-term 
cell survival after MMC treatment. W. Feng et al. (2016) also suggested that TRAIP may be 
directly involved in regulating PCNA levels on chromatin by ensuring PCNA unloading from 
damaged DNA (Figure 1.16c). Indeed, TRAIP depletion was shown to impair the replication 
stress-induced reduction of chromatin-bound PCNA, resulting in excessive levels  of PCNA, as 
well as RPA, on chromatin (W. Feng et al., 2016). The authors also noted the hyper-
accumulation of chromatin-bound RPA in TRAIP knockdown cells after treatment with various 
replication stress-inducing drugs, which is in disagreement with Hoffmann et al. (2016), who 
instead observed a reduction in RPA loading in TRAIP-depleted cells after exposure to DNA 
damaging agents. 
In contrast to the studies discussed above, Soo Lee et al. (2016) suggested a role for 
TRAIP in DDR and DNA repair of IR-induced DSBs (Figure 1.16d). The authors observed an 
increase in IR-induced γH2AX foci at various time points in TRAIP-depleted HeLa cells, which 
was rescued by introducing siRNA-resistant WT TRAIP, but not a TRAIP mutant unable to 
interact with RAP80 (Soo Lee et al., 2016). DNA damage response protein RAP80 recognises 
and binds lysine 63 (K63)-linked poly-ubiquitin chains of chromatin-bound proteins and 
subsequently recruits BRCA1 and its associated factors to DNA damage loci, particularly IR-
induced DSBs (Wu et al., 2012). The result obtained by Soo Lee et al. (2016) therefore suggests 
that the TRAIP–RAP80 interaction aids repair of IR-induced DSBs. Using immunofluorescence 
experiments, the authors showed that TRAIP depletion results in fewer IR-induced 
CCDC98/ABRAXAS and MERIT40/NBA1 foci-positive cells, both of which are known to facilitate 
BRCA1 recruitment to DSBs (L. Feng et al., 2009; Kim et al., 2007). TRAIP knockdown in U2OS 
cells also led to reduced HR efficiency in the DR-GFP (direct repeat-green fluorescent protein) 
reporter assay, as well as a reduction in BRCA1 recruitment to IR-induced DNA damage foci in 
293T cells, and a defective G2/M checkpoint control after IR in HeLa cells. All these defects 
were rescued by re-introduction of WT TRAIP but not the RAP80 interaction mutant of TRAIP 
(Soo Lee et al., 2016). Taken together, these data suggest that TRAIP acts as an upstream 
regulator of the RAP80-dependent IR-induced BRCA1 recruitment to chromatin (Figure 1.16d). 
Overall, the recent studies indicate that TRAIP is mainly required for DDR signalling in 
response to replication-associated DNA lesions. However, there are some contradictions 
between studies. Therefore, it is clear that more work is required to elucidate the precise way 
in which this E3 ubiquitin ligase promotes DDR (see Chapters 4–6 of this thesis).
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1.6. Replication fork protection factor DONSON 
 
1.6.1. Mutations in DONSON cause microcephalic primordial dwarfism 
 
 Mutations in replication fork-associated protein DONSON (DOwnstream Neighbour of 
SON) were recently linked to pathogenesis of MPD by the Andrew Jackson and Grant Stewart 
(University of Birmingham) laboratories (Reynolds et al., 2017). Using WES and targeted re-
sequencing of MPD patients without a molecular diagnosis, 29 affected individuals were shown 
to have rare biallelic mutations in the poorly characterised DONSON gene (Reynolds et al., 
2017). Although various types of mutations were identified, there were no individuals with 
biallelic nonsense or frameshift mutations in DONSON (Reynolds et al., 2017). This suggested 
that DONSON is an essential protein, and was later supported by the observed lethality of the 
DONSON knockout mouse (Evrony et al., 2017). Many of the MPD-associated DONSON variants 
resulted in partial loss of DONSON function, with immunoblotting analyses showing a marked 
decrease of DONSON protein in patient-derived cell lines, but with residual DONSON protein 
detectable in all cases (Reynolds et al., 2017). Moreover, several of the mutations disrupted 
the subcellular localisation of GFP-tagged DONSON, leading to a diffuse pan-cellular GFP signal 
instead of the exclusively nuclear signal seen for wild-type DONSON, suggesting another 
mechanism by which DONSON protein function is compromised in some of the patients 
(Reynolds et al., 2017). All MPD patients with DONSON mutations had pronounced 
microcephaly (OFC -7.5±2.4 SD), as well as highly reduced cerebral cortical size and gyri folding. 
Reduction in height was less marked than reduction in OFC (–3.2±1.4 SD) and less severe than 
in some other MPD patients. Several individuals with DONSON mutations also exhibited subtle 
skeletal abnormalities, including radial ray defects and underdeveloped patellae, alongside 
mild intellectual disability. 
The Walsh laboratory independently identified DONSON as a cause of human disease 
through studying microcephaly-micromelia syndrome (MMS) (Evrony et al., 2017). MMS is an 
extremely rare autosomal recessive condition, so far identified in a single Canadian First 
Nations population in Saskatchewan; it leads to prenatal growth restriction, severely reduced 
brain size, craniofacial and limb abnormalities, and neonatal lethality (Evrony et al., 2017). 
Using linkage analysis of affected pedigrees, Evrony et al. (2017) demonstrated that a locus on 
chromosome 21 was linked to MMS, but no obvious pathogenic protein-coding or splicing 
variant was identified by DNA sequencing. Eventually, RNA-seq analysis showed significantly 
increased retention of DONSON intron 6. This was shown to be caused by a non-coding biallelic 
78 
 
variant in the DONSON gene present within that locus. Retention of intron 6 is predicted to 
cause either NMD of the mutant transcript or to result in a severely truncated protein. Taken 
together, studies by Reynolds et al. (2017) and Evrony et al. (2017) indicate the importance of 
functional DONSON protein for normal development and organism growth.  
 
 
1.6.2. The role of DONSON during genome replication 
 
 The DONSON orthologue in D. melanogaster, Humpty dumpty (Hd), is expressed 
during late G1 and S phases and was previously suggested to play a role in genome replication 
in follicle cells of the ovary and cell proliferation during development, with its depletion 
causing DNA damage and defective DNA replication (Bandura et al., 2005). This study 
prompted Reynolds et al. (2017) to investigate whether these cellular roles of DONSON are 
conserved in humans. DONSON depletion in HeLa cells, pulsed with BrdU, led to an increase in 
BrdU-positive cells observed by FACS, suggesting that DONSON is needed for efficient S phase 
progression. Moreover, DNA fibre analysis of DONSON-depleted HeLa cells showed higher 
levels of spontaneous replication fork stalling and increased replication fork asymmetry, and 
thus fewer ongoing forks. Additionally, unperturbed HeLa cells lacking DONSON, particularly 
EdU-positive S phase cells, exhibited increased levels of γH2AX and 53BP1 foci. Finally, 
DONSON-depleted cells also had higher levels of DSBs, as measured by pulsed-field gel 
electrophoresis. These results indicated that DONSON helps cells to successfully progress 
through S phase by protecting and stabilising replication forks, as well as preventing 
spontaneous DNA damage. 
A mass spectrometry (MS) screen to identify interaction partners of GFP-DONSON 
detected various components of the replisome, such as subunits of the MCM complex and 
PCNA, whose interaction with DONSON was subsequently confirmed by pull-down 
experiments (Reynolds et al., 2017). These observations were further strengthened by 
proximity ligation assay (PLA) and fluorescence cross-correlation spectroscopy (FCCS) 
experiments, demonstrating association of GFP-tagged DONSON with PCNA in replicating HeLa 
cells (Reynolds et al., 2017). Finally, iPOND (isolation of proteins on nascent DNA) technique 
(Sirbu et al., 2012, 2011) combined with MS was used to show the enrichment of DONSON at 
replication forks and nascent DNA, compared to mature chromatin, strongly suggesting that 
DONSON is a novel component of the replication machinery (Reynolds et al., 2017). 
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DNA replication defects in DONSON-deficient cells were further exacerbated by 
exogenous DNA damage (Reynolds et al., 2017). Upon HU and MMC exposure, DONSON-
depleted cells showed high levels of fork stalling and failure to prevent new origin firing, 
compared to wild-type cells, suggesting a defective intra-S phase checkpoint in the absence of 
DONSON. Additionally, HU- or MMC-treated DONSON-depleted cells exhibited reduced 
phosphorylation of ATR and its substrates, higher levels of RPA-coated ssDNA, and increased 
numbers of mitotic cells. Furthermore, elevated levels of micronuclei, chromatid breaks and 
fragmented metaphase chromosomes were observed in DONSON-depleted cells, particularly 
upon exogenous replication stress, consistent with defective intra-S phase ATR-dependent 
checkpoint signalling leading to genome instability. Overall, Reynolds et al. (2017) established 
the importance of DONSON for protection of stalled replication forks, activation of the intra-S 
phase and G2/M checkpoints and maintenance of genome stability (Figure 1.17).  
Previous studies suggested that DNA damage in cells with dysfunctional ATR signalling 
is caused by unscheduled cleavage of stalled replication forks by SLX4-dependent structure-
specific nucleases, such as MUS81-EME1, SLX1 or XPF-ERCC1 (Couch et al., 2013; Forment et 
al., 2011; Hodskinson et al., 2014; Ragland et al., 2013; Svendsen et al., 2009). Indeed, 
Reynolds et al. (2017) showed that DNA damage in DONSON-depleted cells arises via this 
mechanism as well. When MUS81 or XPF were co-depleted from HeLa cells at the same time 
as DONSON, cells exhibited partial rescue of replication fork asymmetry, γH2AX 
hyperphosphorylation, chromatid breaks and chromosome fragmentation (Reynolds et al., 
2017). Thus, the lack of DONSON renders stalled replication forks susceptible to nucleolytic 
processing by structure-specific nucleases MUS81 and XPF, leading to genome instability 
(Figure 1.17). 
Retroviral complementation of patient cells with WT DONSON rescued the replication 
and genome stability-associated defects observed in patient-derived cells, including 
asymmetric replication forks, more frequent fork stalling and defective intra-S phase 
checkpoint activation, as well as elevated levels of chromatid gaps and DNA damage during 
DNA replication (Reynolds et al., 2017). This confirmed the direct causality between these 
cellular phenotypes and insufficient DONSON activity, resulting from biallelic mutations in the 





Figure 1.17. Model for the role of DONSON in maintaining genome stability. 
Upon replication stress (indicated by red diamond) and replication fork stalling, the presence 
of functional DONSON and ATR-dependent replication stress response ensures maintenance 
of replication fork and genome stability. In the absence of functional DONSON, stalled 
replication forks are cleaved by structure-specific nucleases, such as MUS81 and XPF, leading 
to the generation of DSBs in S phase. Impaired S phase and G2/M checkpoints eventually lead 
to elevated mitotic chromosome breaks, increased cell death, and reduced numbers of cells 
generated during development, resulting in the microcephaly and growth failure. Figure 
reproduced from Reynolds et al. (2017). 
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1.7. Aims of this thesis 
 
Multiple microcephalic primordial dwarfism (MPD)-associated genes have important 
functions in DNA replication, DNA damage response signalling and DNA repair (Table 1.1). A 
better understanding of the molecular mechanisms by which mutations in these genes lead to 
reduced cell proliferation is particularly important for elucidating the link between disrupted 
genome maintenance and severely affected human growth. The main objective of my thesis 
work was to advance knowledge of the molecular causes of MPD and gain understanding of 
how the proteins encoded by MPD genes act in cells and during development. 
This thesis focusses on three recently identified MPD genes involved in DNA replication 
and repair: DNA2, TRAIP and DONSON. The main aims of my work described here were to: 
1) Investigate the pathogenicity of biallelic variants at the DNA2 locus; 
2) Establish whether TRAIP-mediated ubiquitination of the protein phosphatase 4 
(PP4) complex is the basis for hypophosphorylation of RPA2 and H2AX in TRAIP 
patient-derived cells;  
3) Determine the molecular mechanisms of TRAIP function in DDR and DNA repair in 
response to different forms of replication-associated DNA damage using TRAIP 
knockout cell lines; 













































2. Materials and methods 
 
2.1. General reagents 
 
2.1.1. Sources of reagents (chemicals, enzymes, growth reagents, antibodies) 
 
Chemicals were purchased from Sigma Aldrich, BDH Laboratory Supplies (AnalaR, 
VWR), Fisher Chemicals, and Amersham Biosciences (GE Healthcare). Enzymes were obtained 
from New England Biolabs, Promega and Roche. Cell culture material was purchased from 
Gibco (Invitrogen) or Sigma-Aldrich unless otherwise stated.  
 
2.1.2. Preparation of buffer solutions 
 
All commonly used buffers (Table 2.1) were made using distilled water (dH2O). 
Solutions were sterilised by autoclaving at 121°C for 15 min. Solutions that could not be 
autoclaved were passed through a 0.22 μm filter (Millipore). 
 
Table 2.1. Commonly used buffers. 
Buffer Chemicals used for preparation 
10X TBE 0.89 M Tris base, 0.89 M boric acid, 20 mM EDTA 
10X TBS 0.5 M Tris base, 1.5 M NaCl (pH adjusted to 7.5 with HCl) 
20X SSC 3 M NaCl, 0.3 M sodium citrate (pH adjusted to 7 with HCl) 
1X urea lysis buffer 
8 M urea, 50 mM Tris (pH 7.5), 150 mM β-mercaptoethanol, 
cOmplete mini EDTA-free protease inhibitor cocktail (Roche, 
catalog number 04693159001) 
10X Tris-glycine SDS-PAGE running 
buffer 250 mM Tris base, 1.92 M glycine, 1% (w/v) SDS 
1X immunoblotting transfer buffer 25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS,  20% (v/v) methanol 
4X SDS protein sample loading 
buffer 
0.5 M Tris-HCl (pH 6.8), 50% (v/v) glycerol, 2% (w/v) SDS, 
0.1% (w/v) bromophenol blue 
1X NETN buffer 20 mM Tris-HCl (pH 8), 100 mM NaCl, 1 mM EDTA,  0.5% NP-40 
1X PreScission cleavage buffer 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA,  1 mM DTT 
1X Pre-extraction buffer 25 mM HEPES (pH 7.4), 50 mM NaCl, 1 mM EDTA,  3 mM MgCl2, 300 mM sucrose and 0.5% Triton X-100 
5X oligo buffer 1 M Tris (pH 8), 1 M KCl 




2.1.3. Preparation of cell culture drug stock solutions 
 
Drugs were added to tissue culture media immediately prior to use and used at the 
working concentrations indicated in Table 2.2. Stock solutions were made from powder in 
tissue culture hoods or purchased already dissolved in dimethyl sulfoxide (DMSO), 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) or autoclaved dH2O. After aliquoting, 
stock solutions were stored at 4˚C, –20˚C or –80˚C. 
 
Table 2.2. Cell culture drug stock solutions. 







Colcemid PBS 10 µg/ml 0.1 µg/ml Biosera LM-T1700 4˚C 
Puromycin H2O 50 mg/ml 20 µg/ml Sigma-Aldrich BP2956-100 –20˚C 
Neomycin H2O 250 mg/ml 500 µg/ml Sigma-Aldrich N6386 –20˚C 
Blasticidin HEPES 10 mg/ml 2 µg/ml InvivoGen Ant-bl-1 4˚C 
Hydrogen 
peroxide H2O 10 M 50–200 mM Sigma-Aldrich H1009 4˚C 
Hydroxyurea H2O 2 M 2 mM Sigma-Aldrich H8627 –20˚C 
Camptothecin DMSO 1 mM 2.5 nM–1 µM Sigma-Aldrich C9911 –20˚C 




Plasmids used throughout this study are listed in Table 2.3 and Table 2.4. Those that 
were created for this work (Table 2.4) were constructed using standard cloning techniques 
(Section 2.4) and oligonucleotides described in Appendices 1a, 1b, 1f, 1g and 1h. 
 
Table 2.3. Plasmids used in this study that were purchased commercially or previously 
generated by other laboratory members. 
Plasmid Description Source 
pSpCas9(BB)-2A-GFP 
(pX458) 
Cas9 from S. pyogenes with 2A-EGFP, and 
multiple cloning site for gRNA 
Addgene (plasmid number: 
48138) (Ran, Hsu, Wright 
et al., 2013) 
pSpCas9n(BB)-2A-GFP 
(pX461) 
Cas9n (D10A nickase mutant) from S. pyogenes 
with 2A-EGFP, and multiple cloning site for gRNA 
Addgene (plasmid number: 
48140) (Ran, Hsu, Wright 
et al., 2013) 
pSpCas9n(BB)-2A-Puro 
(pX462) 
Cas9n (D10A nickase mutant) from S. pyogenes 
with 2A-Puro, and multiple cloning site for gRNA 
Addgene (plasmid number: 
48141) (Ran, Hsu, Wright 
et al., 2013) 
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Plasmid Description Source 
RHCglo 
Minigene reporter for identification and analysis 
of cis elements and trans factors affecting pre-
mRNA splicing  
Addgene (plasmid number: 
80169) (Singh and Cooper, 
2006) 
pGEX-6P-1 
Bacterial expression vector for purification of 
glutathione S-transferase (GST)-tagged 
recombinant proteins with PreScission protease 
cleavage site 
GE Healthcare (product 
number: 28-9546-48) 
pGEX-6P-1-DEST pGEX-6P-1 bacterial expression vector with a gateway cassette 
A. Jackson laboratory, 
created by A. Robertson 
pGEX-6P-1-PP4C 
pGEX-6P-1 bacterial expression vector with the 
GST-tagged protein phosphatase 4 (PP4) catalytic 
subunit PP4C 
A. Jackson laboratory, 
created by M. Harley 
pMSCVpuro 
Retroviral Murine Stem Cell Virus (MSCV) vector 
with puromycin resistance optimized for 
integration and stable expression of a gene of 
interest 
Clontech (catalog number: 
634401)  
pMSCVneo 
Retroviral Murine Stem Cell Virus (MSCV) vector 
with neomycin resistance optimized for 
integration and stable expression of a gene of 
interest 
Clontech (catalog number: 
634401) 
pMSCVneo-TRAIP-WT 
Retroviral Murine Stem Cell Virus (MSCV) vector 
with neomycin resistance and TRAIP-WT cloned 
into a gateway cassette 
A. Jackson laboratory, 
created by M. Harley 
pMSCVneo-TRAIP-
W37A 
Retroviral Murine Stem Cell Virus (MSCV) vector 
with neomycin resistance and TRAIP-W37A 
cloned into a gateway cassette 
A. Jackson laboratory, 
created by A. Fluteau 
pGEX-4T-2 
Bacterial expression vector for purification of 
glutathione S-transferase (GST)-tagged 
recombinant proteins with thrombin site 
GE Healthcare (product 
number: 28-9545-50) 
pGEX-4T-2-TRAIP-N pGEX-4T-N bacterial expression vector with the GST-tagged N-terminal TRAIP Gift from R. Geahlen 
 
Table 2.4. Plasmids that were generated for this thesis. 
Plasmid generated 







DNA2 gRNA1 (CTCTCCGCTCACAGCTCCGC) for 
CRISPR/Cas9-mediated introduction of c.74+4A>C 
mutation in a cell line, cloned into pX461 
pX461 Figure 3.10a 
pX462-DNA2-
c.74+4A>C-gRNA9 
DNA2 gRNA9 (GGAGGGTGTGGGAACAAAGC) for 
CRISPR/Cas9-mediated introduction of c.74+4A>C 
mutation in a cell line, cloned into pX462 
pX462 Figure 3.10a 
pX461-DNA2-
c.1963A>G-gRNA1 
DNA2 gRNA1 (CTACGATATGTACTCTCGTA) for 
CRISPR/Cas9-mediated introduction of c.1963A>G 
mutation in a cell line, cloned into pX461 
pX461 Figure 3.10a 
pX462-DNA2-
c.1963A>G-gRNA9 
DNA2 gRNA9 (GTAGTTGTTTTTCCTGTCCC) for 
CRISPR/Cas9-mediated introduction of c.1963A>G 
mutation in a cell line, cloned into pX462 
pX462 Figure 3.10a 
pX458-DNA2-
c.74+4A>C-gRNA1 
DNA2 gRNA1 (CTCTCCGCTCACAGCTCCGC) for 
CRISPR/Cas9-mediated introduction of c.74+4A>C 
mutation in a cell line, cloned into pX458 











DNA2 gRNA2 (GGAGGAGGCGGAGCTGCCGG) for 
CRISPR/Cas9-mediated introduction of c.74+4A>C 
mutation in a cell line, cloned into pX458 
pX458 Figure 3.11a 
pX458-DNA2-
c.74+4A>C-gRNA3 
DNA2 gRNA3 (GCTGCCGGCGGAGCTGTGAG) for 
CRISPR/Cas9-mediated introduction of c.74+4A>C 
mutation in a cell line, cloned into pX458 
pX458 Figure 3.11a 
pX458-TRAIP-gRNA1 
TRAIP gRNA1 (CTTCGATCACTCCCGCGACG) for 
CRISPR/Cas9-mediated disruption of TRAIP in a cell line, 
cloned into pX458 
pX458 Figure 5.1 
pX458-TRAIP-gRNA2 
TRAIP gRNA2 (ATAGTGCACAGAGCACGGAT) for 
CRISPR/Cas9-mediated disruption of TRAIP in a cell line, 
cloned into pX458 
pX458 Figure 5.1 
pX458-mDonson-
M440T-gRNA 
Donson gRNA (TACCTTAAGCATTTGCATTG) for 
CRISPR/Cas9-mediated introduction of c.1319T>C 
mutation in mouse, cloned into pX458 
pX458 Figure 7.2 
RHCglo-DNA2-ex11-
13-WT 
DNA2 exons 11 to exon 13 (including intervening 
intronic/exonic sequence) amplified from control DNA of 
a healthy individual, cloned into RHCglo 
RHCglo Figure 3.7 
RHCglo-DNA2-ex11-
13-int11ins53bp 
DNA2 exons 11 to exon 13 (including intervening 
intronic/exonic sequence) amplified from DNA of a DNA2 
patient, cloned into RHCglo 
RHCglo Figure 3.7 
RHCglo-DNA2-ex11-
13-c.1764-1G>A 
Splicing control plasmid generated by site-directed 
mutagenesis on RHCglo-DNA2-ex11-13-WT RHCglo Figure 3.7 
RHCglo-DNA2-ex1-
2-WT 
DNA2 exon 1 and exon 2 (including intervening intronic 
sequence) amplified from control DNA of a healthy 
individual, cloned into RHCglo 
RHCglo Figure 3.8 
RHCglo-DNA2-ex1-
2-c.74+4A>C 
DNA2 exon 1 and exon 2 (including intervening intronic 
sequence) amplified from DNA of a DNA2 patient, cloned 
into RHCglo 
RHCglo Figure 3.8 
RHCglo-DNA2-ex1-
2-c.74+1G>A 
Splicing control plasmid generated by site-directed 
mutagenesis on RHCglo-DNA2-ex1-2-WT RHCglo Figure 3.8 
pGEX-6P-1-PP4C-
PP4R2-PP4R3α 
PP4C, PP4R2 and PP4R3α sequentially cloned into pGEX-
6P-1 for bacterial protein expression and purification 
pGEX-6P-
1 Figure 4.5 
pGEX-6P-1-PP4C-
PP4R2-PP4R3β 
PP4C, PP4R2 and PP4R3β sequentially cloned into pGEX-
6P-1 for bacterial protein expression and purification 
pGEX-6P-




Two rounds of site-directed mutagenesis on pGEX-6P-1-
PP4C-PP4R2-PP4R3α to introduce lysine-to-arginine 
substitutions in PP4C 
pGEX-6P-




Two rounds of site-directed mutagenesis on pGEX-6P-1-
PP4C-PP4R2-PP4R3β to introduce lysine-to-arginine 
substitutions in PP4C 
pGEX-6P-




Site-directed mutagenesis on pGEX-6P-1-PP4C-PP4R2-
PP4R3β to introduce K183R substitution in PP4C 
pGEX-6P-




Site-directed mutagenesis on pGEX-6P-1-PP4C(K183R)-
PP4R2-PP4R3β to introduce K21R substitution in PP4C 
pGEX-6P-
1 Figure 4.11 
pGEX-4T-2-
TRAIP(W37A)-N 
Site-directed mutagenesis on pGEX-4T-TRAIP-N bacterial 
expression vector to introduce W37A substitution in 
TRAIP-N 
pGEX-4T-




2.2. Microbial methods 
 
2.2.1. Growth of bacteria 
 
E. coli strains were grown at 37˚C in/on Luria-Bertani (LB) medium (10 g/l tryptone, 5 
g/l yeast extract, 10 g/l NaCl, 1 g/l glucose). To maintain selection for plasmid DNA in 
transformed cells, the relevant antibiotic(s) (Table 2.5) were added to LB at the required 
concentration. 
 
Table 2.5. Antibiotics used for bacterial selection in this study. 
Antibiotic Stock concentration Working concentration Solvent 
Ampicillin 50 mg/ml 50 µg/ml dH2O 
Kanamycin 10 mg/ml 10 µg/ml dH2O 
Chloramphenicol 34 mg/ml 34 µg/ml 100% EtOH 
 
2.2.2. Transformation of E. coli 
 
2.2.2.1. Preparation of chemically-competent bacterial cells for cloning 
 
Preparation of chemically-competent E. coli was performed in-house by M. Reijns and 
A. Fluteau. E. coli DH5α cells were grown overnight on LB agar. The next day, a single colony 
was taken and 5 ml of LB medium with 20 mM MgSO4 was inoculated and grown overnight to 
stationary phase. Following this, 250 ml of LB with 20 mM MgSO4 was inoculated with 2 ml of 
the stationary phase culture and incubated at 23˚C in a shaking incubator at a minimum of 200 
rpm until OD600 reached 0.4–0.6 (usually 8-10 h). The culture was then cooled on ice for about 
15 min and cells were kept on ice for all subsequent steps. Cells were sedimented (10 min, 
3,000 rpm, 4˚C) and gently resuspended in 80 ml of ice-cold sterilised TB buffer (10 mM PIPES-
HCl pH 6.7, 15 mM CaCl2, 0.25 M KCl, 55 mM MnCl2). Cells were left on ice for 10 min, 
centrifuged for 10 min at 3,000 rpm at 4˚C, and gently resuspended in 20 ml of ice-cold TB 
buffer. After adding 1.5 ml of DMSO followed by a final 10 min incubation on ice, cells were 
dispensed into 200 μl aliquots in cold, sterile tubes and snap-frozen in liquid nitrogen. Aliquots 




2.2.2.2. Transformation of chemically competent bacterial cells 
 
For transformation of chemically-competent E. coli, approximately 1 ng of plasmid 
DNA or 1 µl of a ligation reaction was added to 50 µl of competent cells. Cells and DNA were 
incubated on ice for 30 min before 45 sec heat-shock at 42˚C. Following 2 min recovery on ice, 
the cells were resuspended in 1 ml of LB medium and incubated at 37˚C for 60 min with 
shaking. 100 µl of cells was spread onto LB-agar plates containing the appropriate antibiotic(s). 




2.3. Cell culture methods 
 
2.3.1. Preparation and growth of cell lines 
 
2.3.1.1. Human cell lines 
 
Cell culture conditions used for the maintenance of the human cell lines in this thesis 
are summarised in Table 2.6. Cells were trypsinised in trypsin:versene (1:1, v/v) or in 1X 
TrypLE™ Express Enzyme (Thermo Fisher Scientific, catalog number 12605036) at 37°C for 5 
min and passaged at 1:6-1:12, as required. 
 
Table 2.6. Cell culture conditions used for maintaining human cell lines. 
Cell line Cell culture medium Supplements of cell culture medium 
Cell culture 
conditions Source 




10% fetal bovine serum,  
100 U/ml penicillin,  
100 μg/ml streptomycin 37°C, 





Gift from D. Durocher 
(University of Toronto) 








DMEM Medium  
(Thermo Fisher 
Scientific, catalog 
number 41965039)  




HeLa Cas9 Gift from D. Durocher (University of Toronto) 
Phoenix E 
10% fetal bovine serum,  
100 U/ml penicillin,  
100 μg/ml streptomycin,  
1% glutamine 
Gift from G. P. Nolan 
(Stanford University) 
 
2.3.1.2. Mouse embryonic fibroblast (MEF) cell lines 
 
Mouse embryonic fibroblasts (MEFs) were prepared from embryos collected at 13.5 
days post-coitum (E13.5). Each embryo was isolated from the decidua and placed in DMEM 
culture media. The tails were collected for genotyping and the heads and internal organs 
removed. Each embryo was minced using a clean scalpel, transferred into a T25 tissue culture 
flask and maintained in DMEM Medium, supplemented with 10% FBS, 0.1 mM β-
mercaptoethanol (BME), 100 U/ml penicillin and 100 μg/ml streptomycin. Fibroblast colonies 
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were visible following culturing for 48 h at 37° C in 5% CO2 and 3% O2. Cells were trypsinised in 
1X TrypLE™ Express Enzyme (Thermo Fisher Scientific) at 37°C for 5 min and passaged at 1:3 
for up to 4 passages. 
 
2.3.2. Preservation of cell lines 
 
For storage of tissue culture cells, 2–7x106 adherent cells were harvested and 
resuspended in 1 ml of FBS, containing 10% DMSO. The cells were stored in 2 ml cryostat tubes 
and frozen at –80˚C in Styrofoam containers, and transferred for long-term storage in liquid 
nitrogen. 
 
2.3.3. Transfection of cultured mammalian cells 
 
2.3.3.1. Short interfering RNA (siRNA) transfections 
 
 Short interfering RNA (siRNA) oligonucleotides (Table 2.7) were transfected into RPE1 
or RPE1 p53-/- Cas9 cells using Lipofectamine™ RNAiMAX transfection reagent (Invitrogen), 
whereas Oligofectamine transfection reagent (Invitrogen) was used for transfections into HeLa 
cells. RPE1 or HeLa cells were 30-50% confluent at time of transfection. For each transfection 
of a 100 mm tissue culture dish, two complexes were prepared. The first contained 40–50 nM 
siRNA in 500 μl of Opti-MEM Medium (Thermo Fisher Scientific, 31985062) and the second 
contained 12 μl of transfection reagent in 500 μl Opti-MEM. After 5-10 min incubation, the 
solutions were combined for 15-20 min and then added to the cells. The cells were incubated 
in 7 ml Opti-MEM with the transfection mixture for 24 h, after which Opti-MEM was replaced 
with fresh medium. 
 
Table 2.7. Sequences of siRNA oligonucleotides used in this thesis. 
 siRNA oligonucleotide  Sequence (5'-3')  Reference 
 siLUC  CUUACGCUGAGUACUUCGA[dT][dT]  Harley et al., 2016 
 siTRAIP-524  AGCAGAUGAAGUACUUAGA[dT][dT]  Harley et al., 2016 
 siTRAIP-2  CCGUGAUGAUAUUGAUCUCAA[dT][dT]  Hoffmann et al., 2016 
 siTRAIP-B  GAACCAUUAUCAAUAAGCU[dT][dT]  Hoffmann et al., 2016 




2.3.3.2. CRISPR/Cas9 transfections 
 
Plasmids expressing guide RNAs (gRNAs) and Cas9 were introduced into cultured 
human cells (HCT116, RPE1, RPE1 p53-/- Cas9 and HeLa Cas9) using the Neon® Transfection 
System (Invitrogen) following the manufacturer's instructions (Table 2.8). Alternatively, 
cultured human cells (U2OS and RPE1) were transfected using Lipofectamine™ 2000 
transfection reagent (Invitrogen) according to manufacturer's instructions. Cells expressing 
GFP were sorted by fluorescence-activated cell sorting (FACS) into 96-well plates 24 h after 
transfection. Once confluency was reached, clones were replated and collected for rapid 
preparation of DNA using 40–80 μl DirectPCR Lysis Reagent (Viagen) and 0.4 μg/μl Proteinase 
K enzyme (Roche). Genomic DNA was isolated from CRISPR clones at 55°C for 16 h, followed 
by heating to 85°C for 45 min to inactivate Proteinase K. Isolated DNA was used for PCR 
amplification of the genomic region around the expected nucleotide change. PCR products 
were sent for Sanger sequencing, and sequencing traces were analysed with Sequencher 4.8 
DNA Sequence Analysis Software (Gene Codes Corporation). 
 
Table 2.8. Electroporation conditions used for Neon® transfection of different cell types. 
Neon® electroporation parameters 




























2 10 μl 12-well plate 




HeLa 1005 35 









2.3.3.2.1. Guide RNA (gRNA) design and Cas9-expressing plasmid construction 
 
Guide RNAs (gRNAs) for CRISPR/Cas9-based genome editing experiments were 
designed using the online CRISPR Design Tool created by Feng Zhang laboratory 
(http://crispr.genome-engineering.org/) and CRISPR gRNA Design Tool DNA2.0 (now ATUM), 
and ordered from Sigma-Aldrich (Table 2.9). The 5’ and/or 3’ overhangs were added to forward 
and reverse oligonucleotides to allow cloning into BbsI site of Cas9 vector. The forward 
oligonucleotide had a 5’ overhang CACCG(G)-, whereas the reverse oligonucleotide had a 5’ 
overhang AAAC- and a 3’ overhang –(C)C. 
The top and bottom strands of oligonucleotides (20 μl of 100 μM oligonucleotide) for 
each gRNA design were first annealed at 95°C for 5 min in 5X oligo buffer (Table 2.1) and 
allowed to cool down to room temperature. The mixture was then diluted (1:40 in dH20) and 
used to set up ligation reactions to insert the guiding sequence into a BbsI-digested Cas9-
expressing plasmid (Addgene) plasmid using T4 ligase enzyme, as described by Ran, Hsu, 
Wright et al. (2013). Ligation reactions (10 μl) contained 10X T4 DNA ligase reaction buffer 
(NEB), 1 μl diluted oligonucleotide duplex, 100 ng Cas9 plasmid, and 0.5 μl T4 DNA ligase (NEB). 
Ligation was carried out for a minimum of 1.5 h at room temperature. Ligated plasmids were 
transformed into DH5α competent E. coli, purified and sequenced by the Sanger method. 
CRISPR/Cas9 transfections were carried out as described in Section 2.3.3.2, together with 
antisense single-stranded oligodeoxynucleotide (ssODN) ultramers (Table 2.10), ordered from 
Integrated DNA Technologies (IDT), or a plasmid generated using Gibson Assembly Cloning Kit 
(NEB) (Section 2.3.3.2.2). 
 
Table 2.9. List of guide RNAs (gRNAs) used in this thesis. 
Targeted 
gene Species Guide RNA (gRNA) Sequence (5'-3') 
Cas9 plasmid 




c.74+4A>C gRNA1 CTCTCCGCTCACAGCTCCGC pX461, pX458 Figure 3.10a, Figure 3.11a 
c.74+4A>C gRNA2 GGAGGAGGCGGAGCTGCCGG pX458 Figure 3.11a 
c.74+4A>C gRNA3 GCTGCCGGCGGAGCTGTGAG pX458 Figure 3.11a 
c.74+4A>C gRNA9 GGAGGGTGTGGGAACAAAGC pX462 Figure 3.10a 
c.1963A>G gRNA1 CTACGATATGTACTCTCGTA pX461 Figure 3.10a 
c.1963A>G gRNA9 GTAGTTGTTTTTCCTGTCCC pX462 Figure 3.10a 
TRAIP Human 
TRAIP gRNA1 CTTCGATCACTCCCGCGACG pX458 Figure 5.1 
TRAIP gRNA2 ATAGTGCACAGAGCACGGAT pX458 Figure 5.1 
Donson Mouse c.1319T>C gRNA TACCTTAAGCATTTGCATTG pX458 Figure 7.2 
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Table 2.10. List of single-stranded oligodeoxynucleotides (ssODNs) used in this thesis. 
Targeted 










































2.3.3.2.2. Generation of CRISPR template plasmid 
 
As an alternative CRISPR repair template to ssODNs, a plasmid containing DNA2 
c.74+4A>C (mutation of interest) and synonymous c.69G>C (PAM site mutation) substitutions 
was generated using Gibson Assembly Cloning Kit (NEB) according to manufacturer’s 
instructions. RHCglo plasmid (Table 2.3), linearised with restriction enzyme SalI (Section 
2.4.2.3), was used as a vector. The insert was generated by PCR amplification (Section 
2.4.2.5.2) of a 2,018 bp-long DNA2 fragment from DNA2 patient P4 (see Section 3.1) genomic 
DNA using primers RHCglo-DNA2-5UTR-F and RHCglo-DNA2-int1-R (Table 2.11). Gibson 
reaction (20 μl) contained: 2X Assembly Master mix; 100 ng vector; 200 ng insert; and dH2O up 
to 20 μl. The reaction was incubated at 50°C for 15 min and transformed to chemically-
competent E. coli (Section 2.2.2.2). Site-directed mutagenesis (Section 2.4.2.8) was used to 
introduce c.69G>C mutation into the plasmid using primers DNA2-c.69G>C F and DNA2-
c.69G>C R (Table 2.11). DNA2 c.74+4A>C plasmid was used for CRISPR/Cas9 transfections 
together with DNA2 c.74+4A>C gRNA1; DNA2 c.74+4A>C/c.69G>C plasmid was used together 
with DNA2 c.74+4A>C gRNA2 and gRNA3. 
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Table 2.11. Oligonucleotides used for generating the DNA2 CRISPR template plasmid. 
Oligo 








Forward primer to clone DNA2 5’ 
upstream sequences, 5’UTR, exon 1 







Reverse primer to clone DNA2 5’ 
upstream sequences, 5’UTR, exon 1 




c.69G>C F GAGCTGCCGGCCGAGCTGTGCGCGG 
Forward primer to introduce 
c.69G>C substitution in DNA2 Figure 3.11b  
DNA2-
c.69G>C R CCGCGCACAGCTCGGCCGGCAGCTC 
Reverse primer to introduce 
c.69G>C substitution in DNA2 Figure 3.11b 
 
2.3.3.2.3. In vitro guide RNA (gRNA) testing 
 
Donson c.1319T>C gRNA (Table 2.9), cloned into the pX458 plasmid, was amplified by 
polymerase chain reaction (PCR) (see Section 2.4.2.5.2) using a specific forward primer T7-
mDonson-M446T-F (TGTAATACGACTCACTATAGGGTACCTTAAGCATTTGCATTG) and the 
universal reverse primer (AAAAGCACCGACTCGGTGCC). In vitro transcription of gRNA was 
performed using The HiScribe T7 High Yield RNA Synthesis Kit (New England Biolabs, NEB) 
according to manufacturer’s instructions. The gRNA was treated with 30 U RNase-free DNase 
I (Qiagen) for 15 min, followed by RNA clean-up using the RNeasy Mini Kit (Qiagen). The in vitro 
cutting reaction, containing Buffer 3 (NEB), bovine serum albumin (BSA, NEB), 60 ng of Donson 
template (amplified using primers mDonson-F2 and mDonson-R2, Appendix 1e), 20–40 ng 
gRNA and 200–680 ng recombinant Cas9 enzyme (Canopy Biosciences) was incubated at 37°C 
for 3 h. The reaction products were visualised on 2% agarose gels. 
 
2.3.3.3. DNA transfections 
 
DNA was transfected into monolayer cells using Lipofectamine™ 2000 (Invitrogen) 
according to manufacturer’s instructions. HeLa cells were 90% confluent at time of 
transfection. For each transfection of a well of a 6-well plate two complexes were prepared. 
The first contained 800 ng – 1 μg of DNA in 500 μl of Opti-MEM reduced serum medium 
(Invitrogen), and the second contained 1.5 μl Lipofectamine in 500 μl Opti-MEM. After 5 min 
incubation, the solutions were mixed for 20 min and then added to the cells. The cells were 
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incubated in 1.5 ml Opti-MEM with the transfection mixture for 4–6 h, after which Opti-MEM 
was replaced with fresh medium. 
 
2.3.4. Retroviral transduction of cultured mammalian cells 
 
Retroviruses encoding TRAIP-WT and TRAIP-W37A transgenes were generated in 
amphotropic Phoenix E packaging cell line. Phoenix E cells were plated in 100 mm tissue culture 
dishes and grown for 24 h, and transfected with 20 μg of pMSCVpuro, pMSCVneo-TRAIP-WT 
or pMSCVneo-TRAIP-W37A plasmids (Table 2.3) using calcium phosphate transfection kit 
(Sigma-Aldrich, catalog number K278001). 20 μg plasmid DNA was mixed with 37 μl 2 M CaCl2 
(provided by manufacturer), and the total volume was made up to 370 μl with dH2O (provided 
by manufacturer). The mixture was added dropwise to 370 μl 2X HEPES Buffered Saline (HeBS; 
provided by manufacturer) while bubbling air through HeBS with another pipette. After 20 min 
incubation at room temperature, the transfection mix was added to Phoenix E cells. 16 h later 
medium was replaced. Virus-containing supernatant was collected 48 h post-transfection and 
filtered through a 0.2 μm Millex-HV sterile filter with PVDF membrane (Millipore). The filtrated 
viral supernatant was immediately used for infection or aliquoted into 1.5 ml cryovials and 
stored at –80°C. 
 
2.3.5. Relative surface area of cell culture vessels 
 
The volumes of reagents given for mammalian cell transfections describe either the 6-
well plate or 100 mm dish format. Other formats, such as 12-well plates, were also used. The 
equivalent volumes can be calculated from Table 2.12 below. 
 
Table 2.12. Relative surface area of cell culture vessels. 
Culture  
Vessel 24-well 12-well 6-well 60 mm 100 mm 150 mm T25 T75 
Surface area 
(cm2) 2 4 9 28.2 78.5 176.7 25 75 
Ratio to  




2.4. Nucleic acid methods 
 
2.4.1. General methods 
 
2.4.1.1. Spectrophotometric quantification of nucleic acids 
 
The concentration of nucleic acids was determined by measuring the optical density 
at 260 nm using a NanoDrop 1000 UV-Vis Spectrophotometer (Thermo Fisher Scientific). 1 µl 
of each sample was used for each measurement. The purity of the nucleic acid sample was 
determined by measuring the absorbance at 230 nm, 260 nm and 280 nm. The 260/280 ratio 
of a sample free of protein contamination should be 1.8-2.2 and a 230/260 ratio ≥1.7 indicates 
a sample free of carbohydrates and lipids. 
 
2.4.1.2. Agarose gel electrophoresis 
 
Nucleic acid samples were analysed by agarose electrophoresis on gels ranging from 
0.8% to 2% agarose in TBE (w/v). Gels were prepared by dissolving agarose (Hi-Pure Low EEO 
agarose, Biogene) in 0.5X TBE buffer by boiling in a microwave oven and adding ethidium 
bromide (after cooling to ~50°C) to a final concentration of 0.5 µg/ml. DNA samples were 
mixed with 6X DNA loading buffer (30% (v/v) glycerol, 0.4% (w/v) Orange G), loaded on to the 
gel, and 5 volts/cm voltage was used to resolve the nucleic acid fragments by size. The nucleic 
acids were visualised using a UV transilluminator (BioDoc-It System, UVP). For reference, 
markers containing DNA fragments of known sizes were included (1kb DNA Ladder (Invitrogen) 
or 100bp DNA Ladder (Promega)). 
 
2.4.2. DNA methods 
 
2.4.2.1. Purification of DNA from E. coli cells 
 
2.4.2.1.1. Small scale preparation of plasmid DNA 
 
Plasmid DNA was prepared using the QIAprep Spin Miniprep Kit (Qiagen) following the 
manufacturer’s instructions. DNA was extracted from 5 ml of stationary phase E. coli culture 
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and eluted in 50 µl of elution buffer (10mM Tris-HCl pH 8.5) or DNAse/RNAse-free distilled 
water (Gibco).  
 
2.4.2.1.2. Large scale preparation of plasmid DNA 
 
For larger scale preparation of plasmid DNA, the ZymoPURE II Plasmid Maxiprep Kit 
(Zymo Research) was used. DNA was extracted from 100-150 ml of stationary phase E. coli 
following the manufacturer’s instructions and eluted in 400 µl of the provided elution buffer. 
 
2.4.2.2. DNA sequencing 
 
Dye terminator sequencing reactions (ABI) were performed and processed by the 
Institute of Genetics and Molecular Medicine (IGMM) sequencing service on a 3130/3730 
genetic analyser (Applied Biosystems). DNA sequencing data was analysed using Sequencher 
5.4.6 (Gene Codes Corp.). 
 
2.4.2.2.1. Sanger sequencing of DNA2 in MPD patients 
 
A typical PCR mixture to screen for DNA2 mutations contained: 1-50 ng template DNA, 
ThermoPrime 2X ReddyMix PCR master mix (Thermo Scientific) with 1.5 mM MgCl2, 0.1–0.5 
µM forward primer (Table 2.13), 0.1–0.5 µM reverse primer (Table 2.13), and dH2O up to a 
total reaction volume of 10 µl. PCR reactions were performed on a DNA Engine Tetrad 2 
thermal cycler (MJ Research) using a touchdown PCR program for increased specificity and 
sensitivity (Korbie and Mattick, 2008) (see below).  
PCR products were separated on a 1.5% 0.5X TBE agarose gel to confirm correct 
amplification. Successfully amplified exons were sequenced using dye-terminator chemistry 
and electrophoresed on an ABI 3730 capillary sequencer (Applied Biosystems). Sequences 
were then analysed using Mutation Surveyor software (Soft Genetics). The frequency of 
mutations within the normal population was determined using the Exome Aggregation 






Table 2.13. List of DNA2 primers used for Sanger sequencing of the DNA2 gene in MPD 
patients. 











































Touchdown PCR program: 
           Denaturation  94˚C             5 min 
  Denaturation  94˚C             30 sec 
  Annealing  68˚C             30 sec 
  Extension  72˚C             45 sec per kb 
  Denaturation  94˚C             30 sec 
  Annealing  65˚C             30 sec 
  Extension  72˚C             45 sec per kb 
  Denaturation  94˚C             30 sec 
  Annealing  62˚C             30 sec 
  Extension  72˚C             45 sec per kb 
  Denaturation  94˚C             30 sec 
  Annealing  59˚C             30 sec 
  Extension  72˚C             45 sec per kb 
          Extension   72˚C             10 min 
 
2.4.2.3. Restriction digests 
 
Plasmid DNA was digested with the appropriate restriction endonuclease in the buffer 
supplied by the manufacturer (NEB or Roche). To ensure complete restriction digestion before 
subsequent cloning steps, the digest was performed in a 100 µl of buffer with 2–5 µg of DNA 
and 20 U of the appropriate enzyme(s) overnight at the appropriate temperature, generally 
37°C. For double digests, the optimal buffer conditions were selected for both enzymes using 
the manufacturer’s guidelines.  
 
2.4.2.4. Purification of restriction digested DNA 
 
DNA fragments produced by restriction digestion were resolved by agarose gel 
electrophoresis. The desired DNA fragment was excised from the gel using a scalpel and 
purified using the QIAquick Gel Extraction kit (Qiagen) according to the manufacturer’s 












2.4.2.5. Amplification of DNA by polymerase chain reaction (PCR) 
 
2.4.2.5.1. Primer design to amplify DNA for cloning 
 
Primers to amplify DNA were designed using the primer design program Primer3 
(available online at http://primer3.sourceforge.net/). The primers selected usually had a 
melting temperature (Tm) of around 55˚C (45–65˚C) which did not differ by more than 4°C 
between the forward and reverse primers in a pair. The nearest neighbour formula was used 
to predict the Tm (˚C) of primers (SantaLucia, 1998).  
 
2.4.2.5.2. Polymerase chain reaction (PCR) 
 
Specific regions of DNA were amplified using the polymerase chain reaction (PCR). The 
designed oligonucleotide primers (see Appendix 1c-e) were annealed to denatured template 
DNA and extended by a thermostable DNA polymerase. Different DNA polymerase-containing 
PCR master mixes were utilised: ThermoPrime 2X ReddyMix PCR Master Mix with 1.5 mM 
MgCl2 (Thermo Fisher Scientific, catalog number AB0575DCLDB) for standard PCR, FastStart 
PCR Master Mix (Roche, catalog number 04710436001) for colony PCR, and Phusion Flash 
High-Fidelity PCR Master Mix (Thermo Fisher Scientific, catalog number F548S) for when a high 
level of polymerase accuracy was required. 
A typical PCR mixture using ThermoPrime 2X ReddyMix PCR Master Mix contained: 1–
100 ng template DNA (plasmid or genomic), 1X ReddyMix PCR Master Mix (provided by 
manufacturer), 0.1–0.5 µM forward primer, 0.1–0.5 µM reverse primer, and dH2O up to a total 
reaction volume of 10–25 µl.  
A typical PCR using ReddyMix PCR Master Mix was performed on a DNA Engine Tetrad 
2 thermal cycler (MJ Research) as follows: 
 
  Denaturation  95˚C 1 min 
  Denaturation  95˚C              30 sec 
  Annealing  55-65˚C1 30 sec 
  Extension  72˚C              60 sec per kb 
 Extension  72˚C 5 min 
                                                          








A typical colony PCR mixture using FastStart PCR Master Mix contained: plasmid 
template DNA (a single bacterial colony picked with a sterile pipette tip), 1X FastStart PCR 
Master Mix (provided by manufacturer), 0.1–0.5 µM forward primer, 0.1–0.5 µM reverse 
primer, and dH2O up to a total reaction volume of 10 µl.  
A typical PCR using FastStart PCR Master Mix was performed on a DNA Engine Tetrad 
2 thermal cycler (MJ Research) as follows: 
 
  Denaturation  96˚C 10 min 
  Denaturation  95˚C              30 sec 
  Annealing  58˚C  30 sec 
  Extension  72˚C              60 sec per kb 
 Extension  72˚C 2 min 
 
A typical PCR mixture using Phusion Flash High-Fidelity PCR Master Mix contained: 1–
100 ng template DNA (plasmid or genomic), 1X Phusion Flash PCR Master Mix (provided by 
manufacturer), 0.1–0.5 µM forward primer, 0.1–0.5 µM reverse primer, and dH2O up to a total 
reaction volume of 10–20 µl.  
A typical PCR using Phusion Flash PCR Master Mix was performed on a DNA Engine 
Tetrad 2 thermal cycler (MJ Research) as follows: 
 
  Denaturation  98˚C 10 s 
  Denaturation  98˚C              1 sec 
  Annealing  55-65˚C 2 5 sec 
  Extension  72˚C              15 sec per kb 
 Extension  72˚C 1 min 
 
2.4.2.6. Purification of PCR products 
 
To purify PCR products, the QIAquick PCR Purification kit (Qiagen) was used according 
to the manufacturer’s instructions. DNA was eluted in 30 µl of elution buffer and stored 
indefinitely at –20˚C.  
                                                          
2 For primers >20 nt, annealing was done for 5 sec at a melting temperature (Tm) +3°C of the lower Tm 












2.4.2.7. Genotyping of mice and mouse embryos 
 
To genotype mice or mouse embryos for mutations in Donson, a PCR was performed 
using DNA isolated from mouse ear clips or embryonic tails, respectively. Each ear clip was 
lysed in 50 µl of 25 mM NaOH and 0.2 mM EDTA by boiling at 95°C for 30 min. After boiling, 
the mixture was cooled to room temperature for 5 min and then 50 µl of 40 mM Tris-HCl pH 
7.5 was added to neutralise the base. Each embryonic tail was placed into DirectPCR Lysis 
Reagent (Viagen) with added Proteinase K enzyme, and incubated at 55˚C for 16 h, followed 
by heating at 85˚C for 45 min. 
The PCR consisted of 0.5 µl of template, ThermoPrime 2X ReddyMix PCR Master Mix 
(Thermo Scientific) and 0.5–1 μM of each oligonucleotide (Appendix 1e) in a 10 µl final volume. 
Thermal cycling conditions were as follows: 
 Denaturation  95˚C 1 min 
  Denaturation  95˚C 30 sec 
  Annealing  60˚C 30 sec 
  Extension  72˚C 35 sec 
 Extension  72˚C 5 min 
 
2.4.2.8. Site-directed mutagenesis 
 
2.4.2.8.1. Primers for site-directed mutagenesis 
 
Primers for use in site-directed mutagenesis were designed using the QuikChange 
Primer Design Program (available online at http://www.genomics.agilent.com). The design 
algorithm adhered to a number of rules. The primers were between 25 and 55 bases in length, 
with a melting temperature (Tm) of ≥78˚C (see below), and the desired mutation was located 
near the middle of the primer with a minimum of ~10–15 bases of correct sequence on either 
side. The Tm of primers was calculated using the following formula: 
Tm = 81.5 + 0.41(%GC) – 675/N – %mismatch 
in which N = the primer length in bases, 
percentage GC = (#G bases + #C bases)/oligonucleotide length, and 






2.4.2.8.2. Site-directed mutagenesis 
 
Point mutations were introduced into plasmid vectors using the PCR based 
QuikChange method (Stratagene). Primers containing the desired mutation(s) (Appendices 1f, 
1g, and 1h) were designed to anneal to the same sequence on opposite strands of the plasmid 
and were extended by PCR, generating a mutated plasmid. The PCR contained: 50 ng plasmid, 
0.25 mM dNTPs, 0.2 µM mutagenic primers (forward and reverse), 1X DNA polymerase buffer 
with MgCl2 (Stratagene) and 1.25 U of PfuTurbo DNA polymerase (Stratagene). Cycling 
parameters for site-directed mutagenesis were as follows: 
 
 Denaturation  95˚C 1 min 
  Denaturation  95˚C 30 sec 
  Annealing  55˚C 1 min  
  Extension  68˚C 1 min per kb 
 Extension  68˚C 10 min 
 
The PCR product was treated with 10 U of DpnI (NEB) at 37˚C overnight to digest the 
methylated parental vector DNA and thereby select for the mutation-containing synthesised 
DNA. Following incubation, 0.5–1 μl of the DpnI treated DNA was used for transformation into 
DH5α E. coli (Section 2.2.2.2). Resulting colonies were mini-prepped and screened by Sanger 
sequencing (see Section 2.4.2.2). 
 
2.4.2.9. Ligation of DNA molecules 
 
Ligation reactions contained: 100–200 ng of vector DNA, 2–3X this molar amount of 
insert DNA, 1 U T4 DNA Ligase (Roche) and 1X Ligation Buffer (Roche). Following incubation for 
4–5 h at room temperature, 1 μl ligation mixture was used to transform E. coli (Section 2.2.2.2). 
 
2.4.3. RNA methods 
 
2.4.3.1. Purification of RNA from human cells 
 
RNA was prepared from approximately 1.2x106 cells using the RNeasy Mini Kit (Qiagen) 





column (Qiagen) by centrifugation at 16,000 x g for 2 min. To eliminate genomic DNA 
contamination, an on-column treatment with 30 U RNase-free DNase I (Qiagen) for 15 min was 
also included. RNA was eluted into 50 μl RNase-free water and stored indefinitely at –80°C. 
 
2.4.3.2. Reverse transcription of RNA 
 
cDNA (DNA complementary to first strand RNA) was generated using reverse 
transcriptase and random oligomer primers. A typical reaction mixture contained 1 μg of each 
RNA sample, 125 ng random primers (Promega) and 1 μl dNTPs (10 mM each), made up to 
13.5 µl with RNase-free dH2O. To melt RNA secondary structures, the reaction was incubated 
at 65°C for 5 min, immediately followed by 5 min on ice. The 6.5 μl reverse transcription mix 
(Invitrogen) was then added (4 μl 5X First Strand Buffer, 1 μl 0.1 M DTT, 0.5 μl RNaseOUT 
Recombinant Ribonuclease Inhibitor and SuperScript III Reverse Transcriptase). The reaction 
was incubated at 25°C for 5 min, followed by 50°C for 60 min, after which the enzyme was 
deactivated at 70°C for 15 min. cDNA was stored at –20°C until required.  
 
2.4.3.3. Reverse transcription PCR (RT-PCR) 
 
RT-PCR amplification was performed on cDNA generated as described in Section 
2.4.3.2. A typical RT-PCR mixture contained: 0.2–0.5 µl cDNA, ThermoPrime 2X ReddyMix PCR 
master mix with 1.5 mM MgCl2, 0.1 µM forward primer (Appendices 1i and 1j), 0.1 µM reverse 
primer (Appendices 1i and 1j), and dH2O up to a total reaction volume of 10 µl. PCRs were 
performed on a DNA Engine Tetrad 2 thermal cycler (MJ Research) using the PCR program 
described below: 
 
           Denaturation  95˚C             5 min 
  Denaturation  94˚C             30 sec 
  Annealing  62˚C             30 sec 
  Extension  72˚C             45 sec 






2.5. Protein methods 
 
2.5.1. Protein preparation from cultured mammalian cells 
 
2.5.1.1. Whole cell protein preparations 
 
For whole cell extract preparation, cultured mammalian cells were harvested and lysed 
by resuspending in appropriate volume (50–80 μl per 106 cells) of urea lysis buffer (Table 2.1), 
followed by 2 cycles of sonication for 30 sec (with a 30 sec gap in between) at 4˚C using the 
Diagenode Bioruptor 300 Sonicator device. The volume of urea lysis buffer was adjusted 
according to the type and number of cells harvested. The extract was clarified by centrifugation 
at 17,000 x g for 30 min at 4˚C. The supernatant was removed and stored at –80°C until 
required. 
 
2.5.1.2. Chromatin-enriched protein lysate preparation 
 
To isolate the Triton-insoluble (chromatin-enriched) fraction, adherent cells in their 
culture dish were rinsed twice in cold PBS, washed once with pre-extraction buffer (Table 2.1), 
and incubated for 5 min on ice with gentle shaking in pre-extraction buffer, supplemented with 
1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma) and protease inhibitors (Roche, catalog 
number 04693159001). After removal of buffer and rinsing in PBS, adhering cellular material 
(Triton-insoluble fraction) was harvested by scraping the cells into an appropriate volume (50–
80 μl) of urea lysis buffer (Table 2.1). The chromatin-enriched fraction was then denatured by 
heating at 95˚C for 5 min, sonicated, and, after addition of sample loading buffer (Table 2.1), 
analysed by immunoblotting (see Section 2.5.8). 
 
2.5.2. Protein quantification 
 
Total protein concentrations in cell extracts or purified recombinant protein eluates 
were determined using Quick Start Bradford Protein Assay (Bio-Rad). Initially, a standard curve 
was drawn using a BSA concentration range of 0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml, provided by 
manufacturer. 10 µl of each solution was mixed with 190 μl of 1X Bradford dye reagent and 
the absorbance at 595 nm (A595) was measured after 5 min. Absorbance readings were plotted 
against protein concentration, and a line of best fit was used. To measure unknown protein 
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concentrations, 1 µl of protein sample was mixed with 9 µl dH2O and 190 μl of 1X Bradford dye 
reagent, and A595 was measured after 5 min. The absorbance reading was compared to the BSA 
standard curve to calculate protein concentration.  
 
2.5.3. Design and purification of recombinant polycistronic protein complexes 
 
Polycistronic PP4 construct was designed to express all the subunits of the complex 
simultaneously, as previously performed for other protein complexes (Reijns et al., 2011). 
Subunits of human PP4 complex (PP4C, PP4R2, and PP43Rα/β) were sequentially cloned into 
pGEX-6P-1 vector (Addgene) (see Figure 4.4). The first subunit cloned, PP4C, was tagged with 
GST. The plasmid was Sanger-sequenced after each round of cloning to confirm that no 
unexpected mutations had been introduced.  
 
2.5.4. Recombinant protein purification after expression in Rosetta-2 cells 
 
For recombinant protein expression, plasmids were introduced into Rosetta-2 E. coli 
cells. Bacterial cells were grown in 400 ml LB medium until OD595 0.7 was reached, and protein 
expression was induced by adding 0.1 mM IPTG, followed by incubation at 18˚C overnight. 
Bacterial cultures were harvested by centrifugation at 4,400 x g for 4 min at 4°C and 
resuspended in 10 ml NETN buffer (Table 2.1) with 1 mM PMSF (Sigma). Bacterial cells were 
lysed by sonication (3 cycles of 15 sec at 24 μ), and the soluble and insoluble fractions were 
separated by centrifugation at 24,000 x g for 15 min at 4°C.  
For recombinant PP4 complexes, the soluble fraction was incubated with 250 μl 50% 
Amersham Glutathione bead slurry on a roller for 4 h at 4˚C. The beads were centrifuged at 
500 x g for 2 min at 4°C, followed by washes in ice-cold NETN buffer (1X 10 ml, 2X 5 ml, 1X 1 
ml). The beads were washed once with 1 ml PreScission Cleavage Buffer (GE Healthcare) (Table 
2.1), and incubated in 500 μl PreScission Cleavage Buffer with 5 μl PreScission Protease (GE 
Healthcare) on a rotator at 4˚C overnight. The following day, beads were centrifuged at 500 x 
g for 1 min. Resulting supernatant, containing purified protein(s) (‘eluate’, E1), was removed, 
aliquoted and stored at –80˚C. The beads were washed with 250 μl PreScission Cleavage Buffer 
to obtain the second eluate (‘wash’, E2). 
For recombinant N-terminal TRAIP, the soluble fraction was incubated with 25 μl 50% 
Amersham Glutathione bead slurry on a roller for 4 h at 4˚C. The beads were centrifuged at 
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500 x g for 2 min at 4°C, followed by washes in ice-cold NETN buffer (2X 5 ml, 1X 1 ml). The 
beads were washed once with 100 μl Thrombin 1X Cleavage Buffer (Novagen) and incubated 
in 50 μl Thrombin 1X Cleavage Buffer with 1 μl Biotinylated Human Thrombin (Novagen) on a 
rotator at 4˚C overnight according to manufacturer’s instructions. The following day, beads 
were centrifuged at 500 x g for 1 min. 25 µl pre-washed streptavidin beads were added to the 
resulting supernatant, followed by 30 min of incubation on a rotator at room temperature. The 
beads were centrifuged at 500 x g for 5 min at 4˚C, and the supernatant, containing purified 
cleaved protein (‘eluate’), was removed, aliquoted and stored at -80˚C. 
To assess the efficiency of purification, eluates were mixed with 2X SDS protein sample 
loading buffer and separated by SDS-PAGE (10% acrylamide) (Section 2.5.6). 
 
2.5.5. In vitro protein ubiquitination assay 
 
 In vitro ubiquitination assays were used to assess the ability of TRAIP E3 ligase to 
ubiquitinate substrate proteins. In the 20 μl reactions, putative substrates (1 μg monomeric 
PP4C or 2 μg recombinant PP4 complexes) were incubated with the E3 ligase (0.4 μg N-terminal 
TRAIP) in the presence of 5 μg ubiquitin (Enzo), 10X ATP regeneration buffer (Enzo), 0.2 μg E1 
ubiquitin-activating enzyme (UBE1-His, Enzo), 0.5 μg E2 ubiquitin-conjugating enzyme 
(UbcH5b-His, Enzo), and ubiquitination buffer (1 M Tris pH 7.5, 1 M MgCl2, 1 M DTT) for 3 h at 
37˚C. Reactions were stopped by the addition of 4X SDS loading buffer. Proteins were resolved 
by SDS-PAGE (Section 2.5.6) and transferred to nitrocellulose membrane. Immunoblots were 
performed using the appropriate antibodies, and proteins visualized using the Amersham ECL 
Prime Western Blotting Reagent (GE Healthcare LifeSciences) (Section 2.5.8). 
 
2.5.6. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein samples were separated according to their molecular weight by SDS-PAGE 
(sodium dodecyl sulphate-polyacrylamide gel electrophoresis) using either the 10% or 4–12% 
Bis-Tris NuPAGE® Novex (Invitrogen) gel system or home-made Tris-glycine gels. 
For Tris-glycine gels, the resolving gel was composed of 375 mM Tris (pH 8.8), 0.1% 
(w/v) SDS and 0.1% (w/v) ammonium persulphate. For different resolving concentrations, the 
amount of 30% acrylamide/bis-acrylamide (Sigma-Aldrich) and TEMED (N’N’N’N’-
tetramethylethylenediamine) was adjusted accordingly (0.08 µl/ml TEMED in 6% acrylamide, 
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0.06 µl/ml TEMED in 8% acrylamide or 0.04 µl/ml TEMED in 10-15% acrylamide). The stacking 
gel contained 125 mM Tris (pH 6.8), 0.1% SDS, 0.1% ammonium persulphate, 4.2% 
acrylamide/bisacrylamide and 1 μl/ml TEMED. Protein samples were electrophoresed 
alongside Precision Plus Protein All Blue Prestained Protein Standards (Bio-Rad).  
Protein samples were denatured by heating at 95°C for 5 min in 1X SDS protein sample 
loading buffer (Table 2.1) and loaded onto the gel. The gels were electrophoresed in different 
types of running buffer depending on the gel composition: 1X Tris-glycine running buffer (Table 
2.1) for Tris-glycine gels or NuPAGE MOPS SDS running buffer (Thermo Fisher Scientific, 
NP0001) for Bis-Tris NuPAGE® gels. A constant voltage of 150–200 volts was applied until the 
desired separation was achieved. 
 
2.5.7. Coomassie Blue staining of protein gels 
 
To allow visualisation of abundant protein bands following SDS-PAGE, Coomassie stain 
(0.1% Coomassie Brilliant Blue R-250 dye, 50% methanol, 10% acetic acid) was used. After 
electrophoresis, the gel was washed three times for 5 min in 100 ml of dH2O and then stained 
in 100 ml of the Coomassie staining solution for 1 h, followed by destaining for 1–3 h in destain 




 Proteins resolved by SDS-PAGE were transferred to nitrocellulose membrane 
(Amersham) using a Mini-Trans-Blot Cell system (Bio-Rad). Electrophoretic blotting was 
performed in 1X immunoblotting transfer buffer (Table 2.1) at 100 V for 1–1.5 h.  
After electrophoretic transfer, the nitrocellulose membrane was blocked. To block, the 
membrane was incubated with either 5% milk solution (prepared using Marvel milk powder, 
Premier Foods) or 5% bovine serum albumin fraction V (BSA) (Roche) in TBS/T (1X TBS with 
0.2% Tween-20) for 1 h at room temperature with constant agitation. Primary antibodies were 
added to the blocking solution at the appropriate dilution (Appendix 2a) and incubated 
overnight at 4°C. The membrane was washed 3 times for 15 min in TBS/T and then the 
appropriate horseradish peroxidase (HRP)-labelled secondary antibody (Appendix 2b), diluted 
in appropriate blocking solution, was added to the membrane for 1 h at room temperature. 
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To detect HRP immobilised on the membrane, Amersham ECL Prime Western Blotting 
Reagent (GE Healthcare LifeSciences) was used according to the manufacturer’s instructions. 
For a 20 cm2 nitrocellulose membrane, 2 ml of ECL solution (1:1 mixture of solutions A and B) 
was added to the protein side of the nitrocellulose membrane and incubated for 5 min at room 
temperature. The membrane was blotted to remove any excess liquid, placed between two 
acetate sheets and exposed to photographic film (Kodak Biomax XAR Film), which was 
developed using a Konika SRX-101A Developer. Alternatively, chemiluminescence signal on the 




TRAIP antibody was previously generated by A. Robertson (A. Jackson laboratory) from 
recombinant N-terminal fragment of TRAIP protein (aa1–275) using pGEX-4T-2-TRAIP-N (gift 
from Robert Geahlen, Purdue University, USA). The construct was expressed in bacteria as GST-
fusion protein and used as antigen for the immunisation of rabbits (Eurogentec). TRAIP 
antibody was affinity purified using the fusion protein immobilized on glutathione-agarose and 
its specificity established using patient cell lysates and RNAi.  
All antibodies (Appendix 2a-b) were diluted in 5% milk (Marvel milk powder, Premier 
Foods) or 5% BSA (Roche). 
 
2.5.10. Immunoblotting image analysis 
 
Quantification of relative band intensities on unsaturated immunoblots, obtained 
using ImageQuant LAS 4000 camera system, was performed using Fiji/ImageJ software (US 
National Institutes of Health) (Abràmoff et al., 2004; Schneider et al., 2012). An area 
encompassing a protein band was defined manually and kept constant for each measurement 
within the same immunoblot. The mean pixel intensity was calculated for each area. Signal 








2.5.11. Protein ubiquitination site mapping by mass spectrometry (MS) 
 
2.5.11.1. Sample preparation 
 
The in vitro ubiquitination reactions with and without TRAIP were set up as described 
in Section 2.5.5, with wild-type PP4 complexes PP4C-PP4R2-PP4R3β and PP4C-PP4R2-PP4R3α 
as substrates. The reactions were incubated for 3 h at 37°C and stopped by freezing on dry ice 
for subsequent liquid chromatography (LC)-tandem MS (MS/MS) (performed by Alex Von 
Kriegsheim, IGMM Mass Spectrometry facility) (Section 2.5.11.2). 
 
2.5.11.2. Sample processing and analysis 
 
To prepare samples for MS analysis, an 8 M urea buffer with 100 mM Tris (pH 8.5) was 
added to ubiquitination reactions to a final concentration of 2 M urea, followed by addition of 
a 1 M DTT to a final concentration of 10 mM. Reactions were incubated at 50°C for 30 min. 
Iodoacetamide was added to the samples to a final concentration of 10 mg/ml (55 mM), 
followed by incubation for 30 min in the dark. MS grade trypsin (Promega) was added to the 
samples at 1/100 ratio (trypsin/substrate concentration), and the digestion was carried out at 
37°C overnight.  
Next day, samples were treated with 1 μl trifluoroacetic acid (TFA) to stop the 
digestion and desalted in C18 stagetips. The tips were prepared as described by Rappsilber, 
Ishihama & Mann (2003), placing a small Empore™ disc (3M™) in an ordinary pipette tip for 
each sample. Tips were activated with 50 μl of 50% acetonitrile and 0.1% TFA-containing buffer 
and washed with 50 μl of 0.1% TFA. 100 μl of sample was added to the column and washed 
twice with 50 μl 0.1% TFA solution. Liquid was passed through the pipette tip manually with 
the aid of a syringe or with a light centrifugation step. Peptides were then eluted with the help 
of a syringe using 25 μl of 50% acetonitrile and 0.1% TFA-containing buffer twice. Samples were 
evaporated in a SpeedVac Concentrator™ (Thermo Scientific), resuspended in 12 μl 0.1% TFA 
buffer and analysed by MS. 
The tryptic peptides were analysed on a mass spectrometer connected to an Ultimate 
Ultra3000 chromatography system (Thermo Scientific) incorporating an autosampler. For each 
sample, 5 μl of the tryptic peptides were loaded on a homemade column (100 mm length, 75 
μm inside diameter) packed with 1.9 μm ReprosilAQ C18 (Dr. Maisch HPLC) and separated by 
an increasing acetonitrile gradient (3%–32%) at a flow rate of 250 nl/min. The mass 
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spectrometer was operated in positive ion mode with a capillary temperature of 220°C, with 
2,000 V applied to the column. Data were acquired with the mass spectrometer operating in 
automatic data-dependent switching mode, selecting the 12 most intense ions prior to tandem 
MS (MS/MS) analysis. Mass spectra were analysed and label-free quantitation performed using 







2.6. Microscopy methods 
 
2.6.1. Fixation of cells 
 
Adherent human cells or MEFs were plated onto untreated coverslips (VWR) at 
appropriate density. After any required treatment, the cells were pre-extracted in pre-
extraction buffer (Table 2.1) for 5–10 min on ice, followed by fixation in 4% formaldehyde 
(w/v) in PBS for 12–15 min. Cells were then washed in PBS three times for 5 min and stored at 




Fixed cells were blocked in 3% fetal bovine serum (FBS) in PBS for at least 30 min. 
Primary antibodies were diluted in blocking solution (3% FBS in PBS) and incubations were 
performed for 1.5 h at room temperature in a humidified chamber. The cells were then washed 
three times in wash buffer (0.2% Triton-X100 in PBS) for 5 min before incubation with 
appropriate Alexa Fluor–488, and –568 conjugated secondary antibodies (1:1,000) (Appendix 
2b). The cells were then again washed three times in wash buffer for 5 min. Coverslips were 
mounted with Vectashield® medium containing DAPI (4',6-diamidino-2-phenylindole) (Vector 
Laboratories, catalog number H-1200-10) and sealed. Samples were analysed by microscopy 




2.6.3.1. Immunofluorescence microscopy 
 
Imaging was performed using a Zeiss Axioplan 2 wide-field fluorescence microscope 
(Zeiss) with iVision image capture software (BioVision Technologies) or Micro-Manager Open 
Source Microscopy Software at the IGMM Advanced Imaging Facility. Single images or Z-series 
were captured with a CoolSnap camera (Roper Scientific) using 40X or 63X Plan-APOCHROMAT 
(1.4 NA) oil-immersion objective. Exposure time, binning, microscope settings and light source 






Imaging of Donson embryos was performed using a Nikon brightfield macroscope with 
Micro-Manager Open Source Microscopy Software at the IGMM Advanced Imaging Facility. 
Single images were captured with a CoolSnap camera (Roper Scientific) using 0.5X-2X 
objectives. 
 
2.6.4. Image analysis 
 
Acquired images were analysed using ImageJ/Fiji software (US National Institutes of 
Health) (Abràmoff et al., 2004; Schneider et al., 2012). Nuclei were segmented on the basis of 
DAPI staining and then mean pRPA2-S4/S8 signal intensity or γH2AX/53BP1/native BrdU foci 
were quantified for each nuclear region using defined protocols (scripts) (Sections 2.6.5 and 
2.6.6). 50–100 cells were analysed per experiment per condition, as indicated in figure legends 
for individual experiments. 
 
2.6.5. Quantitative pRPA2, γH2AX and 53BP1 immunofluorescence 
 
Cells were seeded on coverslips and 16-24 h later treated with the drug (e.g. 1 μM 
CPT). To label cells undergoing DNA replication, 10 μM EdU (5-ethynyl-2´-deoxyuridine) was 
added for 20 min; if a drug treatment was used, EdU was added for the last 20 min of the drug 
treatment. To remove soluble proteins prior to immunofluorescence, cells were pre-extracted 
for 10 min on ice with ice-cold pre-extraction buffer (Table 2.1) and then fixed with 4% 
formaldehyde for 15 min. EdU immunolabeling was performed using the Click-iT EdU Imaging 
Kit (Invitrogen, C10337) according to the manufacturer’s protocol. Cells were washed with PBS, 
blocked in 3% FBS in PBS for 30 min at room temperature, and stained for pRPA2-S4/S8 (Bethyl 
Laboratories, A300-245A; 1:2,000), γH2AX (Cell Signaling Technology, 20E3, #9718; 1:2,000) or 
53BP1 (Novus Biologicals, NB100-904; 1:2,000), the secondary Alexa Fluor-linked antibody 
(Appendix 2b) and DAPI (Vector Laboratories, catalog number H-1200-10). Images were 
captured as described in Section 2.6.3.1. For quantification of mean signal intensities, nuclei 
were defined on the basis of DAPI staining and mean intensity of pRPA2-S4/S8 signal was 
detected using ‘Analyze particles’ function of ImageJ/Fiji software within each nuclear region. 
For quantification of γH2AX or 53BP1 foci, nuclei were defined on the basis of DAPI staining 
and foci were counted using ‘Find maxima’ function of ImageJ/Fiji software within each nuclear 
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region. During image analysis, the settings in ‘Analyze particles’ or ‘Find maxima’ functions 
were kept constant for all samples within an experiment. 
 
2.6.6. Quantification of native BrdU foci 
 
For quantification of native BrdU foci, cells were incubated in medium containing 10 
μM BrdU (5-bromo-2'-deoxyuridine) for 24 h prior to harvesting. 90 min prior to harvesting, 1 
μM CPT was added to the media. To visualise ssDNA foci, cells were pre-extracted for 10 min 
on ice with ice-cold pre-extraction buffer (Table 2.1) and then fixed with 4% formaldehyde for 
15 min at room temperature. After fixation, cells were washed with PBS and blocked in 3% FBS 
in PBS for 30 min at room temperature. ssDNA was visualised using a BrdU antibody (Abcam, 
ab6326; 1:500). To detect BrdU in dsDNA, DNA was denatured by incubation in 2 M HCl in PBS 
for 30 min prior to addition of BrdU antibody. Images were acquired with fluorescence 
microscope and quantified using Fiji/ImageJ software. Nuclei were defined on the basis of DAPI 
staining and native BrdU foci were detected using ‘Find maxima’ function of ImageJ/Fiji 
software within each nuclear region. During image analysis, the settings in ‘Find maxima’ 
function were kept constant for all samples within an experiment. More than 100 cells were 




2.7. Generation and maintenance of transgenic mouse models 
 
2.7.1. Animal husbandry 
 
Transgenic mice were housed at the Central Bioresearch Services (CBS) Transgenic 
Core Facility (University of Edinburgh). All procedures were carried out under personal and 
project home office licences by the qualified facility staff. 
Mice of mixed background (C57BL/6, CBA and CD-1) and up to 1 year of age were used 
for the experimental work described in this thesis. 
 
2.7.2. Cytoplasmic injection of CRISPR reagents 
 
Cytoplasmic injections of CRISPR reagents into fertilised eggs were performed to 
generate transgenic Donson mice. The CRISPR injection mix (20 μl) to target mDonson 
contained: Cas9 mRNA (50 ng/μl), guide RNA (gRNA) (25 ng/μl) (Table 2.9) and repair template 
DNA (150 ng/μl) (Table 2.10) in nuclease-free water. The prepared mix was spun down at 
17,000 x g for 30 min at 4°C, 18 μl of it was transferred to a new tube and stored at –20°C until 
injection.  
Injections were performed by the staff of CBS Transgenic Core Facility (University of 
Edinburgh). Fertilised eggs were obtained from super-ovulated female donor mice that were 
mated with fertile (stud) males. The CRISPR reagents were then microinjected into the 
cytoplasm of each egg. Injected eggs and un-injected controls were cultured overnight to the 
two-cell stage and then transferred to the oviducts of pseudo-pregnant ‘recipient’ females 
(recipients were generated by mating females with vasectomised males so the females do not 




2.8. Cell-based assays 
 
2.8.1. Chromosome metaphase spreads 
 
Chromosomal aberrations were scored in DAPI-stained metaphase spreads. 60 nM 
mitomycin C (Sigma Aldrich) was added to cells for 24 h. Three hours prior to harvesting, 100 
ng/ml colcemid (Biosera) was added to cells. Growth medium was removed and stored in a 15 
ml tube. Cells were gently washed with 1 ml TrypLE™ Express Enzyme (1X) (Thermo Fisher 
Scientific, catalog number 12605036) (the trypsin wash was combined with the original 
medium), trypsinised, resuspended in the original conditioned medium (with a trypsin wash) 
and centrifuged (250 x g, 5 min, 4°C). Cells were then washed with PBS, spun down, 
resuspended in pre-warmed 75 mM potassium chloride (KCl) and incubated for 30 min at 37°C. 
Cells were centrifuged again, the supernatant was removed and cells were fixed by drop-wise 
addition of 1 ml fixative (ice-cold methanol:acetic acid, 3:1) while gently vortexing. An 
additional 10 ml of fixative was then added and cells were fixed at 4°C for at least 16 h. Once 
fixed, metaphases were dropped on glass slides humidified with methanol:acetic acid (3:1), 
rinsed with fixative, air-dried, mounted using Vectashield® medium containing DAPI (Vector 
Laboratories, catalog number H-1200-10), and imaged at 63X objective on fluorescence 
microscope. 
 
2.8.2. Sister chromatid exchange assay 
 
Homologous recombination (HR) proficiency of cells was determined by scoring sister 
chromatid exchanges (SCEs). 10 μM BrdU was added to RPE1 p53-/- Cas9 cells for 2 cycles of 
replication (47–48 h). For the first cycle, 5 nM CPT or 20 mM MMC was added to cells as well. 
After 24 h, the drug was washed off with PBS, BrdU-containing medium was refreshed, and 
cells were grown for another 24 h (second round of DNA synthesis). Three hours prior to 
harvesting, 100 ng/ml colcemid (Biosera) was added to cells.  
Growth medium was removed and stored in a 15 ml tube. Cells were gently washed 
with 1 ml TrypLE™ Express Enzyme (1X) (Thermo Fisher Scientific, catalog number 12605036) 
(the trypsin wash was combined with the original medium), trypsinised, resuspended in the 
original conditioned medium (with a trypsin wash) and centrifuged (250 x g, 5 min, 4°C). Cells 
were then washed with PBS, spun down, resuspended in pre-warmed 75 mM potassium 
chloride (KCl) and incubated for 30 min at 37°C. Cells were centrifuged again, the supernatant 
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was removed and cells were fixed by drop-wise addition of 1 ml fixative (ice-cold 
methanol:acetic acid, 3:1) while gently vortexing. An additional 10 ml of fixative was then 
added and cells were fixed at 4°C for at least 16 h. Once fixed, metaphases were dropped on 
glass slides humidified with methanol:acetic acid (3:1), rinsed with fixative and air-dried 
overnight (protected from light).  
To visualize SCEs, slides were rehydrated in PBS for 5 min and stained with 2 μg/ml 
Hoechst 33342 (Molecular Probes/Thermo Fisher Scientific) in 2X SSC (300 mM NaCl, 30 mM 
sodium citrate, pH 7.0) (Table 2.1) for 15 min. Stained slides were placed in a plastic tray, 
covered with a thin layer of 2X SSC and irradiated with 254 nM UV light (~5400 J/m2). Slides 
were subsequently dehydrated in a 70%, 95% and 100% ethanol series (5 min each), air-dried 
and mounted using Vectashield® medium containing DAPI (Vector Laboratories, catalog 
number H-1200-10). Images were captured as described in Section 2.6.3.1. 
 
2.8.3. Clonogenic cell survival assay 
 
For colony formation assays, cells were plated at low densities (125–4,000 cells per 
100 mm tissue culture dish) and treated with the indicated doses of CPT or MMC for 24 h. Cells 
were then washed extensively, culture medium was replaced, and cells were allowed to form 
colonies for 8–9 days, at which point they were fixed and stained with 2% methylene blue 
solution (2% methylene blue solution in 50% EtOH). Colonies were counted manually by visual 
inspection. The surviving fraction at each dose was calculated after normalisation to the colony 
number detected for untreated samples. When siRNA transfection (Section 2.3.3.1) was 
required before plating cells for clonogenic survival assay, cells were treated with drug 48 h 
post-transfection. 
 
2.8.4. Minigene splicing assay 
 
The splicing minigene reporter RHCglo, generated by the Thomas Cooper laboratory 
(Singh and Cooper, 2006), was used for all minigene experiments in this thesis. Exons and 
introns of interest were amplified from control and patient genomic DNA using primers with 
restriction enzyme sites (Appendix 1a). The PCR products and RHCglo vector were digested 
with the appropriate restriction enzymes (New England Biolabs, NEB) at 37°C overnight. 
Digested RHCglo plasmid was treated with Antarctic Phosphatase enzyme (NEB) for 1 h at 37°C 
to prevent self-ligation. Ligation reactions between RHCglo plasmids and inserts were 
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performed (Section 2.4.2.9), and the ligated plasmids were transformed into competent DH5α 
E. coli strain (Section 2.2.2.2). A positive control for splicing was generated by introducing a 
point mutation into the splice donor or acceptor site using site-directed mutagenesis (Section 
2.4.2.8) and primers indicated in Appendix 1f. 
HeLa cells, used for minigene transfections, were plated in 6-well plates and 
transfected with 800 ng of minigene plasmids, as described in Section 2.3.3.3. Cells were 
harvested 24 h after transfection, followed by the total cellular RNA extraction (Section 2.4.3.1) 
and cDNA generation (Section 2.4.3.2). RT-PCR amplification with RHCglo or gene-specific 
primer mix (Appendix 1i) was then performed on cDNA (Section 2.4.3.3). Wild-type and mutant 
cDNA amplicons were resolved on a 2% agarose gel to visualise splicing differences (Section 
2.4.1.2). PCR products were cloned into pGEM-T Easy Vector (Promega), and the plasmids were 
transformed into competent DH5α E. coli strain (Section 2.2.2.2). Colony PCR on colonies was 


































3. DNA2 mutations in microcephalic primordial dwarfism 
 
DNA2 is an ATP-dependent helicase/nuclease, which has been demonstrated in recent 
years to play multiple important roles during DNA replication and repair. Most of the well-
studied cellular functions of DNA2 have been attributed to its nuclease activity, whereas the 
helicase activity of DNA2 long remained unclear. However, more recently it was shown to act 
as an ATP-dependent translocase to promote rapid ssDNA degradation during DNA end 
resection (Levikova et al., 2017; Miller et al., 2017) (see Section 1.4 for details). 
In 2014, DNA2 was proposed as a candidate Seckel syndrome gene based on the 
identification of a homozygous intronic mutation in two related individuals (Shaheen et al., 
2014) (Figure 3.1). This study suggested the mutation to alter splicing of DNA2 transcripts, 
resulting in reduced protein levels and DNA damage. However, the report would have greatly 
benefited from the analysis of more cases, as it was based on a single identified mutation. 
Identification of multiple individuals exhibiting a specific phenotype with mutations in the 
same gene can significantly strengthen the association of that gene with a disease. 
Additionally, analysis of unrelated affected individuals allows better separation of mutation-
specific effects and background genetic noise, as well as providing confirmation of the disease-
causing nature of a gene. Although some analysis of patient-derived cell lines was provided by 
Shaheen et al. (2014), the mechanism by which mutations in DNA2 would cause MPD remained 
to be established. Additionally, monoallelic mutations in DNA2 were reported to result in 
muscle deficiency and mitochondrial disease (Chae et al., 2015; Phowthongkum and Sun, 2017; 
Ronchi et al., 2013), and it is yet to be explained why heterozygous and homozygous mutations 
in this gene are associated with different phenotypes (see Section 3.6 for discussion). 
In the Andrew Jackson laboratory, extensive whole exome sequencing (WES) was 
performed on a group of MPD patients with unknown molecular cause of disease. This study 
helped to identify several novel candidate MPD genes, including DNA2. In this chapter, the 
identification and phenotypic characterisation of the individuals with DNA2 mutations is 
described, as well as various attempts to address the consequences of the identified variants 
on DNA2 transcript splicing and protein levels.
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3.1. Identification and phenotypic characterisation of MPD patients with DNA2 
mutations 
 
The novel link established between DNA2 and MPD by Shaheen et al. (2014) was based 
on the identification of a single variant. Significantly, four patients with biallelic mutations in 
the DNA2 gene were identified in the WES study performed in our laboratory on a cohort of 
332 individuals, 192 of which were severely affected MPD patients with no known genetic 
cause for their disease (Figure 3.1; Table 3.1; Table 3.2; performed by Louise Bicknell). In total, 
we identified two intronic variants and one missense mutation in four individuals that are not 
known to be related to each other. These DNA2 variants have not been reported in the general 
population (genome Aggregation Database (gnomAD)), consistent with them being disease-
causing. The affected individuals were Sanger-sequenced to confirm the variants identified 
during WES (Figure 3.2). The parents of the affected individuals were shown to be 
heterozygous for these variants, demonstrating the necessity for biallelic mutations to cause 




Figure 3.1. Disease-associated variants within the DNA2 gene. 
DNA2 mutations identified in MPD patients are shown in red on a schematic model of DNA2 
gene and protein structure. Variants c.74+4A>C, c.1763+26_1763+27ins53bp (also referred to 
as int11ins53bp) and c.1963A>G (p.T655A) were identified in four affected individuals by our 
laboratory, whereas c.3114+6delC mutation (shown in dark red) was described by Shaheen et 
al. (2014). Several monoallelic DNA2 mutations (shown in purple) were linked to muscle 
deficiency and mitochondrial disorders (Chae et al., 2015; Phowthongkum and Sun, 2017; 
Ronchi et al., 2013). Single amino acid substitutions D227A and K654E (shown in light blue) 
have been employed by multiple studies as separation of function (SoF) mutations to unlink 
nuclease and helicase activities, with the D277A mutation obliterating the nuclease activity 
and unmasking the helicase/translocase function, and the K654E mutation abolishing the 





Table 3.1. List of novel mutations in DNA2 in four MPD-affected individuals. 
The table indicates biallelic variants in DNA2 that were found during WES analysis in four MPD 
patients (P1–P4), as well as the predicted consequences at protein level that these variants 
would cause. 
Pt 
Nucleotide mutations Amino acid 
alterations Sex 
Country 
of origin Allele 1 Allele 2 
P1 c.1763+26_1763+27ins53bp c.1763+26_1763+27ins53bp ? F Italy 
P2 c.1763+26_1763+27ins53bp c.1763+26_1763+27ins53bp ? F USA 
P3 c.1963A>G c.74+4A>C p.T655A / ? F USA 
P4 c.74+4A>C c.74+4A>C ? M Sri Lanka 
 
 
Table 3.2. Phenotypic characteristics of individuals with DNA2 mutations. 
The table provides a summary of the phenotypic measurements of P1, P3 and P4, as provided 















P1 36 1.68 -2.5 N/A N/A 5y 8m 43 -7.5 88 -5.3 
P3 34 0.9 -4.1 N/A N/A 15y 9m 42.1 -9.6 95.5 -11.1 




Figure 3.2. Electrophoretic DNA sequencing traces of DNA2 mutations in MPD patients. 
The DNA2 regions shown by WES analysis to contain rare variants were PCR-amplified and 
Sanger-sequenced to confirm the presence of biallelic DNA2 mutations (marked in red). 
 
 
All four patients exhibited severe microcephaly at the time of their postnatal exam, 
with the OFC ranging from −5.6 SD to −9.6 SD, as well as markedly reduced height, ranging 
from −4.6 SD to −11.1 SD (Table 3.2; Figure 3.3a). No obvious unifying physical appearance 
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was found to distinguish the individuals with DNA2 mutations from other MPD patients, 
although three out of four patients with DNA2 mutations seem to have minor facial similarities, 
such as small mouths or large teeth (Figure 3.3b). Patient 1 (P1) was reported to have a 
prominent nose, mild hypertelorism (increased distance between the eyes), delayed dental 
age, and ichthyotic (fish scale-resembling) skin over her legs. Not much information was 
available for P2, as the patient was lost to follow-up, although she was noted to have large 
front teeth. P3 was reported to have severe kyphoscoliosis, a very small jaw, big teeth, and to 
experience recurrent chest infections. Finally, P4 was described to have very long arms 
(relative to body size) and arachnodactyly (abnormally long and slender fingers and toes), large 
ears, a small mouth, hyperextensible joints, winging of the scapulae and lumbar lordosis, a 
short broad neck, and sparse hair. No intellectual disability was noted in any of the patients, 





Figure 3.3. Phenotypic characteristics of DNA2 patients.  
a) Affected individuals show extremely reduced birth weight, postnatal height and OFC 
measurements (the black bar represents the mean), indicating global growth failure of 
prenatal onset and extreme microcephaly (plotted based on Table 3.2). b) DNA2 patients share 
some craniofacial similarities, including small mouths and prominent teeth, as seen in the 




Two of the MPD patients with DNA2 mutations (P1 and P2) are homozygous for the 
same variant, a 53 bp-long insertion in the middle of the small 78 bp-long intron 11 of DNA2. 
These two individuals are not known to be related, but the presence of the same rare mutation 
in both might suggest at least distant relatedness. The identified insertion results in an intron 
that is almost double the size of the original one and was detected by WES due to the small 
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size of intron 11. Using the CADDv1.4-GRCh38 (Combined Annotation Dependent Depletion 
version 1.4 for Genome Reference Consortium human build 38) tool, the CADD score, which 
predicts the deleteriousness of variants in the human genome (Kircher et al., 2014), was 
estimated to be 6.013 for this insertion, indicating a benign variant. In contrast, preliminary 
bioinformatic analysis, which compared the predictions of five different splicing prediction 
tools, suggested that this variant might affect splicing of DNA2 transcript, introducing either a 
new donor or acceptor splice site (Figure 3.4). Although the cause of the 53 bp insertion is 
unknown, it is noteworthy that the first 37 bp of the insertion can be mapped to a non-coding 
region on chromosome 3, whereas the following 16 bp of the insertion appear to be a small 
duplication of part of DNA2 intron 11 just upstream of the insertion.  
 
 
Figure 3.4. DNA2 int11ins53bp variant is predicted to introduce novel splice sites in intron 
11. 
The visualisation using Alamut Visual Interactive Biosoftware (a) and the cartoon model (b) of 
the insertion c.1763+26_1763+27ins53bp (marked in red), which is present in homozygous 
state in P1 and P2. This variant is predicted to alter DNA2 transcript splicing by creating a new 
intronic donor splice site (blue arrow in the cartoon model) and/or a new acceptor splice site 
(green arrow in the cartoon model). 
 
 
One of the other patients (P4) is homozygous for a putative splice site mutation in 
intron 1 (c.74+4A>C). The CADD score for this mutation is 16.43, indicating a potentially 
deleterious variant, with similar score commonly found for missense and canonical splice site 
variants (Kircher et al., 2014). This mutation is predicted to diminish the usage of the splice 
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donor site and may therefore be expected to result in aberrant splicing of the DNA2 transcript, 
either through retention of intron 1 or activation of cryptic splice sites within intron 1, both of 
which would result in a frameshift and premature stop codon (p.L25fs*) (Figure 3.5). Lastly, 
patient P3 was found to be compound heterozygous for two DNA2 variants predicted to be 
pathogenic: the already mentioned c.74+4A>C mutation and a missense mutation in exon 13 
(c.1963A>G, p.T655A). The latter affects the evolutionarily highly conserved ATP-binding motif 
of the DNA2 helicase domain and may therefore be expected to impact on the 
helicase/translocase function of DNA2 (Figure 3.6). Moreover, it has the CADD score of 28.2, 
associated with deleterious variants (Kircher et al., 2014). It is also worth mentioning that P3 
has the most severe reduction in height and the smallest head circumference out of the four 
patients with DNA2 mutations (Table 3.2). 
The identification of four MPD patients with biallelic DNA2 variants that are not 
present in the general population provides a strong case for DNA2 as a novel MPD-associated 
gene. The mutations identified were predicted to cause partial loss of DNA2 function, and 
experiments testing these predictions are described in Sections 3.3 and 3.4. 
 
 
Figure 3.5. DNA2 c.74+4A>C variant is predicted to weaken the splice donor site of intron 1. 
P4 is homozygous and P3 is heterozygous for the intronic DNA2 variant c.74+4A>C, which is 
predicted to alter DNA2 transcript splicing by reducing the probability of splicing donor site 
being used. Above: cartoon model representing the splicing change. Below: visualisation of the 
splicing prediction in NetGene2 v2.4 neural network splicing prediction tool, available at 
http://www.cbs.dtu.dk/services/NetGene2. The panel ‘Coding’ represents prediction of 
coding regions (values close to 0.0 indicate introns; values close to 1.0 indicate exons). In the 
‘Donor’ and ’Acceptor’ panels, splice donor/acceptor site predictions are shown as impulses, 
with the height of the line representing the strength of the site (values close to 1.0 indicate 
strong splice donor/acceptor sites). Blue arrows indicate the disappearance of the line 
representing the splice donor site of intron 1 in the presence of the c.74+4A>C variant. Green 






Figure 3.6. DNA2 threonine 655, mutated in MPD patient P3, is highly conserved through 
evolution. 
c.1963A>G (p.Thr655Ala, p.T655A; shown in red) in exon 13 of DNA2 affects a highly conserved 
last residue of the 8 amino acid-long ATP binding motif (shown in dark green) within the 
helicase/translocase domain. Conservation score of each residue is provided; a yellow star 
indicates complete conservation of a residue in human, mouse, chicken, African clawed frog 
and budding yeast. Alignment was generated using Jalview multiple sequence alignment 
software (Waterhouse et al., 2009).
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3.2. Sanger sequencing-based screening of the MPD patient cohort to identify 
additional variants in DNA2 
 
With the aim of identifying additional DNA2 disease mutations, Sanger sequencing was 
performed on a group of 76 MPD patients with unknown molecular diagnosis that were not 
included in the original WES study. The aim was to identify any additional potentially harmful 
coding and splicing variants in DNA2. The primers used for the screen were designed to cover 
all 21 exons of the gene as well as all the intron-exon junctions (see Section 2.4.2.2.1 for 
details). Intronic base substitutions, intronic microdeletions and silent exonic variants were 
detected within this cohort. However, none of these variants is likely to be pathogenic. All of 
the synonymous exonic variants identified in our cohort occur in the homozygous state in 
unaffected individuals, with an allele frequency of 0.05% or greater (Table 3.3). Therefore, it 
is highly unlikely that these variants are the cause of the extreme reduction in brain size and 
growth. Most non-coding variants identified are also commonly found in the healthy 
population in homozygous state (Table 3.4). Small intronic deletions of DNA2 in the MPD 
patients were mostly found to occur within long poly(A/T) tracts that frequently flank DNA2 
exons. The majority of identified intronic variants are located far from intron-exon junctions, 
reducing the likelihood of any influence on splice donor or acceptor sites. However, there 
remains a possibility that these intronic variants subtly affect DNA2 transcript splicing by 
altering important cis-acting DNA sequence elements, such as intronic splicing enhancers. 
 
 
Table 3.3. Synonymous coding variants in DNA2 identified in our cohort of MPD patients with 
unknown genetic cause of disease.  
The table shows how many of the sequenced MPD patients from our cohort were found to be 
homozygous and heterozygous for each variant and provides the calculated minor allele 
frequency (MAF). The proportion of the general population homozygous for the variant and 
MAF data were obtained from gnomAD Browser Database. 
Variant Amino acid alteration 
Our PD cohort gnomAD Browser data 
Hom Het MAF Hom MAF 
10:70227964 C / T 
(rs10998205) p.L205L 1/75 14/75 10.67% 3261/274866 13.10% 
10:70225504 G / T 
(rs3758626) p.A255A 2/72 26/72 20.83% 11943/272136 28.20% 
10:70191703 C / T 
(rs116704917) p.A719A 0/76 2/76 1.32% 11/276736 0.28% 
10:70191631 C / T 
(rs61855090) p.T743T 0/76 2/76 1.32% 418/275884 4.42% 
10:70178815 A / G 
(rs538200699) p.F1067F 0/72 1/72 0.69% 1/266294 0.05% 
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Table 3.4. Non-coding variants in DNA2 identified in our cohort of MPD patients with 
unknown genetic cause of disease. 
The table shows how many of the sequenced MPD patients from our cohort were found to be 
homozygous and heterozygous for each variant and provides the calculated minor allele 
frequency (MAF). The proportion of the general population homozygous for the variant and 
MAF data were obtained from gnomAD Browser Database. A star (*) indicates a variant that 
was not reported in gnomAD Browser Database but was indicated as a common single-
nucleotide polymorphism (SNP) in Single Nucleotide Polymorphism database (dbSNP 150; 
NCBI), which reports SNPs found in ≥1% population.  




Our PD cohort gnomAD Browser  (*or dbSNP 150) data 
Hom Het MAF Hom MAF 
10:70231701 A / G 
(rs1535539) c.-79T>C 2/75 16/75 53.33% 6434/276410 19.73% 
10:70231513 G / T 
(rs192015602) c.75+35C>A 0/75 2/75 1.33% 17/212750 1.10% 
10:70206033 TA / T 
(rs770415045) c.1057+18delT 1/64 1/64 2.34% 1654/102086 13.47% 
10:70204845 GA / G 
(rs747930650) c.1058-6delT 0/73 1/73 0.68% 26/239414 0.85% 
10:70197115 G / A 
(rs12775711) c.1416-117C>T 0/72 2/72 1.39% 672/5008* 13.42% 
10:70190155 A / G 
(rs12221039) c.2208+38T>C 1/75 13/75 10.00% 2377/187032 13.89% 
10:70182697 GT / G 
(rs141172562) c.2209-51delA 0/71 2/71 1.41% 417/184322 2.44% 
10:70181968 AT / A 
(rs746777672) c.2697+13delA 0/74 7/74 4.73% 747/29402 8.78% 
10:70179713 C / G 
(rs7912227) c.2698-64G>C 2/75 12/75 10.67% 1312/30926 25.29% 
10:70179006 T / C 
(rs41305002) c.2788-36A>G 0/72 3/72 2.08% 10/119050 1.16% 
10:70174885 A / G 
(rs17460571) c.3015-21T>C 1/73 14/73 10.96% 2588/189470 14.38% 
 
 
A few coding and non-coding variants identified, such as exonic rs538200699 or 
intronic rs1535539, are moderately over-represented in the MPD cohort compared to the 
healthy population (Table 3.3 and Table 3.4). However, this apparent over-representation is 
likely caused by the low number of patients sequenced in our study and would be matched to 
the healthy population when more patients are screened. I decided to not pursue any of these 
variants further, since high allele frequency in general population and existence of multiple 
unaffected individuals homozygous for a specific variant markedly reduces the probability of 
the variant being pathogenic and disease-causing.
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3.3. Assessing transcript splicing changes caused by DNA2 mutations 
 
3.3.1. DNA2 patient mutation int11ins53bp affects the presence of exon 12 in DNA2 
transcripts 
 
To establish the pathogenicity of a variant, it is important to demonstrate that it alters 
transcript splicing and protein levels. Due to the lack of available patient-derived cell lines to 
study the effects of DNA2 mutations on transcript and protein levels, I chose to make use of a 
minigene-based splicing assay. The minigene splicing assay is a method that can be used to 
assess the impact of a specific mutation on transcript splicing in a cell line of choice. Transient 
expression of minigenes in cells has been employed as a valuable tool in various recent studies 
to address transcript splicing, as well as study cis-acting elements that may modulate inclusion 
or exclusion of exons (Aparisi et al., 2013; Cooper, 2005; De Crescenzo et al., 2015; Steffensen 
et al., 2014). 
The bioinformatics-based modelling of the int11ins53bp mutation suggested that this 
variant is likely to create a new intronic splicing donor and/or acceptor site (Figure 3.4). 
Experimental demonstration that the 53 bp intronic insertion in the intron 11 of DNA2 leads 
to alternative splicing of DNA2 transcript was required to support our hypothesis of this variant 
being a pathogenic MPD-causing mutation. Control and DNA2 patient genomic regions 
surrounding DNA2 intron 11 were cloned into the splicing minigene reporter RHCglo (Singh 
and Cooper, 2006) (Figure 3.7a). A splicing control was generated by introducing a nucleotide 
substitution (c.1764-1G>A) into the acceptor splice site of intron 11 within the wild-type DNA2 
minigene (Figure 3.7a). Gel electrophoresis analysis of RT-PCR products generated using 
minigene backbone primers showed that the most abundant transcript in DNA2 int11ins53bp 
minigene has higher electrophoretic mobility than the product of the wild-type DNA2 minigene 
(Figure 3.7b). The control with a disrupted splice site, c.1764-1G>A, demonstrated complete 
abrogation of correct splicing (Figure 3.7b). In contrast, DNA2 int11ins53bp mutant had some 
residual amount of normally spliced transcript. Given that DNA2 is an essential gene during 
mammalian development (Lin et al., 2013), low residual level of wild-type DNA2 transcript may 






Figure 3.7. DNA2 int11ins53bp mutation alters correct splicing of DNA2 transcript. 
a) A cartoon model of RHCglo-based constructs used in the minigene splicing assay to assess 
the effect of int11ins53bp mutation in cells. Minigene plasmids were generated by PCR 
amplification of intron 11 and the nearby exons from control DNA and patient DNA, and 
subsequent cloning into the RHCglo minigene plasmid. A positive control for splicing was 
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generated by introducing a point mutation (c.1764-1G>A) into the acceptor splice site of DNA2 
intron 11. Black arrowheads indicate the locations of primers used for PCR analysis. 
b) DNA2 int11ins53bp mutation affects splicing of DNA2 transcript. HeLa cells were transfected 
with minigene constructs, followed by RNA extraction, cDNA generation and RT-PCR analysis 
to assess DNA2 transcript splicing patterns caused by the int11ins53bp mutation (see Section 
2.8.4). RT-PCR products amplified from the HeLa cDNA of the minigene assay samples using 
RSV5U and RTRHC primers (indicated by short black arrows) were run on an agarose gel and 
subsequently cloned for sequencing. Samples where no reverse transcriptase was added 
during cDNA generation are labelled as ‘-RT’. Sanger sequencing analysis of the products 
revealed that the PCR product with higher electrophoretic mobility represents the mutant 
isoform lacking exon 12, and the lower mobility product the correctly spliced transcript. 
c) The splicing defect caused by DNA2 int11ins53bp can be confirmed by RT-PCR using a blood 
sample obtained from P1. PCR products were amplified from HeLa cDNA of the minigene assay 
samples and from peripheral blood leukocyte cDNA from Patient 1 using primers located in 
exon 11 and exon 13 of DNA2 (indicated by short black arrows), run on an agarose gel and 
subsequently cloned for sequencing. Sanger sequencing analysis of the products recapitulated 
the previous findings. 
d) Sanger electropherograms of RT-PCR products demonstrate that the DNA2 int11ins53bp 
mutation results in the skipping of exon 12 in DNA2 transcript. 
 
 
To understand the splicing alterations that the obtained RT-PCR products represented, 
the PCR amplicons of each sample were cloned for Sanger sequencing. Sequencing analysis 
showed that the PCR band of the WT DNA2 minigene represented the correctly spliced mRNA, 
which included all the exons cloned into RHCglo vector (exons 11-13) (Figure 3.7b,d). In 
contrast, a fraction of DNA2 int11ins53bp transcript was spliced abnormally, containing full-
length exons 11 and 13 but lacking exon 12 (Figure 3.7b,d). This finding was confirmed using a 
set of internal primers designed to amplify a cloned region of the minigene and screen 
specifically for the presence of exon 12 (Figure 3.7c-d). 
Although DNA2 int11ins53bp variant was predicted to create either a new donor or 
acceptor splice site (Figure 3.4), the data obtained using the minigene splicing assay suggest 
that this mutation affects the presence of exon 12 in DNA2 transcript. Given that the absence 
of DNA2 exon 12 results in a frameshift and a premature termination codon in exon 13 
(p.S588Rfs*4), DNA2 int11ins53bp mutation is likely to cause reduced levels of functional 
cellular DNA2. Further validation for the disruption of splicing was obtained by DNA2 transcript 
splicing analysis of a blood sample donated by P1, demonstrating the same result as the one 
obtained using the minigene splicing assay (Figure 3.7c-d). The concordance between these 
results not only confirms the likely pathogenicity of the DNA2 int11ins53bp mutation, but also 




3.3.2. DNA2 patient mutation c.74+4A>C alters splicing of DNA2 transcript 
 
To analyse the consequences on transcript level of the intronic DNA2 patient variant 
c.74+4A>C (Figure 3.5), I again employed the minigene assay. Control and DNA2 patient 
genomic regions surrounding DNA2 c.74+4 were cloned into the RHCglo reporter and 
transfected into HeLa cells, alongside the splicing control, c.74+1G>A, where the splice donor 
site of intron 1 was mutated (Figure 3.8a). 
RT-PCR products were amplified using minigene backbone primers, and gel 
electrophoresis analysis showed the disruption of splicing in the presence of c.74+4A>C 
variant, indicated by the appearance of a higher electrophoretic mobility band, which was also 
present in the control sample with disrupted splice site (Figure 3.8b). Interestingly, as seen for 
DNA2 int11ins53bp, the c.74+4A>C mutant had some residual amount of correctly spliced 
transcript, indicating that this variant is not likely to cause complete loss of normal DNA2 
splicing and suggesting that reduced levels of wild-type DNA2 protein may account for severe 
growth restriction. 
Sequencing analysis of the cloned PCR products showed that the WT DNA2 minigene 
product represented the correctly spliced mRNA, which included both exon 1 and 2 that had 
been cloned into the RHCglo vector (Figure 3.8b). In contrast, a large proportion of the DNA2 
c.74+4A>C transcript was spliced unconventionally, containing exon 2 alone and lacking exon 
1 (Figure 3.8b). The same type of abnormal splicing was also seen for the splicing control 
c.74+1G>A, where almost no normal splicing could be detected (Figure 3.8b). 
The data obtained using the minigene splicing assay suggest that the DNA2 c.74+4A>C 
mutation affects the presence of exon 1 in DNA2 transcript. However, as we are looking at the 
first exon of the transcript, this assay may not be entirely representative of what happens in 
this situation in vivo. In patient cells, such aberrant splicing might substantially disrupt 
production of wild-type DNA2 transcript and functional protein, either through retention of 
intron 1 or activation of cryptic splice sites within intron 1. Alternatively, skipping exon 1 may 
turn exon 2 into the first exon in the case of this abnormal splicing event, or a portion of the 
non-coding region upstream of the gene may get included into the mutant transcript to 
‘replace’ the missing exon 1. The most biologically relevant way the consequences of the 
c.74+4A>C mutation on transcript splicing could be elucidated is the analysis of RNA obtained 
from a blood sample of P4. However, this could not be done, as the patient was not prepared 




Figure 3.8. DNA2 c.74+4A>C variant disrupts correct splicing of DNA2 transcript. 
a) A cartoon model of RHCglo-based constructs used in the minigene assay to assess the effect 
of DNA2 c.74+4A>C mutation in cells. Minigene plasmids were generated by PCR amplification 
of the DNA2 5’ UTR, exon 1, intron 1 and exon 2 (based on the full-length isoform DNA2-201 
(Ensembl genome browser)) from control DNA and patient DNA, and subsequent cloning into 
the RHCglo minigene plasmid. A positive control for splicing was generated by introducing a 
point mutation (c.74+1G>A) into the splice donor site of intron 1. Black arrowheads indicate 
the locations of primers used for PCR analysis. 
b) DNA2 c.74+4A>C variant affects splicing of DNA2 transcript. PCR products amplified from 
the HeLa cDNA of the minigene assay samples using RSV5U and RTRHC primers (indicated by 
black arrowheads) were run on an agarose gel and subsequently cloned for sequencing. 
Samples where no reverse transcriptase was added during cDNA generation are labelled as ‘-
RT’. Sanger sequencing analysis of the products revealed that the PCR product with higher 
electrophoretic mobility represents the mutant isoform lacking exon 1 and the lower mobility 
product the correctly spliced transcript. 
c) Aside from affecting the canonical splicing isoform DNA2-201, the c.74+4A>C mutation may 
also disrupt splicing of the isoform DNA2-203, leading to the exclusion of its exon 2. This can 
be experimentally tested in the future by cloning longer 5’ sequences upstream of DNA2 into 
the RHCglo vector. Genomic coordinates (GRCh38/hg38 assembly, UCSC Genome Browser) are 
indicated in the figure. 
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A possible alternative approach to pinpoint the extent of c.74+4A>C pathogenicity 
could be the cloning of longer DNA sequences upstream of the 5’ UTR (untranslated region) of 
DNA2 into the RHCglo reporter, together with exon 1, intron 1 and exon 2. In the experiment 
described above, the cloned DNA fragment included all 51 bp of 5’ UTR and additional 84 bp 
upstream of it, as indicated by Ensembl genome browser for the full-length DNA2 splicing 
isoform DNA2-201 (1060 amino acids). However, a shorter protein-coding splicing isoform 
DNA2-203 (687 amino acids), which lacks the canonical C-terminus (exons 15-21), contains a 
different first exon than DNA2-201 (Figure 3.8c). It is therefore possible that the c.74+4A>C 
mutation is additionally deleterious to the shorter DNA2 splicing isoform by reducing the 
presence of exon 2 (canonical exon 1) in this transcript. At the same time, the presence of the 
c.74+4A>C mutation may lead to the increased usage of the alternative start site and exon 1 
in the full-length DNA2 splicing isoform DNA2-201 as well, to replace the spliced-out canonical 












3.4. DNA2 patient mutation c.1963A>G (p.T655A) is predicted to affect ATP/ADP 
binding 
 
The only exonic DNA2 patient mutation we identified, c.1963A>G, affects threonine 
655 of DNA2 and changes it to an alanine. The affected amino acid represents the last residue 
of an evolutionarily highly conserved ATP-binding motif within the helicase/translocase 
domain (Figure 3.6). Two recent studies demonstrated that both yeast (S. cerevisiae) and 
human DNA2 function together with a cognate RecQ family helicase and use their ATP 
hydrolysis-dependent motor activity to translocate in a 5′-3′ direction on the unwound 5′-
terminated DNA strand, which is rapidly digested by the nuclease activity (Levikova et al., 2017; 
Miller et al., 2017) (Figure 1.14). Moreover, both studies showed that the ATP motif mutant of 
DNA2 (K1080E in scDNA2 or K654E in hDNA2) displays reduced resection speed at DSBs in vitro, 
leading to slower DNA degradation and shorter digestion products.  
ATP-binding pockets of nucleotide-binding enzymes interact with the substrate ATP 
and hydrolyse it to the products ADP and a phosphate. The mutation K1080E in scDNA2 (and 
later its equivalent K654E in hDNA2) was chosen to study helicase activity due to the position 
of this lysine within the major nucleotide-binding loop of DNA2 (Gly-Lys-Thr, GKT) and its 
invariability within the so-called consensus Kinase-1a NTP-binding motif of various enzymes, 
where the lysine is essential for binding the phosphates of the ligand (Budd et al., 1995; Traut, 
1994). The DNA2 K654E mutant was demonstrated to have no ATPase activity in vitro (Budd et 
al., 1995; Masuda-Sasa et al., 2006). It is therefore plausible that the substitution of T655, 
directly adjacent to K654, will affect the binding or hydrolysis of ATP as well, thus reducing the 
rate of translocation of DNA2 along DNA and diminishing efficient DNA2 nuclease-dependent 
degradation of long stretches of ssDNA. This could occur either due to structural domain 
changes caused by mutations in the ATP motif or more direct impact on ATP binding and 
processing. 
To test the hypothesis that the mutation p.T655A is deleterious to either protein 
domain structure or ATP/ADP binding in silico, the mutation was modelled based on the crystal 
structure of mouse DNA2 bound to ADP moiety published by Zhou, Pourmal and Pavletich 
(2015) (Protein Data Bank (PDB) accession number 5EAW; modelling performed by Joseph 
Marsh, IGMM) (Figure 3.9a). Due to extensive evolutionary conservation of the amino acid 
sequence of the ATP motif (Figure 3.6), the crystal structure of mouse DNA2 provides a good 
estimation of the effect the mutation has on DNA2 structure. Modelling the effects of the 
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p.T655A mutation on protein stability using the program FoldX (Guerois et al., 2002) showed 
that it does not alter any important residue-residue interactions and therefore would result in 
almost negligible changes on the overall structure of the protein (ΔΔG = -0.24 kcal/mol). 
Importantly, the affected residue makes extensive contacts with the ADP molecule, burying 
25.1 Å2 of solvent-accessible surface area, suggesting that modulation of this interaction could 
explain pathogenicity of the mutation. The effect of the p.T655A mutation on ADP binding was 
thus modelled using the program mCSM-lig (Pires et al., 2016). Surprisingly, this approach 
predicted that the mutation would in fact strengthen the interaction (ΔΔG = -0.81 kcal/mol). 
This observation was also visualised in PyMOL Molecular Graphics System (Schrödinger, Inc.), 
demonstrating how the substitution of T655 to A655 reduces the distance between the residue 
and ADP (Figure 3.9b). The interaction with ATP itself could not be modelled with much 
confidence, as it is likely that ATP hydrolysis induces conformational changes.  
The in silico data obtained support the possibility that human DNA2-T655A mutation 
affects ADP binding by increasing the affinity of DNA2 to this moiety and likely the time the 
mutant isoform spends in a nucleotide-bound conformation. The slower release of the 
hydrolysis products ADP and a phosphate will have an impact on the subsequent ATP binding 
and processing event, thus disrupting normal ATP hydrolysis rate and resulting in reduced 
processivity of DNA2 motor, as well as reduced speed at which DNA2 nuclease can cleave DNA. 
Further work to test the consequences of p.T655A on the enzymatic activities of DNA2 in vitro 
would be necessary to strengthen the obtained data. Testing this model in patient-derived or 
engineered cell lines with the p.T655A mutation would also be beneficial in providing further 




Figure 3.9. In silico modelling predicts that DNA2 p.T655A affects ATP/ADP binding. 
The DNA2 mutation p.T655A was modelled based on the published crystal structure of mouse 
DNA2 bound to ADP moiety (Zhou, Pourmal and Pavletich, 2015) (PDB ID 5EAW) in PyMOL 
Molecular Graphics System (Schrödinger, Inc.).  
a) DNA2 protein domains (N-terminal domain, nuclease and helicase/translocase) are 
represented in different colours. ADP moiety is shown in light green spheres; threonine 655 
(Thr655) residue is shown in red.  
b) Thr655, mutated in MPD, makes extensive contacts (represented by dashes) with the ADP 
moiety (left), and its substitution to Ala655 further reduces the distance between the residue 








3.5. Using CRISPR/Cas9 genome editing to generate cell lines with DNA2 patient 
mutations 
 
 The recent emergence of CRISPR/Cas9-mediated genome editing has greatly 
facilitated the study of cellular phenotypes caused by disruption of any particular gene. This 
genome editing technology was developed independently by several research groups in 2012–
2013 (Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013). It relies on bacterial Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) genes, 
which jointly act as an adaptive immune system enabling bacterial cells to protect themselves 
against foreign genetic material (Barrangou et al., 2007). In the most widely studied Type II 
CRISPR system, foreign DNA is fragmented and inserted into a CRISPR locus, flanked by 20 bp-
long repeats. The subsequent transcription of these loci generates small non-coding RNAs 
called CRISPR RNAs (crRNAs), which achieve their maturation through interactions with trans-
activating crRNAs (tracrRNAs) and can bind Cas9, guiding this endonuclease to the 
complementary target sequences (Jinek et al., 2012). Cas9 cleavage generates a DSB at sites 
complementary to the 20 nt target sequence within crRNA (Jinek et al., 2012; Nishimasu et al., 
2014), but only when a short 3 nt site (NGG or NAG), called the protospacer-associated motif 
(PAM), is present 3’ of the crRNA-complementary sequence, as it was shown to be essential 
for Cas9 endonucleolytic activity (Sternberg et al., 2014). 
 In 2012, the Doudna and Charpentier laboratories were the first ones to demonstrate 
the potential of adapting the Type II CRISPR/Cas9 system for genome editing (Jinek et al., 
2012). A synthetic single guide RNA (sgRNA) was generated to combine functions of both 
tracrRNA and crRNA, and was shown to be equally efficient at directing Cas9 to the target loci 
(Jinek et al., 2012). Wild-type Cas9 nuclease generates DSBs, which are most commonly 
repaired by NHEJ and can lead to insertions or deletions (indels) that disrupt the target locus. 
In the presence of a donor template, homology-directed repair (HDR) mechanism can be used 
to generate precise genetic modifications, including nucleotide substitutions (Ran, Hsu, Lin et 
al., 2013). A Cas9 mutant Cas9-D10A, developed by Cong et al. (2013), cleaves only one DNA 
strand, with this nickase activity facilitating HDR when a donor template is present (Bothmer 
et al., 2017). Using two paired offset guide RNAs (gRNAs) with Cas9 nickase (Cas9n) to 
introduce DNA nicks on opposing strands surrounding the target locus also provides increased 
target specificity, reducing the rate of off-target effects (Ran, Hsu, Lin et al., 2013). More 
recently, it was shown that in the presence of synthetic single-stranded 
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oligodeoxyribonucleotides (ssODNs), Cas9-induced single-stranded template repair (SSTR) 
requires the FA pathway, implicated in ICL repair (Richardson et al., 2018). 
Given the lack of the availability of DNA2 patient-derived cells and no prospect of 
obtaining them, I decided to use CRISPR/Cas9-based genome editing to engineer cell lines with 
DNA2 patient mutations. Studying the effects of the identified mutations in other species (e.g. 
developing a mouse model) was not applicable in this situation due to the intronic nature of 
the homozygous patient mutations, combined with the lack of sequence conservation at these 
sites between species. Meanwhile, isogenic human cell lines carrying DNA2 patient mutations 
would allow me to assess changes in DNA2 protein levels caused by those mutations and 
provide a useful tool for studying the effects of patient mutations on cellular functions of 
DNA2. Moreover, an isogenic cell system with DNA2 mutations would make it easier to 
attribute any observed cellular effects to the introduced mutations in the DNA2 gene and not 
to other background genetic differences that are present in primary patient fibroblasts. In the 
initial CRISPR/Cas9 experiment, I attempted to engineer the DNA2 point mutations c.74+4A>C 
(affecting the splice donor of intron 1) and c.1963A>G (resulting in a missense mutation in exon 
13) into a human cell line. 
The human osteosarcoma U2OS cell line was chosen for CRISPR/Cas9-mediated 
targeting due to its good characterisation and suitability for a broad panel of DNA repair assays. 
To introduce specific point mutations in DNA2, I used the Cas9n to generate two ssDNA breaks 
based on co-expression of two gRNA target sequences and a repair template carrying the 
desired point mutations. The designed pairs of offset gRNAs complementary to opposite 
strands of the target site for each of the two mutations are shown in Figure 3.10a. Two suitable 
gRNAs with 3 bp offset were identified for the c.74+4A>C mutation; however, the only suitable 
pair of gRNAs to introduce the c.1963A>G mutation had a small overlap of 4 bp. This is not an 
ideal setup for Cas9n-mediated targeting, given that such overlaps may cause steric hindrance 
between two adjacent Cas9–gRNA complexes and thus affect cooperative nicking (Ran, Hsu, 
Lin et al., 2013). However, due to constraints introduced by the locus specification, this gRNA 
pair was the highest-scoring one based on CRISPR Design Tool created by Feng Zhang 
laboratory (http://crispr.mit.edu/). For each of the targets, a 200 nt-long antisense ssODN with 
the desired mutation in the middle of the sequence was designed to serve as a repair template. 
Introduction of a repair template with a silent mutation within the PAM site is known to help 
prevent further Cas9-mediated activity at the target site after correct editing. However, given 
that three out of four PAM sites are located in protein-coding regions or close to the exon-
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Figure 3.10. Using CRISPR/Cas9 genome editing to generate U2OS cell lines with DNA2 
patient mutations. 
a) A representation of gRNA design to introduce DNA2 mutations c.74+4A>C and c.1963A>G 
into a cell line. Coding (exonic) sequences are shown in uppercase; non-coding (intronic) are 
shown in lowercase. The 20 nt-long genomic sequences targeted by gRNAs are highlighted in 
green; 3 nt-long PAM sites are shown in blue. The target nucleotides c.74+4 and c.1963 are 
marked in red. The nucleotide changed to alter PAM site in the repair template (g>t) is shown 
in red.  
b) The genotypes of U2OS clones targeted for DNA2 c.74+4A>C. The genotypes of the clonal 
cell lines #1, #79 and #2 represent the outcomes observed after targeting DNA2 c.74+4 locus 
in the U2OS cell line. The target nucleotide c.74+4 is marked in red; red dotted lines indicate 
deletions; green nucleotides indicate insertions. 
 
 
After inserting guiding sequences into GFP-Cas9n-expressing plasmids, U2OS cells 
were co-transfected with the relevant plasmids and ssODNs. 85 GFP-FACS-sorted U2OS cells 
targeted for c.74+4A>C mutation and 123 cells targeted for c.1963A>G mutation survived and 
formed clones. All clones were screened for the presence of the expected mutations by 
amplifying ~200 bp-long genomic region surrounding the targeted locus and sending 
amplicons for Sanger sequencing. Out of 85 DNA2 c.74+4A>C U2OS CRISPR clones, DNA 
sequences of the screened locus remained unchanged in 65 clones, staying identical to the 
parental wild-type sequence of DNA2. The remaining 20 clones were targeted by the 
CRISPR/Cas9 system. The targeting outcomes observed could be classified into a few distinct 
categories: 1) monoallelic targeting introducing the mutation of interest (c.74+4A>C), as well 
as an additional intronic indel (e.g. clone #1); 2) monoallelic targeting introducing intronic 
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indels (e.g. clone #79); 3) monoallelic targeting introducing exonic/intronic indels (e.g. clone 
#2) (Figure 3.10b). Therefore, even when the targeting of c.74+4A>C was successful and 
resulted in the desired substitution, it happened on one allele only, and other undesired 
genetic alterations were introduced at the same time.  
Overall, this experiment suggests that targeting of the c.74+4A>C locus was inefficient, 
with only 24% of clones being targeted by CRISPR/Cas9 machinery on one allele. Whenever 
targeting took place, cells appear to have used either NHEJ pathway exclusively or both NHEJ 
and HDR pathways to repair the lesion instead of relying solely on the supplied repair template 
for ‘clean’ HDR repair. The clonal cell lines produced during this experiment could therefore 
not be used for studying the cellular consequences of the patient mutation c.74+4A>C. For 
example, if the cell line #1 was used for transcript splicing or protein level analysis, any effect 
observed could not be clearly attributed to the presence of the variant c.74+4A>C and could 
be argued to have been caused by the larger intronic deletion downstream. Nevertheless, 
some of these cell lines could potentially be hypomorphic with lower levels of DNA2 protein 
(e.g. clone #2) and be useful for broader studies of cellular roles of DNA2. 
In the attempt to introduce DNA2 c.1963A>G mutation, the Sanger sequencing 
analysis of only 2 out of 123 analysed clones demonstrated any targeting. Instead of containing 
the c.1963A>G substitution, both mutant clones had monoalellic indels at the target locus in 
exon 13. The mutations in these clones are predicted to lead to premature stop codons and 
subsequent degradation of the mutant transcript though nonsense-mediated decay (NMD), a 
eukaryotic surveillance pathway to eliminate erroneous mRNA transcripts (Hug et al., 2016). 
Therefore, these cell lines are not suitable for the analysis of the consequences of a precise 
nucleotide substitution. 
 I made further attempts to use CRISPR/Cas9 genome editing to introduce the DNA2 
c.74+4A>C mutation. Multiple permutations of the protocol were performed, such as using the 
wild-type Cas9 nuclease to improve cutting efficiency and testing two additional gRNAs (gRNA2 
and gRNA3) (Figure 3.11a). The U2OS cell line I used for targeting is known to be hypertriploid, 
which may have contributed to the experienced difficulties targeting all alleles. To rule out the 
cell line-specific challenges in successful DNA2 targeting, human hTERT-immortalised retinal 
pigmented epithelium cell line, RPE1, and colorectal carcinoma cell line HCT116, both near-
diploid, were selected for further experiments. Lastly, a plasmid generated using Gibson 
Assembly Cloning Kit (NEB) with c.74+4A>C substitution was used as an alternative repair 
template, and a more efficient transfection system, Neon® (Invitrogen), was adopted, allowing 
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to achieve higher levels of transfected GFP-positive cells upon GFP-FACS single cell sorting. All 




Figure 3.11. Summary of variations of the CRISPR protocol used for editing and their 
observed outcomes. 
a) Design of additional gRNAs for DNA2 c.74+4A>C targeting. Two additional gRNAs (gRNA2 
and gRNA3) were designed using CRISPR Design Tool (F. Zhang laboratory) and CRISPR gRNA 
Design Tool DNA2.0 (now ATUM). All three gRNAs shown were cloned into a plasmid encoding 
WT Cas9 nuclease (pX458). The 20 nt-long genomic sequences targeted by gRNAs are 
highlighted in green; 3 nt-long PAM sites are shown in blue. The target nucleotide c.74+4 is 
marked in red. The nucleotides changed in the repair templates to alter PAM sites or introduce 
synonymous substitutions in other loci (G>C) are shown in red. Coding (exonic) sequences are 
shown in uppercase; non-coding (intronic) are shown in lowercase. 
b) Table summarising variations of the CRISPR/Cas9 genome editing protocol at two DNA2 loci 
and their outcomes. 
 
 
Furthermore, I designed a screening method to facilitate the initial screening for the 
desired point mutation c.74+4A>C without the need to Sanger-sequence all the clones. The 
c.74+4A>C mutation introduces a HhaI restriction enzyme site (GCGC), which is not present in 
exon 1 of DNA2 (Figure 3.12a). The screening method involved crude genomic DNA isolation 
from clones, PCR amplification of the locus of interest, subsequent restriction digestion with 
HhaI restriction nuclease, and analysis of products on an agarose gel. However, none of the 
multiple targeting perturbations (Figure 3.11b) gave the expected results, only very 
occasionally resulting in any targeting events at all (Figure 3.12b).  
Despite the extensive efforts to generate a cell line harbouring the c.74+4A>C 
mutation in DNA2, the targeting was not successful. Targeting of a specific locus for HDR puts 
restrictions on available gRNAs, making it more difficult to optimise the targeting strategy. Due 
to variability of targeting efficiency between different genomic loci, disrupting a gene is much 
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easier than introducing a specific mutation, since one can select the most optimal gRNA for 
the experiment. Taking all the alterations to the protocol together (Figure 3.11b), the most 
efficient cutting was achieved using Cas9 nickase and a combination of gRNA1 and gRNA9 in 
the U2OS cell line. However, in the event of cutting by Cas9n, the targeting exclusively resulted 
in indels disrupting one allele of DNA2. It is also plausible that successfully introduced biallelic 
c.74+4A>C mutation would have caused reduced cell fitness, thus decreasing the probability 
of recovering a clone with this mutation. Overall, no cell lines with c.74+4A>C or c.1963A>G 
mutations were generated using CRISPR/Cas9-mediated targeting. It was therefore not 
possible to address the consequences of these patient mutations on DNA2 protein levels using 
CRISPR/Cas9 genome editing. 
 
 
Figure 3.12. The HhaI restriction digestion-based screening for correctly targeted DNA2 
c.74+4A>C clones. 
a) The design of a screening method for the desired point mutation c.74+4A>C without the 
need to Sanger-sequence the clones. Black arrowheads indicate the locations of primers used 
for PCR amplification of a 476 bp product, including 5’ upstream DNA sequences of DNA2, 5’ 
UTR, exon 1 and a part of intron 1 of DNA2. Six HhaI cutting sites in the 5’ region upstream of 
DNA2 would produce very short digestion products in the presence of HhaI, likely too small to 
visualise on an agarose gel, leaving only the 357 bp product large enough to be detected. In 
the presence of c.74+4A>C substitution, a new HhaI cutting site would be created, leading to 
the generation of two shorter digestion products instead (162 bp and 195 bp).  
b) Undigested and HhaI-digested PCR amplicons of c.74+4A>C locus were run in parallel for 
accurate identification of clones containing the desired c.74+4A>C mutation. In this gel, 
negative control (—) indicates the wild-type exon 1-intron 1 PCR product, amplified from the 
RPE1 parental cell line. A fragment of exon 18 containing HhaI restriction site (GCGC) was used 
as a positive control (+). Red star indicates a targeting event (insertion); black star indicates 
restriction digestion products of the positive control, 154 bp and 101 bp. 
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3.6. Summary and discussion: DNA2 mutations in human disease 
 
DNA2 is an ATP-dependent helicase/nuclease, extensively studied due to its important 
roles in DNA end resection and Okazaki fragment maturation, as well as telomere and mtDNA 
maintenance (see Section 1.4 for details). In this chapter, the identification of four MPD-
affected individuals with biallelic DNA2 mutations was described, as well as various 
experiments to address the consequences of the identified variants for DNA2 transcript 
splicing and enzymatic activities. 
The results described in this chapter, combined with previous reports by Shaheen et 
al. (2014), Ronchi et al. (2013), Chae et al. (2015) and Phowthongkum and Sun (2017), link 
mutations in DNA2 with two distinct clinical phenotypes: muscle disorders associated with 
mitochondrial genome instability and MPD showing severe reduction in growth. The first link 
between DNA2 and human disease was established in 2013, when monoallelic missense 
mutations in DNA2 (R198H, K227E and V637I) were demonstrated to cause adult-onset 
autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 
type 6 (PEOA6) (Ronchi et al., 2013) (Figure 3.1). Moreover, a nonsense mutation in DNA2 
(Q630*) was reported in a single case of metabolic myopathy (Chae et al., 2015), and a recent 
case study reported on a 17 month-old girl with congenital-onset myopathy and ptosis, who 
had a novel monoallelic DNA2 frameshift mutation (N568Ifs*4) (Phowthongkum and Sun, 
2017) (Figure 3.1). Phowthongkum and Sun (2017) postulated that DNA2 protein 
haploinsufficiency due to truncating mutations may be causing the observed mitochondrial 
genome instability and clinical symptoms of early-onset myopathy. Comparison of the 
mutations identified in individuals with DNA2-associated mitochondrial disease and growth 
restriction point towards zygosity underlying the observed phenotypic differences, as all 
studied individuals with muscle deficiency were heterozygous for coding mutations in DNA2. 
Ronchi et al. (2013) tested the effect of the three mutations they identified on enzymatic DNA2 
activities in vitro, revealing diminished nuclease activity and dysregulated helicase activity. 
Thus, the disrupted allele in PEOA6 patients alters DNA2 enzymatic activities, but its 
detrimental effect is likely ameliorated by the fully functional allele. It is not clear yet why 
mitochondrial functions of DNA2 are particularly susceptible to this partial loss of function. 
DNA2 was shown to play a critical role in mitochondrial long-patch base-excision repair (LP-
BER), a pathway employed by cells to repair DNA damage caused by oxidative stress, alkylating 
agents and spontaneous hydrolysis (Robertson et al., 2009; Zheng et al., 2008). Ronchi et al. 
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(2013) proposed that disruption of this role of DNA2 may underlie the observed clinical 
phenotype due to a significant threat of oxidative DNA damage encountered by mitochondria. 
In contrast, the six individuals with biallelic mutations in DNA2, identified by our 
laboratory and Shaheen et al. (2014), exhibit distinct clinical characteristics, indicative of Seckel 
syndrome or MPD. Surprisingly, not even a mild mitochondrial phenotype was observed in any 
of the MPD patients, even though a few previously identified mitochondrial disease-causing 
DNA2 mutations affect the helicase domain, where the majority of MPD-associated mutations 
are found.  
In my study, the lack of patient-derived cells and failure to generate CRISPR/Cas9 
engineered cell lines with patient mutations in DNA2 hampered the analysis of the impact of 
the biallelic non-coding variants. My unsuccessful attempts to generate a suitable CRISPR/Cas9 
cell line for this study emphasise the continued importance of patient-derived cell lines for 
functional analyses. The minigene-based splicing assay proved an important tool, allowing me 
to determine the effects of these mutations on transcript splicing. The non-coding variants 
found in MPD patients, c.74+4A>C and int11ins53bp, were demonstrated using this assay to 
result in the disruption of normal DNA2 transcript splicing. It is clear from this assay that in 
both cases the normal transcript splicing is not abolished completely, and that a fraction of 
normally spliced DNA2 is retained (Figure 3.7 and Figure 3.8). Collectively, my data and the 
findings by Shaheen et al. (2014) strongly suggest that the MPD-associated non-coding DNA2 
mutations result in reduced levels of canonical DNA2 transcript, ultimately leading to a global 
reduction in DNA2 protein levels and all enzymatic functions. Moreover, in silico modelling 
showed that the missense mutation within the highly conserved ATP-binding motif of DNA2, 
c.1963A>G (p.T655A), is likely to increase the affinity of DNA2 to the ATP hydrolysis product 
ADP (Figure 3.9). Speculatively, this substitution might result in altered dynamics and 
processivity of DNA2 motor activity, impacting on efficient processive cleavage by the 
nuclease. Nevertheless, p.T655A is unlikely to completely disrupt translocation along DNA, 
strongly supporting the unifying hypomorphic nature of all biallelic mutations identified.  
It was previously reported that homozygous DNA2 knockout is embryonic lethal in 
mice, indicating the importance of DNA2 during mammalian embryonic development (Lin et 
al., 2013). It is therefore not surprising that both DNA2-associated syndromes result from 
variable degree insufficiency of its enzymatic activities. It appears that while DNA2 
haploinsufficiency results in myopathy phenotype, severe DNA2 deficiency arising from 
biallelic mutations impairs nuclear genome replication and DNA repair, causing MPD. In 
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summary, both non-coding and coding DNA2 mutations identified in MPD patients are likely 
to cause disease via reduction of both nuclease and motor activities of DNA2. The non-coding 
mutations are predicted to equally diminish both enzymatic activities via reduced DNA2 
protein levels, whereas the coding mutation p.T655A may affect the motor activity directly and 
the nuclease activity indirectly, likely through a reduction in processivity. The data obtained in 
this chapter further supports the necessity of adequate DNA2 protein levels during embryonic 
development, where cell cycle is short and tightly regulated, and the disruption of timely DNA 



























Regulation of the PP4 complex  










4. Regulation of the PP4 complex by TRAIP-dependent 
ubiquitination 
 
TRAIP was previously reported to undergo auto-ubiquitination in vitro, mediated by 
the E3 ubiquitin ligase activity within its RING finger domain (Besse et al., 2007). Moreover, 
TRAIP was shown to promote lysine 48 (K48)-linked ubiquitination and proteasomal 
degradation of TANK-binding kinase 1 (TBK1), leading to negative regulation of type I 
interferon β (IFN-β) production and the cellular antiviral response in HEK293 cells (Zhang et al., 
2012). Recently, the Andrew Jackson laboratory reported that TRAIP facilitates efficient DDR 
signalling in response to UV-C irradiation in immortalised fibroblast and HeLa cells (Harley et 
al., 2016). In close succession, several other studies linking TRAIP to the cellular response to 
DNA damage were published (Hoffmann et al., 2016; Soo Lee et al., 2016; W. Feng et al., 2016). 
However, it remains unknown what protein substrate(s) TRAIP ubiquitinates to promote DDR 
at DNA lesions, and establishing their identity is critical for advancing the knowledge of the 
DDR-related functions of TRAIP.  
Two recent studies proposed that the E3 ligase activity of TRAIP may be required for 
ubiquitinating PCNA at stalled replication forks (Hoffmann et al., 2016; W. Feng et al., 2016). 
In vitro immunoprecipitation experiments and structural data obtained by Hoffmann et al. 
(2016) demonstrated that TRAIP binds PCNA through its C-terminal PIP-box motif. MS analysis 
and pulldown experiments performed by W. Feng et al. (2016) confirmed TRAIP-PCNA 
interaction. As upon HU-induced replication fork stalling PCNA is rapidly lost from chromatin 
in both yeast and human cells (Sirbu et al., 2011; Yu et al., 2014; Dungrawala et al., 2015; 
Hoffmann et al., 2016; W. Feng et al., 2016), both Hoffmann et al. (2016) and W. Feng et al. 
(2016) suggested that TRAIP-mediated PCNA ubiquitination could promote its unloading from 
chromatin upon replication stress. However, neither study provided in vitro or in vivo evidence 
supporting this hypothesis. Using the PIP-box mutant of TRAIP, Hoffmann et al. (2016) showed 
that TRAIP interaction with PCNA is less important than its E3 ligase activity in facilitating CPT- 
and HU-induced RPA2 phosphorylation, as well as promoting cell survival in response to MMC 
treatment. Additionally, W. Feng et al. (2016) demonstrated by immunoblotting that TRAIP 
depletion in U2OS cells did not significantly affect the level of ubiquitinated PCNA in response 
to HU- and UV- induced replicative stress. Moreover, this study showed that transient 
proteasome inhibition did not exacerbate replication stress-induced fork defects (W. Feng et 
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al., 2016), leading to the conclusion that TRAIP may promote PCNA unloading by non-catalytic 
means. 
Another DNA replication and repair factor, the TLS polymerase eta (Pol ŋ), was also 
suggested as a putative protein substrate of the TRAIP E3 ligase (Wallace et al., 2014). Human 
TRAIP and its D. melanogaster orthologue, Nopo, were shown to co-immunoprecipitate with 
Pol η, and the overexpression of TRAIP in HeLa cells enhanced Pol ŋ ubiquitination in a cellular 
ubiquitination assay (Wallace et al., 2014). The authors of the study proposed that TRAIP-
dependent ubiquitination of Pol η promotes its recruitment to nuclear foci in human cells, 
facilitating DNA damage tolerance. However, it is not clear whether these observations are 
functionally relevant due to several reasons. Firstly, the data supporting TRAIP-mediated 
ubiquitination of Pol η were obtained from examining the gain-of-function situation, which 
may not be representative of the ubiquitination events in vivo. Moreover, the experiments 
were conducted in the absence of exogenous DNA damage. The clinical phenotypes of 
xeroderma pigmentosum variant (XP-V) (Lehmann et al., 2011), caused by mutations in Pol η 
(Johnson et al., 1999; Masutani et al., 1999), and TRAIP patients are also different, with XP-V 
not reported to cause growth failure or microcephaly. Hoffmann et al. (2016) also investigated 
Pol η as a potential DDR-related substrate of TRAIP and concluded that Pol η ubiquitination is 
unlikely to explain the role of TRAIP in maintaining genome stability after replication stress. 
TRAIP knockdown in U2OS cells did not decrease the formation of DNA damage-induced Pol η 
foci and Pol η poly-ubiquitination levels (Hoffmann et al., 2016). Additionally, the RING and PIP 
domain mutants of TRAIP were as efficient at Pol η poly-ubiquitination in U2OS cells as wild-
type TRAIP (Hoffmann et al., 2016). Lastly, the authors showed that overexpression of Pol η 
did not rescue MMC sensitivity, observed in TRAIP-depleted U2OS cells. Therefore, more work 
is required to identify DDR-relevant substrates of TRAIP and to understand the role of TRAIP in 
responding to replication stress. 
 In this chapter, the experimental work investigating another potential substrate of 
TRAIP, the protein phosphatase 4 (PP4) complex, is described. I postulated that after UV-C 
irradiation PP4 may be negatively regulated by TRAIP-dependent ubiquitination of its subunits 
and performed in vitro experiments to address this hypothesis. Finally, the relevance of these 




4.1. Protein phosphatase 4 (PP4) complex: a potential substrate of TRAIP 
 
Although our laboratory demonstrated that TRAIP is required for RPA2 and H2AX 
phosphorylation following UV-C-induced DNA damage (Harley et al., 2016), the molecular 
mechanisms underlying this regulation remained unknown. One of the possible explanations 
is TRAIP-mediated positive regulation of a DDR protein kinase of PIKK family, such as ATR, ATM 
or DNA-PK, which are known to phosphorylate RPA2 (S. Liu et al., 2012) and H2AX (reviewed 
by Podhorecka, Skladanowski and Bozko (2010)) in response to replication stress. 
Alternatively, TRAIP-mediated inhibition of PP2A or PP4 protein phosphatase complexes that 
dephosphorylate pRPA2-S4/S8 and γH2AX (Chowdhury et al., 2008, 2005; J. Feng et al., 2009; 
Lee et al., 2010; Nakada et al., 2008) could take place in response to UV-C-induced DNA 
damage.  
To identify potential ubiquitination targets and binding partners of TRAIP, MS analysis 
of proteins co-immunoprecipitated with GFP-TRAIP was performed in the Andrew Jackson 
laboratory. Regulatory subunits of the protein phosphatase 4 (PP4) complex, PP4R3α (SMEK1) 
and PP4R3β (SMEK2), emerged as the most enriched proteins identified in this screen, with 
1,000-fold enrichment in the GFP-TRAIP sample, relative to the control GFP sample (M. Harley, 
unpublished) (Figure 4.1a). These interactions were confirmed by reciprocal 
immunoprecipitations of endogenous PP4R3α and PP4R3β by GFP-tagged TRAIP and 
endogenous TRAIP by HA-tagged PP4R3α and PP4R3β (M. Harley, unpublished) (Figure 4.1b-
c).  
Protein phosphatase 4 (PP4) is a ubiquitous serine/threonine phosphatase known to 
play multiple distinct roles in different cellular processes, including DDR (J. Liu et al., 2012), cell 
cycle regulation (Zhuang et al., 2014), embryo development (Helps et al., 1998), tumor necrosis 
factor α (TNF-α) signalling pathway (Mihindukulasuriya et al., 2004; Zhou et al., 2002) and 
glucose metabolism (Yoon et al., 2010). A combined tandem affinity purification (TAP) tagging 
and MS approach was previously used to delineate distinct multi-molecular complexes 
containing the catalytic subunit of PP4 phosphatase, PP4C, in mammalian cells (Gingras et al., 
2005). Overall, the data suggested that PP4C forms four distinct complexes: a complex 
containing regulatory subunits PP4R2 and PP4R3β, a complex containing regulatory subunits 
PP4R2 and PP4R3α, a binary complex with a regulatory subunit PP4R1, and a complex involving 
α4 and the chaperone TriC/CCT. These data were later confirmed by Chowdhury et al. (2008); 
however, no interaction between PP4C and α4 was observed. Although human PP4R3β and 
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PP4R3α share 67% sequence identity and 77% homology at the amino acid level (Gingras et 
al., 2005), only PP4R3β-containing PP4 complex was implicated in DNA repair. It was previously 
shown that deletion of the yeast orthologue of PP4R3β, Psy2, renders cells hypersensitive to 
the DNA crosslinking agent cisplatin (Wu et al., 2004). Gingras et al. (2005) demonstrated that 
deletion of other components of this PP4 complex, PP4C-PP4R2-PP4R3β, also induced cisplatin 
hypersensitivity in yeast, giving this complex a new name PP4cs (protein phosphatase 4, 
cisplatin-sensitive) and suggesting its importance for DDR. Moreover, the knockdown of PP4cs 
components PP4C and PP4R3β was reported to induce replication-associated DNA damage, as 
well as to impair HR at DSBs in HeLa cells (Chowdhury et al., 2008). Significantly, the PP4C-
PP4R2-PP4R3β complex was demonstrated to be required for efficient dephosphorylation of 
γH2AX, both induced by exogenous and endogenous DNA damage in human cells (Chowdhury 
et al., 2008; Nakada et al., 2008). Additionally, the PP4C-PP4R2 heterodimer was shown to be 
involved in efficient dephosphorylation of pRPA2 both in vitro and in U2OS cells, as well as 
required for HR-mediated DSB repair (Lee et al., 2010).  
 Ubiquitination is critical for the post-translational regulation of cellular protein 
functions, as well as cell signalling cascades (Udeshi et al., 2013). The observations that the 
PP4R3β-containing ternary PP4 complex is implicated in DDR signalling and DNA repair led to 
my hypothesis that TRAIP might act as a negative regulator of PP4 complex activity by 
ubiquitination (Figure 4.2). According to this working model, TRAIP-deficient patient cells 
would show constitutively increased PP4 phosphatase activity, which would subsequently 
reduce cellular levels of phosphorylated H2AX and RPA2. However, protein levels of PP4C and 
the regulatory subunits PP4R3α and PP4R3β were not increased in TRAIP patient-derived cells, 
compared to wild-type control cells (M. Harley, unpublished). This suggested that rather than 
leading to a global proteasome-mediated reduction in PP4 protein levels, TRAIP-mediated 
ubiquitination of PP4 would more likely result in reduced activity or local degradation of PP4 
complex (Figure 4.2). Only low levels of TRAIP-mediated ubiquitination of one of the regulatory 
PP4 subunits identified by MS, PP4R3α, were detected in the in vitro ubiquitination assays (J. 
Ding and O. Murina, unpublished). Instead, purified recombinant catalytic subunit PP4C was 
found to be strongly ubiquitinated by TRAIP (O. Murina, unpublished) (Figure 4.3a). These in 
vitro data were also supported by the cellular ubiquitination assays (M. Harley, unpublished) 
(Figure 4.3b). This suggests that while the regulatory subunit PP4R3β might mediate 
interaction between TRAIP and the PP4 complex, the substrate of TRAIP is more likely to be 
the catalytic subunit PP4C. In the following sections of this chapter, approaches taken to 
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extend these data and provide additional insights into the interplay between TRAIP and the 
PP4cs complex (PP4C-PP4R2-PP4R3β) are described. 
 
Figure 4.1. TRAIP interacts with PP4R3α and PP4R3β, the regulatory subunits of the PP4 
complex. 
a) A volcano plot representing the MS analysis of proteins co-immunoprecipitated with GFP-
tagged TRAIP, which was expressed at near endogenous levels, enriched versus GFP control 
(empty) construct that can be used for N-terminal tagging of proteins with GFP (experiment 
and analysis of the results performed by M. Harley and M. Halachev, respectively). P-value (-
log10), indicating significance of the hit, is plotted against fold enrichment (log2) of the protein 
in a sample, representing results of n=6 replicates from 3 independent experiments. Several 
of the most enriched proteins (shown as red dots) are indicated in the graph.  
b, c) Reciprocal immunoprecipitation (IP) experiments show that endogenous PP4R3α and 
PP4R3β co-immunoprecipitate with GFP-tagged TRAIP (b), and that endogenous TRAIP is 
immunoprecipitated by HA-tagged PP4R3α or PP4R3β (c) (experiments performed by M. 
Harley). GFP control (empty) construct (b) and control IP (agarose without HA antibody) (c) 





Figure 4.2. A model for the TRAIP-mediated regulation of PP4 complex. 
a) Unpublished data from the Andrew Jackson laboratory suggest that TRAIP may regulate PP4 
complex by ubiquitination to promote DNA repair. I propose that upon DNA damage, TRAIP 
may interact with and ubiquitinate one or more of the PP4 complex subunits, which would 
reduce PP4 activity by yet unknown mechanism or result in local degradation of PP4 complex. 
In turn, this would preserve H2AX and RPA2 phosphorylation during the initial stages of DNA 
repair, as well as stimulate the recruitment of DNA repair factors to damaged DNA. In the 
absence of TRAIP or upon its degradation in a proteasome-dependent manner after the onset 
of UV-C-induced DDR (Harley et al., 2016), PP4 protein levels or activity would increase, 




Figure 4.3. TRAIP ubiquitinates PP4C, the catalytic subunit of PP4 complex. 
a) Immunoblot showing that PP4C protein is ubiquitinated by the RING domain of TRAIP in 
vitro (experiment performed by O. Murina). Purified recombinant PP4C and ubiquitin (Ub) 
were incubated in the presence or absence of the recombinant N-terminal part of TRAIP 
(TRAIP-N), containing the RING domain and E3 ligase activity. Anti-TRAIP and anti-PP4C 
antibodies were used for immunoblotting. 
b) Immunoblot showing that PP4C protein is likely to be poly-ubiquitinated by TRAIP in HeLa 
cells (experiment performed by M. Harley). HeLa cells were transfected with GFP-tagged PP4C, 
HA-tagged ubiquitin and FLAG-tagged TRAIP. 24 h post-transfection, proteasome inhibitor 
MG132 (20 μM) was added for 6 h to prevent degradation of ubiquitinated proteins. Cell 
lysates were used for GFP immunoprecipitation (IP), and the IP and input samples were 





4.2. Design, construction and purification of recombinant heterotrimeric PP4 
complexes 
 
Given that TRAIP can ubiquitinate PP4C, but likely interacts with the regulatory subunit 
PP4R3β, the presence of the ternary PP4cs complex may potentiate the PP4C ubiquitination 
by TRAIP. Therefore, to further investigate whether PP4 is a ubiquitination substrate of TRAIP, 
I decided to construct a recombinant PP4cs complex expressed from a polycistronic plasmid 
and use it in the in vitro ubiquitination assays together with TRAIP. The polycistronic expression 
construct is expected to result in complex formation upon expression in bacteria, instead of in 
vitro reconstitution of individually expressed and purified subunits. In vitro reconstitution can 
be time-consuming, and the yield may be quite low (Selleck and Tan, 2008). In contrast, 
complex formation in bacterial cells is faster and more efficient, requiring a single round of 
expression and purification. Moreover, it may improve solubility of the recombinant proteins. 
This is particularly relevant to this experiment as the regulatory subunit PP4R3β was found to 
be insoluble and could not be purified separately (J. Ding, unpublished). Additionally, folding 
and complex assembly takes place in a cellular environment with native folding enzymes, 
contributing to the stability of a complex and preventing aggregation of nascent unfolded 
peptides (Ellis and Hartl, 1999; Jaenicke, 1998; Tan, 2001). Thus, a better stoichiometry and 
solubility of the complex of interest may be achieved through complex formation in bacterial 
cells.  
For co-expression of a protein complex in bacteria, I decided to clone the three 
subunits of human PP4cs – PP4C, PP4R2, and PP4R3β – into the pGEX-6P-1 bacterial expression 
vector in the order listed, with the glutathione S-transferase (GST) affinity tag placed at the N-
terminus of the catalytic subunit PP4C (Figure 4.4a-b). Additionally, the trimeric PP4 complex 
containing PP4C, PP4R2, and PP4R3α was constructed to act as a control for further studies, 
as this complex was not shown to be involved in DDR and DNA repair (Figure 4.4a-b). It was 
demonstrated that the order of expression of the co-expressed genes from a polycistronic 
plasmid does not have a major impact on the differential expression levels of the subunits (Tan 
et al., 2005). Nevertheless, I decided to proceed with the aforementioned order due to 
previously reported requirement of pre-assembly of the PP4C-PP4R2 binary complex for the 
subsequent interaction with PP4R3β and formation of the trimeric complex (Gingras et al., 
2005). Regarding the position of the affinity tag, its potential interference with the complex 
formation needs to be carefully considered. Moreover, Selleck and Tan (2008) advise to restrict 
tagging to a single subunit, since additional tags would increase the chances of inadvertent 
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destabilisation of the complex. As no data showing the impact of either N- or C-terminal 
tagging of PP4C on its folding or PP4cs complex formation were available, I decided to tag the 
N-terminus of PP4C, based on the previous successful expression and purification of the GST-




Figure 4.4. Construction of the pGEX-6P-1-based PP4C-PP4R2-PP4R3α/β co-expression 
vector. 
a) Step-by-step cloning of PP4 complex subunits into pGEX-6P-1 bacterial vector for expressing 
GST fusion proteins with a PreScission (PS) protease site. Restriction endonuclease sites used 
for cloning are indicated in the plasmid maps. MCS = multiple cloning site; AmpR = ampicillin 
resistance gene; lacI = the lac repressor. 
b) The representation of co-expression and in vivo reconstitution of the ternary PP4 complex. 




 The two generated pGEX-6P-1 co-expression plasmids, PP4C-PP4R2-PP4R3β and PP4C-
PP4R2-PP4R3α, were transformed into bacterial Rosetta-2 cells, expressed and purified as 
described in Section 2.5.4. The eluate fractions in the Coomassie-stained gels of both co-
expression constructs (PP4C-PP4R2-PP4R3β and PP4C-PP4R2-PP4R3α) contained two visible 
bands, whose sizes corresponded to PP4C (~35 kDa) and PP4R2 (~66 kDa) (Figure 4.5a-b). 
Additionally, a very faint lower mobility band, likely corresponding to PP4R3α (~105 kDa), could 
be observed in the PP4C-PP4R2-PP4R3α gel. To confirm that the eluates contained PP4R3β and 
PP4R3α regulatory subunits, immunoblotting was performed. PP4R3β and PP4R3α were 
indeed present in the recombinant complexes (Figure 4.5c-d), indicating that the whole 
trimeric PP4 complex was successfully purified using GST-tagged PP4C and confirming that 
PP4C-PP4R2-PP4R3β and PP4C-PP4R2-PP4R3α complexes were reconstituted in bacteria.  
However, the analysis of Coomassie-stained protein gels strongly suggests that the PP4 
subunits are not present at 1:1:1 stoichiometry within the recombinant complexes. The two 
visible bands of PP4C and PP4R2 indicate that the large proportion of the purified complex is 
composed of the PP4C-PP4R2 dimer, with only a small fraction representing the ternary 
complex with the regulatory subunit PP4R3β or PP4R3α. Overall, the stoichiometry achieved 
by expression and purification of heterotrimeric PP4 complex is not optimal. However, I 
postulated that using the ternary complex may nevertheless allow me to determine 
ubiquitination of all three subunits in the PP4 complexes in a single experiment. Moreover, if 
the regulatory subunits strongly impact on PP4C ubiquitination, the effect may be detectable 
despite low levels of PP4R3β/α. Thus, I decided to use the eluates containing PP4C-PP4R2-
PP4R3β and PP4C-PP4R2-PP4R3α in in vitro ubiquitination assay to assess whether and which 




Figure 4.5. Purification of recombinant ternary PP4C-PP4R2-PP4R3α and PP4C-PP4R2-
PP4R3β complexes. 
a, b) Coomassie Blue-stained protein gels of PP4C-PP4R2-PP4R3α (a) and PP4C-PP4R2-PP4R3β 
(b), representing several steps of protein purification: T = total protein, S = soluble fraction, FT 
= flow-through, BB = beads before PS cleavage, E1 = eluate, E2 = second eluate / wash, BA = 
beads after PS cleavage. Eluate fractions were collected and used as substrates in the in vitro 
ubiquitination reactions. Bands corresponding to the known sizes of GST, PP4C, GST-PP4C, 
PP4R2, PP4R3α and PP4R3β are indicated. 
c, d) Immunoblots showing the presence of all three PP4 subunits within the recombinant 
complexes PP4C-PP4R2-PP4R3α (c) and PP4C-PP4R2-PP4R3β (d). Samples representing key 
stages of protein purification were analysed. To control for antibody specificity, samples 
without the regulatory subunits (eluate of the recombinant PP4C monomer and the total 






4.3. TRAIP-dependent in vitro ubiquitination of PP4C and the regulatory 
subunits of PP4 complex 
 
To test whether the heterotrimeric PP4 complexes are better substrates for TRAIP-
mediated ubiquitination than PP4C subunit alone, in vitro ubiquitination reactions using 
recombinant PP4 complexes were set up. As recombinant full-length TRAIP was found to be 
insoluble (M. Harley, unpublished data), catalytically active N-terminal part of TRAIP was used 
in in vitro ubiquitination assay instead. Thus, each reaction contained the N-terminal TRAIP 
and other components required for reconstitution of ubiquitination in vitro (see Section 2.5.5). 
In the absence of TRAIP, 5–7% of total PP4C was ubiquitinated in vitro, indicating the 
background level of non-specific ubiquitination (Figure 4.6a-b). As expected, addition of TRAIP 
to the reaction enhanced PP4C ubiquitination in vitro, compared to the conditions without 
TRAIP or ubiquitin (Figure 4.6a-b), confirming the previous finding that TRAIP can ubiquitinate 
PP4C in vitro. However, no strong improvement in PP4C ubiquitination was observed in the 
presence of the whole ternary PP4 complex, compared to PP4C alone, with 25–30% total PP4C 
ubiquitinated by TRAIP in each case (Figure 4.6b). This result may imply that the regulatory 
subunits of PP4 complex either do not participate or play a very minor role in facilitating TRAIP-
dependent ubiquitination of PP4C in vitro. Alternatively, even a small increase in PP4C 
ubiquitination contributed by the presence of the regulatory subunits PP4R3α and PP4R3β 
may be meaningful, as PP4R3α/β-containing heterotrimeric complex constitutes only a small 
fraction of each eluate, used as a substrate. Strong background signal, including PP4C and 
PP4R3α mono-ubiquitination, was observed in the absence of TRAIP (Figure 4.6a), suggesting 
that a co-purified contaminant might mono-ubiquitinate these subunits in vitro. Moreover, 
using excessive amount of the E2 enzyme could also have resulted in the strong background 
seen in the immunoblot. In addition to that, the low specificity of the PP4C antibody may have 
contributed to the background signal observed in the PP4C immunoblot. 
In the previous experiments conducted in the Andrew Jackson laboratory, weak TRAIP-
dependent in vitro ubiquitination of PP4R3α was observed when it was tested individually in 
the absence of the ternary complex (J. Ding and O. Murina, unpublished). I was able to confirm 
this finding by demonstrating TRAIP-dependent ubiquitination of PP4R3α in my assay (Figure 
4.6a). TRAIP-dependent PP4R2 ubiquitination was not detected when the PP4C-PP4R2-PP4R3α 
complex was used as a substrate (Figure 4.6a). Meanwhile, the weak chemiluminescence 
signal detected for PP4R2 and PP4R3β when using the PP4C-PP4R2-PP4R3β complex was 
164 
 
difficult to interpret. The loss of signal may potentially indicate a shift due to ubiquitination, 
but no clear lower mobility bands were observed (Figure 4.6a). 
 
 
Figure 4.6. TRAIP-dependent in vitro ubiquitination of the wild-type ternary PP4 complexes. 
a) Immunoblot showing that PP4C protein is poly-ubiquitinated by the RING domain of TRAIP 
in vitro. Ubiquitin (Ub) and the purified recombinant ternary PP4 complexes (PP4C-PP4R2-
PP4R3α and PP4C-PP4R2-PP4R3β) or PP4C monomer were incubated in the presence of the 
recombinant N-terminal portion of TRAIP (N-TRAIP), containing the RING domain and E3 ligase 
activity. All ubiquitination reactions were supplemented with ATP, as well as E1 and E2 
enzymes, and incubated for 3 h at 37˚C. Reactions were stopped by adding sample loading 
buffer and analysed by immunoblotting with anti-TRAIP, anti-PP4C, anti-PP4R2, anti-PP4R3α 
and anti-PP4R3β antibodies. Anti-PP4R3α blot was re-probed for anti-PP4R3β. 
b) Image analysis to compare PP4C ubiquitination of ternary PP4 complexes and PP4C alone 
was performed using Fiji/ImageJ software. For ubiquitination analysis, the background signal 
intensity, defined as signal detected in the lanes without ubiquitin (–Ub), was subtracted from 
the lanes that contained ubiquitin (+Ub) after the ratio of Ub-PP4C/total PP4C was calculated. 
‘-TRAIP’ samples represent control conditions lacking TRAIP but containing all other 
constituents needed for ubiquitination in vitro, including ubiquitin. 
 
 
The protein-protein interactions between the catalytic and regulatory subunits within 
the PP4 complex may influence TRAIP-mediated PP4C ubiquitination. However, further 
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experimental work will be necessary to validate this hypothesis. Firstly, it will be important to 
generate the ternary PP4 complexes with 1:1:1 stoichiometry, as this would allow better 
assessment of the role played by PP4R3α/β on the PP4C ubiquitination. Moreover, the N-
terminal part of TRAIP was used in our in vitro analyses, and the capacity of TRAIP to 
ubiquitinate PP4C may be altered by the presence of its C-terminus. Therefore, the ability of 
full-length TRAIP to ubiquitinate PP4C and the regulatory subunits will need to be determined 





4.4. Identifying the residues of PP4 complex subunits that are ubiquitinated by 
TRAIP in vitro 
 
My working model was that TRAIP acts as a negative regulator of PP4 complex that 
contains the regulatory subunit PP4R3β (Figure 4.2). Therefore, I hypothesised that if TRAIP-
dependent ubiquitination of the PP4 complex is implicated in the DDR during S phase, then 
expression of non-ubiquitinatable PP4 mutant would be expected to phenotypically mimic the 
DDR signalling defects observed in TRAIP-deficient cells. As PP4 complex was shown to have 
several distinct cellular roles (Cohen et al., 2005), its depletion from cells would likely affect all 
cellular functions, making interpretion of results difficult. Therefore, to study the potential 
DDR function of PP4, regulated by TRAIP, I first focussed on identifying the lysine residues of 
PP4C and the regulatory subunits that are ubiquitinated by TRAIP. Using site-directed 
mutagenesis, I expected to identify the residues of the PP4 complex that are essential for 
TRAIP-mediated ubiquitination in vitro, followed by assessing their functional significance in 
cell-based assays. 
 To get an insight which residues of PP4C could be ubiquitinated by TRAIP in vitro, I 
searched the PhosphoSitePlus protein post-translational modification database (Hornbeck et 
al., 2015) for the lysine residues of the PP4 subunits that were previously observed to be post-
translationally modified by ubiquitination. At the time of my inquiry, three lysine residues of 
PP4C were reported to be ubiquitinated by high throughput proteomic discovery-mode MS 
studies: K26 (reported by 31 studies), K31 (reported by 22 studies) and K63 (reported by 2 
studies). I substituted these three lysines to the arginines (K>R) within the co-expression 
vector, as this is predicted to make the residues non-ubiquitinatable by the E3 ligase, while 
retaining their positive charge and thus diminishing chances of destabilisation and incorrect 
folding of PP4C. Once the mutations in these residues within PP4C were introduced, the 
mutant PP4 complexes were purified and their ability to act as substrates for TRAIP-mediated 
ubiquitination in vitro was tested.  
 As seen previously for wild-type complexes, the purified triple mutant complexes 
PP4C(K26R/K31R/K63R)-PP4R2-PP4R3β and PP4C(K26R/K31R/K63R)-PP4R2-PP4R3α were 
mostly composed of the binary PP4C-PP4R2 complex, with the band corresponding to PP4R3β 
or PP4R3α almost invisible on a Coomassie-stained protein gel (Figure 4.7a-b). Moreover, it 
became clear that the four complexes purified so far (the WT and mutant complexes with 
either PP4R3β or PP4R3α) differed in the amounts of each subunit. Thus, an immunoblotting 
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experiment was performed to compare the levels of PP4C, PP4R2 and PP4R3β/PP4R3α in these 
complexes and estimate how much of each eluate to use as an input for the in vitro 
ubiquitination assay to equilibrate the subunit levels (Figure 4.7c-d). The volume of each eluate 
representative of approximately equivalent input for a fair comparison between the 
complexes was chosen based on these immunoblots. 
 However, the in vitro ubiquitination assay comparing WT and mutant PP4 complexes 
showed no substantial decrease in TRAIP-mediated ubiquitination of the mutant complexes, 
compared to WT complexes (Figure 4.7e-h), suggesting that the mutated lysine residues do 
not have a strong influence on TRAIP-dependent ubiquitination of PP4C. As before, TRAIP-
dependent ubiquitination of PP4R3α was observed; additionally, PP4R3β was also 
ubiquitinated in a TRAIP-dependent manner (Figure 4.7e-f). Although PP4C, PP4R3α and 
PP4R3β showed mono-ubiquitination pattern in the absence of TRAIP in the in vitro 
ubiquitination assay, the more extensive multi-mono-ubiquitination or poly-ubiquitination of 
these subunits required TRAIP (Figure 4.7e-h). In the future, to distinguish between multi-
mono-ubiquitination and poly-ubiquitination, which look similar in immunoblots but may lead 
to distinct fates of the substrate protein, a ubiquitin mutant unable to form chains (where all 
seven lysines have been mutated to arginines) can be used instead of wild-type ubiquitin. 
Overall, these experimental data demonstrate that TRAIP promotes ubiquitination of PP4C, 
PP4R3β and PP4R3α, and that lysines 26, 31 and 63 of PP4C are not the key substrate residues 






Figure 4.7. Triple mutants of PP4C (K26R/K31R/K63R) do not abolish TRAIP-dependent in 
vitro ubiquitination of the ternary PP4 complexes. 
a, b) Coomassie-stained protein gels showing purification of the recombinant ternary 
PP4C(K26R/K31R/K63R)-PP4R2-PP4R3α (a) and PP4C(K26R/K31R/K63R)-PP4R2-PP4R3β (b) 
complexes. Key steps of protein purification are shown: T = total protein, S = soluble fraction, 
FT = flow-through, BB = beads before PS cleavage, E1 = eluate, E2 = second eluate / wash, BA 
= beads after PS cleavage. Eluate fractions were collected and used as substrates in in vitro 
ubiquitination reactions. Bands corresponding to the known sizes of GST, PP4C, GST-PP4C, 
PP4R2, PP4R3α and PP4R3β are indicated. 
c, d) Immunoblots showing the presence of all three PP4 subunits within the recombinant 
complexes PP4C(K26R/K31R/K63R)-PP4R2-PP4R3α (c) and PP4C(K26R/K31R/K63R)-PP4R2-
PP4R3β (d). Eluate fractions of wild-type (WT) and triple mutant PP4C(K26R/K31R/K63R)-
containing (M) recombinant PP4 complexes were analysed by immunoblotting with anti-PP4C, 
anti-PP4R2, anti-PP4R3α and anti-PP4R3β antibodies. Stars below indicate the amounts of 
each WT and mutant complex (1X or 2X) that were used for the in vitro ubiquitination assay 
shown below. 
e, f) Immunoblots showing that both wild-type (WT) and triple mutant K26R/K31R/K63R (M) 
PP4C proteins within the recombinant PP4R3α (e) and PP4R3β (f) containing complexes are 
ubiquitinated by the RING domain of TRAIP in vitro. Ubiquitin (Ub) and the purified 
recombinant ternary PP4 complexes (PP4C-PP4R2-PP4R3α and PP4C-PP4R2-PP4R3β) with or 
without PP4C(K26R/K31R/K63R) mutations were incubated in the presence of the 
recombinant N-terminal part of TRAIP (N-TRAIP), containing the RING domain required for its 
E3 ligase activity. All ubiquitination reactions were supplemented with ATP, as well as E1 and 
E2 enzymes, and incubated for 3 h at 37˚C. Reactions were stopped by adding sample loading 
buffer and analysed by immunoblotting with anti-PP4C, anti-PP4R2, anti-PP4R3α and anti-
PP4R3β antibodies. 
g, h) Image analysis to compare ubiquitination (the ratio of Ub-PP4C versus total PP4C) of wild-
type (WT) and triple mutant K26R/K31R/K63R (M) PP4C proteins within the recombinant 
PP4R3α (g) and PP4R3β (h) containing complexes was performed using Fiji/ImageJ software. 
‘-TRAIP’ samples represent control conditions lacking TRAIP but containing all other 





4.5. Mass spectrometry reveals lysine residues of PP4C, PP4R3β and PP4R3α 
that are ubiquitinated by TRAIP in vitro 
 
Previous results suggested that other lysine residues of PP4 complex subunits are 
targeted by TRAIP ubiquitination. Given that hypothesis-driven approach did not reveal the 
key ubiquitination sites in vitro, I employed mass spectrometry (MS) to find these residues 
(performed in collaboration with Alex Von Kriegsheim, IGMM Mass Spectrometry facility 
(Figure 4.8a). A semi-quantitative interaction proteomic approach was used to analyse in vitro 
ubiquitination reactions with and without TRAIP, containing wild-type PP4 complexes PP4C-
PP4R2-PP4R3β and PP4C-PP4R2-PP4R3α as substrates. Immunoblotting was performed to 
confirm PP4C ubiquitination (Figure 4.8b), and the samples were subjected to in-solution 
trypsin digestion and label-free quantification by liquid chromatography (LC)-tandem MS 
(MS/MS).  
Although signal intensity is proportional to the quantity of analyte, it does not provide 
a precise quantification due to potential differences in peptide ionisation (Jarnuczak et al., 
2016). Nevertheless, the MS experiment allowed semi-quantitative evaluation of the lysine 
residues ubiquitinated by N-terminal TRAIP in vitro. The analysis of MS data revealed five lysine 
residues of PP4C (lysines 21, 26, 31, 133, and 183) whose ubiquitination in vitro was increased 
in the reactions containing TRAIP, compared to the ones without TRAIP (Figure 4.8c). Notably, 
the three lysine residues of PP4C that were previously not reported in the PhosphoSitePlus 
protein post-translational modification database (K21, K133 and K183) are now in the list of 
PP4C residues that were found to be ubiquitinated. Moreover, one residue of PP4R3β, lysine 
36 (K36), and one residue of PP4R3α, lysine 733 (K733), were identified by the MS analysis as 
ubiquitinated in a TRAIP-dependent manner in vitro (Figure 4.8c). In contrast, the 
ubiquitination of these two residues is not reported by the PhosphoSitePlus database. 
The results obtained by MS indicate that PP4 complex is ubiquitinated by TRAIP in 
vitro, with several lysine residues of PP4 complex as its main targets. However, various 
limitations of these data have to be considered. In vitro experiments may provide an indication 
of the events in vivo; however, the relatively high protein concentration and the absence of 
substrate competition or regulation have to be taken into consideration. Additionally, only N-
terminal part of TRAIP was used in in vitro ubiquitination experiments and MS analysis, and it 
is plausible that more specific or efficient TRAIP-mediated ubiquitination of PP4 complex 
would be achieved in the presence of full-length TRAIP. Finally, other or additional factors, 
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such as a different E2 ubiquitin-conjugating enzyme, may be necessary to enhance TRAIP-




Figure 4.8. MS analysis of TRAIP-dependent in vitro ubiquitination of PP4 detects lysine 
residues targeted by TRAIP. 
a) Schematic depiction of the MS strategy to identify ubiquitination sites. Proteins post-
translationally modified by ubiquitin moieties are digested with trypsin, leaving a di-glycine 
remnant attached to the ε-amine of the lysine where ubiquitin was attached (Lys-ɛ-Gly-Gly, or 
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K-ɛ-GG). Thus, K-ɛ-GG is indicative of proteins containing ubiquitinated lysine side chains. This 
is followed by the identification of ubiquitinated lysine residues by liquid chromatography (LC)-
tandem MS (MS/MS). The obtained raw data contain intensities of K-ɛ-GG signals for all 
ubiquitinated lysine residues that were present in the analysed reactions. Image adapted from 
Lumpkin et al. (2017). 
b) Immunoblot showing TRAIP-dependent PP4C ubiquitination in the in vitro ubiquitination 
reactions, subsequently analysed by MS. Ubiquitin (Ub) and the purified recombinant ternary 
PP4 complexes (PP4C-PP4R2-PP4R3α and PP4C-PP4R2-PP4R3β) were incubated in the 
presence or absence of the recombinant N-terminal part of TRAIP (N-TRAIP). All ubiquitination 
reactions were supplemented with ATP, as well as E1 and E2 enzymes, and incubated for 3 h 
at 37˚C. Reactions were stopped by adding sample loading buffer and analysed by 
immunoblotting with anti-PP4C antibody.  
c) Plot representing all lysine (K) residues of PP4 complex subunits PP4C, PP4R2, PP4R3β and 
PP4R3α that were identified as ubiquitinated by MS analysis in the in vitro ubiquitination 
reactions containing N-TRAIP as an E3 ligase and PP4 complex as a substrate. Ubiquitination 
reactions were stopped by freezing on dry ice, and samples were subjected to in-solution 
trypsin digestion to enrich for the di-glycine remnant (K-ɛ-GG), followed by LC-tandem MS 
(performed by Alex Von Kriegsheim, IGMM Mass Spectrometry facility). Signal normalisation 
was performed by dividing raw signal intensity of a ubiquitinated lysine residue ([KGG]) by the 
total signal intensity of the protein to which the lysine residue belongs ([total protein 
intensity]). The [KGG]/[total protein intensity] ratios were further normalised within the graph 
to the highest ratio observed. 
 
 
 The lysine residues of TRAIP that were auto-ubiquitinated by its E3 ligase activity in 
vitro were plotted as well. The MS analysis revealed that TRAIP auto-ubiquitinates at multiple 
lysines, with three of them preferentially used in vitro: K150, K235, and K251 (Figure 4.9). 
According to the PhosphoSitePlus protein post-translational modification database, several 
discovery-mode MS studies observed ubiquitination of K150 and K235 of TRAIP. In contrast, 
K251 was not previously reported to be post-translationally modified, although the 







Figure 4.9. MS analysis of TRAIP auto-ubiquitination in vitro. 
Plot representing all lysines (K) residues of TRAIP that were identified by MS analysis in the in 
vitro ubiquitination reactions containing E3 ligase N-TRAIP and PP4 complex. These sites 
therefore represent auto-ubiquitinated TRAIP residues. Samples were subjected to in-solution 
trypsin digestion to enrich for the di-glycine remnant (K-ɛ-GG), followed by LC-tandem MS 
(performed by Alex Von Kriegsheim, IGMM Mass Spectrometry facility). Signal normalisation 
was performed by dividing raw signal intensity of a ubiquitinated lysine residue ([KGG]) by the 
total signal intensity of the protein to which the lysine residue belongs ([total protein 
intensity]). The [KGG]/[total protein intensity] ratios were further normalised within the graph 
to the highest ratio observed. 
 
 Ubiquitination is an abundant post-translational modification that involves the 
generation of an isopeptide linkage between the C-terminus of the ubiquitin moiety and the 
ε-amino group of a lysine residue on the substrate protein (mono-ubiquitination). Multi-mono-
ubiquitination occurs when a single ubiquitin moiety is attached to multiple lysine residues on 
the same substrate (Akutsu et al., 2016). Moreover, ubiquitin itself has seven lysine residues 
(lysines 6, 11, 27, 29, 33, 48 and 63), all of which can be further ubiquitinated to generate poly-
ubiquitin chains with ubiquitin molecules attached end-to-end to one lysine residue on a 
substrate protein (Akutsu et al., 2016). The potential of ubiquitin to form a multitude of 
differently structured chains makes ubiquitin signalling a particularly versatile cellular system 
capable of regulating and influencing a variety of cellular processes. Alongside other data 
obtained from the TRAIP-PP4 MS screen of the in vitro ubiquitination reactions, I analysed 
ubiquitin chain linkage distribution by quantifying ubiquitinated ubiquitin peptides. Three 
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types of ubiquitin chains were strongly enriched in the ubiquitination reactions containing both 
TRAIP and PP4 complex: K11, K48, and K63 (Figure 4.10). The lack of these ubiquitin chain 
linkages in the reactions without TRAIP suggest that these data are specific to either TRAIP-
dependent ubiquitination of PP4 or TRAIP auto-ubiquitination. However, it is difficult to 
distinguish between these scenarios without additional data. Furthermore, poly-ubiquitin 
chains can be not only homotypic (single linkage type) but also heterotypic (mixed linkage 
types; either branched on non-branched), further complicating the analysis. Nevertheless, the 
most abundant ubiquitin chain linkages can give us some insight into the potential cellular fate 
of ubiquitinated TRAIP and PP4 complex. To distinguish between TRAIP-dependent 
ubiquitination of PP4 or TRAIP auto-ubiquitination, further MS analyses with TRAIP as the only 
substrate of the in vitro ubiquitination reaction need to be performed. 
 
 
Figure 4.10. MS analysis of TRAIP-dependent in vitro ubiquitin chain linkage. 
Plot representing the types of ubiquitin chain linkage that were identified by MS analysis in the 
in vitro ubiquitination reactions containing E3 ligase N-TRAIP and PP4 complex. Samples were 
subjected to in-solution trypsin digestion to enrich for the di-glycine remnant (K-ɛ-GG), 
followed by LC-tandem MS (performed by Alex Von Kriegsheim, IGMM Mass Spectrometry 
facility). Signal normalisation was performed by dividing raw signal intensity of a ubiquitinated 
lysine residue ([KGG]) by the total signal intensity of the protein to which the lysine residue 
belongs ([total protein intensity]). The [KGG]/[total protein intensity] ratios were further 
normalised within the graph to the highest ratio observed.
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The differences in ubiquitin chain composition are thought to encode distinct signals, 
and structurally different chains participate in distinct cellular processes and signalling 
pathways (Akutsu et al., 2016). The best-studied types of poly-ubiquitin chains are K48- and 
K63-linked chains, both of which were abundant in the in vitro ubiquitination reactions (Figure 
4.10). K48-linked poly-ubiquitin chains have long been understood to be a canonical signal 
promoting proteasomal degradation, whereas K63-linked poly-ubiquitin chains are often 
associated with non-proteolytic roles, instead mediating signal transduction, intracellular 
trafficking and chromatin localisation of DNA damage factors (Lee et al., 2017; Li and Ye, 2008). 
Meanwhile, K11 poly-ubiquitin chains have been proposed to be involved in regulating cell 
cycle and proteasomal degradation (Akutsu et al., 2016). As mentioned before, it is not 
immediately obvious which types of identified linkages indicate poly-ubiquitination of PP4 
subunits and TRAIP. However, TRAIP was previously observed to be degraded via the 
proteasome in response to UV damage (Harley et al., 2016). Moreover, the addition of 
proteasome inhibitor MG132 in the cellular ubiquitination assay increased the stability of 
TRAIP (Figure 4.3). It is therefore likely that TRAIP auto-ubiquitination in vitro is mainly 
represented by K48 ubiquitin linkages, suggesting that PP4 subunits may be ubiquitinated by 
TRAIP via K63-linked and/or K11-linked ubiquitin chains. If this is confirmed by other 
experiments, such as in vitro ubiquitination reactions using only K63-linked ubiquitin moieties 
or immunoblotting with the anti-K63-specific ubiquitin antibody in cells, it would suggest that 
TRAIP is involved in non-proteolytic regulation of PP4 activity, such as its re-localisation or 
recruitment to sites of DNA damage. 
Overall, the MS analysis of in vitro ubiquitination reactions allowed identification of 
seven lysine residues of PP4 complex subunits PP4C (K21, K26, K31, K133, and K183), PP4R3β 
(K36) and PP4R3α (K733), ubiquitinated in vitro in a TRAIP-dependent manner. Moreover, 
ubiquitinated residues of TRAIP itself were detected, indicating positions of three lysine side 
chains (K150, K235, and K251) that are particularly enriched in this post-translational 
modification. Finally, certain ubiquitin chain linkages (K11, K48, and K63) were found to be 
prevalent in the in vitro ubiquitination reactions studied. These data constitute important 
initial observations, which will need to be tested using cell-based experiments in the future 






4.6. PP4C K183R has reduced levels of TRAIP-dependent ubiquitination in vitro 
  
The analysis of TRAIP-dependent ubiquitination sites of PP4 complex by MS revealed 
high signal intensity of the ubiquitinated PP4C lysine residue 183 (K183) in both wild-type PP4 
complexes, PP4C-PP4R2-PP4R3β and PP4C-PP4R2-PP4R3α. Thus, I tested whether a 
substitution of this lysine to another positively-charged but non-ubiquitinatable residue, an 
arginine, would diminish the levels of TRAIP-mediated ubiquitination of PP4C in vitro. Site-
directed mutagenesis was performed on the wild-type PP4 co-expression construct to 
generate the PP4C(K183R)-PP4R2-PP4R3β plasmid. Once the K183R substitution was 
confirmed by Sanger sequencing, an additional round of site-directed mutagenesis introduced 
the second mutation, K21R, into PP4C. As the K21 residue of PP4C was also shown to be 
extensively ubiquitinated in the MS analysis (see Figure 4.8c), I expected to observe further 
reduction in TRAIP-mediated ubiquitination of PP4C(K21R/K183R)-PP4R2-PP4R3β in vitro, 
compared to PP4C(K183R)-PP4R2-PP4R3β. 
Like wild-type PP4 complexes, the purified mutant PP4C(K183R)-PP4R2-PP4R3β and 
PP4C(K21R/K183R)-PP4R2-PP4R3β complexes contained large amounts of the binary PP4C-
PP4R2 complex, with only a small proportion of the eluate corresponding to PP4R3β on a 
Coomassie-stained protein gel (Figure 4.11a-b). Therefore, as before, immunoblotting analysis 
was conducted to compare the levels of PP4C, PP4R2 and PP4R3β subunits in the mutant and 
wild-type complexes and to decide how much of each eluate to use as a substrate for the in 
vitro ubiquitination assay (Figure 4.11c). The in vitro ubiquitination assay comparing wild-type, 
single mutant (PP4C(K183R)) and double mutant (PP4C(K21R/K183R)) PP4R3β-containing PP4 
complexes was performed. The PP4C(K183R)-PP4R2-PP4R3β complex showed a 2-fold 
reduction in TRAIP-dependent ubiquitination of PP4C, compared to the wild-type complex 
(Figure 4.11d-e), demonstrating that the K183 mutation has a major effect on the fraction of 
PP4C ubiquitinated by TRAIP in vitro. However, PP4C ubiquitination was not abolished 
completely, suggesting that ubiquitination of other lysine residues of PP4C also contributes to 
the overall ubiquitination signal. Surprisingly, the double mutant PP4C(K21R/K183R)-PP4R2-
PP4R3β did not exacerbate the observed ubiquitination defect (Figure 4.11d-e). While this 
observation could suggest that instead of potentiating the effect of K183R, the K21R 
substitution ameliorates it, the reduction is not significantly different from the single mutant 




Figure 4.11. TRAIP-dependent in vitro ubiquitination of the ternary PP4C-PP4R2-PP4R3β 
complex with wild-type, K183 and K21R/K183R PP4C identifies K183 as a TRAIP target. 
a, b) Coomassie-stained protein gels showing purification of the recombinant ternary 
PP4C(K183R)-PP4R2-PP4R3β (a) and PP4C(K21R/K183R)-PP4R2-PP4R3β (b) complexes. Key 
steps of protein purification are shown: T = total protein, S = soluble fraction, FT = flow-
through, BB = beads before PS cleavage, E1 = eluate, E2 = second eluate / wash, BA = beads 
after PS cleavage. Eluate fractions were collected and used as substrates in the in vitro 
ubiquitination reactions. Bands corresponding to the known sizes of GST, PP4C, GST-PP4C, 
PP4R2 and PP4R3β are indicated. 
c) Immunoblot showing the presence of all three PP4 subunits within the eluate fractions of 
the recombinant PP4C(K183R)-PP4R2-PP4R3β and PP4C(K21R/K183R)-PP4R2-PP4R3β 
complexes. Immunoblotting analysis was conducted using anti-PP4C, anti-PP4R2 and anti-
PP4R3β antibodies. Stars below indicate the amounts of each WT and mutant complex that 
were used for in vitro ubiquitination assays. 
d) Representative immunoblot (n=2 independent experiments) showing reduced TRAIP-
mediated in vitro ubiquitination of PP4C(K183R)-PP4R2-PP4R3β compared to the WT PP4C-
PP4R2-PP4R3β complex. Ubiquitin (Ub) and the recombinant ternary wild-type or mutant PP4 
complexes (PP4C-PP4R2-PP4R3β, PP4C(K183R)-PP4R2-PP4R3β and PP4C(K21R/K183R)-PP4R2-
PP4R3β) were incubated in the presence of the recombinant N-terminal part of TRAIP (N-
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TRAIP). All ubiquitination reactions were supplemented with ATP, as well as E1 and E2 
enzymes, and incubated for 3 h at 37˚C. Reactions were stopped by adding sample loading 
buffer and analysed by immunoblotting with anti-PP4C and anti-TRAIP antibodies.  
e) Image analysis to compare PP4C ubiquitination of wild-type and mutant PP4 complexes was 
performed using Fiji/ImageJ software. For ubiquitination analysis, the background signal 
intensity, defined as signal detected in the lanes without ubiquitin (–Ub), was subtracted from 
the lanes that contained ubiquitin (+Ub) after the ratio of Ub-PP4C/total PP4C was calculated. 
‘-TRAIP’ samples represent control conditions lacking TRAIP but containing all other 
components of the in vitro ubiquitination reaction, including ubiquitin. Results (mean ± SD) 
from n=2 independent experiments are shown; statistics: unpaired two-tailed t-test. 
 
One of the possible explanations for this result is that differential levels of PP4R3β, 
which was predicted by MS to mediate TRAIP-PP4 interaction (Figure 4.1), may impact on PP4C 
ubiquitination. As the PP4 complexes used in the in vitro ubiquitination reactions did not have 
1:1:1 stoichiometry, optimisation of PP4C levels between the wild-type and mutant complexes 
required compromising on the levels of regulatory subunits. Thus, different amounts of 
PP4R3β were present in ubiquitination reactions analysed in this section (see Figure 4.11c), 
with the lowest PP4R3β levels in the PP4C(K183R)-PP4R2-PP4R3β complex, for which the 
weakest TRAIP-dependent ubiquitination was observed. Alternatively, it is plausible that the 
structural changes within PP4C due to the introduced K21R mutation may cause 
conformational changes and promote surface exposure of buried lysine residues, which would 
not be ubiquitinated due to their position in the wild-type PP4C. In other words, the double 
K21R/K183R mutation within PP4C may destabilise the protein, resulting in the unveiling of 
additional ubiquitinatable lysine residues. 
Overall, these data suggest that lysine residue 183 (K183) of PP4C is a major TRAIP 
target in vitro. The role of K21 residue was not determined with certainty, as the 
PP4C(K21R/K183R) mutant was ubiquitinated by TRAIP more efficiently, but not significantly 
so, than the single K183R mutant. In the future, the importance of K21 residue can be assessed 
by testing wild-type, PP4C(K183) and PP4C(K21R/K183R) monomers for TRAIP-dependent 
ubiquitination in vitro, in the absence of the regulatory PP4 subunits. Furthermore, to confirm 
these in vitro findings, the K183 and K21 residues of PP4C will need to be to be tested in cellular 





4.7. Summary and discussion: PP4 as a substrate of TRAIP 
 
In this chapter, in vitro analysis of the E3 ligase activity of TRAIP on protein 
phosphatase 4 (PP4) complexes was described. The conducted experiments demonstrated the 
TRAIP-mediated in vitro ubiquitination of the catalytic PP4 subunit, PP4C, as well as the 
regulatory PP4 subunits PP4R3β and PP4R3α. Additionally, the MS analysis of ubiquitination 
sites of PP4 complex subunits identified seven lysine residues of PP4C, PP4R3β and PP4R3α, 
whose ubiquitination was highly enriched in the presence of TRAIP in vitro. Finally, subsequent 
in vitro experiments indicated the importance of lysine 183 (K183) of PP4C for TRAIP-mediated 
ubiquitination in vitro. 
Overall, the experimental work described in this chapter shows the interaction 
between TRAIP and PP4 complex, as well as its TRAIP-mediated ubiquitination, a relationship 
that could be relevant to a regulatory role in vivo. My initial hypothesis was that TRAIP 
ubiquitinates PP4 complex in a time-dependent manner in response to DNA damage, leading 
to the negative regulation of PP4 to maintain phosphorylation of the DNA damage markers 
RPA2 and H2AX. Upon degradation of TRAIP, the DDR-mediating accumulation of pRPA2 and 
γH2AX would be dissipated, contributing to the resolution of the DNA damage. Although the 
TRAIP-dependent ubiquitination of several PP4 subunits was observed in vitro, the 
ubiquitination analyses described in this chapter have technical limitations that make it 
difficult to confirm this model.  
Firstly, only a small increase in TRAIP-mediated PP4C ubiquitination was observed in 
the presence of the regulatory subunits PP4R3β and PP4R3α, compared to the monomeric 
PP4C (Figure 4.6). However, considering that TRAIP-PP4 interaction is mediated by PP4R3α/β, 
as suggested by MS, and that only a small amount of heterotrimeric PP4R3α/β-containing PP4 
complex is present in the eluates analysed, this result may still be meaningful. Further in vitro 
ubiquitination analyses using ternary PP4 complexes with the optimal 1:1:1 stoichiometry will 
need to be performed to establish the role of PP4R3β and PP4R3α in promoting TRAIP-
mediated PP4C ubiquitination. To overcome solubility issues posed by purification of individual 
PP4 complex subunits, particularly PP4R3β, C-terminal tagging of PP4R3β and PP4R3α in the 
co-expression vector may be employed in addition to the N-terminal tagging of PP4C to 
increase the ratio of the heterotrimeric complex. To achieve a defined stoichiometry of 
subunits, Frey and Görlich (2014) suggest using orthogonal affinity tags and protease cleavage 
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sites, followed by successive rounds of affinity capture and proteolytic release, thus ensuring 
the presence of each tagged subunit individually.  
Secondly, in vitro ubiquitination reaction conditions may need to be adjusted to better 
delineate the role of the regulatory subunits PP4R3β and PP4R3α, as well as of the lysine 
residues of PP4 complex identified by MS (Section 4.5), for the TRAIP-PP4 interaction. RING 
domain E3 ligases, such as TRAIP, do not form a covalent ligase-ubiquitin intermediate but 
rather facilitate the direct transfer of ubiquitin from the E2 to the target protein (Deshaies and 
Joazeiro, 2009) and are not strictly required for non-specific ubiquitination to occur (David et 
al., 2011). Thus, the excessive amount of the E1 and E2 enzymes in the in vitro ubiquitination 
reactions may have resulted in the strong background signal observed in the immunoblots 
even in the absence of TRAIP or ubiquitin. This could have also led to the non-specific multi-
mono-ubiquitination instead of specific and physiologically relevant poly-ubiquitination. 
Therefore, precise quantification of functional E1 and E2 concentrations and additional 
controls in the in vitro ubiquitination reactions, such as reactions set up in the absence of E2 
and ATP, could facilitate detection of specific TRAIP-mediated PP4 ubiquitination (Ronchi and 
Haas, 2012). Finally, the incubation time of the ubiquitination reaction may need to be 
optimised by measuring the rate of pyrophosphate production to reduce the risk of reaction 
saturation and ensure sensitivity of the assay (Berndsen and Wolberger, 2011). 
Using the full-length TRAIP, rather than the N-terminal TRAIP, in the in vitro 
ubiquitination reactions may have provided a better insight into the ability of TRAIP to mediate 
ubiquitination of PP4 complex. As recombinant full-length TRAIP was found to be insoluble in 
bacterial cells (M. Harley, unpublished data), other methods to generate it could be employed, 
such as baculovirus–insect cell expression system, routinely used for recombinant protein 
production (Kost et al., 2005; Kost and Condreay, 1999).  
As the UbcH5 class of E2 ubiquitin-conjugating enzymes was shown to be required for 
TRAIP auto-ubiquitination in vitro (Besse et al., 2007), I used the E2 enzyme UbcH5b/UBE2D2 
in my in vitro ubiquitination reactions. As humans have 38 distinct E2 enzymes (Deshaies and 
Joazeiro, 2009), and the identity of the E2 enzyme is important for determining the type of 
ubiquitination produced by RING E3 ligases (Christensen et al., 2007; Windheim et al., 2008), 
it is plausible that different E2 enzymes are necessary to potentiate TRAIP-dependent 
ubiquitination of PP4 complex. Moreover, additional cellular factors that were not present in 
the in vitro ubiquitination reactions may be needed to assist TRAIP-dependent ubiquitination 
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of PP4 complex. For example, RING domain activity of BRCA1 was shown to increase 
dramatically upon binding the RING domain of BARD1 (Hashizume et al., 2001).  
My in vitro experiments did not model the presence of DNA damage either, providing 
limited indication whether the observed interaction between TRAIP and PP4 is enhanced in 
the presence of a DNA damaging agent. Protein phosphorylation-driven DDR signalling, 
mediated by PIKK kinases ATR, ATM and DNA-PK (Blackford and Jackson, 2017), may be 
required to facilitate TRAIP-PP4 interaction in vivo, making other in vitro systems, such as 
Xenopus laevis cell-free egg extracts, more suitable for modelling TRAIP-mediated PP4 
ubiquitination in the context of DDR and the cell cycle (Garner and Costanzo, 2009). 
In my in vitro experiments, no significant differences between TRAIP-dependent 
ubiquitination of PP4R3α- and PP4R3β-containing PP4 complexes was observed. As only the 
PP4R3β-containing PP4 complex was implicated in DDR signalling (Chowdhury et al., 2008; Lee 
et al., 2010; Nakada et al., 2008), it suggests that the interaction between TRAIP and PP4 and 
TRAIP-mediated PP4 ubiquitination may not be relevant to the DDR function of TRAIP. Due to 
their artificial nature, the in vitro studies can only give indication of the events in vivo, and cell-
based analyses are required to establish the importance of the obtained results. Thus, cellular 
ubiquitination assays using a tagged full-length TRAIP will be necessary to confirm the impact 
of the lysine mutations on the TRAIP-dependent ubiquitination of PP4 complex subunits, as 
well as to test the significance of TRAIP-PP4 interaction for DNA repair. 
Meanwhile, I decided to prioritise experimental work aimed at generating a TRAIP 
knockout cell line (Chapter 5). Instead of focusing on a single candidate-based investigation, 
this allowed me to address the more general questions regarding the TRAIP role in DDR, as 
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5. Generation and characterisation of a TRAIP-KO cell line 
 
When the laboratory of Andrew Jackson demonstrated that biallelic mutations in 
TRAIP cause microcephalic primordial dwarfism (MPD) (Harley et al., 2016), not much was 
known about the cellular functions of TRAIP, aside from its role in regulating TRAF2-mediated 
NF-κB activation (Lee et al., 1997), its ability to auto-ubiquitinate through its RING-dependent 
E3 ubiquitin ligase activity (Besse et al., 2007) and its involvement in TBK1 ubiquitination to 
mediate antiviral responses (Zhang et al., 2012). Using TRAIP patient-derived cell lines and 
TRAIP-depleted HeLa cells, Harley et al. (2016) established that TRAIP is required for efficient 
DDR signalling in response to UV-C irradiation. Consistent with these findings, three other 
studies demonstrated the involvement of TRAIP in the cellular response to other types of DNA 
damage (Hoffmann et al., 2016; Soo Lee et al., 2016; W. Feng et al., 2016). However, the 
molecular mechanisms underlying the role of TRAIP as a novel DDR signalling factor and its 
causative link to human disease still remained elusive. 
All of the recent studies addressing the role of TRAIP in DDR and DNA repair used either 
hypomorphic patient-derived cell lines (Harley et al., 2016) or siRNA-mediated depletion of 
TRAIP in a cancer cell line (Harley et al., 2016; Hoffmann et al., 2016; Soo Lee et al., 2016; W. 
Feng et al., 2016). However, it is plausible that residual TRAIP present in all these cell systems 
has an impact on the observed phenotypes, i.e. complete absence of TRAIP may show more 
severe and/or different phenotypes, relevant to its biological functions. Therefore, one of the 
aims of my PhD project was to study the consequences of complete TRAIP ablation on cellular 
phenotypes, particularly on maintenance of genome stability, both in unperturbed conditions 
and in response to DNA damage. Additionally, my aim was to address whether TRAIP is 
essential for cell viability. 
In this chapter, the generation of TRAIP knockout (KO) cell lines using CRISPR/Cas9-
mediated genome editing is described. Moreover, detailed characterisation of the TRAIP-KO 
cell lines is reported, using genotyping, analysis of TRAIP protein expression by 
immunoblotting and karyotyping. Finally, I present and discuss the analysis of DNA damage 
signalling in TRAIP-KO cells upon exposure to genotoxic agents. Overall, this chapter provides 
comprehensive analysis and characterisation of the cellular system that was used for further 
experimental work described in Chapter 6. 
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5.1. CRISPR/Cas9-mediated targeting of TRAIP in human cell lines 
 
To elucidate the cellular functions of TRAIP in DDR, I designed a CRISPR/Cas9-mediated 
editing strategy to generate a TRAIP knockout (KO) cell line. Such a TRAIP-KO cell line would 
be a valuable tool for investigating the roles of TRAIP both in unperturbed conditions and in 
response to DNA damage, for the following reasons. Firstly, a TRAIP-KO cell line generated in 
parallel with a WT cell line that was not targeted but underwent clonal expansion would 
constitute an isogenic system, allowing me to study phenotypes specific to TRAIP loss. 
Secondly, well-characterised fast proliferating human cell lines, such as RPE1 or HeLa, are more 
suitable for cell biology experiments than the slow-dividing TRAIP patient fibroblast cell lines. 
Lastly, a TRAIP-KO cell line would enable us to perform CRISPR/Cas9 genome-wide screens. A 
dropout viability screen with TRAIP-KO could elucidate cellular pathways, loss of which is 
synthetic lethal with TRAIP deficiency, whereas suppressor screen could potentially identify 
genetic interactors and substrates of TRAIP. 
Three human cell lines were used for the editing experiment: a near-diploid hTERT-
immortalised retinal pigmented epithelium cell line RPE1; hTERT-immortalised RPE1 p53-/-; 
and the HeLa cervical carcinoma cell line, all well-characterised and frequently used for DDR 
studies. RPE1 p53-/- and HeLa cell lines stably expressed FLAG-Cas9 to facilitate gene targeting. 
Also, stable Cas9 expression would be beneficial for use of resulting TRAIP-KO cells in genome-
wide CRISPR/Cas9 screens. Two guide RNAs (gRNAs) were designed to target exon 1 of TRAIP, 
which encodes a large part of the RING domain (Figure 5.1). I chose to target this domain as it 
is essential for catalytic activity, and abolishing E3 ligase activity of TRAIP should render it 
unable to perform its cellular functions. In addition, disruption of the first exon is more likely 
to disrupt protein expression altogether. It is likely to result in a premature stop codon, 
followed by degradation of the mutant transcript through NMD pathway (Hug et al., 2016). 
The gRNAs were selected based on their evaluations by CRISPR Design Tool (Feng Zhang lab; 
http://crispr.mit.edu/) and the CRISPR gRNA Design Tool DNA2.0 (now ATUM) and cloned into 
the pX458 vector, encoding wild-type GFP-tagged Cas9. For TRAIP targeting, two gRNAs were 
simultaneously introduced into each of the cell lines to enhance the probability of the Cas9-
mediated cutting and the introduction of indels. GFP-positive cells were subsequently sorted 
into individual wells of a 96-well plate and grown for 1-2 weeks until they formed colonies that 




Figure 5.1. Targeting TRAIP exon 1, encoding the N-terminal portion of the RING domain, by 
CRISPR/Cas9 genome editing.  
A schematic structure of TRAIP protein with a focus on its exon 1 (amino acid (above) and 
genomic (below) sequences). The four distinct domains of TRAIP are indicated (PIP = PCNA-
interacting protein box motif). The 20 nt-long genomic sequences targeted by gRNAs in exon 
1 of TRAIP are highlighted in green; 3 nt-long PAM sites are shown in blue. Red arrows point 





5.2. Genotypes and TRAIP protein levels of CRISPR clones 
 
CRISPR/Cas9 targeting efficiency in all three cell lines was evaluated at several stages. 
Firstly, transfection efficiency was estimated during the GFP-FACS single cell sorting procedure. 
Secondly, some of the GFP-positive cells (200-400 cells) were sorted into individual wells for 
clonal outgrowth; the rest of the GFP-positive cell pool was used for crude genomic DNA 
extraction and PCR analysis to determine the presence of indels, as an indicator of successful 
targeting. Finally, established CRISPR clones were analysed using the same protocol to quantify 
targeting efficiency and to identify a set of candidate TRAIP-KO and WT clones. Several were 
selected for each cell line and subsequently analysed by Sanger sequencing and/or 
immunoblotting to determine which genomic alterations were present and their 
consequences on TRAIP protein levels. 
Good CRISPR/Cas9 transfection efficiency was achieved in RPE1 and RPE1 p53-/- cell 
lines, where 65% and 70% of cells, respectively, were GFP-positive, indicating successful 
introduction of gRNAs into cells. The PCR analysis of GFP-positive cells revealed that both RPE1 
and RPE1 p53-/- cell lines were targeted, leading to introduction of indels of various sizes in 
exon 1 of TRAIP (Figure 5.2a). However, only 2 out of 288 (0.7%) GFP-FACS-sorted single TRAIP 
CRISPR RPE1 cells survived and formed clones, both of which turned out to be wild-type upon 
Sanger sequencing of the targeted locus (Table 5.1). Meanwhile, 125 out of 384 (33%) single-
sorted RPE1 p53-/- cells formed colonies. 55 of these clones were screened for editing at the 
targeted TRAIP locus by PCR. The majority of analysed clones displayed PCR products of 
different sizes compared to the parental cell line, and Sanger sequencing analysis confirmed 
editing at the TRAIP locus (Figure 5.2b, Table 5.1). Eight successfully edited RPE1 p53-/- clonal 
cell lines were selected for further analysis. Firstly, their genotypes were determined by sub-
cloning of the PCR products, followed by Sanger sequencing. This revealed that a single large 
deletion frequently occurred at the targeted locus, which in all cases analysed was predicted 
to lead to a premature stop codon in the 5’ end of TRAIP exon 2 and protein truncation (Table 
5.2). Immunoblotting analysis was subsequently performed to evaluate the effect of the indels 
on TRAIP protein levels. Clonal cell lines selected for immunoblotting showed a strong 
reduction in TRAIP protein levels with almost undetectable TRAIP levels in the majority of the 
cell lines tested (Figure 5.2c). In summary, TRAIP was successfully knocked-out in RPE1 p53-/- 
cells, producing multiple clonal cell lines lacking TRAIP that can be used for studying its cellular 
roles. My results targeting TRAIP in RPE1 and RPE1 p53-/- cells suggest that TRAIP-KO cells may 




Figure 5.2. Targeting of TRAIP exon 1 in RPE1 and RPE1 p53-/- cells by CRISPR/Cas9 genome 
editing. 
a) PCR analysis of CRISPR/Cas9-targeted GFP-positive RPE1 and RPE1 p53-/- cells indicates the 
presence of indels in TRAIP exon 1. Genomic DNA was isolated from untransfected (Parental) 
and FACS-sorted CRISPR/Cas9-targeted GFP-positive (CRISPR) RPE1 and RPE1 p53-/- cells. PCR 
amplification of the 277 bp product encompassing exon 1 of TRAIP and exon-intron junctions 
was carried out to screen for CRISPR/Cas9-mediated targeting of TRAIP (black arrowheads 
indicate the positions of primers used for screening). The presence of targeted alleles was 
visualised on 2% agarose gel. 
b) PCR analysis of CRISPR/Cas9 edited RPE1 p53-/- clonal cell lines indicates the presence of 
indels in TRAIP exon 1. Agarose gel represents PCR screening of the targeted TRAIP locus (277 
bp product encompassing exon 1 of TRAIP and exon-intron junctions) in a few of the analysed 
clonal cell lines. Genomic DNA was extracted from untransfected (Parental, P) and clonal 
(indicated by numbers and letters) RPE1 p53-/- cells. Primers used for PCR amplification are 
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indicated by black arrowheads. Clones with biallelic targeting of TRAIP confirmed by Sanger 
sequencing are shown in red; clones confirmed to be wild-type for TRAIP are shown in green. 
c) Immunoblotting of RPE1 p53-/- TRAIP CRISPR clonal cell lines showing several targeted 
clones with strongly reduced TRAIP protein levels. The expanded clones (targeted clones 
shown in red; wild-type clones shown in green) were harvested for immunoblotting with 
affinity-purified rabbit anti-TRAIP antibody raised against recombinant TRAIP protein (Harley 
et al., 2016). Vinculin served as a loading control. 
d) Both alleles of TRAIP are disrupted in the RPE1 p53-/- TRAIP CRISPR clone 1.29. PCR 
amplification, agarose gel analysis and Sanger sequencing of the clone 1.29 demonstrate 
biallelic editing, in contrast to the wild-type clonal cell line 1.30. Clone 1.29 is compound 
heterozygous for two deletions within TRAIP exon 1 (c.58_70del (Allele 1) and 
c.52del+c.55_82del (Allele 2)), resulting in a biallelic genomic disruption of the catalytic RING 
domain as determined by Sanger sequencing. Both mutant alleles are predicted to lead to a 




Table 5.1. Efficiency of targeting TRAIP exon 1 by CRISPR/Cas9 genome editing in different 
cell lines. 











after FACS (%) Targeted clones (%) 
Null clones 
confirmed 
 RPE1 65 + 0.7% (2/288) 0% (0/2) (Sanger sequencing) 0/0 
 RPE1 p53-/- 70 + 32.6% (125/384) 72.7% (40/55)  (Sanger sequencing) 8/8 
 HeLa N/A + N/A   24.5% (13/53) (PCR analysis) 0/4 
 
 
Table 5.2. The genotypes of RPE1 p53-/- TRAIP CRISPR clones and predicted consequences 
on TRAIP protein. 
A star (*) indicates a premature stop codon; hom = homozygous; aa = amino acids; NMD = 
nonsense-mediated decay. 
Clone 




2B None 469 aa WT 
12B None 469 aa WT 
1.30 None 469 aa WT 
24B c.10_55del (46 bp deletion) (Hom) 18 aa (MPITWPPSTAATPSTCSA*) NMD 
29B c.10_55del (46 bp deletion) (Hom) 18 aa (MPITWPPSTAATPSTCSA*) NMD 
36B c.12_55del (44 bp deletion) (Hom) 23 aa (MPIRRGRHPLRPHLPLAVPNSVV*) NMD 









c.10_14del (5 bp deletion) + 
c.33_58del (26 bp deletion) + 
c.61_91del (31 bp deletion) 
(Hom) 
17 aa (MPISVHYLLCAVPNSVV*) NMD 




c.58_70del (13 bp deletion)  
(Allele 1);  
c.52del (1 bp deletion) + 








insA (1bp insertion after c.50) 
+ c.51_86 (36 bp deletion) 
(Hom) 
26 aa (MPIRALCTICSDFFDHSPLAVPNSVV*) NMD 
 
 
The TRAIP gene was also targeted in HeLa cells in a separate CRISPR/Cas9 experiment 
to generate a complementary TRAIP-KO cell line that could be used together with RPE1 p53-/- 
to rule out cell line-specific differences. I noted that FACS-sorting of HeLa cells into individual 
wells of a 96-well plate negatively affected formation of clonal cell lines, as only approximately 
2% of non-transfected or CRISPR/Cas9-transfected FACS-sorted HeLa cells survived. Therefore, 
CRISPR/Cas9-transfected HeLa cells were plated at low density, grown for two weeks, and 
replated into individual wells of a 96-well plate by scraping. Successful TRAIP targeting in HeLa 
cells was confirmed by PCR analysis of transfected cell pool (Figure 5.3a). PCR analysis of 53 
clonal cell lines showed that 40 were apparently not targeted (single band of the same size as 
detected in the parental cell line), while the other 13 displayed multiple bands of different 
sizes (in most cases, three bands could be resolved using >2% agarose gels) (Figure 5.3b, Table 
5.1). As HeLa cells are hypertriploid (Landry et al., 2013), it is not surprising that three alleles 
of TRAIP could be seen by PCR analysis. Eight clonal cell lines (4 apparently wild-type and 4 
targeted) were selected for further analysis by Sanger sequencing and immunoblotting. The 
HeLa clones that displayed a single band in PCR analysis were confirmed to be wild-type. In the 
targeted HeLa clonal cell lines analysed by Sanger sequencing, double or triple 
electropherograms were observed, showing that one or two out of three alleles of TRAIP had 
indels at the targeted TRAIP locus, while at least one allele remained wild-type. Subcloning and 
Sanger sequencing of separate alleles of the four clonal cell lines confirmed this observation 
(Table 5.3). Immunoblotting analysis revealed reduced TRAIP protein levels for the targeted 
clonal cell lines #10 and #23 (Figure 5.3c). However, cell line #15, which has the same genotype 
as cell line #23, displayed only a modest reduction in TRAIP protein levels, suggesting that the 
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two cell lines have different levels of expression of the same alleles. In summary, disruption of 
two out of three alleles of TRAIP in HeLa cells has an effect on TRAIP protein levels, but it seems 
to be influenced by non-genetic factors as well (Figure 5.3c). TRAIP targeting in HeLa cells was 
efficient but yielded only hypomorphic cell lines, which cannot be used for studying the effects 
of complete loss of TRAIP. 
 
 
Figure 5.3. Targeting of TRAIP exon 1 in HeLa cells by CRISPR/Cas9 genome editing. 
a) PCR analysis of CRISPR/Cas9 transfected HeLa cells indicates the presence of indels in TRAIP 
exon 1. Genomic DNA was isolated from untransfected (Parental) and CRISPR/Cas9-targeted 
(CRISPR) HeLa cells. PCR amplification of the 277 bp product encompassing exon 1 of TRAIP 
and exon-intron junctions was carried out to screen for CRISPR/Cas9-mediated targeting of 
TRAIP (black arrowheads indicate the positions of primers used for screening). The presence 
of targeted alleles was visualised on a 2% agarose gel. 
b) PCR analysis of CRISPR/Cas9 edited HeLa clonal cell lines indicates the presence of indels in 
TRAIP exon 1. Agarose gel represents PCR screening of the targeted TRAIP locus (277 bp 
product encompassing exon 1 of TRAIP and exon-intron junctions) from selected clonal cell 
lines analysed. Genomic DNA was extracted from untransfected (Parental, P) and clonal 
(indicated by numbers) HeLa cells. Primers used for PCR amplification are indicated by black 
arrowheads. Clones with targeting of TRAIP confirmed by Sanger sequencing are shown in red; 
clones confirmed to be wild-type for TRAIP are shown in green. 
c) Immunoblotting of HeLa TRAIP CRISPR clonal cell lines showing several targeted clones with 
reduced TRAIP protein levels. The expanded clones (targeted clones shown in red; wild-type 
clones shown in green) were harvested for immunoblotting with affinity-purified rabbit anti-
TRAIP antibody raised against recombinant TRAIP protein (Harley et al., 2016). Vinculin served 
as a loading control. An RPE1 p53-/- TRAIP CRISPR cell line (37B) was used as a knockout (KO) 
control to demonstrate that TRAIP protein levels in the hypomorphic HeLa CRISPR cell lines are 
higher than in the RPE1 p53-/- TRAIP-KO cells. 
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Table 5.3. The genotypes of HeLa TRAIP CRISPR clones and predicted consequences on TRAIP 
protein. 
A star (*) indicates a premature stop codon; aa = amino acids. 
Clone 
# Mutation(s) Predicted TRAIP protein 
1 None 469 aa 
2 None 469 aa 
21 None 469 aa 
22 None 469 aa 
10 
Allele 1: none 
Allele 2: c.56_73del (18 bp deletion) 
+ c.12_40dup (29 bp insertion of 
duplicated sequence) 
Allele 3: c.10_55del (46 bp deletion) 
Allele 1: 469 aa 
Allele 2: 37 aa 
(MPIRALCTICSDFFDHSRVLCALSAPTSAATPSTCSA*) 
Allele 3: 18 aa (MPITWPPSTAATPSTCSA*) 
13 Allele 1: none Allele 2: c.11_55del (45 bp deletion) 
Allele 1: 469 aa 
Allele 2: 454 aa (16 aa deletion (R4-D19) and 1 aa 
insertion (H4)) 
15 
Allele 1: none 
Allele 2: c.11_55del (45 bp deletion) 
Allele 3: c.10_55del (46 bp deletion) 
Allele 1: 469 aa 
Allele 2: 454 aa (16 aa deletion (R4-D19) and 1 aa 
insertion (H4)) 
Allele 3: 18 aa (MPITWPPSTAATPSTCSA*) 
23 
Allele 1: none 
Allele 2: c.11_55del (45 bp deletion) 
Allele 3: c.10_55del (46 bp deletion) 
Allele 1: 469 aa 
Allele 2: 454 aa (16 aa deletion (R4-D19) and 1 aa 
insertion (H4)) 
Allele 3: 18 aa (MPITWPPSTAATPSTCSA*) 
 
 
The data obtained during these CRISPR/Cas9 targeting experiments suggest a 
correlation between the p53 status of a cell line and the efficiency with which a TRAIP-KO can 
be generated in that background. Given the genome instability observed in TRAIP-deficient 
cells (see Section 5.3), it is plausible that p53-proficient cells undergo a p53-mediated cell cycle 
arrest and apoptosis following TRAIP knockout. Indeed, hTERT-immortalised RPE1 cell line has 
two fully proficient copies of the TP53 gene, which may have prevented the cells with 
biallelically disrupted TRAIP from surviving and proliferating. At the same time, the lack of RPE1 
clones heterozygous for indels in TRAIP could be explained by the high editing efficiency in 
targeted cells, as none of such clones were found on the RPE1 p53-/- background either. 
Similar to RPE1 cells, no TRAIP-KO clones were established in HeLa cells, but several TRAIP 
hypomorphic clones were generated. It was previously reported that p53 protein levels in HeLa 
cells are low, as E6 protein expressed by an endogenous human papilloma virus (HPV) 
ubiquitinates p53, targeting it for proteasomal degradation (Scheffner et al., 1990). Moreover, 
apoptosis in HeLa is also attenuated by HPV E7 oncoprotein that binds to retinoblastoma 
tumour suppressor protein and limits its ability to control cell division (Darnell et al., 2007; 
Goodwin and DiMaio, 2000). However, even low levels of p53 may be sufficient to prevent 
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proliferation in HeLa cells following TRAIP disruption, which could explain why only 
hypomorphic cells survived. In summary, a complete KO of TRAIP was achieved solely in RPE1 
p53-/- cells that are genetically null for TP53. These results therefore imply that TRAIP is 
essential for cell viability unless TP53 is disrupted, and that the lack of proliferation of TRAIP-
KO cells is mediated by p53. In the future, an attempt to generate a KO of TRAIP in another 
pair of isogenic cell lines that differ in p53 status only could provide further validation for this 
hypothesis. 
To study the cellular consequences of TRAIP absence, an isogenic pair of TRAIP-KO and 
WT CRISPR clones in the RPE1 p53-/- background were selected for further analysis. RPE1 p53-
/- TRAIP clone 1.29 with biallelic deletions resulting in a premature stop codon in each allele, 
which is predicted to lead to transcript degradation through NMD (Figure 5.2d), was chosen 
as the TRAIP-KO cell line. RPE1 p53-/- clone 1.30, confirmed to be wild-type for TRAIP by Sanger 
sequencing, was selected as a control cell line that underwent single cell sorting and clonal 




5.3. Genomic instability in TRAIP-KO cell lines 
 
 Various proteins associated with replication fork and involved in DDR signalling 
contribute to protection of cells from DNA damage and genomic instability by recruiting DNA 
repair factors to sites of damage, activating cell cycle checkpoints, or, if damage is unrepaired, 
by triggering apoptosis (see Section 1.3). Genomic instability is a hallmark of cancer, where 
inactivating mutations in DDR factors are frequently associated with tumour initiation and 
progression (Broustas and Lieberman, 2014). It has been demonstrated that the absence of 
functional DDR factors, such as BLM and FA proteins, that occurs in cancer-predisposing 
syndromes leads to increased levels of genomic instability and loss of heterozygosity, which 
may facilitate tumour formation (Moldovan and D’Andrea, 2009; Traverso et al., 2003). 
 TRAIP was previously identified by several research groups, including our laboratory, 
as a protein associated with stalled replication forks and required for efficient DDR signalling 
after cell exposure to various exogenous DNA damaging agents, such as UV-C, CPT, MMC and 
HU (Harley et al., 2016; Hoffmann et al., 2016; Soo Lee et al., 2016; W. Feng et al., 2016). I 
therefore postulated that cells lacking TRAIP protein may exhibit higher levels of chromosomal 
rearrangements and abnormal karyotypes, since they lose their ability to promote signalling in 
response to DNA damage. Indeed, U2OS cells depleted for TRAIP were reported to have 
increased levels of chromosomal aberrations such as chromatid breaks and radial 
chromosomes in unperturbed cells and upon exposure to MMC (Hoffmann et al., 2016), as 
well as following HU treatment (W. Feng et al., 2016). Moreover, both unperturbed and HU-
treated TRAIP-depleted cells were more likely to display aberrant mitotic structures, such as 
misaligned and lagging chromosomes (W. Feng et al., 2016). To examine whether TRAIP is 
necessary for maintaining genome stability in unperturbed TRAIP-KO cells, karyotype analysis 
on RPE1 p53-/- TRAIP-KO (clone 1.29) and RPE1 p53-/- parental cells was performed. The cell 
lines were re-genotyped to confirm their TRAIP status and sent for cytogenetic analysis of their 
karyotypes at 4-5 passages (approximately 12-15 cell divisions) after their generation. The 
karyotyping data were obtained by Dr Lin Deng through the Brigham & Women's Hospital 
CytoGenomics Core Facility (Boston, MA). 
In the parental RPE1 p53-/- cell line, chromosome counts in all 20 cells analysed were 
normal (46 chromosomes), with XX sex chromosomes, which is consistent with a female origin 
of the original hTERT RPE1 cell line (Potapova et al., 2015). All cells karyotyped (6 of the 20) 
had the typical derivative X chromosome with additional chromosomal material at the terminal 
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end of the q-arm, a feature previously reported for these hTERT RPE1 cells (Potapova et al., 
2015) (Table 5.4, Figure 5.4). Interestingly, no other clonal structural or numerical 
abnormalities were observed, suggesting that the KO of p53 did not induce gross chromosomal 
instability in RPE1 cells. 
 
 
Table 5.4. Cytogenetic analysis of RPE1 p53-/- TRAIP CRISPR clonal cell lines. 
Chr = chromosome; p = short arm of a chromosome; q = long arm of a chromosome. Clonal 
chromosomal abnormalities indicate recurrent karyotypic alterations observed in multiple 
karyotyped cells, whereas non-clonal rearrangements indicate karyotypic alterations observed 
in a single karyotyped cell. 
Cell line 
Karyotype  














Parental 100% 0% 0% 6 + — — 
1.29 10% 55% 35% 14 + + (loss of chr18) + 
1.29 + 
TRAIP-WT 55% 45% 8 + + (loss of chr18) — 
24B 80% 20% 8 + + (deletions in chr5q) + 
36B 0% 80% 20% 9 + + (additional material in chr21p) + 
37B 40% 60% 8 + + (additional material in chr21p) + 





Figure 5.4. Absence of TRAIP in RPE1 p53-/- cell line 1.29 is associated with the increased 
frequency of gross chromosomal abnormalities in unperturbed cells. 
Representative karyotypes of the parental RPE1 p53-/- cells, TRAIP-KO cell line 1.29 and TRAIP-
KO cell line 1.29 retrovirally complemented with pMSCV-TRAIP-WT plasmid. Black arrows 
indicate clonal abnormalities, including the typical derivative X chromosome, observed in 
hTERT RPE1 cells. Yellow arrows indicate non-clonal abnormalities, and down-facing red 
arrows indicate clonal loss of chromosome(s) (non-clonal losses are likely to be due to technical 
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factors). The number of bands observed for all chromosomes in this analysis was 400 or 
greater. Marker chromosomes (mar) seen in TRAIP-KO cells signify chromosomal fragments 
that cannot be identified with certainty due to their small size. 
 
 
In the RPE1 p53-/- TRAIP-KO cell line analysed (1.29), chromosome counts were 46 in 
10% (2/20) metaphase spreads, 44-45 in 50% (10/20), 51 in 5% (1/20), 76 in 5% (1/20), and 82-
86 in 30% (6/20) spreads (Table 5.4). It is unclear whether hypotetraploid TRAIP-KO cells with 
76 and 82-86 chromosomes represent actual chromosome losses or random losses due to 
technical artefacts. Fourteen of the 20 cells were karyotyped, and the cells with 46 
chromosomes turned out to be karyotypically normal, containing the typical derivative X 
chromosome but no additional chromosomal rearrangements. All the other karyotyped cells 
had one or two copies of the typical derivative X chromosome of the parental RPE1 cell line, 
as well as additional structural and/or numerical abnormalities (Figure 5.4). A clonal loss of 
chromosome 18 was observed: all karyotyped cells with counts of 44-45 were missing one copy 
of it, and all karyotyped hypotetraploid cells were missing two copies, consistent with being 
derived from a doubling of the hypodiploid clone lacking chromosome 18. Additional clonal 
chromosome losses may have been present in the hypotetraploid sub-clone, however, the 
quality of the metaphases did not permit complete identification of all chromosome 
aberrations at this level of analysis. Four of the 10 hypodiploid cells contained one or two 
structural changes, including deletions, additions of unknown material and a balanced 
translocation, which were apparently non-clonal in this analysis. The hypotetraploid cells 
contained 3-9 structural rearrangements, all apparently non-clonal in this analysis as well. 
These results demonstrate spontaneous chromosomal instability in the RPE1 p53-/- TRAIP-KO 
1.29 cell line, suggesting that the loss of TRAIP may be associated with inability of cells to 
resolve endogenous DNA damage, eventually leading to the proliferation of damaged cells 
with unstable karyotypes. 
Retroviral complementation of TRAIP-KO cells with TRAIP was performed, with the 
TRAIP-KO cell line 1.29 transduced with a wild-type TRAIP-containing vector, followed by drug 
selection to kill non-transduced cells (for extended characterisation of the complemented cell 
line, see Chapter 6). Chromosome counts in complemented cells were 44-46 in 55% (11/20) 
spreads, 67 in 5% (1/20), 79 in 5% (1/20), and 83-90 in 35% (7/20) spreads (Figure 5.4, Table 
5.4). Eight of the 20 cells were karyotyped; all had one or two copies of the typical derivative 
X chromosome of the parental RPE1 cell line, as well as additional structural and/or numerical 
abnormalities. As in the TRAIP-KO cell line 1.29, a clonal loss of chromosome 18 was observed. 
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The two karyotyped hypotetraploid cells contained no obvious structural rearrangements, in 
contrast to the TRAIP-KO cell line 1.29 (Figure 5.4). These results indicate chromosome 
instability in this cell line, but to a lesser extent than that observed in the TRAIP-KO cell line 
1.29, indicating that the addback of wild-type TRAIP either reduces the elevated levels of gross 
structural abnormalities observed in TRAIP-KO cells or prevents further rearrangements from 
taking place. 
 Four additional RPE1 p53-/- TRAIP-KO clonal cell lines with distinct deletions in TRAIP 
(24B, 36B, 37B and 78B) (Table 5.2) were analysed to confirm genomic instability of TRAIP-KO 
cells and exclude a possibility of it being a spurious observation in the clone 1.29. All four cell 
lines had a variety of non-clonal and clonal structural abnormalities, such as deletions or 
additional material on several chromosomes (Figure 5.5, Table 5.4). 
 The karyotyping data obtained in five distinct TRAIP-KO cell lines strongly suggest that 
the absence of TRAIP is associated with the increased frequency of tetraploidy and both clonal 
and non-clonal chromosomal abnormalities in unperturbed cells. The data also show that the 
genomic instability observed is not due to the absence of p53 per se, as the parental RPE1 p53-
/- cell line was karyotypically normal. The complementation of TRAIP-KO cells with wild-type 
TRAIP reduced the number of non-clonal structural rearrangements observed in metaphase 
spreads, although clonal abnormalities of the clone 1.29 persisted in this cell line. In summary, 
although TRAIP-KO cells are viable, they accumulate chromosomal instability and can 
proliferate only in a p53-deficient background. This observation suggests an important role of 
TRAIP in maintaining genome stability in unperturbed cells, and further work will be required 




Figure 5.5. RPE1 p53-/- TRAIP-KO cell lines 24B, 36B, 37B and 78B show increased levels of 
genomic instability in the absence of DNA damage. 
Representative karyotypes of the TRAIP-KO cell lines 24B, 36B, 37B and 78B. Black arrows 
indicate clonal abnormalities, including the typical derivative X chromosome, observed in 
hTERT RPE1 cells. Yellow arrows indicate non-clonal abnormalities, and down-facing red 
arrows indicate clonal loss of chromosome(s) (non-clonal losses are likely to be due to technical 




5.4. Characterisation of DDR signalling in TRAIP-KO cells 
 
DNA damage response (DDR) signalling collectively describes cellular responses 
required for maintaining genetic information intact by detecting DNA lesions, signalling their 
presence and facilitating their repair. Previous studies reported a role for TRAIP in protecting 
genome integrity and demonstrated that TRAIP-depleted cells exhibit changes in DDR 
signalling, particularly deregulated phosphorylation of DNA damage markers RPA2 and H2AX 
(Harley et al., 2016; Hoffmann et al., 2016; Soo Lee et al., 2016; W. Feng et al., 2016) (see Table 
1.2). However, some of the findings were contradictory. Our laboratory (Harley et al., 2016) 
and Hoffmann et al. (2016) observed impaired phosphorylation of H2AX (γH2AX) in response 
to replication-blocking DNA lesions in TRAIP-compromised cells, whereas other studies 
reported an increase in γH2AX signalling in response to HU (W. Feng et al., 2016) and IR (Soo 
Lee et al., 2016). Moreover, the studies did not agree on the types of DNA lesions that require 
TRAIP for efficient repair. Soo Lee et al. (2016) reported the involvement of TRAIP in mediating 
HR repair at IR-induced DNA lesions. In contrast, Hoffmann et al. (2016) described the 
requirement of TRAIP for repair of ICLs and HU- and CPT-induced DNA lesions, W. Feng et al. 
(2016) reported the role of TRAIP after HU treatment, and Harley et al. (2016) detected 
impaired DDR signalling in cells with partial loss of TRAIP only in response to UV-C irradiation 
(Table 1.2). The experiments described below were aimed at delineating whether cells with 
the complete absence of TRAIP have the DDR signalling defects previously described by our 
laboratory (Harley et al., 2016) in TRAIP patient cells after UV-C irradiation. Additionally, DDR 
signalling after other types of DNA damage was examined in TRAIP-KO cells. 
To confirm the impact of TRAIP depletion on DDR signalling in RPE1 p53-/- cells, I 
tested whether the phenotype previously observed in TRAIP patient-derived and HeLa siTRAIP 
cells after UV-C irradiation (Harley et al., 2016) could be recapitulated in this cell line. siRNA-
mediated TRAIP depletion in the RPE1 p53-/- parental cell line, used for CRISPR/Cas9-mediated 
TRAIP targeting, was performed. TRAIP-depleted cells were treated with UV-C and collected 8 
hours post-treatment, when pRPA2-S4/S8 and γH2AX signalling was previously detected by 
immunoblotting in TRAIP patient fibroblasts and TRAIP-depleted HeLa cells (Harley et al., 
2016). Immunoblotting on TRAIP-depleted RPE1 p53-/- cells showed a reduction in pRPA2-
S4/S8 and γH2AX signalling after UV-C irradiation (Figure 5.6). This result demonstrates 
reproducibility of the DDR signalling defect after UV-C irradiation in TRAIP-deficient HeLa and 




Figure 5.6. pRPA2-S4/S8 and γH2AX levels are reduced in TRAIP-depleted RPE1 p53-/- cells 
after UV-C irradiation. 
RPE1 p53-/- cells were treated with siLUC or siTRAIP and exposed to UV-C 48 h post-
transfection. Cells were collected for immunoblotting 8 h after UV-C irradiation and compared 
to the untreated samples (0 h after 10 J/m2 UV-C) for phosphorylation of DNA damage markers 
pRPA2-S4/S8 and γH2AX. UV-C-induced pRPA2-S4/S8 signalling was reduced by 81% and 
γH2AX signalling by 54% in TRAIP-depleted cells, compared to siLUC-treated cells (quantified 
using Fiji/ImageJ software). Affinity-purified rabbit anti-TRAIP antibody raised against 
recombinant TRAIP protein (Harley et al., 2016) was used for immunoblotting, demonstrating 
a 93% reduction of TRAIP protein levels upon UV-C treatment (quantified using Fiji/ImageJ 
software). Vinculin served as a loading control. 
 
 
To test whether partial and complete loss of TRAIP lead to the same DDR signalling 
defects after UV-C irradiation, I conducted a UV-C time-course experiment in TRAIP-KO cells, 
followed by immunoblotting analysis. Unexpectedly, no significant changes in phosphorylation 
of RPA2 and H2AX were observed in TRAIP-KO cell line compared to the WT cell line (Figure 
5.7). In contrast, it was previously demonstrated by Harley et al. (2016) that both TRAIP 
patient-derived fibroblasts and TRAIP-depleted HeLa cells exhibit reduced pRPA2-S4/S8 and 
γH2AX signalling after UV-C irradiation at all three time points analysed. The discrepancy 
between these results could be explained by the differences in TRAIP status in the two 
experiments. This would suggest that reduction in TRAIP protein levels and complete loss of 
TRAIP lead to distinct cellular outcomes. Certain adaptations in DNA damage signalling 
pathways may have arisen in TRAIP-KO cells allowing them to cope with the intrinsic genomic 
instability (see Section 5.3). Cells without TRAIP may have upregulated DDR signalling cascades 
to facilitate the repair of spontaneous and exogenous DNA damage, and the higher levels of 
pRPA2-S4/S8 and γH2AX could be reflective of it. Indeed, pRPA2-S4/S8 and γH2AX signal was 
found to be significantly increased in unperturbed TRAIP-KO cells, compared to WT cells, as 




Figure 5.7. pRPA2-S4/S8 and γH2AX levels are not reduced in RPE1 p53-/- TRAIP-KO cell line 
after UV-C irradiation. 
a) Representative immunoblot (n=3 experiments) demonstrating UV-C-induced pRPA2-S4/S8 
and γH2AX levels in WT (1.30) and RPE1 p53-/- TRAIP-KO (1.29) cell lines, as well as temporary 
TRAIP protein degradation upon UV-C treatment in WT cells. Vinculin served as a loading 
control. Cells were exposed to UV-C irradiation, harvested for immunoblotting 4, 8 or 24 h 
post-treatment, and untreated (0 h after 10 J/m2 UV-C) and UV-C-treated samples were 
compared for phosphorylation of DNA damage markers pRPA2-S4/S8 and γH2AX.  
b) Quantification of pRPA2-S4/S8 and γH2AX levels demonstrates no significant changes in UV-
C-induced pRPA2-S4/S8 and γH2AX levels between WT and TRAIP-KO cell lines at each time 
point analysed. Image analysis was performed using Fiji/ImageJ software; pRPA2-S4/S8 and 
γH2AX levels were normalised to vinculin. Results (mean ± SEM) from three independent 
experiments are shown. 
 
 
Figure 5.8. pRPA2-S4/S8 signal intensity and the number of γH2AX foci are increased in 
unperturbed RPE1 p53-/- TRAIP-KO cells. 
Immunofluorescence quantification to detect pRPA2-S4/S8 signal (a) and γH2AX foci (b) in 
EdU-negative and EdU-positive cell populations. RPE1 p53-/- TRAIP-KO (1.29) and WT (1.30) 
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cells were exposed to 10 μM EdU for 20 min to label cells undergoing DNA replication. 
Detergent pre-extraction of non-chromatin-bound proteins was performed before cell fixation 
with formaldehyde. Cells were immunostained for EdU and pRPA2-S4/S8 or γH2AX and 
visualised using fluorescence microscopy. Image analysis was performed using Fiji/ImageJ 
software. Black bars indicate the mean, and each dot in the graph represents one cell (more 
than 45 cells analysed per condition). Statistics: Mann-Whitney test. 
 
 
 Given that partial depletion and complete absence of TRAIP have different 
consequences for DDR signalling in response to UV-C, I decided to test whether RPE1 p53-/- 
TRAIP-KO cells are sensitive to other sources of DNA damage, as identifying such DNA damage-
inducing agents would be beneficial for studying the role of TRAIP in DDR. Furthermore, at the 
time this experimental work was performed, sensitivity of TRAIP-depleted cells to replication 
stress-inducing agents, such as CPT, MMC and HU, was reported by two other groups 
(Hoffmann et al., 2016; W. Feng et al., 2016). First, I compared the effect of the DNA damaging 
agents UV-C, CPT and HU on TRAIP-KO cells. Doses and times of treatment were adapted from 
previous reports investigating pRPA2 and γH2AX signalling (Harley et al., 2016; Hoffmann et 
al., 2016; Jeong et al., 2013). The immunoblot and its quantification confirmed that no changes 
in pRPA2-S4/S8 and γH2AX signalling occurred in TRAIP-KO cells after UV-C irradiation (Figure 
5.9). HU treatment did not affect pRPA2-S4/S8 and γH2AX signalling in TRAIP-KO cells either. 
In contrast, CPT treatment caused detectable reduction in both pRPA2-S4/S8 and γH2AX 
signalling in TRAIP-KO cells (Figure 5.9), suggesting that TRAIP may be required for DDR 
signalling induced upon DNA-TOP1 adduct formation (see Chapter 6 for further experimental 
work).  
During embryonic development, oxidative damage (Cooke et al., 2003) and aldehydes 
(Langevin et al., 2011) can induce endogenous DNA lesions. Due to the requirement for TRAIP 
for body and brain growth in utero (Harley et al., 2016), I tested whether TRAIP is involved in 
DDR signalling in response to oxidative stress, induced by hydrogen peroxide (H2O2) treatment. 
While the low dose (10 μM) of H2O2 did not result in RPA2 phosphorylation, the higher dose 
(100 μM) caused an increase in pRPA-S4/S8 signal in WT cells, which was less pronounced in 
TRAIP-KO cells (Figure 5.10), suggesting that TRAIP may also play a role in responding to 





Figure 5.9. pRPA2-S4/S8 and γH2AX levels are reduced in RPE1 p53-/- TRAIP-KO cells after 
CPT but not UV-C and HU treatment. 
a) Immunoblot demonstrating DNA damage-induced pRPA2-S4/S8 and γH2AX levels in 
untreated (NT) and drug-treated WT (1.30) and RPE1 p53-/- TRAIP-KO (1.29) cells, which were 
exposed to UV-C (10 J/m2), CPT (1 μM) and HU (2 mM) treatment and harvested for 
immunoblotting 4, 1 or 8 hours post-treatment, respectively. Vinculin served as a loading 
control. In WT cells, TRAIP protein depletion upon UV-C treatment and to the lesser extent 
upon CPT and HU treatment can be observed.  
b) Quantification of pRPA2-S4/S8 and γH2AX levels demonstrates no alterations in UV-C- and 
HU-induced pRPA2-S4/S8 and γH2AX levels between WT and TRAIP-KO cell lines. In contrast, 
a strong reduction in pRPA2-S4/S8 and γH2AX levels can be observed upon exposure to CPT. 
Image analysis was performed using Fiji/ImageJ software; pRPA2-S4/S8 and γH2AX levels were 




Figure 5.10. pRPA2-S4/S8 levels are reduced in RPE1 p53-/- TRAIP-KO cells after H2O2 
treatment. 
a) Immunoblot demonstrating H2O2-induced pRPA2-S4/S8 and γH2AX levels in RPE1 p53-/- WT 
(1.30) and TRAIP-KO (1.29) cells, which were exposed to H2O2 treatment (10 μM or 100 μM) 
and harvested for immunoblotting 4 or 8 h after addition of H2O2. Untreated (—) and H2O2-
treated samples of both cell lines were compared for phosphorylation of DNA damage markers 
pRPA2-S4/S8 and γH2AX by immunoblotting. Vinculin served as a loading control. 
b) Quantification of pRPA2-S4/S8 and γH2AX levels demonstrates a reduction in pRPA2-S4/S8 
signal in TRAIP-KO cells, compared to WT cells, upon exposure to 100 μM H2O2. Image analysis 
was performed using Fiji/ImageJ software; pRPA2-S4/S8 and γH2AX levels were normalised to 




5.5. Summary and discussion: characterisation of TRAIP-KO cells 
 
TRAIP encodes an E3 ubiquitin ligase and was established by our laboratory to be 
mutated in MPD (Harley et al., 2016). Furthermore, in recent years, TRAIP was demonstrated 
by several studies to be involved in DDR signalling in response to various types of DNA damage 
(Hoffmann et al., 2016; Soo Lee et al., 2016; W. Feng et al., 2016). In this chapter, the 
generation and characterisation of TRAIP-KO cells was described, including analyses of their 
genotypes, karyotypes, TRAIP protein expression levels and cellular response to DNA damaging 
agents. 
The CRISPR/Cas9 editing strategy employed to generate a TRAIP-KO cell line suggested 
the importance of p53 status for a successful KO. As discussed in Section 5.2, clonal TRAIP-KO 
cell lines were generated only in the RPE1 p53-/- background, whereas RPE1 and HeLa cells did 
not produce any KO clones. The D. melanogaster homologue of TRAIP, Nopo, was proposed to 
be required for the maintenance of genomic integrity during early embryogenesis, and 
mutations in this gene were shown to lead to maternal effect lethality (Merkle et al., 2009). 
Moreover, TRAIP-KO mice die early in embryonic development (E6.5–7.5), as dysregulation of 
cell proliferation and increased levels of apoptosis result in loss of primitive embryonic tissues 
(Park et al., 2007). Similarly, loss of an important mammalian genome surveillance enzyme, 
RNase H2, activity also resulted in p53-mediated arrest of cell growth, leading to embryonic 
lethality of RNaseH2-null mice (Reijns et al., 2012). Taken together, recent studies on TRAIP 
implicate it as an evolutionarily conserved factor, which maintains genome stability and is 
essential during early embryonic development. It is therefore not surprising that no MPD 
patients with complete loss of TRAIP were identified (Harley et al., 2016) and that only 
inactivation of the major apoptosis regulator p53 (Burns and el Deiry, 1999) allows survival of 
TRAIP-KO cells. 
 The experiments I conducted show a clear difference in DDR signalling in TRAIP-
depleted RPE1 cells (knock-down) and in cells lacking TRAIP (knock-out). RNA interference 
(RNAi), used by previous studies on TRAIP, reduces gene function but does not entirely 
abrogate it. To our knowledge, the TRAIP-KO cell line generated and characterised in this 
chapter is the first true genetic null cell line where both copies of TRAIP gene are disrupted, 
leading to the complete loss of the protein (Figure 5.2). Unexpectedly, TRAIP-KO cells did not 
have the DDR signalling defect observed in TRAIP-depleted cells in response to UV-C irradiation 
by Harley et al. (2016). Phenotypic differences between knockouts and knockdowns in human 
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cell lines are well documented (Evers et al., 2016; Karakas et al., 2007; Morgens et al., 2016), 
and genetic compensation (upregulation of related genes) in response to gene loss was 
proposed as one of the major reasons for these discrepancies (El-Brolosy and Stainier, 2017). 
Therefore, complete loss of TRAIP may result in cellular adaptations to increased genomic 
instability arising from unrepaired endogenous DNA lesions (as shown in Figure 5.4-5.5), at the 
same time impacting DDR signalling after UV irradiation.  
In this chapter, I also demonstrated that TRAIP-KO cells have impaired 
phosphorylation of DNA damage markers RPA2 and H2AX after CPT treatment (Figure 5.9), 
and experiments further investigating the role of TRAIP in DDR after CPT-induced DNA damage 
are described in Chapter 6. Moreover, H2O2-induced RPA2 phosphorylation was also decreased 
in TRAIP-KO cells, compared to WT cells (Figure 5.10). Meanwhile, TRAIP absence did not have 
any effect on the DDR signalling after HU treatment (Figure 5.9), in contrast with the study by 
W. Feng et al. (2016), which reported increased numbers of γH2AX-positive cells in HU-treated 
TRAIP-depleted cells. This again suggests that distinct cellular phenotypes may be observed in 
TRAIP knock-down and knock-out cells after the same type of DNA damage. Moreover, 
additional discrepancies between the reported data may be caused by different cell lines used, 
as all the previous studies on the TRAIP role in DDR used transformed cancer cell lines 
(Hoffmann et al., 2016; Soo Lee et al., 2016; W. Feng et al., 2016). Additionally, the dose and 
length of treatments may influence the results; for example, I used 2 mM HU for 8 h for my 
immunoblotting analysis, whereas W. Feng et al. (2016) used 5 mM HU for 4 h for their 
immunofluorescence experiment. Thus, further experimental work will be required to 
elucidate the actual roles of TRAIP in DDR and to explain the phenotypic differences seen in 
distinct cellular systems and conditions. 
Thus far, the generated RPE1 p53-/- TRAIP-KO cell line has only been used to address 
the role of TRAIP in DDR signalling (Chapter 6). However, additional studies using these cells 
may elucidate other pathways and/or cellular processes TRAIP is required for. The loss of TRAIP 
in mice (Park et al., 2007) and D. melanogaster (Merkle et al., 2009) is known to be embryonic 
lethal primarily due to aberrant proliferation and mitosis. As impaired cell proliferation and an 
increase in late S and/or G2 phase cells was observed in unperturbed TRAIP patient-derived 
fibroblasts and TRAIP-depleted HeLa cells (Harley et al., 2016), prolonged cell cycle and 
inefficient mitosis are also likely to contribute to the reduced growth phenotype of  TRAIP MPD 
patients. Thus, the role of TRAIP in regulating cell cycle and mitosis, previously proposed by 
several studies (Chapard et al., 2015, 2014), could be investigated further. Notably, TRAIP was 
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demonstrated to localise to mitotic chromosomes and regulate the spindle assembly 
checkpoint (SAC), and its depletion in HeLa cells was shown to lead to the faster progression 
through early phases of mitosis, as well as mitotic defects (Chapard et al., 2014). Moreover, 
TRAIP protein expression was reported to peak in G2/M phase of the cell cycle (Chapard et al., 
2015). Thus, it remains to be elucidated whether the loss of TRAIP results in prolonged or 
accelerated cell cycle, and what its precise role in mitosis is. In the future, TRAIP-KO cells may 




































Molecular mechanisms of TRAIP function 










6. Molecular mechanisms of TRAIP function in DDR and DNA 
repair 
 
TRAIP encodes a RING finger domain E3 ubiquitin ligase (Besse et al., 2007). Mutations 
in TRAIP were demonstrated by our laboratory to be linked to microcephalic primordial 
dwarfism (MPD), a reduction of brain and body size (Harley et al., 2016). Biallelic TRAIP 
mutations were shown to result in severely reduced TRAIP protein levels, as well as impaired 
cell cycle progression and cell proliferation (Harley et al., 2016). Moreover, disrupted DDR 
signalling in response to UV-C irradiation was observed in cells lacking functional TRAIP protein 
(Harley et al., 2016). UV-C-irradiated patient-derived cells, as well as TRAIP-depleted HeLa 
cells, exhibited reduced RPA2 and H2AX phosphorylation in S phase, suggesting that DNA 
repair defect may underlie TRAIP-associated MPD phenotype. However, it remained unknown 
whether TRAIP solely promotes the repair of UV-C-induced replication-blocking lesions or 
contributes to the cellular response to other types of DNA lesions as well. TRAIP-KO cells were 
generated to address these questions (see Chapter 5), as they provide a good tool to 
investigate DDR defects and underlying mechanisms. Preliminary data suggested that TRAIP-
KO cells may have defective DDR signalling in response to camptothecin (CPT)-induced DNA 
damage (Figure 5.9), and this observation is further investigated in Section 6.1. 
To understand the role of TRAIP as a DNA repair protein in DDR signalling, the impact 
of another replication-associated DNA damaging agent, mitomycin C (MMC), is investigated to 
determine whether TRAIP acts in the repair of MMC-induced DNA interstand crosslinks (ICLs) 
(Section 6.2). Overall, the objective of the work described in this chapter is to use TRAIP-KO 
cells as a tool to gain a better understanding of the TRAIP function in the cellular response to 









6.1. TRAIP is required for efficient cell response to CPT-induced replication 
blocking DNA lesions 
 
6.1.1. Camptothecin, TOP1-DNA complexes and their repair 
 
 The initial observation that TRAIP-KO cells have reduced pRPA2-S4/S8 and γH2AX 
signal in response to camptothecin (CPT) treatment (see Section 5.4., Figure 5.9) was 
intriguing, and I decided to investigate it further. The anti-tumour agent CPT disrupts DNA 
replication and transcription by trapping DNA topoisomerase I (TOP1) at single-stranded 
breaks (SSBs), thus stabilising TOP1 covalent complex (Top1cc), preventing re-ligation of the 
broken DNA ends and resolution of a SSB (Pommier, 2006) (Figure 6.1) (see Section 1.3.4). The 
toxic DNA-protein adduct needs to be swiftly removed via one of the two main TOP1 excision 
pathways, mediated by either tyrosyl-DNA phosphodiesterase (TDP1) (El-Khamisy and 
Caldecott, 2006) or structure-specific 3’-flap endonucleases, such as XPF/ERCC1, 
MUS81/EME1, and MRE11-RAD50 (Regairaz et al., 2011; Sacho and Maizels, 2011; Takahata et 
al., 2015). In the presence of a low dose of TOP1 inhibitor, SSBs can also be resolved by PARP1- 
and RAD51-mediated replication fork regression (Ray Chaudhuri et al., 2012; Zellweger et al., 
2015), resulting in a ‘chicken foot’-like DNA structure (Figure 6.1). Fork reversal slows down 
replication fork progression, preventing excessive accumulation of ssDNA and allows time for 
repair machinery to remove trapped TOP1 (Neelsen and Lopes, 2015; Ray Chaudhuri et al., 
2012; Zellweger et al., 2015).  
An unrepaired SSB can give rise to a one-ended double-strand break (DSB) upon 
collision with an ongoing replication fork in S phase (Pommier, 2006) (Figure 6.1). CPT-induced 
replication-associated DSBs lead to DDR signalling, such as phosphorylation of H2AX (Furuta et 
al., 2003), RPA (Huang et al., 2010; Shao et al., 1999; Vassin et al., 2009) and checkpoint kinases 
CHK1 and CHK2 (Huang et al., 2010; Pommier, 2006). In proliferating cells, the repair of 
replication-associated DSBs is largely dependent on homologous recombination (HR) 




Figure 6.1. Generation and repair of the TOP1-DNA covalent complex (Top1cc). 
Camptothecin (CPT) is an anti-tumour agent that stabilises and inhibits DNA topoisomerase I 
(TOP1) bound to DNA (Top1cc) and prevents resealing of the broken strand. Upon collision 
with the replication fork, the SSB can be turned into a DSB, which subsequently triggers DDR 
signalling and needs to be rapidly repaired via HR. Alternatively, replication fork reversal can 
take place forming a ‘chicken foot’ DNA structure and facilitating repair of the SSB.
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6.1.2. The TRAIP E3 ligase promotes DDR signalling in response to CPT lesions  
  
Studying the effect of several DNA damaging agents on TRAIP-KO cells suggested that 
phosphorylation of RPA2 and H2AX is impaired in TRAIP-KO cells upon CPT treatment (see 
Section 5.4., Figure 5.9). To confirm this observation and investigate the defective response to 
CPT in TRAIP-KO cells further, RPE1 p53-/- WT (1.30) and TRAIP-KO (1.29) cells were treated 
with 1 μM CPT. At the time points sampled, pRPA2-S4/S8 levels were significantly reduced in 
TRAIP-KO cell line after CPT treatment (23±5.5% of the WT signal 90 min into treatment) 
(Figure 6.2a-b), confirming the previous observation. CPT-induced γH2AX and pCHK1-S345 
signal was also found to be diminished in TRAIP-KO cells, although to a lesser extent (64±11.0% 
and 48±13.3% of the WT signal 90 min into treatment, respectively) (Figure 6.2a-b). 
Altogether, this result demonstrates the diminished ability of TRAIP-KO cells to efficiently 




Figure 6.2. CPT-induced DDR signalling is reduced in RPE1 p53-/- TRAIP-KO cells. 
a) Representative immunoblot (n=3 independent experiments) showing reduced CPT-induced 
pRPA2-S4/S8, γH2AX and pCHK1-S345 levels in RPE1 p53-/- TRAIP-KO (clone 1.29) cells, 
compared to WT (clone 1.30) cells. Cells were exposed to CPT treatment (1 μM) and harvested 
for immunoblotting 30, 60 or 90 min after addition of CPT. Untreated (0 min after adding 1 μM 
CPT) and CPT-treated samples of both cell lines were compared for phosphorylation of DNA 
damage markers pRPA2-S4/S8, γH2AX and pCHK1-S345 by immunoblotting. Vinculin served as 
a loading control. 
b) Quantification of pRPA2-S4/S8, γH2AX and pCHK1-S345 levels 90 min post-CPT addition 
demonstrates significant reduction of CPT-induced DDR signalling in TRAIP-KO cell lines. Image 
analysis was performed using Fiji/ImageJ software. pRPA2-S4/S8 and pCHK1-S345 levels were 
normalised to vinculin; γH2AX levels were normalised to H2A. Results (mean ± SD) from three 
independent experiments are shown; statistics: unpaired two-tailed t-test. 
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 CRISPR/Cas9-mediated targeting has emerged as a valuable tool to investigate the 
cellular function of a gene allowing the generation and study of knockout cell lines. However, 
the cell lines that I compare (WT and TRAIP-KO) required clonal expansion after CRISPR/Cas9-
mediated gene targeting. It could therefore be argued that in the resulting clones, mutations 
at other sites due to off-target effects of the gRNAs used may account for observed 
phenotypes, rather than TRAIP loss. To demonstrate that the DDR signalling defect seen in 
TRAIP-KO cells is caused specifically by the absence of TRAIP, the TRAIP-KO cell line 1.29 was 
complemented by retroviral infection. KO cells were transduced with either empty or wild-
type TRAIP-containing retroviral vector, followed by drug selection to kill non-transduced cells 
and generate pools of complemented cells. TRAIP protein levels, assessed by immunoblotting, 
revealed that TRAIP is overexpressed in the TRAIP-WT complemented cells, compared to WT 
and parental RPE1 p53-/- cells (Figure 6.3a). DDR signalling in response to CPT, including 
phosphorylation of RPA2, was rescued by the complementation of TRAIP-KO cells with TRAIP-
WT, but not with the empty vector (Figure 6.3b). This experiment therefore demonstrates that 
reduction in pRPA2-S4/S8, γH2AX and pCHK1-S345 signal seen in RPE1 p53-/- TRAIP-KO cell 
line after CPT treatment is specific to TRAIP loss and not due to off-target effects of 





Figure 6.3. Reduction in CPT-induced DDR signalling in RPE1 p53-/- TRAIP-KO cells is specific 
to TRAIP loss. 
a) Complementation of TRAIP-KO cells with TRAIP-WT (KO+WT) leads to overexpression of 
TRAIP, compared to TRAIP levels observed in WT cells. Cell lines used: RPE1 p53-/- parental 
(RPE1 p53-/-), WT (clone 1.30), TRAIP-KO (KO; clone 1.29), TRAIP-KO complemented with 
empty vector (KO+EV), and TRAIP-KO complemented with TRAIP-WT (KO+WT). Vinculin served 
as a loading control. 
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b) Reduction in pRPA2-S4/S8, γH2AX and pCHK1-S345 levels post-CPT treatment is rescued by 
the complementation of TRAIP-KO cells with TRAIP-WT (KO+WT), but not with empty vector 
(KO+EV). RPE1 p53-/- TRAIP-KO cells (clone 1.29) complemented with either empty vector 
(KO+EV) or TRAIP-WT (KO+WT) were exposed to CPT treatment (1 μM) and harvested for 
immunoblotting 30, 60 or 90 min after addition of CPT. Untreated (0 min) and CPT-treated 
samples of both cell lines were compared for phosphorylation of DNA damage markers pRPA2-
S4/S8, γH2AX and pCHK1-S345 by immunoblotting. Vinculin served as a loading control. 
 
 
As TRAIP is a RING finger E3 ligase, an important question is whether this ubiquitin 
ligase activity is essential for its role in DNA replication and repair. TRAIP contains an N-
terminal RING finger motif, a long coiled-coil domain, a leucine zipper domain, and a PIP-box 
domain (Lee, Lee and Choi, 1997; Hoffmann et al., 2016; W. Feng et al., 2016). The coiled-coil 
domain of TRAIP was shown to be required for its homodimerisation (I. S. Park et al., 2015), 
whereas the RING domain was speculated to have NF-κB-unrelated regulatory roles (Lee et al., 
1997). Many RING finger proteins function as E3 ubiquitin ligases, which transfer ubiquitin 
moiety from E2 ubiquitin-conjugating enzyme to the substrate protein, targeting it for 
degradation, affecting its cellular localisation or modulating its activity (Brown and Jackson, 
2015). It is therefore important to understand whether and how the E3 ligase activity aids 
TRAIP-mediated DDR at stalled replication forks. 
A recent study by Hoffmann et al. (2016) tested the importance of TRAIP E3 ligase 
activity in facilitating DNA repair. The group generated a stable cell line expressing a siRNA-
resistant TRAIP mutant lacking the RING domain (ΔRING, Δaa7–50), and showed that it did not 
rescue HU- and CPT-induced RPA phosphorylation defect, observed in siTRAIP-treated U2OS 
cells (Hoffmann et al., 2016). The ΔRING allele also failed to rescue cell survival defect of 
siTRAIP-treated U2OS cells exposed to MMC (Hoffmann et al., 2016). However, the ΔRING 
allele used in this study appeared to be toxic to cells, further reducing RPA phosphorylation 
and exacerbating MMC hypersensitivity in the absence of endogenous TRAIP (Hoffmann et al., 
2016). It is therefore not clear whether the cellular defects observed in the presence of the 
ΔRING mutant are indeed due to its dominant-negative effect or due to the altered protein 
structure. The deletion of the entire protein domain can negatively affect protein folding-
structure-function relationship, resulting in protein misfolding, mislocalisation or altered 
protein-protein interactions, which would not occur in the context of the full-length protein 
(Doyle et al., 1986; W. Feng et al., 2016; Filippello et al., 2013; Izumi et al., 2000). I therefore 
postulated that introduction of point mutations disrupting TRAIP E3 ligase would circumvent 
219 
 
these caveats and provide a better indication of the importance of this activity for DDR and 
DNA repair. 
To address this, a cell line complemented with a TRAIP RING domain mutant C7A/C10A 
was previously generated in our laboratory (performed by M. Harley and O. Murina). In this E3 
ligase mutant, two structurally essential cysteine residues in the catalytic site (C7 and C10) 
were substituted by alanines. DNA fibre experiments showed replication fork asymmetry after 
UV damage in C7A/C10A-complemented cells, suggesting that the role of TRAIP in DNA 
replication is dependent on its E3 ubiquitin ligase activity. However, highly reduced stability of 
the mutant protein was detected by immunoblotting (M. Harley and O. Murina, data not 
shown). TRAIP-C7A/C10A protein expression levels were higher than TRAIP expression in the 
patient-derived cell line, but lower compared to TRAIP expression in wild-type control 
fibroblasts, which was likely caused by reduced protein stability and its degradation. Therefore, 
it was not possible to conclude whether E3 ligase activity of TRAIP is required for its function 
in DNA replication and DNA damage signalling. 
To establish the importance of E3 ubiquitin ligase activity of TRAIP for its role in DDR 
signalling, I utilised a different TRAIP mutant deficient in E3 ligase activity, TRAIP-W37A (based 
on personal communication with Prof Helen Walden, University of Glasgow). The tryptophan 
residue is evolutionarily conserved within the RING domain, and its substitution to alanine has 
been used by several studies to inactivate the ligase activity of other RING domain E3 ubiquitin 
ligases (Brzovic et al., 2001; Dodd et al., 2004; Joazeiro et al., 1999; Katoh et al., 2003). The 
tryptophan-to-alanine substitution of this residue was predicted and demonstrated to disrupt 
the interaction between the E3 ligase and the E2 ubiquitin-conjugating enzyme, which is 
necessary for efficient substrate ubiquitination (Dodd et al., 2004; Joazeiro et al., 1999; Katoh 
et al., 2003). Although the TRAIP-W37A mutant was not predicted to completely obliterate E3 
ligase activity, it was expected to compromise it while retaining structural domain stability and 
allowing mutant protein to reach levels similar to the wild-type protein. TRAIP-KO cells were 
complemented by retroviral transduction with TRAIP-W37A (KO+W37A) and phosphorylation 
of DNA damage markers compared to TRAIP-WT complemented cells (KO+WT) by 
immunoblotting. The reduced pRPA2-S4/S8, γH2AX and pCHK1-S345 signal in TRAIP-KO cells 
was not rescued by the complementation with TRAIP-W37A (Figure 6.4a), suggesting that the 
E3 ligase activity of TRAIP is essential for its role in promoting DDR upon CPT treatment. TRAIP 
protein levels in KO+WT and KO+W37A cells lines were comparable, with no significant 
differences in protein levels, although average TRAIP-W37A mutant levels were slightly lower 
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(83±8.3% TRAIP protein relative to TRAIP-WT complementation) (Figure 6.4b). However, the 
TRAIP protein expression levels of the E3 ligase mutant were 5.5-fold higher than those of the 




Figure 6.4. Reduction in CPT-induced DDR signalling in RPE1 p53-/- TRAIP-KO cells is 
dependent on TRAIP E3 ligase. 
a) Representative immunoblot (n=2 independent experiments) demonstrating that reduction 
in pRPA2-S4/S8, γH2AX and pCHK1-S345 levels post-CPT treatment is rescued by the 
complementation of TRAIP-KO cells with TRAIP-WT (KO+WT), but not with the E3 ligase-
deficient mutant TRAIP-W37A (KO+W37A). RPE1 p53-/- WT, TRAIP-KO (KO; clone 1.29), TRAIP-
KO complemented with TRAIP-WT (KO+WT) and TRAIP-KO complemented with TRAIP-W37A 
(KO+W37A) cells were exposed to CPT treatment (1 μM) for 90 min and harvested for 
immunoblotting. Vinculin served as a loading control. Black arrowhead indicates the pCHK1-
S345 band, as pCHK1-S345 signal was detected by re-probing the membrane fraction used for 
TRAIP detection (lower band). 
b) TRAIP protein levels in KO+WT and KO+W37A cells lines are comparable. The TRAIP-W37A 
mutant complemented cells expressed 83±8.3% TRAIP protein relative to TRAIP-WT 
complemented cells (a non-significant difference). TRAIP protein expression levels of both 
TRAIP-WT and TRAIP-W37A are much higher than those of the WT cell line 1.30 (14.8+11.3% 
TRAIP protein relative to TRAIP-WT complementation). Image analysis was performed using 
Fiji/ImageJ software. TRAIP levels were normalised to vinculin. Results (mean ± SD) from four 
independent immunoblots are shown; statistics: unpaired two-tailed t-test. 
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c) Immunoblotting (left) and quantification (right) of in vitro ubiquitination reactions shows 
that total auto-ubiquitination of TRAIP-W37A is lower than of TRAIP-WT, with strongly reduced 
poly-ubiquitination but relatively normal mono-ubiquitination. Recombinant N-terminal part 
of WT TRAIP (TRAIP-WT) or of W37A mutant (TRAIP-W37A) was used both as an E3 ligase and 
a substrate in in vitro ubiquitination reaction in the absence or presence of ubiquitin (Ub). All 
ubiquitination reactions were supplemented with ATP, as well as E1 and E2 enzymes, and 
incubated for 3 h at 37˚C. Reactions were stopped by adding sample loading buffer and 
analysed by immunoblotting with anti-TRAIP antibody (Harley et al., 2016). Image analysis to 
compare TRAIP-WT and TRAIP-W37A auto-ubiquitination was performed using Fiji/ImageJ 
software. For auto-ubiquitination analysis, the signal intensity of the lanes without ubiquitin 
(–Ub) was subtracted from the lanes that contained ubiquitin (+Ub). 
 
 
TRAIP was previously shown to auto-ubiquitinate through its N-terminal RING-
dependent E3 ubiquitin ligase activity (Besse et al., 2007). To determine the E3 ligase activity 
of the TRAIP-W37A protein, N-terminal TRAIP-WT and TRAIP-W37A proteins were expressed 
in bacterial cells, purified and tested in vitro for their ability to auto-ubiquitinate. TRAIP-W37A 
retained 38% of its auto-ubiquitination activity, compared with TRAIP-WT, showing efficient 
mono-ubiquitination (70% compared to TRAIP-WT) but reduced poly-ubiquitination (4.5% 
compared to TRAIP-WT) (Figure 6.4c). Although TRAIP-W37A must retain some interaction 
with the E2 enzymes as it can still auto-ubiquitinate, at least in vitro, its ability to poly-
ubiquitinate itself is strongly affected. Most significantly, in cells, full-length TRAIP-W37A has 
the same defect in CPT-induced DDR signalling as TRAIP-KO cells (Figure 6.4a). This suggests 
that TRAIP-W37A is not functional in vivo, despite much higher TRAIP protein levels in 
KO+W37A cells than in WT cells, consistent with the lack of rescue in DDR signalling being due 
to its defective E3 ligase activity. 
Next, I assessed whether the observed RPA2 phosphorylation defect was specific to S 
phase. To avoid synchronisation-based experiments, which could potentially induce even more 
DNA damage into cells, the pRPA2-S4/S8 signal was analysed in individual cells by 
immunofluorescence microscopy, using EdU added for the last 20 min of the CPT treatment to 
label cells undergoing DNA replication. There was no significant difference in pRPA2-S4/S8 
mean signal intensity between EdU-negative WT and TRAIP-KO cells, although it was slightly 
decreased in EdU-negative KO+WT cells and increased in KO+W37A cells, relative to WT cells 
(Figure 6.5b). In WT and KO+WT cells undergoing DNA replication (EdU-positive), a significant 
increase in pRPA2-S4/S8 mean signal intensity was observed, compared to EdU-negative cells 
(Figure 6.5a-b). However, no significant increase was observed in KO and KO+W37A cells, 
where pRPA2-S4/S8 signal intensity was similar in EdU-negative and EdU-positive cells (Figure 
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6.5a-b). This result suggests that after CPT treatment, the E3 ligase activity of TRAIP is required 
for efficient RPA2 phosphorylation during S phase. 
 Overall, I conclude that reduction in CPT-induced DDR signalling observed in RPE1  
p53-/- TRAIP-KO cells is caused by disruption of E3 ligase activity of TRAIP, and that TRAIP is 
required for RPA2 phosphorylation at CPT lesions during S phase. In the following sections, 





Figure 6.5. Reduction in CPT-induced pRPA2-S4/S8 signal intensity in EdU-positive TRAIP-KO 
cells is rescued by complementation with TRAIP-WT but not E3 ligase-deficient mutant 
TRAIP-W37A. 
a) Representative images of EdU-positive CPT-treated WT, KO, KO+WT and KO+W37A cells, 
stained for pRPA2-S4/S8 and visualised using fluorescence microscopy. DAPI signal is shown in 
blue; EdU in green; pRPA2-S4/S8 in red. Scale bars: 10 μm. 
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b) Immunofluorescence quantification to detect pRPA2-S4/S8 in EdU-negative and EdU-
positive cell populations. RPE1 p53-/- WT (clone 1.30), TRAIP-KO (KO; clone 1.29), TRAIP-KO 
complemented with TRAIP-WT (KO+WT) and TRAIP-KO complemented with TRAIP-W37A 
(KO+W37A) cells were treated with 1 μM CPT for 1 h, and 10 μM EdU was added for the last 
20 min of the CPT treatment to label cells undergoing DNA replication. Detergent pre-
extraction of non-chromatin-bound proteins was performed before cell fixation with 
formaldehyde. Cells were immunostained for EdU and pRPA2-S4/S8 and visualised using 
fluorescence microscopy. Image analysis was performed using Fiji/ImageJ software. Black bars 
indicate the mean, and each dot in the graph represents one cell (>100 cells analysed per 
condition). Statistics: Mann-Whitney test. 
 
 
6.1.2.1. TRAIP is not depleted after CPT treatment 
 
One notable observation based on the experiments described in Chapter 5 and Section 
6.1 was different regulation of TRAIP protein levels following the treatment with distinct DNA 
damaging agents. To investigate this further, I tested whether TRAIP protein levels change 
following the recovery from CPT treatment for 4 and 8 hours, as they were not observed to 
decrease after short (30–90 min) CPT treatment (see Figure 6.2). Immediately after the 30 min 
CPT treatment, as well as several hours after CPT release, TRAIP levels in WT cells were not 
substantially different, compared to untreated cells (Figure 6.6), indicating that the removal 
of the DNA damaging agent did not result in TRAIP depletion. Additionally, I previously 
observed that TRAIP protein levels were only slightly reduced after CPT, HU and H2O2 
treatment (Figure 5.9-5.10). This is in contrast to UV-C irradiation, after which TRAIP protein 
levels dramatically decrease, as seen in Figures 5.6, 5.7 and 5.9 and shown by Harley et al. 
(2016). This reduction was shown by our laboratory to be caused by proteasome-mediated 
degradation of TRAIP (Harley et al., 2016), suggesting that TRAIP levels are regulated in 
response to UV-C. These results therefore suggest that TRAIP may promote DNA repair via 






Figure 6.6. TRAIP is not depleted after CPT treatment or several hours after its removal. 
Immunoblotting of TRAIP protein levels after CPT treatment in WT and TRAIP-KO cells. RPE1 
p53-/- WT (clone 1.30) and TRAIP-KO (clone 1.29) cells were exposed to CPT treatment (1 μM) 
for 30 min and either harvested for immunoblotting immediately following the treatment 
(CPT) or collected 4 or 8 hours after the drug was removed by extensive PBS washing. 
Untreated (NT) and CPT-treated samples of both cell lines were compared for TRAIP protein 
levels by immunoblotting. Vinculin served as a loading control.  
 
 
6.1.3. Cell survival, HR efficiency and DNA end resection after CPT treatment are 
reduced in TRAIP-KO cells  
 
 Efficient cellular DDR signalling in response to damage is crucial for error-free DNA 
repair, maintenance of genomic stability and long-term cell survival. I therefore postulated 
that the observed defect of TRAIP-KO cells in CPT-induced DDR signalling would lead to adverse 
downstream effects on timely DNA repair and cell survival. 
Firstly, the ability of cells lacking TRAIP to survive and form colonies after CPT 
treatment was assessed in the clonogenic cell survival assays. TRAIP-KO cells were observed to 
be much more sensitive to CPT treatment than WT cells, as they formed fewer colonies at all 
doses of CPT used in the experiment (Figure 6.7). Complementation of KO cells with TRAIP-WT 
(KO+WT) rescued the observed CPT-induced hypersensitivity and colony formation defect of 
TRAIP-KO cells (Figure 6.7). Unexpectedly, complementation with TRAIP-W37A (KO+W37A) 
resulted in an intermediate level of sensitivity to CPT, suggesting a partial rescue by the E3 
ligase-deficient mutant (Figure 6.7). One possible explanation for this observation is the 
residual levels of E3 ligase activity in the TRAIP-W37A mutant, as it was shown to retain some 
E3 ligase activity in the in vitro ubiquitination assay (Figure 6.4c). In addition, it could be that 
overexpression of the ligase-deficient mutant partially restores the reduced interaction with 
the E2 ubiquitin-conjugating enzyme. Together, this may allow sufficient activity to partially 
rescue the cell survival defect. However, this would not explain the complete failure of TRAIP-
W37A to rescue the CPT-induced DDR signalling defect. Therefore, the partial survival rescue 
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could be due to a non-catalytic role of TRAIP that contributes to cell survival after CPT 




Figure 6.7. Reduced colony formation ability and survival of CPT-treated TRAIP-KO cells is 
rescued by complementation with TRAIP-WT, whereas complementation with E3 ligase-
deficient mutant TRAIP-W37A provides a partial rescue. 
RPE1 p53-/- WT, TRAIP-KO (KO; clone 1.29), TRAIP-KO complemented with TRAIP-WT (KO+WT) 
and TRAIP-KO complemented with TRAIP-W37A (KO+W37A) cells were plated at very low 
density and treated with CPT (0.5 nM – 10 nM) for 24 hours. The drug was removed by PBS 
washing, and cells were grown for 8 days until colonies were formed, followed by fixation, 
staining and colony counting. For CPT doses 0.5 nM – 5 nM, mean ± SD of n=2 independent 
experiments is shown (for 7.5 and 10 nM, n=1 experiment). Statistics: two-way ANOVA for 0.5, 
2.5, and 5 nM CPT. 
 
 
The rapid repair of one-ended DSBs breaks in S phase is required to facilitate 
restoration of replication forks and to restart DNA replication, and is largely dependent on HR 
repair (Arnaudeau et al., 2001). On the other hand, NHEJ of one-ended DSBs can lead to gross 
chromosomal rearrangements and formation of radial chromosomes, eventually leading to 
genomic instability and cell death. Having previously shown that TRAIP is important for DDR 
signalling and survival after CPT-induced DNA damage, I next tested whether TRAIP E3 ligase 
activity is necessary for HR in response to CPT. 
To evaluate HR proficiency, sister chromatid exchange (SCE) assays were performed. 
Sister chromatids can physically exchange reciprocal regions of the parental strands during 
unperturbed DNA replication, but in response to DNA damage, the number of SCEs observed 
dramatically increases and is reflective of ongoing HR-mediated DNA repair (Sonoda et al., 
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1999). Thus, assessing these exchanges provides an estimate of HR efficiency in cells. For this 
assay, cells are grown for two rounds of DNA replication in the presence of BrdU, followed by 
preparation of metaphase spreads, treatment with the UV-sensitive dye Hoechst, long-wave 
UV light exposure and DAPI staining. All of the exchanges of genetic material that happen can 
subsequently be visualised by fluorescence microscopy. After the second round of DNA 
replication, the two sister chromatids will have different amounts of BrdU incorporated, 
making one look darker than the other (Wilson and Thompson, 2007). When no exchange 
occurs during either round of DNA replication, one sister chromatid appears uniformly dark 
and the other uniformly light (Figure 6.8a). Meanwhile, an exchange results in an abrupt 
switching of light and dark staining regions of a chromatid (Figure 6.8a) (Stults et al., 2014).  
When unperturbed, all four cell lines (WT, KO, KO+WT and KO+W37A) exhibited 
similarly low levels of sister chromatid exchanges (on average 0.16–0.19 SCEs per chromosome 
per metaphase) (Figure 6.8b-d). CPT treatment resulted in a 13-fold increase in the number of 
SCEs observed in WT cells (2.3±0.5 SCEs per chromosome per metaphase) (Figure 6.8c-d). In 
contrast, a much more modest 5-fold increase was detected in TRAIP-KO cells (1.0±0.2 SCEs 
per chromosome per metaphase), demonstrating an HR defect caused by the absence of TRAIP 
(Figure 6.8c-d). This CPT-mediated recombination deficiency was rescued by the 
complementation of KO cells with TRAIP-WT (KO+WT) but not with the E3 ligase-deficient 
TRAIP-W37A (KO+W37A) (Figure 6.8c-d), indicating that the E3 ligase activity of TRAIP is 
necessary for promoting HR in response to CPT-induced DNA damage. 
Once DNA lesions are sensed by sensor proteins, an important repair step leading to 
efficient HR is DNA end resection at a lesion to generate a 3' overhang, which can be coated 
by RPA and is needed for homology searching (Huertas, 2010; Longhese et al., 2010; Mimitou 
and Symington, 2011). The observed reduction in CPT-induced pRPA2-S4/S8 signal during S 
phase in TRAIP-KO cells could indicate either a direct defect of phosphorylation of these RPA2 
residues or a defect of RPA loading due to impaired DNA end resection reducing available 
ssDNA, which would also lead to reduced levels of RPA2 phosphorylation. I therefore tested 





Figure 6.8. Impaired HR in CPT-treated TRAIP-KO and TRAIP E3 ligase-deficient cells. 
a) Schematic representation of sister chromatid staining using two rounds of BrdU 
incorporation during DNA replication, followed by Hoechst staining, exposure to UV light, and 
staining with DAPI. A SCE event can occur following first round (top panel) or second round 
(bottom panel) of DNA synthesis in the presence of BrdU, resulting in abrupt switching of light 
and dark staining regions of a chromatid. Figure adapted from Stults, Killen and Pierce (2014). 
b) Schematic of the SCE experiment. 
c) Representative images of CPT-treated WT, KO, KO+WT and KO+W37A metaphase spreads, 
stained with DAPI and visualised using fluorescence microscopy. Scale bars: 10 μm. 
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d) Quantification of sister chromatid exchange (SCE) experiment to evaluate HR efficiency in 
the presence or absence of CPT-induced DNA damage. RPE1 p53-/- WT, TRAIP-KO (KO; clone 
1.29), TRAIP-KO complemented with TRAIP-WT (KO+WT) and TRAIP-KO complemented with 
TRAIP-W37A (KO+W37A) cells were grown for two rounds of DNA replication (47-48 hours) in 
BrdU-containing medium; for the DNA damage samples, 5 nM CPT was added during the first 
round as well. Cells were fixed, and the prepared metaphase spreads were treated with the 
UV-sensitive dye Hoechst, long-wave UV light exposure and stained with DAPI. Metaphase 
spreads were visualised using fluorescence microscopy, and image analysis was performed 
using Fiji/ImageJ software. Results (mean ± SD) from one experiment are shown, and each dot 
in the graph represents one metaphase spread (16-17 spreads analysed per condition). 
Statistics: unpaired two-tailed t-test. 
 
 
To test whether TRAIP and its E3 ligase activity are required for efficient CPT-induced 
DNA end resection, I quantified native BrdU foci as a proxy for ssDNA formation, as under 
native conditions, BrdU antibody will only detect patches of ssDNA, indicating DNA end 
resection. In unperturbed conditions, all four cell lines analysed (WT, KO, KO+WT and 
KO+W37A) had similarly low levels of native BrdU foci, with the average number of foci per 
cell ranging from 0.8 in KO+WT cells to 2 in KO cells (Figure 6.9b). There was a rise in the 
number of native BrdU foci in CPT-treated WT cells, averaging 6.5 foci per cell (Figure 6.9a-b). 
However, no such increase was observed in CPT-treated TRAIP-KO cells, where the average of 
only 1.5 foci per cell was detected (Figure 6.9a-b). The complementation of TRAIP-KO cells 
with TRAIP-WT (KO+WT), but not TRAIP-W37A (KO+W37A), rescued the formation of native 
BrdU foci in response to CPT (Figure 6.9a-b), suggesting the importance of E3 ligase activity of 
TRAIP in promoting DNA end resection at CPT-induced breaks. To ensure that the reduction in 
native BrdU foci is not primarily caused by reduced BrdU incorporation in TRAIP-KO cells, e.g. 
due to reduced proliferation, all cell lines were treated with 2 M HCl to denature DNA prior to 
addition of the BrdU antibody. This control condition did not reveal any substantial differences 
of BrdU incorporation in the four cell lines (Figure 6.9c), indicating that the differences in cell 
cycle progression were unlikely to have a major influence on the results obtained. Consistent 
with this result, Hoffmann et al. (2016) showed that TRAIP-depleted U2OS cells generate less 
ssDNA in response to CPT treatment, compared to wild-type cells. Overall, the observed DNA 
end resection defect provides an explanation for the reduced pRPA2-S4/S8 signalling in TRAIP-
KO cells as less ssDNA is available for RPA binding, resulting in diminished RPA2 
phosphorylation. As this result suggests that the reduced pRPA2 signal in TRAIP-deficient cells 
may be caused indirectly, it provides an alternative explanation to the dysregulated PP4-




Figure 6.9. CPT-induced ssDNA formation is reduced in TRAIP-KO and E3 ligase-deficient cells. 
a) Representative images of CPT-treated (+CPT) WT, KO, KO+WT and KO+W37A cells, stained 
for BrdU (FITC; green channel) under native conditions. Scale bars: 5 μm. 
b) Quantification of native BrdU foci formation to assess ssDNA generation in the presence and 
in the absence of CPT treatment. RPE1 p53-/- WT, TRAIP-KO (KO; clone 1.29), TRAIP-KO 
complemented with TRAIP-WT (KO+WT) and TRAIP-KO complemented with TRAIP-W37A 
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(KO+W37A) cells were grown in the presence of 10 μM BrdU for 24h, and 1 μM CPT was added 
for the last 90 min before cell fixation. Detergent pre-extraction of non-chromatin-bound 
proteins was performed before cell fixation with formaldehyde. Cells were immunostained for 
BrdU and visualised using fluorescence microscopy. Image analysis was performed using 
Fiji/ImageJ software. Results from one experiment are shown; black bars indicate the mean, 
and each dot in the graph represents one cell (more than 100 cells analysed per condition). 
Statistics: unpaired two-tailed t-test. 
c) Representative images of CPT-treated (+CPT) WT, KO, KO+WT and KO+W37A cells, stained 
for BrdU (FITC; green channel) under denatured conditions (treatment with 2 M HCl prior to 
addition of BrdU antibody). Scale bars: 5 μm. 
 
 
6.1.4. Chromatin recruitment of BRCA1 and 53BP1 is not affected in TRAIP-KO cells 
 
The results described in the previous section suggest that TRAIP may be involved in 
promoting DNA end resection after CPT treatment and therefore may act as a regulator of DSB 
repair pathway choice, potentiating HR and suppressing NHEJ. The possible ways to achieve 
this could be either a) TRAIP-dependent ubiquitination of a DNA end resection protagonist (a 
component of HR machinery) to activate it or promote its translocation or recruitment to 
chromatin, or b) TRAIP-dependent ubiquitination of a DNA end resection antagonist (a 
component of NHEJ machinery) to promote its proteasomal degradation, inactivation or 
relocalisation. 
To investigate what proteins are affected by TRAIP in response to CPT-induced DNA 
damage, I conducted immunoblotting analysis in CPT-treated TRAIP-KO cells to detect 
chromatin recruitment of replication fork-associated proteins that are known components of 
DNA end resection machinery or DNA end protection. Using a candidate approach, I looked at 
chromatin enrichment of two key players in DSB repair pathway choice: BRCA1, which 
promotes DNA end resection and HR repair in response to replication stress, and 53BP1, which 
facilitates DNA end protection and NHEJ (Daley and Sung, 2014) (see Section 1.3.3). If TRAIP 
was involved in regulating one of these factors in response to CPT-induced DNA damage, one 
may expect to see changes in the recruitment of these proteins to chromatin. Notably, siTRAIP-
treated cells were previously reported to show reduced BRCA1 recruitment to sites of IR-
induced DNA damage (Soo Lee et al., 2016); however, it is not known if this occurs at CPT-
induced DNA lesions as well. 
No major changes in the recruitment of BRCA1 and 53BP1 to chromatin took place in 
KO and KO+W37A cells, compared to WT and KO+WT cells (Figure 6.10). In both total protein 
and chromatin-enriched fractions, a shift for BRCA1 and 53BP1 protein bands was observed 
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after CPT-induced DNA damage, likely indicating DNA damage-dependent phosphorylation of 
these proteins. Although slightly reduced total BRCA1 levels in KO and KO+W37A cells were 
observed, the CPT-induced recruitment of this factor to chromatin was unaffected (Figure 
6.10). As BRCA1 protein expression is regulated in a cell cycle-dependent manner (Vaughn et 
al., 1996), this result could potentially reflect cell cycle differences between the cell lines 




Figure 6.10. CPT-induced BRCA1 and 53BP1 recruitment to chromatin is unaffected in RPE1 
p53-/- TRAIP-KO and E3 ligase-deficient cells. 
Immunoblotting demonstrates CPT-induced chromatin recruitment of BRCA1, 53BP1 and 
PCNA. RPE1 p53-/- WT, TRAIP-KO (KO; clone 1.29), TRAIP-KO complemented with TRAIP-WT 
(KO+WT) and TRAIP-KO complemented with TRAIP-W37A (KO+W37A) cells were exposed to 
CPT treatment (1 μM) for 90 min and harvested for immunoblotting without (total protein) or 
with pre-extraction step (chromatin-enriched fraction). Untreated (–) and CPT-treated (+) 
samples of the four cell lines were compared for protein levels of BRCA1, 53BP1 and PCNA by 
immunoblotting. Vinculin served as a loading control. Black arrowhead indicates the expected 
53BP1 protein band. 
 
 
As previously observed by multiple studies (Görisch et al., 2008; Sirbu et al., 2011; W. 
Feng et al., 2016), PCNA was unloaded from chromatin in response to replication-associated 
DNA damage in this analysis, while total PCNA levels remained constant (Figure 6.10), 
demonstrating successful enrichment of chromatin-bound proteins in the chromatin-enriched 
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fraction. W. Feng et al. (2016) suggested that TRAIP depletion disrupts efficient PCNA 
unloading, however, this was not observed in this experiment.  
 In summary, alterations in BRCA1 and 53BP1 chromatin recruitment were not 
detected by immunoblotting in CPT-treated TRAIP-KO and E3 ligase-deficient cells. Although 
defective DNA end resection at CPT-induced one-stranded DSBs was observed in TRAIP-KO 
cells, BRCA1 recruitment to chromatin was not impaired, suggesting that TRAIP mediates CPT-




6.1.5. Summary: TRAIP and CPT-induced DNA damage 
 
 In this section, it was shown that TRAIP-KO cells do not properly respond to CPT 
treatment, demonstrating reduced DNA end resection, lower levels of phosphorylation of DNA 
damage markers, defective HR, and reduced cell survival. Furthermore, using cells deficient in 
E3 ligase activity (TRAIP-KO cells complemented with TRAIP-W37A mutant), proper E3 
ubiquitin ligase activity of TRAIP was shown to be required for all the above functions of TRAIP. 
However, cell survival was not fully dependent on the E3 ligase activity of TRAIP, suggesting 
that either residual levels of E3 ligase activity due to overexpression of the TRAIP-W37A 
mutant or a potential non-catalytic role of TRAIP in mediating CPT resistance contribute to 
maintaining cell viability. 
 The most pronounced DDR signalling defect observed in TRAIP-KO cells, impaired 
pRPA2-S4/S8 signal, is likely due to TRAIP promoting DNA end resection at one-ended DSBs, 
which allows RPA loading onto ssDNA. Upon CPT treatment, the absence of TRAIP may lead to 
an increase in collapsed and unrepaired replication forks, eventually resulting in the cell 
survival defect. TRAIP-KO cells also exhibited reduced levels of γH2AX and pCHK1-S345 in 
response to CPT treatment. The effect of the absence of TRAIP on these DNA damage markers 
may be indirectly mediated through reduced RPA2 loading and phosphorylation, as RPA-
coated ssDNA is a well-established signal for ATR activation and subsequent phosphorylation 
of its downstream effectors (Zeman and Cimprich, 2014) (Figure 6.11b). An alternative 
explanation is that TRAIP instead promotes efficient CPT-induced phosphorylation of H2AX and 
CHK1, which subsequently allows timely DNA end resection, RPA loading and RPA2 
phosphorylation (Figure 6.11a). Distinguishing between these possibilities and defining the 
mechanism by which TRAIP works at CPT-induced DNA lesions will require further 
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experiments, and establishing the targets of TRAIP-mediated ubiquitination will be of 
particular importance. Moreover, given the reduced numbers of sister chromatid exchanges 
in CPT-treated TRAIP-KO cells, TRAIP may also be considered a novel HR-promoting factor, 
which indirectly facilitates it by allowing efficient DNA end resection to take place.  
Overall, consistent with findings by Hoffmann et al. (2016), my current data indicate 
that TRAIP supports ATR-dependent checkpoint signalling in response to CPT-induced DNA 
damage, likely by facilitating processes at replication fork that result in the formation of RPA-




Figure 6.11. A model for the role of TRAIP in responding to CPT-induced DNA damage. 
In this section of my thesis, TRAIP-KO cells were shown to fail at responding to CPT-induced 
DNA damage, demonstrating reduced DNA end resection, lower levels of phosphorylation of 
DNA damage markers, defective HR, and reduced cell survival. CPT treatment causes 
stabilisation of the TOP1 covalent complex (Top1cc) and a SSB, which is turned into a one-
ended DSB upon collision with the replication fork. I postulate that TRAIP may promote the 
repair of CPT-induced DNA damage by acting on DDR signalling (a), e.g. ensuring efficient 
phosphorylation of DNA damage markers H2AX and CHK1, which subsequently allows efficient 
DNA end resection and RPA2 phosphorylation. Alternatively, TRAIP may be involved in directly 
promoting DNA end resection (b), which then allows efficient RPA2 phosphorylation and 
stimulates H2AX and CHK1 phosphorylation.
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6.2. The role of TRAIP in MMC-ICL repair 
 
6.2.1. Does TRAIP mediate CMG unloading and replisome disassembly, required for ICL 
repair?  
 
 Having established the importance of TRAIP for DNA repair of CPT-induced DNA 
lesions, I decided to investigate whether TRAIP has a role at other types of DNA lesions that 
induce replication fork stalling. In particular, I focussed on the DNA interstrand crosslinking 
(ICL) agent mitomycin C (MMC), as TRAIP was shown to be involved in ICL repair in egg extracts 
of African clawed frog (Xenopus laevis) (personal communication with Prof Johannes Walter 
and Prof David Pellman; Wu, Semlow et al., unpublished). 
 ICLs are one of the most toxic types of DNA lesions, blocking both DNA replication and 
transcription (Kee and D’Andrea, 2010). Endogenous ICLs emerge following accumulation of 
reactive aldehydes, the by-products of several metabolic processes (Langevin et al., 2011; 
Pontel et al., 2015), whereas various chemotherapeutic agents, such as psoralens, platinum 
compounds and mitomycins, are exogenous sources of ICLs (reviewed by Deans and West, 
2011). Canonical ICL repair involves the Fanconi Anaemia (FA) pathway to recognise and 
unhook the DNA lesion, followed by TLS-mediated lesion bypass and HR to repair the 
generated DSB (see Section 1.3.5 and Figure 1.10). Recently, an alternative ICL repair pathway 
was discovered in X. laevis (Semlow et al., 2016). This pathway was shown to be dependent on 
the NEIL3 glycosylase and mainly involved in processing psoralen- and abasic 
(apurinic/apyrimidinic) site ICLs (AP-ICLs) (Figure 6.12). The NEIL3 pathway does not require 
introduction of a DSB or involvement of FA proteins; instead, NEIL3 unhooks an ICL by N-
glycosylation, allowing TLS to take place (Semlow et al., 2016). Semlow et al. (2016) also 
observed that in the absence of NEIL3, psoralen- and AP-ICLs can be repaired by the FA 
pathway, which is preferred for repairing MMC- and cisplatin-ICLs (Figure 6.12). Overall, the 
FA pathway is the main choice of cells for repairing MMC- and cisplatin-ICLs, whereas psoralen- 
and AP-ICLs are preferentially repaired by the NEIL3 pathway, which avoids the introduction 





Figure 6.12. A model for the role of TRAIP in ICL repair. 
Unpublished data by Wu, Semlow et al. (Prof Johannes Walter and Prof David Pellman 
laboratories) suggest that TRAIP is involved in both FA- and NEIL3-mediated ICL repair 
pathways by promoting replisome disassembly and NEIL3 recruitment, respectively. According 
to their recent findings using X. laevis egg extracts, TRAIP-mediated addition of longer ubiquitin 
chains on the CMG component MCM7 facilitates its unloading from stalled replication forks, 
subsequently destabilising the replisome and promoting its extraction from chromatin (FA 
pathway). Alternatively, TRAIP-mediated addition of shorter ubiquitin chains on MCM7 is 
required for the recruitment of NEIL3 glycosylase (NEIL3 pathway), suggesting that TRAIP 
dictates ICL repair pathway choice. Figure modified and adapted from Semlow et al. (2016). 
 
 
 One of the first events leading to efficient FA-mediated ICL repair is the unloading of 
CMG helicase complex, which includes MCM2-7, CDC45, and GINS, from DNA and dissolution 
of the replisome at the site of stalled replication (Fullbright et al., 2016; Semlow et al., 2016). 
In a cell-free system, CMG removal is necessary for replication fork reversal and subsequent 
generation of a DNA structure that allows cisplatin-ICL incision, unhooking and repair 
(Amunugama et al., 2018). It was reported that E3 ligase-dependent ubiquitination of the CMG 
subunit MCM7 is the key requirement for efficient unloading of the CMG helicase, its 
extraction from chromatin by the ATPase p97/VCP and subsequent recycling (Fullbright et al., 
2016; Long et al., 2014; Semlow et al., 2016). Significantly, TRAIP was recently shown to be 
required for MCM7 ubiquitination at cisplatin- and AP-ICLs, leading to CMG unloading (FA 
pathway) and NEIL3 recruitment (NEIL3 pathway), respectively, in X. laevis egg extracts (Wu, 
Semlow et al., unpublished) (Figure 6.12). These observations suggest that TRAIP is a key 
mediator of ICL repair pathway choice in a cell-free system. TRAIP-mediated deposition of 
longer ubiquitin chains on the CMG component MCM7 was shown to promote its unloading 
from stalled replication forks, resulting in replisome destabilisation and its extraction from 
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chromatin in the ATPase p97/VCP-dependent manner, which initiated FA pathway (Wu, 
Semlow et al., unpublished). Meanwhile, TRAIP-mediated deposition of short ubiquitin chains 
on MCM7 was required for NEIL3 recruitment and ICL repair via NEIL3 pathway (Wu, Semlow 
et al., unpublished). Overall, TRAIP-dependent ubiquitination of MCM7 was observed to be 
essential for both ICL repair pathways in X. laevis, but the relevance of these findings in 
mammalian cells remained unclear. 
 In the following sections of this chapter, the experiments conducted to establish the 
role of TRAIP in ICL repair in a mammalian cell system are described. If TRAIP is involved in 
MCM7 ubiquitination in mammalian cells as well, epistatic relationship between TRAIP and FA 
pathway, as well as between TRAIP and NEIL3 pathway, would be expected. In the following 
section (Section 6.2.2), experiments delineating effects of MMC treatment on TRAIP-KO cells 
are described, providing a set of readouts to study whether TRAIP is epistatic with FANCD2, a 
key component of the FA pathway (Section 6.2.3). 
 
 
6.2.2. Phenotypic characterisation of TRAIP-KO cells in response to MMC 
 
 Firstly, the RPE1 p53-/- TRAIP-KO cell line was used to establish the phenotype of the 
cells lacking TRAIP in response to the ICL-inducing drug MMC. The sensitivity of TRAIP-depleted 
U2OS cells to MMC was previously demonstrated by Hoffmann et al. (2016), and so I tested 
whether this finding could be replicated in RPE1 p53-/- TRAIP-KO cells. In clonogenic cell 
survival assay, TRAIP-KO cells formed fewer clones than WT cells at all doses tested, with only 
1.1% of the plated single cells surviving and forming clones at the highest MMC dose tested 
(60 nM), compared to 54.7% of the WT cells (Figure 6.13). This result confirmed that TRAIP-KO 





Figure 6.13. TRAIP-KO cells are hypersensitive to MMC. 
RPE1 p53-/- WT and TRAIP-KO (KO; clone 1.29) cells were plated at very low density and 
treated with MMC (5 nM – 60 nM) for 24 hours. The drug was removed by extensive PBS 
washing, and cells were grown for 8 days until colonies were formed, followed by fixation, 
staining and colony counting. Results (mean ± SD) from 2-4 independent experiments where 
those doses were examined are shown (5 nM and 60 nM MMC: 2 independent experiments; 
20 nM and 40 nM MMC: 3 independent experiments; 10 nM MMC: 4 independent 
experiments). Two-way ANOVA was used for statistical analysis. 
 
 
To understand whether the same DDR signalling defect underlies MMC and CPT 
hypersensitivity of TRAIP-KO cells, immunoblotting analysis of pRPA2-S4/S8, γH2AX and 
pCHK1-S345 in RPE1 p53-/- TRAIP-KO cells exposed to MMC treatment was performed. 
Surprisingly, the effect opposite to the one seen after CPT treatment was observed. At each of 
the three time points tested (16 h, 24 h and 32 h post-addition of MMC), pRPA2-S4/S8 
phosphorylation was elevated in TRAIP-KO cells, compared to WT cells (Figure 6.14a-b). The 
complementation of TRAIP-KO cells with TRAIP-WT (KO+WT) rescued the pRPA2-S4/S8 
increase (Figure 6.14c), showing it to be specific to TRAIP loss. Although MMC-induced pRPA2-
S4/S8 levels were significantly elevated in TRAIP-KO cells (4±1.8 times increase 24 h post-
MMC), no consistent changes in H2AX and CHK1 phosphorylation were observed (Figure 
6.14b). These observations suggest that disruption of distinct mechanisms underlies the 
sensitivity of TRAIP-KO cells to MMC and to CPT (described in Section 6.1), as upon CPT 
treatment, TRAIP-KO cells have lower levels of replication-associated ssDNA generation, 
reduced pRPA2-S4/S8 signal and HR efficiency, while showing hypersensitivity to this drug. 
However, differences in the time points analysed need to be considered as well, as MMC-
induced RPA2 phosphorylation is detected much later (16–32 h post-treatment) than the CPT-




Figure 6.14. MMC-induced RPA2 phosphorylation is increased in RPE1 p53-/- TRAIP-KO cells. 
a) Representative immunoblot (n=3 independent experiments) demonstrating MMC-induced 
pRPA2-S4/S8, γH2AX and pCHK1-S345 levels in RPE1 p53-/- WT (clone 1.30) and TRAIP-KO 
(clone 1.29) cell lines. Untreated (0 h) cells and cells exposed to MMC treatment (360 nM) for 
16, 24 or 32 h were harvested and analysed by immunoblotting. Vinculin served as a loading 
control. 
b) Quantification of pRPA2-S4/S8, γH2AX and pCHK1-S345 levels 24 hours post-MMC addition 
demonstrates significant increase in MMC-induced pRPA2-S4/S8 in TRAIP-KO cell lines. Image 
analysis was performed using Fiji/ImageJ software. pRPA2-S4/S8, γH2AX and pCHK1-S345 
240 
 
levels were normalised to RPA2, H2A and CHK1, respectively. Results (mean ± SD) from n=3 
independent experiments are shown; statistics: unpaired two-tailed t-test. 
c) Immunoblotting experiment demonstrating that the increase in pRPA2-S4/S8 levels post-
MMC treatment is rescued by the complementation of TRAIP-KO cells with TRAIP-WT 
(KO+WT). Black arrowhead indicates the pCHK1-S345 band, as pCHK1-S345 signal was 
detected by re-probing the membrane used for TRAIP detection (lower band). 
 
 
To establish more details on the mechanism underlying the MMC sensitivity of TRAIP-
KO cells, I decided to use sister chromatid exchange assay to assess HR, which was observed 
to be defective in CPT-treated TRAIP-KO cells (Figure 6.8). Strikingly, the SCE assay indicated 
no significant change in HR efficiency in MMC-treated TRAIP-KO cells, compared to WT cells 
(Figure 6.15). This result suggested that TRAIP does not promote HR in response to MMC-
induced DNA damage, in agreement with different mechanisms behind the role of TRAIP in 
response to CPT and MMC. 
 
 
Figure 6.15. HR efficiency is not affected in TRAIP-KO cells exposed to MMC. 
a) Schematic of the SCE experiment. 
b) Quantification of sister chromatid exchange (SCE) experiment to evaluate HR efficiency in 
the presence or absence of MMC-induced DNA damage. RPE1 p53-/- WT and TRAIP-KO (KO; 
clone 1.29) cells were grown for two rounds of DNA replication (47-48 hours) in BrdU-
containing medium; for the DNA damage samples, 20 nM MMC was added during the first 
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round as well. Cells were fixed, and the prepared metaphase spreads were treated with the 
UV-sensitive dye Hoechst, long-wave UV light exposure and stained with DAPI. Metaphase 
spreads were visualised using fluorescence microscopy, and image analysis was performed 
using Fiji/ImageJ software. Results (mean ± SD) from one experiment are shown, and each dot 
in the graph represents one metaphase spread. Statistics: unpaired two-tailed t-test. 
 
 
Cells deficient of FA factors are known to exhibit increased levels of genomic instability 
(rewieved by Palovcak et al., 2017). TRAIP-depleted U2OS cells were also observed to have 
elevated levels of chromatid breaks and radial chromosomes in response to MMC treatment 
(Hoffmann et al., 2016). Additionally, multiple chromosomal aberrations in karyotypes of 
unperturbed TRAIP-KO cells were previously observed (see Section 5.3). To establish if 
elevated levels of genomic instability were present in MMC-treated TRAIP-deficient cells, RPE1 
p53-/- WT, TRAIP-KO and KO+WT cells were treated with MMC for 24 h, followed by 
preparation and analysis of metaphase spreads. As expected, the loss of TRAIP contributed to 
the increase in genomic instability in cells exposed to MMC, represented by elevated numbers 
of chromatid breaks, compared to MMC-treated WT cells (Figure 6.16a-b). Additionally, a few 
metaphases with radial chromosomes were observed in MMC-treated TRAIP-KO cells (Figure 
6.16c). Even in unperturbed conditions, TRAIP-KO cells exhibited higher levels of genomic 
instability (Figure 6.16b-c), consistent with the karyotyping analyses performed in Section 5.3. 
The chromosomal aberrations in unperturbed and MMC-treated TRAIP-KO cells were shown 
to be TRAIP-specific, as complementation of KO cells with TRAIP-WT rescued the phenotype 
(Figure 6.16b-c).  
In summary, the experiments described in this section showed that after MMC 
treatment TRAIP is needed for optimal cell survival, as well as for proper RPA2-S4/S8 






Figure 6.16. Genomic instability is increased in TRAIP-KO cells after MMC treatment. 
a) Representative images of chromosomal aberrations in MMC-treated TRAIP-KO metaphase 
spreads, stained with DAPI and visualised using immunofluorescence microscopy. Scale bars: 
5 μm. 
b, c) Quantification of chromatid breaks (b) and radial chromosomes (c) in RPE1 p53-/- WT, 
TRAIP-KO and TRAIP-KO complemented with TRAIP-WT (KO+WT) cells with and without MMC 
treatment demonstrates significant increase in genomic instability in MMC-treated TRAIP-KO 
cell lines, which is rescued by complementation with TRAIP-WT. To visualise chromosomal 
abnormalities, cells were grown in the presence or absence of 60 nM MMC for 24 h, followed 
by cell fixation and preparation of metaphase spreads, which were stained with DAPI. Image 
analysis was performed using Fiji/ImageJ software. Approximately 40 metaphase spreads were 
evaluated per condition. Results from one experiment are shown. Statistics: unpaired two-
tailed t-test between the average number of chromosomal aberrations per metaphase spread. 
 
 
6.2.3. TRAIP is not epistatic with the FA pathway in MMC-ICL repair  
 
 In X. laevis egg extracts, TRAIP is required for MCM7 ubiquitination for ICL repair 
through both the FA and NEIL3 pathways (Wu, Semlow et al., unpublished). To elucidate the 
role of TRAIP in MMC-ICL repair in mammalian somatic cells, I analysed the epistatic 
relationship between TRAIP and the FA pathway in the context of MMC-induced ICLs. Epistasis 
between them would mean that, after MMC treatment, the lack of TRAIP and the depletion of 
a FA pathway factor would result in the same cellular outcome, and that the absence of both 
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proteins would not cause a more severe phenotype than loss of each one individually. For 
these epistasis experiments, I chose to deplete FANCD2, a central component of the FA 
pathway. Mono-ubiquitination of FANCD2 in response to DNA damage is the key regulatory 
step in MMC-ICL repair, triggering its re-localisation to ICLs. Mono-ubiquitinated FANCD2 then 
coordinates downstream repair events, including HR (Garner and Smogorzewska, 2011) (see 
Section 1.3.5). Therefore, depletion of FANCD2 is expected to abrogate the ability of cells to 
repair MMC-induced ICLs. 
FANCD2 was depleted from WT and TRAIP-KO cells, and the effects of this depletion 
on DDR signalling, chromosomal abnormalities and cell survival were analysed (Figure 6.17). 
Consistent with my previous results (Figure 6.14b), immunoblotting analysis revealed a 
significant increase in pRPA2-S4/S8 signal in siLUC-treated TRAIP-KO cells, compared to siLUC-
treated WT cells (Figure 6.18a-b). Although the lack of TRAIP and of FANCD2 resulted in similar 
levels of pRPA2-S4/S8 signal, it was not found to be significantly elevated in FANCD2-depleted 
WT cells, compared to siLUC-treated WT cells, due to large experiment-to-experiment 
variation (Figure 6.18a-b). 
 
 
Figure 6.17. Experimental setup of TRAIP and FANCD2 epistasis analysis in mammalian 
somatic cells. 
RPE1 p53-/- WT and TRAIP-KO (clone 1.29) cells were transfected with siFANCD2 and 
subsequently used for three different analyses: immunoblotting to assess RPA2 
phosphorylation, metaphase spreads for detecting chromosomal aberrations, and clonogenic 




Figure 6.18. pRPA2-S4/S8 levels are similarly increased in TRAIP-KO and siFANCD2-treated 
WT cells after MMC treatment. 
a) Representative immunoblot (n=3 independent experiments) demonstrating MMC-induced 
pRPA2-S4/S8 levels in RPE1 p53-/- WT (clone 1.30) and TRAIP-KO (clone 1.29) cells, which were 
transfected with siLUC or siFANCD2 for 48 hours, exposed to MMC treatment (360 nM) and 
harvested for immunoblotting 24 h after the treatment was started. Untreated (–) and MMC-
treated (+) samples were compared for phosphorylation of pRPA2-S4/S8; vinculin served as a 
loading control. 
b) Quantification of pRPA2-S4/S8 levels 24 h post-MMC addition in the four conditions. Image 
analysis was performed using Fiji/ImageJ software. pRPA2-S4/S8 levels were normalised to 
vinculin. Results (mean ± SD) from n=3 independent experiments are shown; statistics: 
unpaired two-tailed t-test. 
 
 
 Although consistent with epistasis between TRAIP and FANCD2 in MMC-ICL repair, the 
DDR experiments exhibited high experiment-to-experiment variation, preventing me from 
making this conclusion. Thus, in addition to the DDR signalling, I decided to assess the epistasis 
between these factors at maintaining genome stability. Metaphase spreads were prepared 
using FANCD2-depleted WT and TRAIP-KO cells, with or without MMC treatment, and analysed 
for chromatid breaks and radial chromosomes. In unperturbed cells, the lack of TRAIP, but not 
FANCD2 depletion, resulted in the significantly increased numbers of chromatid breaks per 
metaphase (Figure 6.19b), consistent with a requirement of TRAIP during unperturbed cell 
cycle progression. This observation recapitulates the overall increase in gross chromosomal 








a) Representative images of chromosomal aberrations in MMC-treated FANCD2-depleted 
TRAIP-KO metaphase spreads, stained with DAPI and visualised using immunofluorescence 
microscopy. Scale bars: 5 μm. 
b, c) Quantification of chromatid breaks (b) and radial chromosomes (c) in siLUC- or siFANCD2-
treated RPE1 p53-/- WT and TRAIP-KO cells with and without MMC treatment is shown. To 
visualise chromosomal abnormalities, cells were grown in the presence or absence of 60 nM 
MMC for 24 h, followed by cell fixation and preparation of metaphase spreads, which were 
stained with DAPI. Image analysis was performed using Fiji/ImageJ software. Approximately 
20-25 metaphase spreads were analysed per condition. Results from one experiment are 
shown. Statistics: unpaired two-tailed t-test between the average number of chromosomal 
aberrations per metaphase spread. 
 
 
More MMC-induced chromatid breaks were detected in FANCD2-depleted WT cells 
than in siLUC-treated WT cells or TRAIP-KO cells (Figure 6.19b). An additive exacerbation of 
this phenotype was observed in cells lacking both of these factors (Figure 6.19a-b). These data 
indicate that TRAIP and FANCD2 likely operate in different pathways to maintain genomic 
stability upon MMC exposure, as the absence of both factors results in a more severe effect 
on genome stability than the lack of each of them individually. 
Inactivation of the FA pathway was previously demonstrated to cause increased 
appearance of toxic radial chromosomes (Deans and West, 2011; Newell et al., 2004) as a 
result of NHEJ-mediated repair of DSBs. Indeed, while a few radial chromosomes were 
observed in TRAIP-KO cells after MMC treatment, FANCD2 depletion had a much stronger 
effect on radial chromosome frequency (Figure 6.19c). The highest average number of radial 
chromosomes was observed in MMC-treated cells lacking both factors, again suggesting 
additive effect (Figure 6.19a-c). Thus, this result is consistent with the lack of epistasis between 
TRAIP and FANCD2 in maintaining genome stability upon MMC treatment. 
 Lastly, I used clonogenic cell survival assays to analyse whether TRAIP and FANCD2 are 
epistatic regarding cell survival after MMC treatment. This revealed an additive effect of the 
loss of TRAIP and FANCD2 depletion towards cell sensitivity to MMC (Figure 6.20). FANCD2-
depleted WT cells were substantially more sensitive to MMC treatment than TRAIP-KO cells, 




Figure 6.20. TRAIP and FANCD2 are not epistatic in terms of cell sensitivity to MMC. 
siLUC- or siFANCD2-depleted RPE1 p53-/- WT and TRAIP-KO (KO; clone 1.29) cells were plated 
at very low density and treated with several doses of MMC (5 nM – 60 nM) for 24 hours. The 
drug was removed by extensive PBS washing, and cells were incubated for 8 days to form 
colonies, followed by fixation, staining and colony counting. Results (mean ± SD) from 2 
independent experiments are shown. Two-way ANOVA was used for statistical analysis. 
 
 
As chronic loss of a protein may lead to cellular adaptations, the comparison between 
the depletion of one protein and the complete absence of another may not be adequate for 
these experiments, and so it may be more relevant to either deplete both factors by RNAi or 
generate double knockout cell lines. To rule out the possibility of the experimental design 
affecting the results obtained, I knocked-down TRAIP and FANCD2 in RPE1 p53-/- cell line and 
performed the clonogenic cell survival assay. First, three different siTRAIP oligonucleotides 
were tested, all showing similar effect on TRAIP depletion and cell survival after MMC 
treatment (Figure 6.21a-b). As TRAIP-depleted cells were less sensitive to MMC treatment 
than TRAIP-KO cells, higher doses of MMC were used in cell survival assays (Figure 6.21b). The 
RNAi-mediated depletion of TRAIP and FANCD2 was observed to result in very distinct effects 
on RPE1 p53-/- cell survival after MMC treatment (Figure 6.21c). siTRAIP-treated cells showed 
a much milder MMC-induced cell survival defect than FANCD2-depleted cells (Figure 6.21c). 
These results and the experimental work conducted using RPE1 p53-/- TRAIP-KO cells strongly 
suggest that TRAIP and FANCD2 are not epistatic during MMC-ICL repair. Consequently, it is 
possible that TRAIP is instead required for the alternative NEIL3-mediated ICL repair pathway 
in human cells. Therefore, in the future it will be of interest to experimentally address whether 




Figure 6.21. Depletion of TRAIP and of FANCD2 are not epistatic in terms of cell survival after 
MMC treatment. 
a) Immunoblot demonstrating that TRAIP depletion using different siRNA oligonucleotides 
results in similar depletion efficiency. RPE1 p53-/- cells were treated with 50 nM siRNA (siLUC 
or siTRAIP) and harvested for immunoblotting 48 h after the treatment was started. Old and 
new stocks of the siTRAIP-524 oligonucleotide were used for the experiment, as indicated in 
the figure. Vinculin served as a loading control.  
b) RPE1 p53-/- cells depleted of TRAIP using various siRNA oligonucleotides were plated at very 
low density and treated with several doses of MMC (30 nM – 120 nM) for 24 h. The drug was 
removed by extensive PBS washing, and cells were incubated for 8 days to form colonies, 
followed by fixation, staining and colony counting. Results from one experiment are shown. 
c) Cell survival experiment showing that TRAIP-depleted cells (siTRAIP#2) formed significantly 
fewer colonies at all doses of MMC tested, compared to siLUC-depleted cells. However, 
FANCD2 depletion resulted in a much more severe MMC-induced cell survival defect than 
TRAIP depletion, consistent with a lack of epistasis between TRAIP and FA pathways in 
response to MMC-induced DNA damage. RPE1 p53-/- cells were treated with siRNA for 48 h 
prior to start of MMC treatment. Cells treated with siLUC, siTRAIP or both siRNAs were plated 
at very low density and treated with MMC (7.5 nM – 60 nM) for 24 h. The drug was removed 
by extensive PBS washing, and cells were incubated for 8 days to form colonies, followed by 





6.2.4. Summary: TRAIP in MMC-ICL repair 
 
In this section, I demonstrated that TRAIP-KO cells are hypersensitive to MMC 
treatment and exhibit reduced cell survival. TRAIP was also required for normal RPA2 
phosphorylation following MMC treatment, as well as the maintenance of genomic stability. 
In contrast to CPT treatment, TRAIP-KO cells were not observed to have defective HR in 
response to MMC. Further experiments were conducted to investigate the potential 
mechanistic link between TRAIP and the FA pathway, based on the observations that TRAIP is 
required for efficient ICL repair in X. laevis egg extracts (Wu, Semlow et al., unpublished). 
However, the experiments in TRAIP-KO cells provided no evidence to support the existence of 
an epistatic relationship between TRAIP and FA pathways in repairing MMC-ICLs in mammalian 
somatic cells. 
There are several possible explanations for the observed lack of experimental support 
for the epistatic model. Firstly, although widely used to study genome maintenance pathways 
(Hoogenboom et al., 2017), X. laevis egg extract is a cell-free in vitro system, which provides 
an indication of the events in vivo but has a limited power to mimic circumstances of a living 
cell. Moreover, our cell line choice for these experiments may have influenced the results, as 
gene expression patterns, physiological properties and the tissue of origin differ between 
cultured human cell lines (Ross et al., 2000). Single cells in genetically homogeneous 
populations of cultured mammalian cells were also noted to spontaneously develop 
phenotypic heterogeneity (Stockholm et al., 2007). Thus, testing the effects of DNA damage in 
several TRAIP-KO cell lines with different tissue origins and phenotypic characteristics could be 
used to exclude cell line-specific findings, whereas clone variability could be addressed by using 
several RPE1 p53-/- TRAIP-KO clones for the epistasis experiments. 
However, if our current findings were replicated in other TRAIP-KO cell lines as well, 
what could be the alternative mechanism by which TRAIP contributes the resolution of MMC-
ICLs? One of the possibilities is that in mammalian somatic cells, the FA pathway-dependent 
repair of MMC-ICLs does not rely on the upstream event of CMG unloading, which is mediated 
by TRAIP in X. laevis (Figure 6.22a). This hypothesis would suggest that both TRAIP and FA 
pathways contribute to efficient MMC-ICL resolution but are not dependent on each other. 
However, such a model is not supported by experimental data obtained in X. laevis egg extracts 
and is only a speculation based on my findings in TRAIP-KO cells. As TRAIP-mediated 
ubiquitination of MCM7 is yet to be demonstrated in mammalian cells, another possibility is 
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that CMG unloading during MMC-ICL repair is mediated not by TRAIP, but by a different E3 
ligase, whereas TRAIP works in a distinct pathway to contribute to genome stability and cell 
survival after MMC treatment (Figure 6.22b). In summary, none of these alternative 
possibilities is currently supported by experimental data, and extensive further work will be 
needed to delineate the role of TRAIP in mammalian ICL repair. However, such analyses may 
be challenging due to the lack of available reagents and assays to assess CMG unloading in 
mammalian systems, as well as the cellular abundance of MCM complex subunits and their 




Figure 6.22. Cartoon models representing hypothetical roles of TRAIP in MCM-ICL repair. 
a) The model suggesting that the FA pathway-dependent repair of MMC-ICLs acts in parallel to 
TRAIP to promote genome stability and cell survival, implying that the TRAIP-mediated CMG 
unloading is not required for efficient MMC-ICL repair in mammalian cells. 
b) The model suggesting that CMG unloading during MMC-ICL repair is mediated not by TRAIP, 
but by a different E3 ligase. Meanwhile, TRAIP works in a distinct pathway to contribute to 






6.3. Discussion: the role of TRAIP in DDR and DNA repair 
 
 In this chapter, extensive analysis on the role of TRAIP in promoting the repair of 
replication-associated DNA damage was described. Firstly, I experimentally tested whether 
TRAIP facilitates resolution of CPT-induced DNA damage. Using TRAIP-KO cells, complemented 
with either wild-type TRAIP or its E3 ligase-deficient variant, TRAIP E3 ligase activity was 
demonstrated to mediate CPT-induced DNA end resection, DDR signalling and efficient HR 
(Figure 6.11). Overall, these results indicate the importance of the proper E3 ligase activity of 
TRAIP in resolving CPT-induced DNA damage. Nevertheless, E3 ligase-deficient TRAIP-W37A 
mutant provided partial rescue in cell survival assays. I demonstrated that TRAIP-W37A retains 
partial auto-ubiquitination proficiency (Figure 6.4c), suggesting that the W37A mutation may 
not fully abolish the interaction between E2 and E3, but rather confers partial loss of E3 ligase 
activity. Indeed, a recent nuclear magnetic resonance-based report investigating the effects of 
the tryptophan-to-alanine (W>A) subsitution within the RING domain of E3 ligases 
demonstrated only minor structural differences between W>A mutant and WT RING (Birkou 
et al., 2017). Alanine was also shown to have a substantial intrinsic α-helix-stabilising tendency 
(Rohl et al., 1999; Spek et al., 1999), and the W37A substitution may have conferred structural 
rigidity and the lack of flexibility to the whole RING domain and other domains of TRAIP, 
subsequently negatively affecting its cellular function. It is likely that TRAIP domain structure 
would have been better preserved by substituting the tryptophan residue with a more 
structurally similar residue, such as another aromatic amino acid. Additionally, Birkou et al. 
(2017) demonstrated that tryptophan-to-arginine (W>R) mutant induces structural changes 
within the RING domain that completely obliterate the interaction with E2. Thus, 
complementing TRAIP-KO cells with a more suitable TRAIP RING domain point mutant, such as 
TRAIP-W37R, may give us a clearer insight into the cellular roles of the E3 ligase activity of 
TRAIP. However, the structural changes introduced by W37R mutation could also lead to the 
complete destabilisation of the RING domain and significant reduction of TRAIP protein levels, 
as previously seen with C7A/C10A mutant (see Section 6.1.2). It is therefore possible that 
deleting the entire RING domain rather than using point mutants would allow the best 
preservation of native TRAIP folding, stability and function required for investigating the role 
of its E3 ligase activity in DNA replication and repair. 
 Previous report by Hoffmann et al. (2016) demonstrated that siTRAIP-treated U2OS 
cells do not properly respond to replication-associated DNA damage, including CPT treatment, 
as indicated by reduction in RPA foci intensity, ssDNA generation, and S phase phosphorylation 
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of RPA, CHK1 and H2AX (see Figure 1.16b). Overall, my experiments, together with the data 
obtained by Hoffmann et al. (2016), strongly implicate TRAIP E3 ligase in contributing to the 
resolution of CPT-induced DNA damage, likely by facilitating ATR-dependent checkpoint 
signalling. However, it remains unclear which step of CPT-induced DNA repair TRAIP directly 
contributes to. Extensive CHK1 and RPA2 phosphorylation indicates activation of the 
replication checkpoint, and is known to persist until DNA damage is resolved and DNA 
synthesis restored (Pommier, 2006; Shao et al., 1999). Such phosphorylation, particularly of 
RPA2, is reduced in TRAIP-KO cells, and it remains to be established whether the observed 
defect is due to a reduced rate (delay) or failure of phosphorylation. 
 W. Feng et al. (2016) suggested that TRAIP promotes PCNA unloading from chromatin 
after HU treatment (see Figure 1.16c), having observed that TRAIP depletion impaired the HU-
induced reduction of chromatin-bound PCNA. Although I did not perform extensive analysis of 
how TRAIP-KO cells respond to HU treatment, CPT-induced PCNA unloading from chromatin 
was not disrupted in TRAIP-KO cells (Figure 6.10). This suggests that TRAIP may be involved in 
unloading PCNA specifically upon HU-induced replication stress. The recent study by Soo Lee 
et al. (2016) proposed that TRAIP mediates recruitment of BRCA1 to IR-induced DSBs (see 
Figure 1.16d). Although I did not test the role of TRAIP in responding to IR-induced DNA lesions, 
BRCA1 recruitment to chromatin following CPT treatment in TRAIP-KO or E3 ligase-deficient 
cells was unaffected (Figure 6.10). This may indicate that distinct TRAIP-dependent DDR 
signalling cascades facilitate the repair of replication-associated one-ended DSBs and IR-
induced two-ended DSBs (Chapman et al., 2012), where TRAIP-mediated BRCA1 recruitment 
to chromatin is required. Alternatively, the distinct experimental setup used by me, W. Feng 
et al. (2016) and  Soo Lee et al. (2016), such as different cell lines and TRAIP depletion methods, 
may have contributed to the conflicting results obtained. 
The identity of the DDR-relevant TRAIP ubiquitination substrates at stalled replication 
forks also remains elusive. Two recent studies on TRAIP proposed PCNA as a potential 
substrate of the E3 ligase activity of TRAIP (Hoffmann et al., 2016; W. Feng et al., 2016) but no 
substantive in vitro or in vivo evidence for the TRAIP-mediated ubiquitination of PCNA was 
provided by either study. Notably, W. Feng et al. (2016) showed that the inactivation of TRAIP 
did not significantly affect the levels of ubiquitinated PCNA in response to replicative stress, 
and that inhibition of the proteasome did not impair fork recovery, leading to their conclusion 
that TRAIP may promote PCNA unloading by non-catalytic means. The TLS polymerase eta (Pol 
ŋ) was proposed as another putative substrate of TRAIP based on the finding that 
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overexpression of the D. melanogaster orthologue of TRAIP (Nopo) promotes Pol ŋ 
polyubiquitination (Wallace et al., 2014). However, follow-up experimental work by Hoffmann 
et al. (2016) suggested that TRAIP-mediated ubiquitination of Pol ŋ was unlikely to underlie 
the role of TRAIP in maintaining genome stability after replication stress. The authors 
demonstrated that TRAIP depletion did not affect formation of Pol ŋ foci upon DNA damage, 
and that TRAIP-mediated ubiquitination of Pol ŋ was not dependent on its RING or PIP domain. 
Furthermore, the sensitivity of TRAIP-depleted cells to replication stress-inducing agents could 
not be rescued by overexpression of Pol ŋ (Hoffmann et al., 2016). Overall, these data implied 
that Pol ŋ is not a substrate of TRAIP that is relevant to its role in maintaining genome stability 
after replication stress. In Chapter 4, the analysis of interaction between TRAIP and protein 
phosphatase 4 (PP4) complex, as well as the possibility of TRAIP-mediated PP4 ubiquitination, 
is described and discussed. However, the experiments in this chapter indicated that reduced 
CPT-induced DDR signalling in TRAIP-deficient cells, particularly RPA2 phosphorylation, is more 
likely to be caused indirectly through defective RPA loading on ssDNA after CPT treatment (see 
Figure 6.9). This alternative explanation minimises the potential role of TRAIP-dependent PP4 
ubiquitination at CPT-induced DNA lesions. However, it remains possible that TRAIP-mediated 
PP4 regulation occurs in response to other types of DNA lesions, such as the ones induced by 
UV irradiation. Overall, the identity of DDR-relevant substrates of TRAIP remains an open 
question, and their identification will be necessary to fully elucidate what role TRAIP has in 
responding to replication stress. 
 In the future, several methods could be employed to facilitate the identification of 
TRAIP interaction partners and substrates. Given that TRAIP adds K48-linked ubiquitin chains 
on its substrates (Zhang et al., 2012), TRAIP-dependent ubiquitination of its DDR substrates 
may well occur and lead to their degradation in a proteasome-dependent manner, detectable 
by mass spectrometry (MS) analysis. Additionally, indirect effects of the TRAIP loss on the 
proteome could be detected as well, providing insight into cellular pathways that are 
upregulated or downregulated in unperturbed or damaged cells when TRAIP is absent. For 
direct detection of CPT-induced proteomic changes at replication forks, isolation of protein on 
nascent DNA (iPOND) method could be applied to purify replication fork-associated proteins, 
followed by their analysis by MS (Leung et al., 2013). Moreover, MS identification of transient 
TRAIP interactions with other proteins in living cells could be achieved using proximity-
dependent biotin identification (BioID) method (Roux et al., 2012). Finally, MS for targeted 
detection of ubiquitination sites may be a valuable direct approach for elucidating the 
substrates of the E3 ligase activity of TRAIP. 
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 In agreement with the results obtained by Hoffmann et al. (2016), I observed the 
elevated rates of chromosomal aberrations and reduced cell survival in response to MMC in 
TRAIP-deficient cells (Section 6.2.2). However, pRPA2-S4/S8 signal in MMC-treated RPE1  
p53-/- TRAIP-KO cells was increased, in contrast to the reduction seen by Hoffmann et al. 
(2016) in TRAIP-depleted U2OS cells. The experiments described in Section 6.2.3 did not 
provide support for epistatic relationship between TRAIP and FA-mediated ICL repair pathway 
in mammalian cells, as the loss of TRAIP led to less severe MMC-induced chromosomal 
instability and cell survival defects than the ones observed in FANCD2-depleted cells. While 
the possibility of the involvement of TRAIP in CMG unloading is exciting, the lack of 
experimental evidence for epistasis between TRAIP and FA pathways at MMC-ICLs in 
mammalian cells prompts consideration of alternative models for the role of TRAIP at ICLs, 
which will need to be explored in the future. Instead of acting upstream of FANCD2 to promote 
CMG unloading needed for MMC-ICL repair, TRAIP may mediate an alternative pathway that 
promotes genome stability and cell survival after MMC-induced DNA lesions. For example, 
replication-independent ICL repair (RIR), which recognises ICL lesions via sensing DNA helix 
distortion or ICL collision with a transcribing polymerase, does not rely on the FA pathway 
(Williams et al., 2013). Moreover, ICL incision and TLS steps in RIR, which often operates 
outside of S phase, involve different set of enzymes than the ones acting in FA-dependent ICL 
repair and include NER proteins (Enoiu et al., 2012; Williams et al., 2013). As the absence of 
TRAIP resulted in milder defects in genome stability and cell survival than FANCD2 depletion, 
TRAIP may be a component of a pathway that normally plays a less prominent role in repairing 
ICLs but is indispensable in the absence of the functional FA pathway. Alternatively, TRAIP may 
contribute to MMC-ICL repair by regulating ATR signalling or DNA end resection, and further 
work is required to address these possibilities.  
The experiments described in this chapter and Chapter 5 also indicate that TRAIP 
promotes DNA repair via distinct mechanisms in response to different types of DNA lesions. 
My results, together with the data presented by Harley et al. (2016), strongly support the 
proteasome-dependent degradation of TRAIP following UV-C irradiation. In contrast to this, 
CPT and MMC treatment did not induce TRAIP depletion in wild-type cells, as shown by 
immunoblotting analyses, pointing towards different roles and cellular fates of TRAIP in 
response to different DNA lesions. UV-induced photoproducts, such as covalent adducts 
between adjacent pyrimidines on the same DNA strand (cyclobutane pyrimidine dimers), cause 
problems primarily by distorting the structure of DNA (Rastogi et al., 2010), whereas CPT or 
MMC treatment creates a direct blockage to DNA replication, either by generating a bulky 
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DNA-protein adduct (CPT) or by sealing the two DNA strands together (MMC-ICL). Although in 
each case collision of the DNA lesion with the replication fork could lead to the emergence of 
DSBs, these can be structurally distinct and require different proteins for their repair (Michl et 
al., 2016; Pommier, 2004; Rastogi et al., 2010). My data suggest that TRAIP facilitates repair of 
replication-associated one-ended DSBs arising upon CPT treatment (see Section 6.1.5) and is 
required for ensuring genome stability and cell survival upon MMC treatment (see Section 
6.2.2), consistent with its adaptation to influence efficient repair of several structurally distinct 
types of DNA damage. 
 Having investigated the effects of two replication-associated DNA damaging agents, 
CPT and MMC, in TRAIP-KO cells, it will be of particular importance to explore the involvement 
of TRAIP in facilitating the repair of endogenously induced DNA lesions. During embryonic 
development, DNA lesions arising from oxidative damage (Cooke et al., 2003) and aldehydes 
(Langevin et al., 2011) are likely to be encountered by cells. Such endogenous DNA damage 
may be deleterious in TRAIP-deficient cells during rapid cell proliferation, eventually leading to 
the loss of cells and restriction of normal body growth. My initial data suggest that hydrogen 
peroxide treatment, which induces oxidative stress, causes a slight reduction in pRPA2-S4/S8 
signal (see Figure 5.10) and cell survival in TRAIP-KO cells, compared to WT cells. In the future, 
further investigation of the role of TRAIP in sensing oxidative stress and repairing aldehyde-
induced DNA damage will be necessary for clarifying the functional link between the 














































7. A mouse model of MPD caused by DONSON deficiency 
 
Multiple DNA damage response (DDR) factors are essential for cell viability due to their 
key role in signalling the presence of DNA lesions and promoting their repair, thus ensuring 
genomic stability. Until recently, little was known about the cellular function of the human 
protein encoded by the DONSON gene. Its orthologue in D. melonogaster, known as Humpty 
dumpty (Hd), was previously demonstrated to be essential for DNA amplification in follicle cells 
of the ovary and required for cell proliferation during development (Bandura et al., 2005). 
Recently, a link between DONSON and human disease was established, as the Andrew Jackson 
and the Grant Stewart (University of Birmingham) laboratories reported that biallelic 
mutations in this gene cause microcephalic primordial dwarfism (MPD) (Reynolds et al., 2017). 
DONSON was demonstrated to encode a replication fork-associated protein, which protects 
and stabilises replication forks and prevents spontaneous DNA damage, thus promoting 
efficient S phase progression (Reynolds et al., 2017). More recently, a biallelic intronic variant 
in DONSON was also implicated as a cause of the rare microcephaly-micromelia syndrome 
(MMS), characterised by severe prenatal growth restriction, microcephaly, craniofacial 
anomalies, skeletal dysplasia and neonatal lethality (Evrony et al., 2017).  
As DONSON emerged as a new disease-associated gene, we decided that a DONSON 
mouse model would provide a valuable tool for studying the biological function of this protein. 
In particular, a DONSON patient mutation knock-in mouse could provide us with a better 
understanding of the impact DONSON mutations have on mammalian organism growth and 
development. Moreover, it would provide an isogenic system allowing verification of the 
cellular defects previously observed in patient-derived cell lines. Lastly, characterising the 
development of the mouse model of MPD caused by mutations in DONSON might enable 
discovery of additional phenotypes associated with biallelic DONSON mutations. 
No viable mouse disease model of MPD caused by DONSON mutations was available; 
therefore, in this chapter, a CRISPR/Cas9 genome targeting strategy to introduce a DONSON 
patient mutation in mouse is described. Its consequences on embryonic development are 





7.1. CRISPR/Cas9-mediated targeting of murine Donson to introduce the MPD 
mutation 
 
 To establish phenotypes associated with a DONSON knock-in mouse at a cellular and 
organism level, I chose to model the DONSON mutation M446T. This mutation, substitution of 
a highly conserved methionine residue to threonine at amino acid position 466 (p.M466T), is 
caused by the homozygous transition c.1337T>C in exon 8 of the human DONSON gene. This 
was identified by WES as a cause of MPD in one consanguineous family of Palestinian descent 
(Reynolds et al., 2017). The three affected individuals were previously reported to have a 
Fanconi Anaemia (FA)-like disorder, with patients exhibiting microcephaly, short stature and 
forearm and thumb dysplasia, although there was no evidence for bone marrow failure (Milner 
et al., 1993). The cells derived from the three affected individuals showed reduced levels of 
DONSON protein, and exogenous expression of p.M446T mutant protein was consistent with 
reduced stability due to this missense mutation (Reynolds et al., 2017). As this mutation is the 
only homozygous exonic mutation identified in the MPD cohort, it was an attractive choice for 
CRISPR/Cas9-mediated genome editing in mouse. Human DONSON (hDONSON) and mouse 
Donson (mDonson) proteins are 76% identical and share 83% similarity at amino acid level, 
and the DNA sequences surrounding p.M446 (corresponding to p.M440 in mouse) are highly 




Figure 7.1. Amino acid sequence alignment of human and mouse DONSON proteins. 
Comparison between amino acid sequences of human and mouse DONSON orthologues, 
performed using NCBI Basic Local Alignment Search Tool (BLAST), indicates a high degree of 
evolutionary conservation of this protein between the two species. Methionine 446 (M446) in 
human DONSON (hDONSON) and its equivalent methionine 440 (M440) in mouse Donson 
(mDonson) are shown in red. The middle lane indicates amino acid conservation between the 
two organisms: amino acids that are identical between human and mouse DONSON are 
named; the plus sign (+) indicates substitutions that preserve the physico-chemical properties 
of the original residue, leading to similarity at amino acid level. Gaps (spaces) in the alignment 




To introduce p.M440T in mouse Donson (mDonson), a gRNA that scored highly based 
on both the CRISPR Design Tool (Feng Zhang lab; http://crispr.mit.edu/) and the CRISPR gRNA 
Design Tool DNA2.0 (now ATUM) was selected for targeting (Figure 7.2). A 108 bp-long ssODN 
repair template was designed to introduce the desired nucleotide substitution (c.1319T>C) 
directly at the predicted Cas9 cutting site, as well as a silent PAM site mutation 5 nt upstream 
(CTT PAM site changed to CAT) (Figure 7.2). The 20 nt-long targeting sequence to allow 
production of the gRNA was inserted into the pX458 plasmid, encoding wild-type Cas9 
nuclease, and tested in vitro to evaluate its efficiency at cutting the Donson DNA template, 
encompassing M440 within exon 8 (Figure 7.3). This in vitro assay showed efficient cutting of 
the template, and the gRNA was therefore used for cytoplasmic injections in BL6CBAF1 zygotes 




Figure 7.2. Targeting c.1319T (p.M440) in mDonson by CRISPR/Cas9 genome editing.  
Above: schematic of the mouse Donson (mDonson) gene with exon 8 and c.1319T (p.M440) 
indicated. Below: alignment of genomic sequences of exon 8 (uppercase) and intron 8 
(lowercase) of human and mouse DONSON. The 20 nt-long genomic sequence targeted by the 
gRNA in exon 8 of mDonson is highlighted in purple; 3 nt-long PAM site is shown in green. Black 
arrow indicates the predicted incision site of WT Cas9. The nucleotides changed to introduce 
the M440T mutation (T>C) and alter PAM site (C>A, silent A438A mutation) in the repair 





Figure 7.3. SgRNA for CRISPR/Cas9-mediated introduction of c.1319T>C (p.M440T) mutation 
in mouse cleaves its template in vitro. 
Analysis of in vitro cutting reaction, containing Donson DNA template, the in vitro transcribed 
sgRNA, and recombinant wild-type Cas9 enzyme (200—680 ng). Donson template (337 bp PCR 
product), encompassing exon 8 of mDonson and exon-intron junctions, was amplified by PCR 
using primers indicated by red arrows. The presence of in vitro digestion products (227 bp and 
110 bp) was visualised on a 2% agarose gel.
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7.2. Screening founder mice for mutations in mDonson  
 
To generate transgenic mice, the CRISPR/Cas9 reagents were microinjected into the 
cytoplasm of a fertilised eggs, which were cultured overnight to the 2-cell stage and then 
transferred to the oviducts of pseudo-pregnant ‘recipient’ females (performed by the staff of 
CBS Transgenic Core Facility, University of Edinburgh) (see Section 2.7.2). Two cytoplasmic 
injection sessions and 6 embryo transfers resulted in a total of 5 pregnant mice, 3 of which 
gave birth. The first injection session yielded only 3 mouse pups, born to 3 pregnant females, 
whereas the second injection session resulted in 13 pups born to 2 pregnant females (7 and 6 
pups, respectively). Tissue biopsies (ear clips) of the 16 infant pups (9 male pups and 7 female 
pups) were collected and used for genomic DNA extraction and PCR amplification of the 
genomic locus surrounding the p.M440T substitution, using primers indicated in Figure 7.3. 
The resulting PCR products were sub-cloned and Sanger-sequenced to determine the 
genotypes of founder (F0) mice (Table 7.1). Four pups were not targeted by CRISPR/Cas9, only 
showing non-mutated Donson. Six pups were heterozygous for the M440T mutation, with the 
second allele shown to be wild-type (Donson M440T/+) (Table 7.1). All these animals except 
one had the PAM site mutation as well. To avoid unanticipated consequences due to the silent 
PAM site mutation, the pup that was wild-type for the PAM site sequence and heterozygous 
for M440T was selected for further breeding to establish the Donson M440T mouse line.  
Mutations other than the intended M440T substitution were found in several animals 
as well (Table 7.1). One pup was shown to be heterozygous for M440T, with the second allele 
harbouring a methionine to isoleucine substitution at amino acid position 440 (M440T/M440I). 
Additionally, 5 pups were demonstrated to be heterozygous for short insertions or deletions 
(1-5 bp long), with the genotypes insT/+, delAA/+, and del5bp/+ (Table 7.1). In all cases, the 
indel was predicted to result in a frameshift and lead to the introduction of a premature stop 
codon in exon 8, likely resulting in the degradation of the mutant transcript through NMD. The 
female Donson del5bp/+ pup was selected for further breeding to establish a Donson knockout 






Table 7.1. Summary of the genotypes of CRISPR/Cas9-targeted founder (F0) mice. 
Genotypes of founder (F0) mice at the intended substitution (mDonson c.1319T>C) and the 
PAM site (c.1314C>A) are indicated, together with the number of F0 mice with that particular 
genotype, the predicted length of Donson protein and the predicted Donson status resulting 
from the mutations. The ATG codon corresponding to methionine 440 (M440) is underlined; 












Mutation Het/Hom Mutation Het/Hom 
WT Hom WT Hom 4 560 aa +/+ 
ATG>ACG (M440T) Het CCT>CAT (A438A) Hom 1 560 aa M440T/+ 
ATG>ACG (M440T) Het CCT>CAT (A438A) Het 4 560 aa M440T/+ 
ATG>ACG (M440T) Het WT Hom 1 560 aa M440T/+ 





(A438A) Het 1 560 aa M440T/M440I 
ATG>ATTG (insT) Het WT Hom 3 
443 aa  
(premature stop 
codon in exon 8) 
+/- 
CAATG>CTG (delAA) Het WT Hom 1 
442 aa  
(premature stop 
codon in exon 8) 
+/- 
ATGCAAATG>AATG 
(delTGCAA; del5bp) Het WT Hom 1 
441 aa  
(premature stop 






7.3. Mice homozygous for Donson M440T and Donson del5bp are not viable 
 
 The selected founder (F0) pups (Donson M440T/+ and Donson del5bp/+) were crossed 
to CD-1 mice once they reached maturity at six weeks to establish germline transmission 
(Figure 7.4). F1 pups heterozygous for each of the Donson mutations were born, and germline 
transmission of the mutations of interest was established. Heterozygous F1 pups on this mixed 
genetic background (50% CD-1, 50% BL6CBAF1) were inter-crossed with the intention of 
generating homozygous mutant mice. Although multiple litters were produced for both mouse 
lines, they contained only wild-type and heterozygote individuals with no homozygous pups 
born, as determined by Sanger sequencing (Figure 7.4). The heterozygous mice with Donson 
M440T/+ and del5bp/+ genotypes did not visibly differ in size, compared to their wild-type 
littermates. No gross phenotypic abnormalities were reported for heterozygotes in either of 
the mouse lines. In contrast, the absence of homozygotes was statistically significant and 
strongly suggested their failure to survive in utero (Figure 7.4).  
 The absence of viable homozygous offspring (del5bp/del5bp) in the Donson-/- line is 
consistent with the early embryonic lethality of Donson-/- embryos recently observed by 
Evrony et al. (2017). However, it is surprising that no homozygous offspring (M440T/M440T) 
were born in the Donson knock-in mouse line, as three MPD patients homozygous for the 
corresponding mutation (M446T) in humans were identified (Reynolds et al., 2017). I next 
determined at what stage of early embryonic development embryos homozygous for Donson 
del5bp/+ and Donson M440T/+ can still be detected.                  
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Figure 7.4. Mice homozygous for Donson M440T or del5bp are not viable. 
Above: schematic representation of the first crosses initiated using Donson founder (F0) pups. 
The two selected founders were first crossed with CD-1 mice, and the heterozygous first filial 
generation (F1) pups were inter-crossed in an attempt to establish homozygous transgenic 
mouse lines. Below: the graphs demonstrating statistically significant absence of homozygous 
second filial generation (F2) animals for both knock-in (M440T) (left) and knock-out (right) 
Donson mouse lines. All weaned animals were wild-type or heterozygous for the Donson 
mutations. The experimentally observed distribution of genotypes is compared to their 
expected Mendelian distribution. The number of mice with each genotype is indicated on the 







7.4. Donson M440T/M440T embryos are present at least up to E16.5 
 
 To determine at what stage of embryonic development M440T/M440T are no longer 
present, dissections of embryonic day 11.5 (E11.5) embryos were performed and the tail clips 
of the dissected embryos used for genotyping. Homozygous M440T/M440T embryos were 
present in the dissected litters, although their numbers were lower than expected (Figure 
7.5a,c). Additionally, several spontaneous embryo resorptions, where the embryo implanted 
but was partially or fully resorbed before dissection, were found. A disproportionately large 
number of embryo resorptions genotyped as homozygotes (5 out of 7; 71%), indicating the 
phenotypic variability of genetically identical embryos. Moreover, a subtle difference in size 
was observed in the homozygous mutant embryos, compared to wild-type or heterozygous 
embryos (Figure 7.5b). The visually indistinguishable +/+ (n=2) and M440T/+ (n=2) embryos 
from the same litter measured 4.4±0.2 mm in length, whereas the smaller littermate 
M440T/M440T embryo (n=1) measured only 3.7 mm. 
 I next analysed the viability and size differences of Donson M440T embryos at later 
stages of development. M440T/M440T embryos were present in the dissected litters and, 
surprisingly, were found at the expected Mendelian ratio at E13.5 (Figure 7.6a). However, a 
statistically significant effect on embryo length and head size was observed during image 
analysis of Donson embryos at this stage of embryonic development (Figure 7.6b-d). The 
average length of a Donson M440T/M440T embryo at E13.5 was 5.1±0.2 mm, and the occipito-
frontal distance was 2.5±0.2 mm; meanwhile, the average length of a wild-type embryo was 
6.5±0.2 mm, with the head size of 3.2±0.1 mm (Figure 7.6c-d). These data indicate clear 
reduction in brain and body size in Donson M440T/M440T embryos at E13.5, when compared 
to wild-type or heterozygous embryos, which are indistinguishable in these parameters. The 
observed reduction in occipito-frontal distance in Donson M440T/M440T embryos was 






Figure 7.5. Embryos homozygous for Donson M440T are present at embryonic day 11.5 
(E11.5) at sub-mendelian frequency. 
a) The graph demonstrating the presence of mouse embryos homozygous for M440T mutation 
at E11.5. The experimentally observed distribution of genotypes is compared to their expected 
Mendelian distribution. Statistically significant reduction in the number of homozygous 
mutants is indicated (statistics: chi-squared test). The number of mice with each genotype is 
indicated on the columns in the graphs.  
b) Representative images of E11.5 littermate embryos wild-type (+/+), heterozygous 
(M440T/+) or homozygous (M440T/M440T) for Donson M440T. Scare bars: 1 mm. 
c) Sequencing electropherograms of embryos wild-type (+/+), heterozygous (M440T/+) or 
homozygous (M440T/M440T) for Donson M440T (indicated in red). Black dotted line indicates 








Figure 7.6. Embryos homozygous for Donson M440T are present at embryonic day 13.5 
(E13.5) and are significantly smaller than their littermates. 
a) Graph demonstrating the presence of mouse embryos homozygous for M440T mutation at 
E13.5. The experimentally observed distribution of genotypes is compared to their expected 
Mendelian distribution (statistics: chi-squared test). The number of mice with each genotype 
is indicated on the columns in the graphs.  
b) Representative images of E13.5 littermate embryos wild-type (+/+), heterozygous 
(M440T/+) or homozygous (M440T/M440T) for Donson M440T. Scare bars: 1 mm. 
c, d) E13.5 embryos homozygous for Donson M440T are significantly smaller in length (c) and 
occipito-frontal distance (d) than wild-type and heterozygous embryos. Each dot represents 
an embryo that was imaged and measured (as demonstrated by the dotted lines) using 




The single dissection performed at E16.5 suggested the Mendelian distribution of 
genotypes, given the presence of two M440T homozygotes out of 11 embryos (Figure 7.7a). 
Both embryos were substantially smaller than their littermates, with extreme but proportional 
reduction in body and head size (Figure 7.7b-d). The average length of a Donson 
M440T/M440T embryo at E16.5 was 10.9±1.2 mm, and the head size was 5.6±0.3 mm; 
meanwhile, the average length of a wild-type embryo was 16.8±0.6 mm, with the head size of 
9.1±0.5 mm (Figure 7.7c-d). This is in contrast to human DONSON patients, who present with 
the marked microcephaly (mean occipito-frontal circumference (OFC) –7.5±2.4 SD), whereas 
their height is reduced to a lesser degree than observed in other MPD-associated disorders  
(–3.2±1.4 SD). 
Moreover, limb abnormalities were observed in the two M440T/M440T embryos at 
this embryonic stage, with upper and lower limbs disproportionately short and 
underdeveloped (Figure 7.8a-b). Digits also appeared to be malformed, suggesting an 
additional effect of the M440T mutation on limb development. Additionally, craniofacial 
dysmorphism, including reduced snout size and underdeveloped jaw, can be observed in the 
two Donson M440T/M440T embryos (Figure 7.8a). Notably, limb abnormalities were displayed 
by human patients with biallelic DONSON mutations as well (Reynolds et al., 2017). These 
results also suggest that Donson M440T/M440T embryos mimic microcephaly-micromelia 
syndrome (MMS), characterised by perinatal lethality, severe microcephaly, craniofacial 
abnormalities and marked limb malformations (Evrony et al., 2017). 
No dissections at later stages of embryonic development were performed due to home 
office licence restrictions. Thus, I concluded that Donson M440T/M440T animals are not viable 
and exhibit embryonic lethality, but can survive at least until E16.5. Mice homozygous for 
Donson M440T are lost between E16.5 and weaning, and their growth is markedly stunted 
from E11.5 through to E16.5. Additionally, my experimental work suggests that the Donson 
M440T mutation leads to a more severe phenotype in mice than in humans, at least on the 





Figure 7.7. Embryos homozygous for Donson M440T are present at embryonic day 16.5 
(E16.5) and are substantially smaller than their littermates. 
a) The graph demonstrates the presence of mouse embryos homozygous for M440T mutation 
at E16.5. The experimentally observed distribution of genotypes in a single litter is compared 
to their expected Mendelian distribution. The number of mice with each genotype is indicated 
on the columns in the graphs.  
b) Representative images of E16.5 littermate embryos wild-type (+/+), heterozygous 
(M440T/+) or homozygous (M440T/M440T) for Donson M440T. Scare bars: 5 mm. 
c, d) E16.5 embryos homozygous for Donson M440T are significantly smaller in length (d) and 
head size (e) than wild-type and heterozygous embryos. Each dot represents an embryo that 
was imaged and measured using ImageJ/Fiji software. Statistics: unpaired t-test; black bars 







Figure 7.8. Embryos homozygous for Donson M440T present with disproportionately shorter 
and abnormal limbs. 
a) Limbs in a wild-type (+/+) and the two Donson M440T/M440T E16.5 embryos are indicated 
by red circles. Scare bars: 5 mm. 
b) Limb/body length ratio in Donson embryos at E16.5. Each dot represents an embryo that 
was imaged and measured using ImageJ/Fiji software. Statistics: unpaired t-test; black bars 





7.5. Mice homozygous for Donson del5bp are not present at E10.5 or later 
 
To determine if DONSON is essential for mammalian embryonic development and to 
establish mouse embryonic fibroblast (MEF) cell lines, embryo dissections of E13.5 Donson 
del5bp/+ crosses were performed, and the tail clips of the dissected embryos were used for 
genotyping. No E13.5 embryos homozygous for Donson del5bp were present (Figure 7.9b-c). 
Embryos heterozygous for Donson del5bp/+ did not visibly differ in size from their wild-type 
littermates at this stage of embryonic development. I then performed embryo dissections of 
Donson del5bp/+ crosses at an earlier developmental stage, E10.5, to assess for the presence 
of Donson del5bp/del5bp embryos. Again, no homozygous null embryos were detected (Figure 
7.9a), and no gross phenotypic abnormalities or differences in size were found in 
heterozygotes at this stage of embryonic development. 
Overall, the absence of Donson del5bp/del5bp embryos even at early stages of 
embryonic development that I tested (E10.5 and E13.5) suggests DONSON to be required for 
early mammalian development. These findings are consistent with work by Evrony et al. 
(2017), showing early embryonic lethality of mice homozygous for a Donson gene-trap KO 






Figure 7.9. Mice homozygous for del5bp (Donson-/-) are not present at embryonic day 10.5 
(E10.5) and 13.5 (E13.5). 
a, b) Graphs demonstrating absence of homozygous offspring for knockout (del5bp) Donson 
mouse line at E10.5 (a) and E13.5 (b). All embryos present were wild-type or heterozygous for 
the del5bp mutation in Donson. The experimentally observed distribution of genotypes is 
compared to their expected Mendelian distribution. The number of mice with each genotype 
is indicated on the columns in the graphs. Statistics: chi-squared test. 
c) Sequencing electropherograms of embryos wild-type (+/+) or heterozygous (+/-) for Donson 





7.6. Phenotypic analysis of Donson mouse embryonic fibroblasts 
 
 As mice homozygous for the Donson M440T were not viable, as initially expected, I 
generated Donson E13.5 mouse embryonic fibroblast (MEF) cell lines and used them for 
functional analysis.  
Firstly, I postulated that the absence of viable Donson M440T/M440T mice may be 
caused by the disrupted splicing of mDonson mRNA, due to the substitution M440T having 
unexpected consequences on splicing, such as an altered exonic splicing enhancer (ESE) site. 
To test this hypothesis, total RNA was isolated from E13.5 MEF cell lines that were wild-type, 
heterozygous or homozygous for Donson M440T mutation. Complementary DNA (cDNA) was 
subsequently generated from the purified RNA and used as a template for reverse 
transcription (RT)-PCR analysis to assess splicing of mDonson exon 8 (Figure 7.10a). The gel 
electrophoresis analysis indicated that no alterations in mDonson exon 8 splicing were 
introduced by the M440T mutation (Figure 7.10b), and to further confirm this, the RT-PCR 
products were analysed by Sanger sequencing, establishing that splicing of mDonson exon 8 is 
not affected by the M440T mutation (Figure 7.10c). This result demonstrates that the failure 
of mice homozygous for Donson M440T to survive during the later stages of embryonic 





Figure 7.10. Splicing of mDonson transcript is unaffected by the M440T mutation. 
a) Schematic representation of the RT-PCR analysis to assess splicing of mDonson exon 8, 
containing methionine 440 (M440). Red arrows indicate the locations of PCR primers used for 
amplification of exon 7, exon 8 and exon 9 from mDonson cDNA, resulting in a 319 bp-long RT-
PCR product. 
b) RT-PCR analysis of Donson E13.5 mouse embryonic fibroblast (MEF) cell lines demonstrates 
that no alterations in Donson transcript splicing occur in the presence of the M440T 
substitution. RNA isolated from six E13.5 MEF cell lines with three different genotypes, Donson 
+/+ (cell lines 1.3 and 1.5), M440T/+ (cell lines 1.1 and 1.2), and M440T/M440T (cell lines 1.7 
and 1.8), was reverse transcribed to generate cDNA, which was used as a template for RT-PCR 
reactions. The RT-PCR products were visualised on a 2% agarose gel and Sanger sequenced. 
c) Sequencing electropherograms of RT-PCR products wild-type (+/+; 1.3), heterozygous 
(M440T/+; 1.1) or homozygous (M440T/M440T; 1.7) for Donson M440T (indicated in red). 
Black dotted line indicates an exon-exon junction. 
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 Human DONSON was implicated in maintaining genome stability, as DONSON 
depletion in HeLa cells was shown to result in a high proportion of cells exhibiting spontaneous 
γH2AX and 53BP1 foci, markers of DNA damage and DSBs (Reynolds et al., 2017). Elevated 
levels of γH2AX and 53BP1 foci were also observed in unperturbed fibroblasts from patients 
with hypomorphic DONSON mutations (Reynolds et al., 2017). To test whether spontaneous 
DNA damage also arises in MEFs homozygous for Donson M440T, numbers of 53BP1 and 
γH2AX foci were assessed in unperturbed MEF lines by immunofluorescence. Image analysis 
revealed significantly elevated levels of 53BP1 and γH2AX foci in Donson M440T/M440T MEFs, 
compared to wild-type (+/+) MEFs (Figure 7.11a-c). No significant increase in 53BP1 foci was 
observed in heterozygous Donson +/- (del5bp/+) and Donson M440T/+ MEF lines (Figure 
7.11b), although numbers of γH2AX foci showed a small but significant increase in Donson +/- 
(del5bp/+) cells (Figure 7.11c). These observations suggest that siRNA-mediated DONSON 
depletion in human cells and the biallelic Donson M440T mutation in mouse cause similar 
genome instability defects, as determined by elevated levels of DNA damage foci, marked by 
53BP1 and γH2AX, in unperturbed cells. Although Donson M440T/M440T MEF lines 1.7 and 
1.8 exhibited different severity of this phenotype (Figure 7.11b-c), potentially due to 
documented heterogeneity of MEF populations (Singhal et al., 2016) or the mixed genetic 
background (Montagutelli, 2000; Schauwecker, 2011), my experiments strongly suggested that 
DNA damage is significantly elevated in the presence of the biallelic M440T mutation in mice. 
 Unresolved replication-associated damage can impair DNA segregation during mitosis, 
giving rise to chromatin bridges, lagging chromosomes or chromatin fragments, each of which 
can subsequently lead to the formation of micronuclei (Terradas et al., 2010). Thus, the 
number of cells with micronuclei is another indicator of unresolved genome instability. As 
significantly elevated levels of spontaneously arising micronuclei were previously observed in 
DONSON-depleted HeLa cells (Reynolds et al., 2017), I determined the proportion of 
unperturbed MEF cells of different genotypes (wild-type (+/+), Donson +/- (del5bp/+), Donson 
M440T/+, and Donson M440T/M440T) containing one or more micronuclei. As expected, 
significantly higher percentage of Donson M440T/M440T MEFs had at least one micronucleus 
(15.5% for both cell lines 1.7 and 1.8), compared to wild-type cells (3.5% and 6.4% for cell lines 
1.3 and 1.5, respectively) (Figure 7.11d). This result, together with elevated levels of 53BP1 
and γH2AX foci, strongly indicates that, like the DONSON-depleted HeLa and DONSON patient-




Figure 7.11. Number of 53BP1 and γH2AX foci, as well as proportion of cells with micronuclei, 
are increased in unperturbed Donson M440T/M440T mouse embryonic fibroblasts. 
a) Representative images of unperturbed E13.5 Donson +/+ (cell line 1.5) and M440T/M440T 
(cell line 1.7) mouse embryonic fibroblasts (MEFs), stained for 53BP1 (FITC; green channel) or 
γH2AX (TxRed; red channel) and visualised using fluorescence microscopy. DAPI signal is shown 
in blue. Scale bars: 10 μm. 
b, c) Immunofluorescence quantification to assess the numbers of 53BP1 (b) and γH2AX (c) foci 
in unperturbed E13.5 Donson MEFs. Two MEF cell lines of each genotype (wild-type (+/+), 
Donson +/- (del5bp/+), Donson M440T/+ and Donson M440T/M440T) were plated on 
279 
 
coverslips. Next day, detergent pre-extraction of non-chromatin-bound proteins was 
performed before cell fixation with formaldehyde. Cells were immunostained for 53BP1 and 
γH2AX and visualised using fluorescence microscopy. Image analysis was performed using 
Fiji/ImageJ software. Black bars indicate the mean, and each dot in the graph represents one 
cell (more than 50 cells analysed per condition). Statistics: unpaired two-tailed t-test. 
d) Left: representative image of an unperturbed E13.5 Donson M440T/M440T (cell line 1.7) 
mouse embryonic fibroblast (MEF) with micronuclei (indicated by white arrows); scale bar: 10 
μm. Right: percentage of unperturbed wild-type (+/+), Donson +/- (del5bp/+), Donson 
M440T/+ and Donson M440T/M440T MEF cells with micronuclei. Cells were visualised using 
fluorescence microscopy, and image analysis was performed using Fiji/ImageJ software. To 
estimate the percentage of cells with micronuclei, more than 100 cells were analysed per 
condition. The dots in the graph represent values obtained for individual MEF cell lines; results 





7.7. Summary and discussion: DONSON MPD mouse model 
 
In summary, this chapter describes the CRISPR/Cas9-based generation and phenotypic 
analysis of a mouse model of MPD caused by mutations in DONSON. I demonstrated that no 
mice homozygous for mDonson M440T, equivalent to MPD patient mutation hDONSON 
M446T, are born, although embryos with this genotype could be found up to embryonic 
development stage E16.5, exhibiting a significant reduction in body and head size. Additionally, 
Donson M440T/M440T embryos presented with craniofacial and limb abnormalities at this 
embryonic development stage, with forelimbs and hindlimbs disproportionately shorter and 
underdeveloped, compared to the wild-type or heterozygous littermates.  
Notably, limb malformations, such as forearm and thumb dysplasia, were displayed by 
MPD patients homozygous for DONSON M446T as well, whereas several individuals with other 
DONSON mutations had fifth finger clinodactyly, syndactyly, brachydactyly, and bilateral radius 
and thumb hypoplasia (Reynolds et al., 2017). In the family with the most extreme phenotype, 
Reynolds et al. (2017) observed substantial limb shortening and fetal lethality. Similar 
phenotypic characteristics were reported in MMS patients as well, where limb malformations 
in most affected individuals showed bilateral oligodactyly with absent thumbs and absent or 
poorly developed fifth fingers, as well as short lower limbs with frequent toe syndactyly 
(Evrony et al., 2017). Furthermore, other diagnostic features for MMS are craniofacial 
anomalies, such as small mouth and undersized jaw, and neonatal lethality (Evrony et al., 
2017), and my Donson M440T/M440T embryos appeared to mimic the phenotypes associated 
with this syndrome.  
Limb abnormalities were previously associated with disruption of other MPD and 
genome maintenance genes as well. Severe limb abnormality phenotype was observed in the 
ORC1 mouse model of MPD, generated in our laboratory, with complete loss of forelimbs and 
shortened hindlimbs with oligodactyly seen in newborn mice (F. Cooper, unpublished). 
Mutations in RECQL4, a DNA replication gene implicated in maintaining genome integrity 
(Bruck and Kaplan, 2014; Kaiser et al., 2017; Petkovic et al., 2005), were shown to cause 
RAPADILINO syndrome, characterised by growth retardation, radial defects, limb 
abnormalities and other malformations (Siitonen et al., 2003). Notably, radial and thumb 
abnormalities are also commonly associated with Fanconi Anaemia (FA), with up to 35% 
patients having a thumb abnormality and another 7% displaying absent or hypoplastic radii 
(Triemstra et al., 2015). Considering that the phenotype of the family with the DONSON M446T 
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mutation was first associated with FA (Milner et al., 1993) and that DONSON-depleted cells 
display various cellular defects after MMC treatment (Reynolds et al., 2017), there may be a 
functional overlap between FA proteins and DONSON, which will need to be addressed in the 
future. 
The statistically significant absence of viable Donson M440T/M440T mice was 
surprising, as the corresponding mutation in hDONSON, M446T/M446T, does not confer 
embryonic lethality (Reynolds et al., 2017). The lymphoblastoid cell lines derived from the 
three MPD patients homozygous for DONSON M446T were shown to have reduced DONSON 
protein levels (Reynolds et al., 2017), potentially due to compromised stability of the mutant 
protein. Moreover, the DONSON mutations identified in MPD patients were demonstrated to 
be hypomorphic, with mutant protein retaining some residual function (Reynolds et al., 2017). 
Unfortunately, the protein levels in my Donson M440T/M440T MEFs could not be assessed by 
immunoblotting due to the lack of a suitable antibody. One possibility is that the missense 
mutation M440T may have a bigger impact on the stability of Donson protein in mice than in 
humans. Additionally, mouse development may be more sensitive to Donson deficiency, thus 
resulting in an early embryonic lethality.  
Alternatively, the absence of Donson M440T/M440T mice may be influenced by the 
genetic background of mice used in my experiments. The genetic background of a mouse strain 
is known to affect the observed phenotype, resulting from a particular mutation, due to 
differences in modifier genes, which act together with the causative gene (Montagutelli, 2000). 
In some cases, the modulation of the phenotype can be considerable, as demonstrated by the 
mouse model with targeted disruption of the epidermal growth factor receptor gene, where 
phenotypes ranged from peri-implantation death of embryos on a CF-1 background to survival 
for up to 3 weeks after birth for animals on a CD-1 background (Threadgill et al., 1995). 
Moreover, mice deficient for RIF1, which interacts with 53BP1 and is involved in DSB repair 
(Silverman et al., 2004), were viable only on the CD-1 background, whereas the same mutation 
in 129/Ola and MF-1 mouse strains resulted in embryonic lethality (Chapman et al., 2013). 
Thus, it may be expected that genetic differences between mouse strains result in varying 
degrees of genome instability in the presence of mutations that disrupt DNA replication and 
repair genes.  
For the breeding of Donson transgenic mice, a mixed background, CD-1 crossed with 
BL6CBAF1, was used. It is worth noting that in the dissections performed on Donson M440T 
E11.5–E16.5 embryos, 14 out of 17 (82%) spontaneous embryo resorptions, for which yolk sac 
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was genotyped, were homozygous for Donson M440T. This observation clearly indicates size 
variability of genetically identical E11.5–E16.5 M440T/M440T embryos, ranging from a 
spontaneous resorption to a small embryo, which may result from the mixed genetic 
background. In the future, it would be interesting to test whether viable mutant homozygotes 
could be obtained by transferring the Donson M440T mutation onto different genetic 
backgrounds, such as the CD-1 strain.  
Rescue experiments could be performed to gain insight into genetic factors that result 
in increased genomic instability in Donson-deficient mice. Reynolds et al. (2017) demonstrated 
that the severe genome instability observed in DONSON-depleted HeLa cells was due to 
unscheduled nucleolytic processing of damaged replication forks by structure-specific 
nucleases, such as MUS81. Moreover, co-depletion of DONSON and MUS81 was shown to 
partially rescue the spontaneous replication fork asymmetry and increased γH2AX 
phosphorylation of DONSON-depleted cells (Reynolds et al., 2017). MUS81 KO mice were 
previously demonstrated to be viable and develop normally, with cultured MUS81-deficient 
MEFs showing elevated levels of DNA damage, chromosomal aberrations and hypersensitivity 
to DNA crosslinking agents (Dendouga et al., 2005). Therefore, crossing Donson M440T mouse 
line with MUS81 KO mice might potentially rescue embryonic lethality of Donson 
M440T/M440T mice, at the same time confirming the mechanism of pathogenicity caused by 
Donson M440T mutation.  
Additionally, the co-deletion of p53 led to the rescue of microcephaly-associated 
phenotypes in several MPD mouse models, such as ASPM (Williams et al., 2015) and CEP63 
(Marjanović et al., 2015) mice, indicating the importance of p53 in mediating pathogenesis of 
MPD syndromes. Mouse embryonic lethality caused by the inactivation of DNA repair genes, 
such as XRCC4, was also rescued by p53 deficiency due to attenuated cell cycle checkpoint 
control, apoptosis and senescence allowing cells with genomic instability to survive (Bogue et 
al., 1996; Gao et al., 2000; Lim et al., 2000). Thus, the cross between Donson M440T and p53 
KO mouse lines may be another way to rescue lethality of biallelic Donson M440T mutation in 
mice. 
As proposed by Reynolds et al. (2017), DONSON may reduce the number of cells 
generated during development via a failure to maintain replication fork stability in the 
presence of endogenous replication stress, thus explaining the decreased organism size 
observed. The importance of the replication stress response in mammalian development was 
highlighted by the mouse model of Seckel syndrome resulting from ATR deficiency (Murga et 
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al., 2009). ATR-Seckel mice underwent high levels of replication stress during embryonic 
development, demonstrating that ATR signalling is required for efficient resolution of 
endogenous DNA damage in utero (Murga et al., 2009). Moreover, ATR-Seckel-derived MEFs 
showed an increase in γH2AX and 53BP1 foci, indicating an activation of the replication stress-
associated DDR (Murga et al., 2009). Similar to observations by Murga et al. (2009), I showed 
that unperturbed fibroblast cell lines derived from Donson M440T/M440T embryos presented 
with significant increase in the numbers of 53BP1 and γH2AX foci, and a larger proportion of 
them had micronuclei, indicating spontaneously arising genome instability in murine Donson 
M440T/M440T cells, recapitulating the human cellular phenotype associated with DONSON 
deficiency (Reynolds et al., 2017). The Donson M440T mouse line could therefore be further 
used to study the involvement of Donson in stimulating the ATR signalling axis, as well as to 
establish the embryonic development stage and brain areas that are particularly susceptible 
to prenatal replication stress.  
At the moment, it is still not clear at which stage of mammalian embryonic 
development DONSON plays an essential role. Taken together, our data and results obtained 
by Evrony et al. (2017) demonstrate early embryonic lethality of Donson-/- mice, indicating 
their absence at embryonic development stage E9.5 and after. These observations suggest that 
Donson is essential for the initial stages of embryonic development in mice, but further 
analyses are needed to pinpoint the mammalian embryonic development stage that is 


































8.1. Summary of the main findings in this thesis 
 
Variation in size is one of the most striking features in mammals, ranging from a tiny 
bumblebee bat to a large blue whale and representing a weight difference of 75 million fold 
(Oldham et al., 2000). Human height is a classical quantitative trait, highly variable between 
and within populations and affected by multiple genes with small effect sizes (Stulp and 
Barrett, 2016; Visscher, 2008). During development, organ size in humans is tightly controlled 
to ensure the symmetry and maintenance of relative proportions (Wolpert, 2010). It is evident 
that regulation of cell proliferation during embryogenesis plays a major role in determining 
body and organ size, but many aspects of it are still poorly understood. The identification and 
characterisation of genes that, when mutated, cause the most extreme human growth 
phenotypes may provide valuable insights into the molecular mechanisms of cell growth and 
proliferation, as well as physiological regulation of organism growth. In this thesis, functional 
analysis and characterisation of three genes that promote genome stability and are associated 
with microcephalic primordial dwarfism (MPD) is described.  
In our laboratory, novel biallelic mutations in DNA2, encoding an ATP-dependent 
helicase/nuclease with multiple roles in DNA replication and repair (Pawłowska et al., 2017; 
Wanrooij and Burgers, 2015) were identified in four MPD patients. In this thesis, the 
experiments to confirm the deleteriousness of these variants were conducted (Chapter 3). 
Using the minigene splicing assay, I showed that DNA2 transcript splicing is altered in the 
presence of the non-coding mutations identified in MPD patients. Additionally, in silico 
analyses predicted that the identified coding mutation within the ATP binding motif of DNA2 
would strengthen the interaction between DNA2 and the ADP moiety, potentially increasing 
the time the mutant isoform spends in a nucleotide-bound conformation. Collectively, these 
data suggest that mutations in DNA2 lead to diminished DNA2 protein levels and enzymatic 
function, contributing to MPD pathogenesis. 
TRAIP, encoding an E3 ubiquitin ligase (Besse et al., 2007), was previously established 
as an MPD gene by our laboratory and implicated in responding to genotoxic lesions during 
genome replication (Harley et al., 2016). My work was to further investigate and elucidate the 
molecular mechanisms by which TRAIP promotes genome stability in unperturbed and 
damaged cells. A putative role for TRAIP in regulating the activity of protein phosphatase 4 
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(PP4) complex by ubiquitination was analysed (Chapter 4). Biochemical experiments, coupled 
with mass spectrometry analysis of TRAIP-dependent PP4 ubiquitination sites, identified lysine 
183 (K183) of PP4 catalytic subunit PP4C as an important residue for TRAIP-mediated 
ubiquitination in vitro. However, my experimental work did not provide evidence that TRAIP-
mediated PP4C ubiquitination is relevant to its DNA damage response (DDR) function. 
Therefore, RPE1 p53-/- TRAIP-KO cell line was generated using CRISPR/Cas9 genome editing 
technology to facilitate the investigation of the DDR function of TRAIP (Chapter 5). Subsequent 
characterisation of these cells demonstrated the disruption of both TRAIP alleles, and the 
absence of TRAIP protein was associated with the increased frequency of tetraploidy and both 
clonal and non-clonal chromosomal abnormalities in unperturbed cells. DDR signalling analysis 
also revealed the failure of TRAIP-KO cells to properly respond to camptothecin (CPT)-induced 
DNA damage, prompting further investigation of the molecular mechanisms underlying this 
defect (Chapter 6). My experimental work showed that diminished response to CPT-induced 
DNA lesions in TRAIP-KO cells, including reduced RPA2 phosphorylation and ssDNA generation, 
defective HR, and reduced cell survival, was dependent on the proper E3 ubiquitin ligase 
activity of TRAIP. Finally, TRAIP-KO cells were used in epistasis experiments to address the 
potential interplay between TRAIP and Fanconi Anaemia (FA) pathways in interstrand crosslink 
(ICL) repair, based on other groups’ work in Xenopus laevis (personal communication with Prof 
Johannes Walter and Prof David Pellman; Wu, Semlow et al., unpublished). Unexpectedly, my 
data indicated an additive effect of the loss of TRAIP and FANCD2 depletion towards cell 
sensitivity to ICL-inducing agent mitomycin C (MMC), suggesting that TRAIP acts in alternative 
FA pathway-independent processes that contribute to ICL tolerance in mammalian cells. 
Finally, I established a murine model of MPD caused by DONSON deficiency (Chapter 
7), which contained a missense mutation corresponding to a human MPD mutation in this 
replication fork protection factor (Reynolds et al., 2017). Homozygous mice showed embryonic 
lethality after embryonic day 16.5 (E16.5), with mutant embryos being substantially smaller 
than control littermates at all embryonic stages sampled. Additionally, limb abnormalities in 
these embryos were prominent at E16.5, phenocopying human MPD patients with the 
equivalent mutation (Reynolds et al., 2017) and microcephaly-micromelia syndrome (MMS), 
also caused by biallelic mutations in DONSON (Evrony et al., 2017). Furthermore, mouse 
embryonic fibroblasts established from these embryos demonstrated increased levels of 
spontaneous DNA damage, recapitulating the phenotype observed in siRNA-depleted and 
DONSON patient-derived cell lines. This further supports the pathogenicity of the biallelic 
mutations in the DONSON gene. Lastly, the early embryonic lethality of DONSON-null mouse 
289 
 
was observed, occurring before E10.5 and, together with the data obtained by Evrony et al. 
(2017), supporting the essential role for DONSON during early mammalian embryonic 
development. 
Collectively, the experiments described in this thesis strengthen previously observed 
links between DNA2, TRAIP and DONSON and human disease, at the same time providing 
additional insights into cellular and/or developmental roles of these MPD genes in DNA 





8.2. How do mutations in DNA2, TRAIP and DONSON result in MPD? 
 
8.2.1. Similarities in molecular mechanisms by which DNA2, TRAIP and DONSON 
maintain genome stability 
 
 Genes associated with microcephaly and MPD encode proteins that participate in 
several key cellular processes, such as DDR (Harley et al., 2016; O’Driscoll et al., 2003; 
Reynolds et al., 2017), DNA replication (Bicknell et al., 2011a, 2011b; Burrage et al., 2015; 
Fenwick et al., 2016; Guernsey et al., 2011; Vetro et al., 2017), DNA repair (Murray et al., 
2015, 2014; Qvist et al., 2011; Shaheen et al., 2014), centriole biogenesis (Bond et al., 2005; 
Guernsey et al., 2010; Kalay et al., 2011; Leal et al., 2003; Martin et al., 2014), cell division 
(Bond et al., 2002; Jackson et al., 2002, 1998; Martin et al., 2016; Moynihan et al., 2000) and 
mRNA processing (Edery et al., 2011; He et al., 2011) (Section 1.1.2). Although their cellular 
functions are distinct, mutations in these genes are thought to cause disease via convergent 
mechanisms, particularly through prolonged cell cycle and impaired cell division, which 
ultimately affect cell numbers throughout the body and brain (Klingseisen and Jackson, 
2011). Collectively, the three MPD genes investigated in this thesis, DNA2, TRAIP and 
DONSON, have important roles during DNA replication and ATR-dependent S phase 
checkpoint signalling, thus facilitating maintenance of genome stability.  
 
 
8.2.1.1. Roles of DNA2, TRAIP and DONSON in DNA replication 
 
It is possible that similar mechanisms underlie reduced cell proliferation, caused by 
biallelic mutations in DNA2, TRAIP and DONSON, as all three factors were shown to be 
physically associated with ongoing and/or stalled replication forks. A direct interaction 
between DNA2 and replisome protein AND-1 was observed in replicating HeLa cells, 
suggesting that DNA2 is a component of the replisome (Duxin et al., 2012). Moreover, the 
crystal structure of mouse DNA2 demonstrated its association with ssDNA and RPA (Zhou et 
al., 2015), while it was shown to interact with PCNA in human breast epithelial cells (Peng et 
al., 2012). Likewise, TRAIP was also found to associate with the replisome through its 
interaction with PCNA, particularly upon genotoxic stress (Hoffmann et al., 2016; W. Feng et 
al., 2016). Additionally, using nascent chromatin capture (NCC) (Alabert et al., 2014) analysis 
in HeLa cells, Hoffmann et al. (2016) showed that TRAIP is present at nascent, but not 
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mature, chromatin, implicating it as a component of the replication machinery. Finally, 
DONSON was demonstrated to interact with multiple components of the replisome, 
including the MCM complex and PCNA, as well as shown to be enriched at replication forks 
and nascent DNA, compared to mature chromatin (Reynolds et al., 2017). Thus, although no 
direct interaction between DNA2, TRAIP and DONSON has been observed so far, all were 
shown to physically associate with PCNA and replication machinery. The close interaction of 
DNA2, TRAIP and DONSON with the replisome could be expected to facilitate their rapid 
response to endogenously arising DNA damage during embryogenesis, thus ensuring 
efficient cell cycle progression.  
 
 
8.2.1.2. DNA2, TRAIP and DONSON in ATR-dependent S phase checkpoint signalling 
and DNA repair 
 
Unresolved endogenous DNA damage is likely to be the major threat to cell viability 
during embryonic development. My work, alongside published studies, established that 
DNA2, TRAIP and DONSON are required for ATR-dependent S phase checkpoint activation in 
response to endogenous and exogenous replication-associated DNA damage, initiating DDR 
and DNA repair. 
In support to this, the deficiency of all three genes, DNA2, TRAIP and DONSON, was 
observed to result in dysregulated cell cycle. DNA2-depleted U2OS cells (Duxin et al., 2012, 
2009) and patient-derived cell lines with mutations in TRAIP (Harley et al., 2016) and 
DONSON (Reynolds et al., 2017) have prolonged cell cycle and accumulate in S and/or G2 
phase, demonstrating the importance of all three proteins for DNA replication and timely 
cell cycle progression. It is likely that the cell cycle defects seen upon DNA2, TRAIP and 
DONSON depletion are linked to the absence of these proteins at stalled replication forks, 
where they are needed to maintain genome stability by responding to spontaneous DNA 
damage. 
The nucleolytic activity of DNA2 was shown to facilitate HR by resecting DNA ends at 
DSBs (Cejka et al., 2010; Karanja et al., 2012; Nimonkar et al., 2011; Niu et al., 2010; 
Sturzenegger et al., 2014) and promote replication fork restart by degrading reversed 
replication forks (Thangavel et al., 2015). While the involvement of DNA2 in regulating 
replication checkpoint activation in unperturbed cells was demonstrated to be dependent 
on both its nuclease and helicase enzymatic activities (Duxin et al., 2012), Karanja et al. 
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(2012) and Thangavel et al. (2015) showed that DNA end resection activity of DNA2 is 
specifically involved in ATR-dependent checkpoint activation under conditions of replication 
stress. DNA2 and exonuclease 1 (EXO1) were demonstrated to play redundant roles in DNA 
end resection at CPT-induced replication-associated DSBs, as indicated by diminished levels 
of CPT-induced pRPA2-S4/S8 signal, RPA foci and pCHK1-S345 levels upon the depletion of 
both factors in U2OS cells (Karanja et al., 2012). Additionally, DNA2 was required for RPA2 
phosphorylation after exposure to DNA crosslinking agent cisplatin, implicating DNA2 in ICL 
repair (Karanja et al., 2012). DNA2-depleted U2OS cells also accumulated unrepaired CPT- 
and cisplatin-induced DSBs, as indicated by increased frequency of chromatid breaks in 
metaphase chromosome spreads (Karanja et al., 2012). Finally, DNA2 was shown to 
physically interact with and function downstream of FANCD2, as well as participate in HDR 
in vivo (Karanja et al., 2012).  
Requirement for TRAIP to promote DDR signalling at damaged replication forks was 
noted by multiple studies (Harley et al., 2016; Hoffmann et al., 2016; W. Feng et al., 2016). 
Additionally, karyotypes of unperturbed TRAIP-KO cells demonstrated accumulation of high 
levels of chromosomal instability (Section 5.3), indicating the importance of TRAIP in 
responding to endogenous replication stress as well. Like DNA2, TRAIP may have a role in 
DNA end resection, as indicated by my experimental work (Chapter 6) showing that the loss 
of TRAIP and its E3 ligase activity result in reduced pRPA2-S4/S8 signal upon CPT treatment, 
as well as defective ssDNA production (also demonstrated by Hoffmann et al., 2016). In 
constrast to DNA2, TRAIP most likely affects DNA end resection indirectly through facilitating 
processes at replication fork that result in the formation of RPA-coated ssDNA regions, such 
as ubiquitination of replication fork-associated proteins and/or DNA repair factors. 
Nevertheless, these findings implicate ligase activity of TRAIP in facilitating ATR-dependent 
checkpoint signalling by promoting DNA end resection in response to CPT-induced 
replication-associated DNA damage. TRAIP was also shown to be necessary for efficient DDR 
signalling, genome stability and cell survival after HU- (W. Feng et al., 2016) and MMC-
induced DNA damage (Chapter 6; Hoffmann et al., 2016). Although no evidence implicating 
TRAIP and FANCD2 in the same ICL repair pathway was found in human cells (Section 6.2.3), 
the importance of TRAIP after MMC-induced DNA damage (Section 6.2.2; Hoffmann et al., 
2016) points to its potential involvement in facilitating ICL repair via mechanism that is yet 
to be established, potentially by promoting ATR-dependent S phase checkpoint signalling, 
DNA end resection and/or HR. However, in contrast to the subtle reduction in MMC-induced 
pCHK1-S345 and γH2AX signal observed by Hoffmann et al. (2016), my data suggested that 
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MMC treatment-induced CHK1 and H2AX phosphorylation is not significantly altered in 
TRAIP-KO cells (Section 6.2.2). As my results also showed that MMC-induced HR is not 
affected in TRAIP-KO cells (Section 6.2.2), it is more likely that TRAIP promotes MMC-ICL 
repair in a different manner, independent of ATR signalling. 
Similar to TRAIP and DNA2, DONSON was shown to promote the ATR-dependent 
replication stress response and stabilise replication forks both upon spontaneous stalling and 
after exogenous DNA damage, as demonstrated by inefficient HU- or MMC-induced RPA2 
and CHK1 phosphorylation in DONSON-depleted HeLa cells (Reynolds et al., 2017). However, 
DONSON depletion led to increased levels of RPA-coated ssDNA following replication stress 
(Reynolds et al., 2017), suggesting that unlike TRAIP or DNA2, DONSON is not required for 
DNA end resection but rather facilitates downstream steps of the ATR-dependent replication 
stress response activation. DONSON-deficient HeLa cells also exhibited spontaneous genome 
instability, further exacerbated by HU and MMC treatment (Reynolds et al., 2017). In support 
to this, DONSON MPD mouse model showed increased levels of unrepaired endogenous DNA 
damage, as indicated by elevated levels of 53BP1 and γH2AX foci and micronuclei (Chapter 
7). Similarly, spontaneously arising genome instability that was further aggravated by 
exogenous DNA damaging agents was observed in DNA2-deficient (Duxin et al., 2012, 2009; 
Karanja et al., 2012) and TRAIP-deficient cells (Chapters 5–6), demonstrating that all three 
proteins analysed in this thesis have important cellular roles that prevent accumulation of 
DNA damage and ensure genome stability.  
Overall, DNA2, TRAIP and DONSON are required for efficient resolution of 
replication-associated DNA damage and proper ATR-dependent S phase checkpoint 
activation, and deficiency of each of these factors results in impaired DDR signalling, genome 
instability and reduced cell survival. Consistent with these three genes being essential for 
cell survival, MPD-associated mutations in DNA2, TRAIP and DONSON were shown to cause 
reduced protein levels (Harley et al., 2016; Reynolds et al., 2017; Shaheen et al., 2014), likely 
resulting in insufficient levels of functional protein needed for efficient cellular response to 
endogenous replication stress and DNA damage. It remains to be defined whether these 
three factors are involved in the same process or pathway to promote genome stability, or 
whether their roles converge on a certain downstream outcome, such as dissipation of 
replication stress. Notably, depletion of all three proteins investigated in this thesis also 
appears to be linked to defective ICL repair and/or signalling of DNA damage induced by DNA 
crosslinking agents. The FA-like limb anomalies observed in humans and mice with DONSON 
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mutations (Reynolds et al., 2017; Chapter 7) suggest that the clinical phenotype caused by 
DONSON deficiency could be considered a variation of FA. However, no limb abnormalities 
or radial ray defects were observed in DNA2 or TRAIP patients (Chapter 3; Shaheen et al., 
2014; Harley et al., 2016) and none of the three genes were associated with bone marrow 
failure, one of the key characteristics of the FA syndrome (Ceccaldi et al., 2012). Additionally, 
my experiments did not show TRAIP to be epistatic with FANCD2, a key component of the FA 
pathway, in ICL repair (Section 6.2.3). Nevertheless, results obtained using X. laevis egg 
extracts suggested that TRAIP plays a major role in ICL repair (Wu, Semlow et al., 
unpublished; Section 6.2.1), and DNA2 was demonstrated to physically interact with FANCD2 
in human cells (Karanja et al., 2012). Therefore, in the future, it remains of interest to further 
elucidate the potential link between mutations in DNA2, TRAIP and DONSON and 
dysfunctional ICL repair. 
 
 
8.2.2. Determination of brain size through regulation of mitosis and replication 
stress-induced cell death 
 
For many years, mice have been used in biomedical research based on their genetic 
and physiological similarities with humans, providing an invaluable tool to study 
development of human diseases (Perlman, 2016). Disruption of DNA2 (Lin et al., 2013), TRAIP 
(Park et al., 2007) and DONSON (Chapter 7; Evrony et al., 2017) confers embryonic lethality 
in mice, reiterating the importance of all three genes for mammalian embryonic 
development. The prenatal development of the mammalian brain appears to be particularly 
susceptible to perturbations in cell division, with alterations in neural progenitor cell 
proliferation, differentiation and apoptosis being important contributors to the final cell 
number and the emergence of microcephaly (Chenn and Walsh, 2002; Klingseisen and 
Jackson, 2011; Kuida et al., 1998; Roth et al., 2000). Although the length of G1 phase is 
modulated throughout murine neuronal cytogenesis by extrinsic and intrinsic mechanisms, 
the length of S phase or combined G2/M phase remains constant (Takahashi et al., 1995). 
This could suggest a crucial role for the timely completion of DNA replication and cell division 
within the specific time frame to ensure unperturbed regulation of cell numbers.  
Although many microcephaly and MPD genes are ubiquitously expressed, the 
developing brain is exceptionally sensitive to mutations in these genes. It was proposed that 
in most developing tissues, reduced cell proliferation and cell number can be counteracted 
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by alternative compensatory mechanisms, which are not available in the developing brain 
due to the strict lineage control pathways (Homem et al., 2015; Malatesta et al., 2000). 
Additionally, rapid cell proliferation was suggested to cause high levels of DSBs, observed in 
mammalian embryonic brain (Barazzuol and Jeggo, 2016), and mutations in some MPD genes 
may hinder the repair of those DNA lesions (Section 1.1.2).  
Several pathways are thought to result in slower cell cycle and cell loss during brain 
development in utero, including aberrant mitosis and defective resolution of DNA damage. 
Mouse models of MPD caused by mutations in centrosomal genes CENPJ (McIntyre et al., 
2012) and CEP63 (Marjanović et al., 2015) highlighted the importance of p53-dependent 
neural progenitor cell death, induced by mitotic errors during embryonic development, for 
the observed reduction in brain size. Additionally, CDK5RAP2 mice exhibited impaired 
mitotic progression and abnormal mitotic spindle orientation, as well as increased apoptosis 
in neuronal progenitor cells (Lizarraga et al., 2010). Furthermore, ASPM deficiency in mouse 
neural progenitor cells led to alterations in division orientation and cell cycle exit kinetics 
(Williams et al., 2015). Overall, centrosome defects caused by mutations in centrosomal 
MPD genes would be expected to affect neurogenesis through mis-positioned spindles, thus 
influencing the early symmetric divisions required for expansion of neuroepithelial cells 
before neurogenesis (Homem et al., 2015). Moreover, further strengthening the link 
between reduction in brain size and disrupted mitosis, hypomorphic NCAPD2 mice displayed 
increased levels of anaphase chromatin bridges in apical neural progenitor cells during 
neurogenesis, indicating dysfunctional sister chromatid separation (Martin et al., 2016). As 
this can lead to chromosome segregation errors and increased aneuploidy in daughter cells, 
this study implicated aberrant mitosis as a key mechanism for the microcephaly phenotype 
observed in these mutant mice. 
Prevention of replication stress and DNA damage in neural progenitor cells is also 
important for normal brain development (Alt et al., 2017; Eguren et al., 2013; McKinnon, 
2017). One of the main sources of replication stress during embryonic development is 
unrepaired DNA lesions, resulting from by-products of cellular metabolism (Zeman and 
Cimprich, 2014). Normal cellular metabolism produces reactive oxygen species (ROS), which 
can result in various oxidised DNA base lesions, such as 8-oxo-2’-deoxyguanosine, that need 
to be removed by base excision repair (BER) or nucleotide excision repair (NER) pathways 
(Cooke et al., 2003). Additionally, naturally produced reactive aldehydes, arising during 
alcohol metabolism (Brooks and Theruvathu, 2005; Langevin et al., 2011) or histone 
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demethylation (Shi et al., 2004), may represent the primary endogenous source of 
replication stress, ICLs and DNA-protein crosslinks (Barker et al., 2005; Cheng et al., 2003; 
Stein et al., 2006; Wang et al., 2000). It is therefore crucial that cellular pathways required 
for signalling and repair of such endogenous DNA damage are intact.  
The importance of the efficient resolution of endogenous replication stress in utero 
was exemplified by the ATR-Seckel mouse model, which underwent high levels of replication 
stress during embryogenesis (Murga et al., 2009). As ATR provides a key genome 
maintenance function in S phase (Brown and Baltimore, 2003) and its complete knockout is 
embryonic lethal in mice (de Klein et al., 2000), the Seckel syndrome-associated ATR 
mutation (O’Driscoll et al., 2003), resulting in a severely hypomorphic ATR protein, was used 
to generate a viable mammalian model to study the developmental function of this kinase 
(Murga et al., 2009). ATR-Seckel mice were born at a sub-mendelian ratio with severe overall 
dwarfism and microcephaly already evident at birth, as well as Seckel syndrome-associated 
characteristics such as an undersized jaw (Murga et al., 2009). All Seckel mice died before 40 
weeks of age, displaying several phenotypes associated with ageing, including hair graying, 
osteoporosis, fat accumulation in the bone marrow, decreased density of hair follicles and a 
thinner epidermis, indicating the development of a progeroid syndrome in Seckel mice 
(Murga et al., 2009). This is in contrast to human MPD patients with mutations in ATR, where 
a progeroid phenotype is not reported (Goodship et al., 2000). Mouse embryonic fibroblasts 
derived from the mutant mice showed increased accumulation of cells in G2 phase, as well 
as elevated numbers of cells with pan-nuclear γH2AX staining, consistent with an activation 
of the replication stress-associated DDR (Murga et al., 2009). Moreover, the mutant cells also 
showed an increase in 53BP1 foci and higher frequency of chromosomal breakage, indicating 
replication fork collapse and accumulation of DSBs (Murga et al., 2009). 
Massive cell death of post-mitotic neurons during cortical development, reported in 
the XRCC4 and LIG4 knockout mice (Gao et al., 1998), may also be explained by a particular 
sensitivity of the developing brain to unrepaired DSBs. Considering the function of DNA2, 
TRAIP and DONSON in maintaining genome stability (Chapters 5–7; Duxin et al., 2009, 2012; 
Karanja et al., 2012; Harley et al., 2016; Hoffmann et al., 2016; W. Feng et al., 2016; Reynolds 
et al., 2017), it is likely that all of them are essential for cellular response to replication stress 
and endogenous DNA damage arising during embryogenesis, with their absence resulting in 
prolonged cell cycle and emergence of DSBs due to unrepaired DNA lesions. Consequently, 
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this would lead to slow proliferation, reducing total cell number, and elevated numbers of 
cells eliminated by apoptosis during embryogenesis, resulting in a smaller organism. 
The coordination between genome duplication, cell cycle and mitotic progression is 
particularly important for the maintenance of genome stability, as unresolved replication 
stress can give rise to under-replicated DNA or problematic DNA structures that may persist 
into mitosis and delay or hinder chromosome segregation, eventually resulting in the gains 
or losses of genetic material (Burrell et al., 2013; Chan et al., 2009; Fragkos and Naim, 2017; 
Naim and Rosselli, 2009; Terradas et al., 2010). Thus, increased replication stress and 
emergence of mitotic problems may be closely interlinked in terms of MPD development, 
with both leading to the similar phenotypes at the cellular and organismal level. Collectively, 
several murine models of congenital human brain size disorders suggest that aberrant 
mitosis, lost self-renewal capacity, premature differentiation and defective resolution of 
DNA damage, which lead to p53-mediated apoptosis of neural progenitor cells, are the major 
causes of reduced brain size in mammals. The co-deletion of p53 often led to the rescue of 
microcephaly-associated phenotypes (Gao et al., 2000; Marjanović et al., 2015; Williams et 
al., 2015), indicating the importance of p53 in mediating pathogenesis of MPD syndromes. 
In contrast to this, a study by Murga et al. (2009) described synthetic lethality between ATR 
and p53, with the loss of both factors greatly exacerbating the microcephaly phenotype, 
replication stress and cell death. The authors suggested that faster replication kinetics may 
be achieved in the absence of p53, leading to the increased accumulation of replication stress 
when ATR signalling is compromised. This exemplifies that distinct molecular mechanisms 
may well underlie different growth reduction syndromes. Therefore, to further delineate the 
molecular mechanisms by which mutations in DNA2, TRAIP and DONSON cause severe 
reduction in growth, crosses between mice deficient in these proteins and p53-null mice 
would be particularly informative. 
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8.3. Future work and outstanding questions 
 
Although this thesis contributes to our current understanding of the importance of 
DNA2, TRAIP and DONSON in DNA replication and repair, there are outstanding questions 
remaining, particularly regarding the links between the cellular function of these proteins and 
human disease.  
The work described here suggested that MPD-associated mutations in DNA2 have an 
effect on its transcript splicing and ATPase activity (Chapter 3). However, I was unable to assess 
DNA2 protein levels in cells with patient mutations, either engineered using CRISPR/Cas9 
technology or obtained from patients, and it will be important to do so in the future. Reduced 
DNA2 protein levels would suggest that both non-coding and coding mutations identified in 
MPD patients likely reduce all enzymatic activities of DNA2. Additionally, biochemical analysis 
of DNA2 protein containing patient mutation p.T655A is necessary to assess whether, as 
predicted, DNA2 ATP-dependent motor function is dysregulated in the presence of this 
alteration, and whether its nuclease activity and overall protein stability are affected. Such 
experiments would provide more support for the interplay between nuclease and 
ATPase/helicase activities of DNA2, as well as the importance of the ATPase/helicase function 
for efficient cell proliferation. Although DNA2 nucleolytic function is well-established (Cejka et 
al., 2010; Karanja et al., 2012; Nimonkar et al., 2011; Niu et al., 2010; Sturzenegger et al., 2014), 
its ATP-dependent helicase domain was only recently implicated in maintaining genomic 
stability in human cells (Duxin et al., 2012) and, using in vitro experiments, proposed to 
promote efficient DNA end resection by mediating ssDNA translocation (Levikova et al., 2017; 
Miller et al., 2017). Collectively, these studies suggest that ssDNA translocation is the main 
function of the DNA2 ATPase/helicase domain in human cells, required to prevent genomic 
instability. In the future, cell-based experiments will be required to confirm this hypothesis and 
elucidate the mechanisms leading to genomic instability in the absence of this DNA2 activity.  
 Recent studies on the involvement of TRAIP in DDR (Harley et al., 2016; Hoffmann et 
al., 2016; Soo Lee et al., 2016; W. Feng et al., 2016), as well as the work described in this thesis 
(Chapter 5–6), established it as a new component of DDR signalling in response to several 
exogenous DNA damaging agents. However, the identity of TRAIP substrate(s) at stalled 
replication forks (discussed in Section 6.3) and the exact DNA structures at which TRAIP acts 
remain to be established. TRAIP  appears to predominantly respond to replication-associated 
DNA damage at stalled replication forks, induced by cell treatments with UV, CPT, MMC and 
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HU (Chapter 6; Harley et al., 2016; Hoffmann et al., 2016; W. Feng et al., 2016), whereas TRAIP 
function at ionising radiation (IR)-induced DNA lesions was reported only by a single study (Soo 
Lee et al., 2016). Failure to stabilise stalled replication forks can lead to their collapse, giving 
rise to one-ended DSBs, which are structurally distinct from the two-ended DSBs induced by 
IR (Chapman et al., 2012). Moreover, distinct cellular mechanisms are required to sense and 
repair these different types of lesions (Pardo et al., 2009). My work demonstrated distinct 
cellular phenotypes to specific forms of DNA damage (Chapters 5–6), and therefore further 
investigation will be needed to determine whether TRAIP promotes DDR at distinct DNA 
lesions via the same mechanism, or whether it is a multi-functional protein that participates in 
more than one DDR signalling pathway. As biallelic TRAIP mutations were linked to severe 
prenatal-onset reduction in human growth (Harley et al., 2016), the importance of TRAIP at 
signalling endogenous DNA lesions, encountered by cells during embryogenesis, will also need 
to be assessed, with both oxidative and aldehyde-mediated lesions being stong candidates 
(Cooke et al., 2003; Langevin et al., 2011). 
 More is currently known about the involvement of DNA2 and TRAIP in maintaining 
genome stability than about the cellular role of DONSON. Mutations in DONSON were only 
recently implicated in the pathogenesis of two distinct human growth retardation syndromes: 
MPD (Reynolds et al., 2017) and microcephaly-micromelia syndrome (MMS) (Evrony et al., 
2017). Human patients described in these studies, together with the DONSON mouse model 
(Chapter 7), suggest particular sensitivity of mammalian limb development to DONSON 
deficiency, which is not commonly observed in other MPD-associated disorders. However, limb 
abnormalities are also associated with other DNA replication disorders, characterised by short 
stature, such as RAPADILINO syndrome (Siitonen et al., 2003), and ICL repair disorders as 
Fanconi Anaemia (FA) (Triemstra et al., 2015). It will therefore be important to understand 
whether the absence of DONSON and other DNA replication and genome stability proteins 
lead to limb anomalies through similar or distinct molecular mechanisms.  
To link mutations in DONSON to disrupted human growth, Reynolds et al. (2017) 
proposed that biallelic DONSON mutations render cells unable to stabilise replication forks and 
efficiently deal with endogenous replication stress during key stages of embryonic 
development, thus leading to cell death and reducing the final number of cells in an organism 
(Figure 1.17). Brain development is particularly sensitive to disruptions in DNA replication, 
since rapid expansion of neural progenitor cell population has to be achieved within a specific 
developmental time frame (Takahashi et al., 1995). This observation may explain why the 
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reduction in head size is much more pronounced in DONSON patients than the reduction in 
height. In the future, additional studies will be necessary to pinpoint the molecular mechanism 
by which DONSON promotes the stability of replication forks and activation of cell cycle 
checkpoints. Moreover, clarification of whether DONSON is directly involved in regulating ATR-
CHK1 pathway will be needed. As DONSON-depleted cells were proficient at generating RPA-
coated ssDNA (Reynolds et al., 2017), their capacity to initiate activation of the ATR pathway 
seemed unchanged, suggesting that DONSON may be involved in indirectly stimulating the ATR 
signalling axis. Additionally, investigating whether DONSON-deficient mice, similarly to the 
ATR-Seckel mice (Murga et al., 2009), exhibit elevated levels of replication stress in utero could 
provide further support for DONSON being a novel factor in the ATR–CHK1 replication stress 
response. 
In summary, my work has confirmed DNA2 to be a human disease gene conferring 
microcephalic primordial dwarfism phenotype, extended our knowledge on cellular roles of 
TRAIP, and established a developmental murine model for DONSON. Given the strong 
phenotypic links at both organismal and cellular levels between the three genes, future studies 
will be important for demonstrating whether the proteins encoded by these genes also 



































Appendix 1. Oligonucleotides 
 
a) Oligonucleotides used for generating minigene plasmids 
 
Oligo 
nucleotide Sequence (5'-3') Description 
dna2-SalI-
int10-F TTTAATAGCTAGTCGACGGCCCATTCATTCATTCTTTTAGC 
Forward primer to clone DNA2 
exon 10, intron 11, exon 12, 
intron 12 and exon 13 into 





Reverse primer to clone DNA2 
exon 10, intron 11, exon 12, 
intron 12 and exon 13 into 
into RHCglo plasmid 
dna2-SalI-
5utr-F ACGCGTCGACCATTTGGGACATCTGCGGG 
Forward primer to clone DNA2 
exon 1, intron 1 and exon 2 
into RHCglo plasmid 
dna2-XbaI-
int2-R CTAGTCTAGACCCTTAAGATTCAAATCGGTG 
Reverse primer to clone DNA2 
exon 1, intron 1 and exon 2 
into RHCglo plasmid 
 
b) Oligonucleotides used for generating polycistronic PP4-expressing plasmids 
 
Oligo 




















































c) Oligonucleotides used for sequencing of minigene plasmids 
 
Oligo 
nucleotide Sequence (5'-3') Description 
RHCglo-F GCAGTTGGATGCTTTCCCCC Forward primer to amplify the 5' of the RHCglo insert 
RHCglo-R GATGCGGCCCTGAAGTTGTTC Forward primer to amplify the 3' of the RHCglo insert 
dna2-ex11-F TTGTCGGTCCTTCCAGAATC Forward primer to to amplify the DNA2 ex11-int11-ex12-int12-ex13 insert in the RHCglo plasmid 
dna2-ex13-R CATCGCTTGCCTCTGAGGC Reverse primer to to amplify the DNA2 ex11-int11-ex12-int12-ex13 insert in the RHCglo plasmid 
dna2-int1a-R TGCTCGGCGAGGGAGAGTC Reverse primer to amplify the first part of the DNA2 ex1-int1-ex2 insert in the RHCglo plasmid 
dna2-int1b-F CCTGCCTCCCAAGGTGTTC Forward primer to amplify the second part of the DNA2 ex1-int1-ex2 insert in the RHCglo plasmid 
dna2-int1c-R CGCAAGATTGGCTATGATGCC Reverse primer to amplify the second part of the DNA2 ex1-int1-ex2 insert in the RHCglo plasmid 
dna2-int1d-F GAGGGACTTTTGCGTTTGGGC Forward primer to amplify the third part of the DNA2 ex1-int1-ex2 insert in the RHCglo plasmid 
dna2-int1e-R CACTGAAAGTCCTATCATGAGCC Reverse primer to amplify the third part of the DNA2 ex1-int1-ex2 insert in the RHCglo plasmid 
dna2-int1f-F CCGGCATTACTTTAGCAGGTTG Forward primer to amplify the fourth part of the DNA2 ex1-int1-ex2 insert in the RHCglo plasmid 
dna2-int1g-R GAGCAAAGACACAGAAGAATTCC Reverse primer to amplify the fourth part of the DNA2 ex1-int1-ex2 insert in the RHCglo plasmid 
dna2-int1h-F GTTTGAAATGGCATTACTTCTGG Forward primer to amplify the fifth part of the DNA2 ex1-int1-ex2 insert in the RHCglo plasmid 
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d) Oligonucleotides used for sequencing of polycistronic PP4 plasmids 
 
Oligo 
nucleotide Sequence (5'-3') Description 
PP4C 1 F ATGGCGGAGATCAGCGACC Forward primer to sequence the first part of PP4C insert in pGEX-6P-1-PP4C 
PP4C 1 R CGAACCTTAAGTGCCAGCAG Reverse primer to sequence the first part of PP4C insert in pGEX-6P-1-PP4C 
PP4C 2 F GACCGTGGCTTCTATAGCG Forward primer to sequence the second part of PP4C insert in pGEX-6P-1-PP4C 
PP4C 2 R CGTTGAACTGGGCCACCAC Reverse primer to sequence the second part of PP4C insert in pGEX-6P-1-PP4C 
PP4C 3 F GGAGCCGGCTACCTATTTG Forward primer to sequence the third part of PP4C insert in pGEX-6P-1-PP4C 
PP4C 3 R TCACAGGAAGTAGTCGGCC Reverse primer to sequence the third part of PP4C insert in pGEX-6P-1-PP4C 
PP4R2 1 F ATGGACGTCGAGAGGCTCC Forward primer to sequence the first part of PP4R2 insert in pGEX-6P-1-PP4C-PP4R2 
PP4R2 1 R GACCTCTTGGCTCAGGAGC Reverse primer to sequence the first part of PP4R2 insert in pGEX-6P-1-PP4C-PP4R2 
PP4R2 2 F GTCGAATATATTCCCTTTGATG 
Forward primer to sequence the second part of PP4R2 
insert in pGEX-6P-1-PP4C-PP4R2 
PP4R2 2 R GTCTGTGCTCTCAGGCAAC Reverse primer to sequence the second part of PP4R2 insert in pGEX-6P-1-PP4C-PP4R2 
PP4R2 3 F GGCCACTTAATCGACCAAAG Forward primer to sequence the third part of PP4R2 insert in pGEX-6P-1-PP4C-PP4R2 
PP4R2 3 R GTGCTGCCGGGTACAACG Reverse primer to sequence the third part of PP4R2 insert in pGEX-6P-1-PP4C-PP4R2 
PP4R2 4 F GGTAGGAGAAACAGAAGCATC 
Forward primer to sequence the fourth part of PP4R2 
insert in pGEX-6P-1-PP4C-PP4R2 
PP4R2 4 R TTAGTCTTGTTCCATTGGTTCAT 
Reverse primer to sequence the fourth part of PP4R2 
insert in pGEX-6P-1-PP4C-PP4R2 
PP4R3α 1 F ATGACCGACACCCGGCGG Forward primer to sequence the first part of PP4R3α insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 1 R CACGACGAAGAGGTGAAGG Reverse primer to sequence the first part of PP4R3α insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 2 F GCTTAGAATTGCCATCTTGTG Forward primer to sequence the second part of PP4R3α insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 2 R GAGTTGGTAGAACCATATCTTG 
Reverse primer to sequence the second part of PP4R3α 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 3 F CATCAGACATACAGAGTTCAG 
Forward primer to sequence the third part of PP4R3α 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 




nucleotide Sequence (5'-3') Description 
PP4R3α 4 F CAGCTTATGGGCCTGCTTC Forward primer to sequence the fourth part of PP4R3α insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 4 R CATCTCTATTATGGCAGAGTTC 
Reverse primer to sequence the fourth part of PP4R3α 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 5 F GAACCAGTAGTGAAAGCATTTC 
Forward primer to sequence the fifth part of PP4R3α 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 5 R GTTAGTCTTCGTTCCACTGG Reverse primer to sequence the fifth part of PP4R3α insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 6 F GCAGAGCCCAAGTTTCAAGC Forward primer to sequence the sixth part of PP4R3α insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3α 6 R TTATGAATCAAATTTTGCTTTCTTT 
Reverse primer to sequence the sixth part of PP4R3α 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3α 
PP4R3β 1 F ATGTCGGATACGCGGCGG Forward primer to sequence the first part of PP4R3β insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 1 R GCTTGGAACAGCTGCAATAG Reverse primer to sequence the first part of PP4R3β insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 2 F CTCTCCTCACCTATCCGTAG Forward primer to sequence the second part of PP4R3β insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 2 R GCCCATTACAATTTCAAGAGC Reverse primer to sequence the second part of PP4R3β insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 3 F GGAGTTTTGTGCATTTTCTCAG 
Forward primer to sequence the third part of PP4R3β 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 3 R CCACACAAAATGTGAGTAACTC 
Reverse primer to sequence the third part of PP4R3β 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 4 F CAAACAGCACAGCTACTTGC Forward primer to sequence the fourth part of PP4R3β insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 4 R CCAGGAGATGTCCTTTTGGG Reverse primer to sequence the fourth part of PP4R3β insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 5 F CCTAAGCCAGAAGATGATTTTC 
Forward primer to sequence the fifth part of PP4R3β 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
PP4R3β 5 R TTATGAGCCAAGACGAGGTCT 
Reverse primer to sequence the fifth part of PP4R3β 
insert in pGEX-6P-1-PP4C-PP4R2-PP4R3β 
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e) Oligonucleotides used for screening of CRISPR/Cas9 cell lines 
 
Oligonucleotide Sequence (5'-3') Description 
DNA2ex1-F CATTTGGGACATCTGCGG 
Forward primer to amplify DNA2 regions 
surrounding c.74+4A>C (ex1-int1 junction) (use 
together with dna2-int1_scr-R primer; product size 
for WT: 382 bp) 
dna2-int1_scr-R GAACACCTTGGGAGGCAG 
Reverse primer to amplify DNA2 regions 
surrounding c.74+4A>C (ex1-int1 junction) (use 
together with dna2ex1-F primer; product size for 
WT: 382 bp) 
DNA2ex13-F AGACTTGGATAGAGACTGCTTTTC 
Forward primer to amplify DNA2 regions 
surrounding c.1963A>G (ex13) (use together with 
dna2-int13_scr-R primer; product size for WT: 312 
bp) 
dna2-int13_scr-R GACACTGAATTAAAATTCAGCCC 
Reverse primer to amplify DNA2 regions 
surrounding c.1963A>G (ex13) (use together with 
dna2ex13-F primer; product size for WT: 312 bp) 
hDNA2-F2 CTGTCTACAGTTTGCGATCC 
Forward primer to amplify DNA2 regions 
surrounding c.74+4A>C (ex1-int1 junction) (use 
together with hDNA2-R2 primer; product size for 
WT: 305 bp) 
hDNA2-F3 CCCTGCTGCTCAGGTGAG 
Forward primer to amplify DNA2 regions 
surrounding c.74+4A>C (ex1-int1 junction) (use 
together with hDNA2-R2 primer; product size for 
WT: 476 bp) 
hDNA2-R2 CAGGCTCTGGCTGAATGTG 
Reverse primer to amplify DNA2 regions 
surrounding c.74+4A>C (ex1-int1 junction) (use 
together with hDNA2-F2 or hDNA2-F3 primer; 
product size for WT: 305 bp and 476 bp, 
respectively) 
hTRAIP-ex1-F GTTGTCACTTCCGGCCCG 
Forward primer to amplify TRAIP exon 1 (use 
together with hTRAIP-ex1-R primer; product size 
for WT: 277 bp) 
hTRAIP-ex1-R GGTACCCGGGCAAACACC 
Reverse primer to amplify TRAIP exon 1 (use 
together with hTRAIP-ex1-F primer; product size 
for WT: 277 bp) 
mDonson-F2 CCTCTGTGAGCTACTTTTGC 
Forward primer to genotype mDonson regions 
surrounding M440T (use together with mDonson-
R2 primer; product size for WT: 337 bp) 
mDonson-R2 GTAGTCTATGTCCAGGACAG 
Reverse primer to genotype mDonson regions 
surrounding M440T (use together with mDonson-








f) Oligonucleotides used for site-directed mutagenesis of minigene plasmids 
 





Forward primer to introduce c.1764-
1A>G mutation in the splice acceptor site 





Reverse primer to introduce c.1764-
1A>G mutation in the splice acceptor site 
of DNA2 intron 11 
dna2-c.74+1G>A F CTGCCGGCGGAGCTATGAGCGGAGAGGG 
Forward primer to introduce c.74+1G>A 
mutation in the splice donor site of DNA2 
intron 1 
dna2-c.74+1G>A R CCCTCTCCGCTCATAGCTCCGCCGGCAG 
Reverse primer to introduce c.74+1G>A 
mutation in the splice donor site of DNA2 
intron 1 
 
g) Oligonucleotides used for site-directed mutagenesis of polycistronic PP4 
plasmids 
 
Oligonucleotide Sequence (5'-3') Description 
PP4C-K26R-K31R 
F GAAGTCAGGGCCCTGTGCGCTAGGGCCAG 
Forward primer to introduce 




Reverse primer to introduce 
K26R and K31R substitutions in 
PP4C 
PP4C-K63R F GACAATTCTATGACCTCAGAGAGCTGTTCAGAGTAGG Forward primer to introduce K63R substitutions in PP4C 
PP4C-K63R R CCTACTCTGAACAGCTCTCTGAGGTCATAGAATTGTC Reverse primer to introduce K63R substitutions in PP4C 
PP4C-K21R F CTGCGAGCTCATCAGGGAGAGCGAAGTC Forward primer to introduce K21R substitutions in PP4C 
PP4C-K21R R GACTTCGCTCTCCCTGATGAGCTCGCAG Reverse primer to introduce K21R substitutions in PP4C 
PP4C-K183R F GACAATCGACCGAAGGCAAGAGGTGCCTC Forward primer to introduce K183R substitutions in PP4C 








h) Oligonucleotides used for site-directed mutagenesis of TRAIP 
 
Oligonucleotide Sequence (5'-3') Description 
TRAIP-W37A F GCAGTGCCTAATTCAGGCGTTTGAGACAGCACCAAG Forward primer to introduce W37A substitution in TRAIP 
TRAIP-W37A R CTTGGTGCTGTCTCAAACGCCTGAATTAGGCACTGC Reverse primer to introduce W37A substitution in TRAIP 
 
i) Oligonucleotides used for RT-PCR analysis of minigene plasmids 
 
Oligonucleotide Sequence (5'-3') Description 
RSV5U CATTCACCACATTGGTGTGC Forward primer in the artificial exon of RHCglo to detect splicing alterations of minigenes 
RTRHC GGGCTTTGCAGCAACAGTAAC Reverse primer in the artificial exon of RHCglo to detect splicing alterations of minigenes 
dna2-ex11-F TTGTCGGTCCTTCCAGAATC Forward primer to detect splicing alterations in the DNA2 intron 11 minigene 
dna2-ex13-R CATCGCTTGCCTCTGAGGC Reverse primer to detect splicing alterations in the DNA2 intron 11 minigene 
 
j) Oligonucleotides used for RT-PCR analysis of mDonson transcript 
 
Oligonucleotide Sequence (5'-3') Description 
mDonson-ex7F GCTGGAAGAGATAGGCGTG Forward primer in exon 7 of mDonson to detect splicing alterations 
mDonson-ex9R CAAACTAAACTTATCTCTGTATC Reverse primer in exon 9 of mDonson to detect splicing alterations 
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Appendix 2. Antibodies 
 
a) Primary antibodies 
 
Antibody Species Dilution for WB or IF Reference 
53BP1 Rabbit 1:2,000 (WB, IF) Novus Biologicals, NB100-904 
BRCA1 (C-20) Mouse 1:200 (WB) Santa Cruz Biotechnology, sc-642 
BrdU (BU1/75 ICR1) Rat 1:500 (IF) Abcam, ab6326 
CHK1 (G-4) Mouse 1:250 (WB) Santa Cruz Biotechnology, sc-8408 
phospho-CHK1 (S345) Rabbit 1:500 (WB) Cell Signaling, 2341 
FANCD2 (FI17) Mouse 1:500 (WB) Santa Cruz Biotechnology, sc-20022 
phospho-H2AX (S139) Mouse 1:1,000 (WB) Millipore, 05-636 
phospho-H2AX (S139) Rabbit 1:2,000 (IF) Cell Signaling, 9718 
H2A Rabbit 1:5,000 (WB) Millipore, 07-146 
Lamin B1 Rabbit 1:20,000 (WB) Abcam, ab16048 
PCNA (PC10) Mouse 1:800 (WB) Santa Cruz Biotechnology, sc-56 
PP4C Rabbit 1:5,000 (WB) Bethyl Labs, A300-835A 
PP4R2 Rabbit 1:2,000 (WB) Bethyl Labs, A300-838A 
PP4R3α / SMEK1 Rabbit 1:1,000 (WB) Bethyl Labs, A300-840A 
PP4R3β / SMEK2 Rabbit 1:1,000 (WB) Bethyl Labs, A300-842A 
phospho-RPA32 (S4/S8) Rabbit 1:1,000 (WB); 1:2,000 (IF) Bethyl Labs, A300-245A 
RPA32 Rabbit 1:1,000 (WB) Santa Cruz Biotechnology, sc-28709 
TRAIP #89 Rabbit 1:50-1:200 (WB) Produced by A. Jackson laboratory 
Vinculin Mouse 1:2,000 (WB) Sigma, V9264 
 
b) Secondary antibodies 
 
Antibody Species Dilution for WB or IF Reference 
Anti-rabbit IgG, HRP linked Goat 1:5000 (WB) Cell Signaling Technology, 7074 
Anti-mouse IgG, HRP linked Goat 1:5000 (WB) Dako, P0447 
Anti-rabbit IgG, Alexa Fluor 488 linked Goat 1:1000 (IF) Invitrogen, A11008 
Anti-rabbit IgG, Alexa Fluor 568 linked Goat 1:1000 (IF) Invitrogen, A11036 
Anti-mouse IgG, Alexa Fluor 488 linked Goat 1:1000 (IF) Invitrogen, A11029 
Anti-mouse IgG, Alexa Fluor 568 linked Goat 1:1000 (IF) Invitrogen, A11031 
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